Introducing PHARMAC

January 2013

Volume 20 Number 0

Editors: Kaye Wilson, Donna Jennings & Sarah Le Leu email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and T_EX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/pub/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.


Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

General Rules 12

Section BAlimentary Tract & Metabolism25Blood & Blood Forming Organs45Cardiovascular System54Dermatologicals63Genito Urinary System74Hormone Preparations – Systemic80Infections – Agents For Systemic Use87Musculoskeletal System106Nervous System123Oncology Agents & Immunosuppressants152Respiratory System & Allergies170

- Sensory Organs 178
 - Various 182

Section C Extemporaneous Compounds (ECPs) 183



Index 223

2

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases.

Members of the PHARMAC Board

Stuart McLauchlan	Kura Denness	David Kerr
Anne Kolbe	Jens Mueller	Jan White

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

The following attend PHARMAC's Board meetings as observers

- Murray Georgel, CE MidCentral DHB
- Kate Russell, Chair Consumer Advisory Committee
- Carl Burgess, Chair Pharmacology and Therapeutics Advisory Committee (PTAC)

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Maori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;

- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC and the Pharmaceutical Schedule:

PHARMAC manages the national Pharmaceutical Schedule, which lists:

- Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and
- some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC.

In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as 'only if prescribed for a dialysis patient' or 'Special Authority - Retail Pharmacy', to ensure that Pharmaceuticals are used by those people who are most likely to benefit from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule.

Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals. Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals.

A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identifies those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets Hospital Pharmaceuticals in the Community approval.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Howard Wilson	BSc, PhD, MB, BS, Dip Obst, FRNZCGP, FRAGCP Deputy Chair
Chris Cameron	MBChB, FRACP, MClin Pharm
Melissa Copland	PhD, BPharm(Hons), RegPharmNZ, FNZCP
Stuart Dalziel	MBChB, PhD, FRACP
lan Hosford	MBChB, FRANZCP, psychiatrist
Sisira Jayathissa	MMBS, MMedSc (Clin Epi), MD, FRCP (Lon, Edin), FRACP, FAFPHM, FNZCPHM, Dip Clin Epi,
	Dip OHP, DipHSM, MBS
George Laking	PhD, MD, FRACP
Dee Mangin	MBChB, DPH, RNZCGP
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician
Marius Rodemater	BM (Soton), FRCP (Edn), FRACP DM
Jane Thomas	MBChB, FANZGL
Mark Weatherall	BA, MBChB, MApplStats, FRACP

Contact PTAC C/- PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz

PHARMAC's consumer advisors

Consumer Advisory Committee (CAC)

The Consumer Advisory Committee is an advisory committee to the PHARMAC Board. It provides written reports to the Board, and its Chair attends Board meetings as an observer to report on the activities and findings of the Committee, and to comment on consumer issues. While accountable to the Board, the Committee's general working relationship is with the staff of PHARMAC. The Committee is made up of people from a range of backgrounds and interests including the health of Māori people, Pacific peoples, older people, women and mental health.

For current membership of the Consumer Advisory Committee, visit our website. The Consumer Advisory Committee can be contacted by email: CAC@pharmac.govt.nz, or you can write to the Consumer Advisory Committee at PHARMAC's postal address.

The PHARMAC Team

The PHARMAC team has a wide range of expertise in health, medicine, economics, commerce, critical analysis, and policy development and implementation.

Steffan Crausaz Paul Alexander Richard Anderson

Katie Appleby Jason Arnold Diana Beswetherick Lauren Bishop Stephen Boxall Lisa Buxton Kate Camp Davina Carpenter Christine Chapman Mary Chesterfield Ian Craigie

Andrew Davies

Natalie Davis Jessica Dougherty

Sean Dougherty

Anrik Drenth Kim Ellis

Simon England Jackie Evans

John Geering Anne Glennie Rachel Grocott Ben Healey Rochelle Harker

Hayden Holmes

Karen Jacobs

Geralt Jones Donna Jennings Belinda Jurgensen

Marcus Kim Catherine Kingsbury

Geoff Lawn

Sarah Le Leu Bridget Macfarlane Chief Executive Health Economist Network and Systems Administrator Panel Co-ordinator Team Leader. Analysis HR Manager Office Services Support Creative Director Senior Receptionist Principal Advisor Public Affairs **Records Manager** Therapeutic Group Manager High Cost Drugs Co-ordinator Manager, Technology and Information Acting Manager, Funding and Procurement Therapeutic Group Manager Corporate Team Executive Assistant Funding Systems Development Manager Database Analyst Access & Optimal Use Co-ordinator Communications Manager Senior Therapeutic Group Manager Systems Architect Panel Co-ordinator Senior Health Economist Analyst PTAC Secretary & Panel Co-ordinator Panel Co-ordinator (Growth Hormone/PAH) National Programme Manager, One Heart Many Lives Formulary Researcher Schedule Analyst Executive Assistant to Chief Executive, Board Secretary & Office Manager Tender Analyst Funding and Procurement Assistant Applications Developer / Team Leader IT Schedule Analyst Programme & Accountability Manager

Geraldine MacGibbon Janet Mackay Rachel Mackay Trish Mahonev Scott Metcalfe Peter Moodie Hew Norris Leigh Parish Kvlie Parker Marama Parore Chris Peck Karen Phillips Matthew Poynton Rachel Pratt Dilky Rasiah Awhimai Reynolds Te Aniwa Robson Alexander Rodgers Brian Roulston Fiona Rutherford **Rico Schoeler** Carsten Schousboe Merryn Simmons Liz Skelley Stuart Sorrel Jude Urlich Javne Watkins Rachel Werner Brvce Wigodsky Greg Williams Lisa Williams Kave Wilson Stephen Woodruffe John Wyeth

Sue Anne Yee Michael Young Senior Therapeutic Group Manager Programme & Accountability Manager Manager, Schedule and Contracts Contract Manager Chief Advisor Population Medicine / Deputy Medical Director Medical Director Analyst PA to Medical Director / Medical Team Assistant Accounts Co-ordinator Manager, Access & Optimal Use & Māori Health Analvst HR Assistant/Payroll Analyst/Health Economist Panel Co-ordinator Deputy Medical Director Māori Health Manager Māori Health Programmes' Assistant Health Economist Contract Manager Establishment Manager, Medical Devices Manager, Analysis and Assessment Health Economist PHARMAC Seminar Series Co-ordinator Finance Manager Panel Co-ordinator Manager, Corporate and External Relations Team Leader. Medical Team Health Economist Policy Analyst Senior Therapeutic Group Manager Legal Counsel Senior Schedule Analyst Therapeutic Group Manager Deputy Medical Director, Secondary Care Therapeutic Group Manager Analyst

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section A lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section B lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into
 one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO).
- Section E Part II lists rural areas for the purpose of PSOs.
- Section F lists the Community Pharmaceuticals dispensing period exemptions.
- Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H:


- Part I lists the rules in relation to Hospital Pharmaceuticals.
- Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are
 listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if
 applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV)
 Pharmaceuticals and DV Limit.
- Part III lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget.

The index located at the back of the Section H supplement can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg	microgram μ g
kilogramkg	milligrammg
international unitiu	millilitreml

millimole	mmol
unit	u

Abbreviations

Ampoule	. Amp	Gra
Capsule	Cap	Infu
Cream	Crm	Inje
Device	Dev	Lin
Dispersible	. Disp	Liq
Effervescent	Eff	Lor
Emulsion	Emul	Oir
Enteric Coated	EC	Sa
Gelatinous	Gel	Sol

Granules		Suppository	
Infusion	Inf	Tablet	Iab
Injection	Inj	Tincture	Tinc
Linctus	Linc	Trans Dermal Delivery	
Liquid	Liq	System	TDDS
Long Acting	LA		
Ointment	Oint		
Sachet	Sach		
Solution	Soln		

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

CE Compounded Extemporaneously.

- CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.
- ECP Extemporaneously Compounded Preparation.

HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

OP Original Pack – subsidy is rounded up to a multiple at whole packs.

PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

- ▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner.
- * Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed "close control" or "cc" and the endorsement is initialled by the prescriber.

Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations.

Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a
manufacturer's surcharge.

S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:

- a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

	Definitions					
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements				
[HP3]	Subsidised when dispensed from pharmacies that	Available from selected pharmacies that have an ex-				
	have a Special Foods Service appended to their Phar-	clusive contract to dispense Special Foods.				
	macy Services Agreement by their DHB.					
[HP4]	Subsidised when dispensed from pharmacies that	Avaliable from selected pharmacies that have an ex-				
	have the Monitored Therapy Variation (for Clozapine	clusive contract to dispense 'Hospital Pharmacy' [HP4]				
	Services)	pharmaceuticals.				

Patient costs

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a \checkmark in the product's Schedule listing.

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee. PRESCRIPTION CHARGE

From 1 January 2013, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$5 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$5 co-payments.

Prescriptions from the following providers are approved for \$5 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, ophthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general
 practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a
 PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

Manufacturer's surcharge to patient = (price - subsidy) \times 1.86

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surcharge of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being

\$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the relevant DHB hospital Funder from its own budget. Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) are funded through the Combined Pharmaceutical Budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patients name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and Medical Council registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Named Patient Pharmaceutical Assessment policy

The Named Patient Pharmaceutical Assessment (NPPA) Policy is PHARMAC's process for considering applications about named patients seeking funding for treatments not listed on the Schedule, either at all or for the named patient's clinical circumstances. For PHARMAC to perform its legislative function of maintaining and managing a Schedule that applies consistently throughout New Scalard the NIDPA Delivery is a second and much access to a schedule that applies are access.

Zealand, the NPPA Policy will, and must, operate in a way that does not undermine the Schedule decision making process. Together, the Schedule process and the NPPA Policy, ensure there is a pathway for consideration of an individual's clinical circumstances. If an individual has a set of clinical circumstances not covered by the NPPA Policy, the Schedule decision making process is available. It is not the purpose of the NPPA Policy to provide access to every treatment not listed on the Schedule.

There are three main pathways by which named patients can be considered for funding under the NPPA Policy. PHARMAC will exercise its discretion to determine the most appropriate pathway for an application under the NPPA Policy based on the information that is provided.

PHARMAC will assess applications that meet the prerequisites described below according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions. For more information on NPPA, or to apply, visit the PHARMAC website at http://www.pharmac.govt.nz/nppa, or call the Panel Coordinators at (04) 9167553 or (04) 9167521.

Unusual Clinical Circumstance (UCC)

The purpose of the Unusual Clinical Circumstances (UCC) pathway is to provide a process for consideration for funding for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule. The prerequisite requirements for UCC consideration are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that are so unusual that PHARMAC is unlikely to consider listing treatments for these on the Schedule; and
- Generally, PHARMAC has not already considered/is not considering, through the Schedule decision making process, the treatment for the patient's clinical circumstances, or has not considered the treatment at all.

Urgent Assessment (UA)

The purpose of the Urgent Assessment (UA) pathway is to provide a process for PHARMAC to consider funding treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing. The prerequisite requirements for UA are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that may be experienced by a population group (either currently or over time); and
- The patient has serious clinical circumstances and not receiving the treatment within six to 12 months would lead to either a significant deterioration in a serious clinical condition or the patient would miss the opportunity for significant improvement in clinical outcome (length or quality of life); and
- The treatment has either not been prioritised by PHARMAC, or if it has, PHARMAC has funded the treatment under the NPPA Policy for the same clinical circumstances prior to prioritisation.
- PHARMAC has not declined to list, on the Schedule, this treatment for these clinical circumstances.

Hospital Pharmaceuticals in the Community (HPC)

The purpose of the Hospital Pharmaceuticals in the Community (HPC) pathway is to allow District Health Board hospitals to fund a medicine for a patient in the community if it would be more affordable for the DHB than paying for the treatment that would otherwise need to be provided. PHARMAC's approval is required for any such funding, given DHBs' legislative obligation to act consistently with the Schedule. The prerequisite requirements for HPC are:

- The patient has reasonably tried and failed all alternative cheaper funded treatments (or these alternative treatments have been contraindicated) or the patient has experienced such serious side effects with all other cheaper relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The application is for a DHB hospital to fund a treatment for use in the community for a patient under the care of a DHB hospital clinician (in-patient or out-patient); and
- The treatment is not being used to treat a cancer; and
- The treatment costs less for the DHB than the most likely alternative intervention or outcome; and
- The treatment is being sought for a short-term episode of care (usually a maximum of three months) and is not generally for the treatment of a chronic condition.

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 January 2013 and is to be referred to as the Pharmaceutical Schedule Volume 20 Number 0, 2013. Distribution will be from 20 January 2013. This Schedule comes into force on 1 January 2013.

PART I

INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria" means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

a) have limited physical mobility;

- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

"Act" means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee" means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy" means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation" means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Assessed Pharmaceuticals" means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC.

"Authority to Substitute" means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order" means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability

Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Class B Controlled Drug" means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

"Community Pharmaceutical" means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor" means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug" means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply" means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

"Dentist" means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber" means a registered nurse practising in diabetes health who has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site.

"Dietitian" means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB" means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital" means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Discretionary Community Supply Pharmaceutical" means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

"Dispensing Frequency Rule" means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

"Doctor" means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical" means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements" - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Funder" means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST" means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator" means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Pharmaceuticals" means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals.

"Hospital Pharmaceuticals in the Community (HPC)" means the pathway under the Named Patient Pharmaceutical Assessment policy to allow District Health Board hospitals to fund a medicine for a patient in the community if this is more affordable for the DHB than paying for the treatment that would otherwise need to be provided.

"Hospital Pharmacy" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

"Hospital Pharmacy-Specialist" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - i) endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the specialist and the General Practitioner must keep a written record of the consultation.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital. "Hospital Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is not eligible for Subsidy unless

it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS" means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination" means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit" means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital" means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot" means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price" means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife" means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month" means a period of 30 consecutive days.

"Monthly Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"Named Patient Pharmaceutical Assessment Advisory Panel" means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms)

"National Contract Pharmaceutical" means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

"National DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"National Immunisation Schedule" means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified

in the schedule.

"Not In Combination" means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Prescriber" means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice including, for the avoidance of doubt, a Diabetes Nurse Prescriber.

"Optometrist" means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

"Outpatient" , in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT" means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only" means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution" means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC" means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

"Pharmaceutical" means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule.

"Pharmaceutical Benefits" means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget" means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment" means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Pharmacist" means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

"Practitioner" means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist or a Pharmacist as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order" means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription" means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine" means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations 1984.

"Private Hospital" means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Residential Disability Care Institution" means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home" means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine" means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist" means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,

- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - i) endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the Specialist and the General Practitioner must keep a written record of consultation.

"Retail Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist. For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Schedule" means this Pharmaceutical Schedule and all its sections and appendices.

"Special Authority" means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a)
- i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and
- ii) the doctor's vocational scope of practice is one of those listed below: anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology;
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine;
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine;
- d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy" means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order" means a Bulk Supply Order or a Practitioner's Supply Order.

"Unapproved Indication" means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5.

"Unusual Clinical Circumstances (UCC)" means the pathway under the Named Patient Pharmaceutical Assessment

policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

"Urgent Assessment (UA)" means the pathway under the Named Patient P harmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II

COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
 - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
 - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
 - 2.2.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
 - 2.2.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III

PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers' and Optometrists' Prescriptions (other than oral contraceptives)

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber or Optometrist unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:

a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the

quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;

- b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is under the Dispensing Frequency Rule,
 - The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Original Packs, and Certain Antibiotics

3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:

- a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
- b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:
 - a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
 - b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Dietitians' Prescriptions

The following provisions apply to every Prescription written by a Dietitian:

- 3.4.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian,
 - providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
- 3.4.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

3.5 Diabetes Nurse Prescribers' Prescriptions

- The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:
- 3.5.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical listed below:

aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.5.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

Note: A list of Diabetes Nurse Prescribers will be published periodically in the Update of the Pharmaceutical Schedule for the duration of an initial pilot scheme. After this period there will be no approved DHB demonstration sites and hence no Diabetes Nurse Prescribers.

3.6 Pharmacists' prescriptions

The following apply to every prescription written by a Pharmacist:

- 3.6.1 Prescriptions written by a Pharmacist for a Community Pharmaceutical will only be subsidised where they are for the CareSens, CareSens N and CareSens N POP blood glucose diagnostic meters and annotated appropriately.
- 3.6.2 The prescribing and dispensing of blood glucose diagnostic meters by Pharmacists must be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

PART IV DISPENSING FREQUENCY RULE

The Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency rule defines patient groups or medicines eligible for more frequent dispensing periods; and the conditions that must be met to enable any claim for payment of handling fees for the additional dispensings made. "Frequent Dispensing" means:

- for a Community Pharmaceutical referred to in Section F Part I, dispensing in quantities less than one
 20 Devict for fourth and the part is the threader 400 Part (a) by the section of the part is the
 - 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
 - for any other Community Pharmaceutical, where any of 4.1, 4.2 or 4.3 of Part IV apply, dispensing in quantities less than a Monthly Lot

NOTE patients who have had more frequent dispensings due to being "intellectually impaired, frail, infirm or unable to manage their medicines" will continue to receive the same frequency of dispensings until they are assessed to see if they are eligible for additional support under the Long-Term Condition (LTC) service. The structure of the remainder fee payment provides funding for pharmacy to continue to provide more frequent dispensings for patients until they are assessed.

4.1 Frequent Dispensings for persons in residential care

- 4.1.1 Pharmaceuticals can be dispensed in quantities of not less than 28 days to:
 - any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
 - a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than 28 days' supply (except under conditions outlined in 4.2.2 below); and
- b) the prescribing Practitioner or dispensing pharmacist has
 - i) included the name of the patient's residential placement or facility on the Prescription; and
 - ii) included the patient's NHI number on the Prescription; and
 - iii) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4.1.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.2.2 below.

4.2 Frequent Dispensings for trial periods or safety medicines

- 4.2.1 If a Pharmacist considers more frequent dispensing is required, this can occur as follows:
 - For Long Term Condition (LTC) patients dispensing frequency can occur as often as the dispensing pharmacist deems appropriate to meet the patients compliance and adherence needs;
 - For non-LTC patients the dispensing frequency should be no more often than monthly. If Frequent Dispensing more often than monthly is necessary for non-LTC patients, prescriber approval is required. Verbal approval is acceptable, provided that it is annotated by the pharmacist on the Prescription and dated.

NOTE this rule does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement, Pharmaceutical Schedule or under rule 4.2.2 Trial Periods or rule 4.2.3 safety and co-prescribed medicines below.

Pharmacy would claim handling fees only on repeats under the above scenarios.

Prescribers can request, and pharmacists may dispense a higher frequency of dispensing in the following circumstances:

4.2.2 Trial Periods

The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only);

and the prescribing Practitioner has:

• endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or

"Trial"; and

- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.
- Patients who reside in Penal Institutions are not eligible for Trial Periods.
- 4.2.3 Safety and co-prescribed medicines
 - a) The Community Pharmaceutical is any of the following:
 - i) a tri-cyclic antidepressant; or
 - ii) an antipsychotic; or
 - iii) a benzodiazepine; or
 - iv) a Class B Controlled Drug; or
 - v) codeine (includes combination products)
 - vi) buprenorphine with naloxone

All of the following conditions must be met:

The Community Pharmaceutical has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The prescribing Practitioner has:

- he prescribing Practitioner has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing; and
 - Specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.
- b) The Community Pharmaceutical is co-prescribed with one of the Community Pharmaceuticals listed in 4.2.3(a) above and has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The dispensing pharmacist has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing;
 - Annotated the Prescription with the amended dispensing quantity and frequency.

4.3 Frequent Dispensing for Pharmaceutical Supply Management

- 4.3.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:
 - a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
 - b) the dispensing pharmacist has:
 - i) clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
 - ii) initialled the annotation in their own handwriting; and
 - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

PART V MISCELLANEOUS PROVISIONS

5 1 Bulk Supply Ordere

5.1 Bulk Supply Orders

- The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:
- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care

under the Health and Disability Services (Safety) Act 2001 and:

- a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
- b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.

5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

5.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.
- 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

5.4 Pharmaceutical Cancer Treatments

- 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
 - b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - c) is being used and funded as part of a paediatric oncology service; or
 - d) was being used to treat the patient in question prior to 1 July 2005.
- 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.3;
 - c) clauses 3.1 to 3.4; and
 - d) clause 5.4,
 - of Section A of the Schedule
- 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

5.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and

c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

5.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

a) there is a clinical reason why substitution should not occur; or

b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

5.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

5.8 Conflict in Provisions

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price \$	e) Su Per	Fully Brand or ubsidised Generic Manufacturer
Antacids and Antiflatulants	<u> </u>	101	
Antacids and Reflux Barrier Agents			
ALGINIC ACID			
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet		30	 Gaviscon Infant
CALCIUM CARBONATE WITH AMINOACETIC ACID * Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of \$6.30 per 100 tab with Endorsement		100	Titralac
Additional subsidy by endorsement is available for pregna Titralac Tab 420 mg with aminoacetic acid 180 mg to be delisted	int women. The pres	cription m	
 SIMETHICONE * Oral liq aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg per 5 ml 		500 ml	Mylanta P
SODIUM ALGINATE * Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour		60	Gaviscon Double Strength
 Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml 		500 ml	Acidex
Phosphate Binding Agents			
ALUMINIUM HYDROXIDE * Tab 600 mg		100	🖌 Alu-Tab
CALCIUM CARBONATE Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) - Subsidy by endorsement Only when prescribed for children under 12 years of ag endorsed accordingly.		500 ml sphate bir	✓ Roxane nding agent and the prescription
Antidiarrhoeals			
Agents Which Reduce Motility			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPH * Tab 2.5 mg with atropine sulphate 25 µg		100	🗸 Diastop
OPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a ★ Tab 2 mg ★ Cap 2 mg	8.95	400 400	 ✓ Nodia ✓ <u>Diamide Relief</u>
Rectal and Colonic Anti-inflammatories			
BUDESONIDE Cap 3 mg – Special Authority see SA1155 on the next page – Retail pharmacy		90	✓ Entocort CIR

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy (Manufacturer's Pric \$	ce) S Per	Fully ubsidised	Brand or Generic Manufacturer
SA1155 Special Authority for Subsidy				
Initial application - (Crohn's disease) from any relevant practi	tioner. Approvals	valid for 6	months fo	or applications meeting the
following criteria:				
 Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disea 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fractul 2.4 Severe acne following treatment with conventional cd 2.5 History of severe psychiatric problems associated w 2.6 History of major mental illness (such as bipolar affection ment causing relapse is considered to be high; or 2.7 Relapse during pregnancy (where conventional corti Initial application — (collagenous and lymphocytic colitis (rr valid for 6 months where patient has a diagnosis of microscopic biopsies. Initial application — (gut Graft versus Host disease) from any has a gut Graft versus Host disease following allogenic bone marr 	re; or orticosteroid thera, ith corticosteroid tu tive disorder) whe icosteroids are cor nicroscopic coliti colitis (collagenou relevant practition	reatment; c rre the risk nsidered to s)) from a us or lymp er. Approv	of conver be contra any releva hocytic co	aindicated). Int practitioner. Approvals plitis) by colonoscopy with
	ow transplantation	· ·		
Note: Indication marked with * is an Unapproved Indication. Renewal from any relevant practitioner. Approvals valid for 6 mor	oths where the tre	atment rer	nains ann	ropriate and the patient is
benefiting from treatment.			namo app	sophate and the patient is
Note: Clinical trials for Entocort CIR use beyond three months der	nonstrated no imp	rovement i	n relapse	rate.
HYDROCORTISONE ACETATE				
Rectal foam 10%, CFC-Free (14 applications)		21.1 g OP	V C	olifoam
MESALAZINE				
Tab 400 mg		100	🖌 A	sacol
Tab EC 500 mg	49.50	100	🖌 A	samax
Tab long-acting 500 mg		100		entasa
Enema 1 g per 100 ml		7		entasa
Suppos 500 mg		20		sacol
Suppos 1 g		28	V P	entasa
OLSALAZINE				
Tab 500 mg		100		ipentum
Cap 250 mg	31.51	100	🗸 D	ipentum
SODIUM CROMOGLYCATE				
Cap 100 mg		100	🖌 N	alcrom
SULPHASALAZINE				
* Tab 500 mg – For sulphasalazine oral liquid formulation refer,				
page 184	11.68	100	V S	alazopyrin
* Tab EC 500 mg		100		alazopyrin EN
,				

26

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Sul Per	osidised Generic Manufacturer
Antihaemorrhoidals	*	-	
Corticosteroids			
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIV		CHOCAINE	
Oint 950 μg, with fluocortolone pivalate 920 μg, and cin- chocaine hydrochloride 5 mg per g		30 g OP	✓ Ultraproct
Suppos 630 μ g, with fluocortolone pivalate 610 μ g, and cin-		-	A 1111
chocaine hydrochloride 1 mg	2.66	12	 Ultraproct
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g		30 g OP	Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	9.90	12	Proctosedyl
Antispasmodics and Other Agents Altering Gut	Motility		
ATROPINE SULPHATE			
* Inj 600 μ g, 1 ml – Up to 5 inj available on a PSO	71.00	50	AstraZeneca
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg	1 / 8	20	✓ Gastrosoothe
 * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO 		5	✓ <u>Buscopan</u>
MEBEVERINE HYDROCHLORIDE			
* Tab 135 mg		90	✓ <u>Colofac</u>
Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL			
* Tab 200 μg		120	✓ Cytotec
Helicobacter Pylori Eradication			
CLARITHROMYCIN			
Tab 500 mg – Subsidy by endorsement a) Maximum of 14 tab per prescription	10.95	14	Apo-Clarithromycin
b) Subsidised only if prescribed for helicobacter pylori erad	dication and prese	cription is end	orsed accordingly.
Note: the prescription is considered endorsed if clarithromycin is	prescribed in cor	njunction with	a proton pump inhibitor and eithe
amoxycillin or metronidazole. H2 Antagonists			
-			
CIMETIDINE – Only on a prescription * Tab 200 mg	5.00	100	
	(7.50)		Apo-Cimetidine
* Tab 400 mg		100	Apo-Cimetidine
FAMOTIDINE – Only on a prescription	(12.00)		Apo officiality
* Tab 20 mg		250	Famox
* Tab 40 mg (Famox Tab 20 mg to be delisted 1 April 2013)	11.35	250	Famox
(Famox Tab 40 mg to be delisted 1 April 2013)			

	Subsidy (Manufacturer's P \$	rice) Sul Per	Fully Brand or osidised Generic ✓ Manufacturer
RANITIDINE HYDROCHLORIDE - Only on a prescription			
* Tab 150 mg		250	Arrow-Ranitidine
* Tab 300 mg		250	Arrow-Ranitidine
* Oral liq 150 mg per 10 ml		300 ml	Peptisoothe
* Inj 25 mg per ml, 2 ml	8.75	5	 Zantac
Proton Pump Inhibitors			
LANSOPRAZOLE			
* Cap 15 mg	2.00	28	 Lanzol Relief Solox
* Cap 30 mg	2.32	28	✓ Solox ✓ Lanzol Relief
			✓ Solox
(Lanzol Relief Cap 15 mg to be delisted 1 April 2013) (Lanzol Relief Cap 30 mg to be delisted 1 April 2013)			
OMEPRAZOLE			
For omeprazole suspension refer, page 187			
* Cap 10 mg	2.91	90	✓ Omezol Relief
* Cap 20 mg		90	✓ Omezol Relief
* Cap 40 mg	5.57	90	✓ Omezol Relief
 Powder – Only in combination Only in extemporaneously compounded omeprazole sus 		5 g	✓ Midwest
* Inj 40 mg		5	✓ Dr Reddy's
, .			Omeprazole
PANTOPRAZOLE			
* Tab 20 mg	1.23	28	✓ <u>Dr Reddy's</u>
* Tab 40 mg	1 5 4	28	Pantoprazole
* Tab 40 mg	1.04	20	Dr Reddy's Pantoprazole
* Inj 40 mg	6.50	1	✓ Pantocid IV
(Pantocid IV Inj 40 mg to be delisted 1 July 2013)			
Site Protective Agents			
SUCRALFATE			
Tab 1 g	35.50	120	
	(48.28)		Carafate
Diabetes			
Hyperglycaemic Agents			
GLUCAGON HYDROCHLORIDE			
Inj 1 mg syringe kit – Up to 5 kit available on a PSO		1	 Glucagen Hypokit
Insulin - Short-acting Preparations			
INSULIN NEUTRAL			
▲ Inj human 100 u per ml	25.26	10 ml OP	 Actrapid
▲ Inj human 100 u per ml, 3 ml		5	 ✓ Humulin R ✓ Actrapid Penfill
	12.00	5	 Humulin R

	Subsidy (Manufacturer's Pi	rice) Sub	Fully Brand or sidised Generic
	\$	Per	✓ Manufacturer
Insulin - Intermediate-acting Preparations			
NSULIN ASPART WITH INSULIN ASPART PROTAMINE		_	
▲ Inj 100 iu per ml, 3 ml prefilled pen		5	NovoMix 30 FlexPen
	17.60	10 ml OP	✓ Humulin NPH
Inj human 100 u per ml	17.00	10 IIII OF	 Protaphane
Inj human 100 u per ml, 3 ml	29.86	5	🖌 Humulin NPH
			Protaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL	05.00	40 ml OD	A 11
Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	 ✓ Humulin 30/70 ✓ Mixtard 30
▲ Inj human with neutral insulin 100 u per ml, 3 ml		5	✓ Humulin 30/70
			PenMix 30
			 PenMix 40 PenMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			F CHIWIX JU
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml,			
3 ml		5	Humalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,3			-
ml	52.15	5	Humalog Mix 50
Insulin - Long-acting Preparations			
NSULIN GLARGINE			
▲ Inj 100 u per ml, 10 ml		1	✓ Lantus
 Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml disposable pen 		5 5	 Lantus Lantus SoloStar
		5	
Insulin - Rapid Acting Preparations			
NSULIN ASPART		_	
 Inj 100 u per ml, 3 ml Inj 100 u per ml, 10 ml 	51.19 30.03	5 1	 NovoRapid Penfill NovoRapid
NSULIN GLULISINE		1	
▲ Inj 100 u per ml, 10 ml	27.03	1	Apidra
Inj 100 u per ml, 3 ml	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen	46.07	5	Apidra SoloStar
NSULIN LISPRO	04.00		<u> </u>
 Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml 		10 ml OP 5	✓ Humalog✓ Humalog
Alpha Glucosidase Inhibitors		5	• numalog
•			
ACARBOSE * Tab 50 mg	0.92	90	Accarb
* Tab 50 mg		90	Glucobay
* Tab 100 mg	15.83	90	✓ Accarb
-			 Glucobay
(Glucobay Tab 50 mg to be delisted 1 March 2013) (Glucobay Tab 100 mg to be delisted 1 March 2013)			
Giucobay iab iou ing io be densieu i Marchi 2013)			

	Subsidy (Manufacturer's Pr \$	ice) Sut Per	Fully Brand or bsidised Generic Manufacturer
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE			
* Tab 5 mg	5.00	100	Daonil
GLICLAZIDE			
* Tab 80 mg	17.60	500	Apo-Gliclazide
GLIPIZIDE			
* Tab 5 mg	3.00	100	Minidiab
METFORMIN HYDROCHLORIDE			
* Tab immediate-release 500 mg		1,000	Apotex
* Tab immediate-release 850 mg	10.10	500	Apotex
PIOGLITAZONE			
* Tab 15 mg		28	✓ <u>Pizaccord</u>
* Tab 30 mg * Tab 45 mg		28 28	✓ <u>Pizaccord</u> ✓ Pizaccord
		20	
Diabetes Management			
Ketone Testing			
BLOOD KETONE DIAGNOSTIC TEST METER Meter funded for the purposes of blood ketone diagnostics of			re episodes of ketoacidosis and is
at risk of future episodes. Only one meter per patient will be			Constant
Meter		1	 Freestyle Optium
KETONE BLOOD BETA-KETONE ELECTRODES – Maximum o Test strip – Not on a BSO		cription 10 strip OP	 Freestyle Optium Ketone
SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescript * Test strip – Not on a BSO		50 strip OP	✓ Accu-Chek Ketur-Test
	14.14		✓ Ketostix

	,			
	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Blood Glucose Testing				
 BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by et a) Maximum of 1 pack per prescription b) A diagnostic blood glucose test meter is subsidised for a p 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant and has diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperg 4) has a genetic or an acquired disorder of glucose syndrome. 	patient who: glycaemia; or	g type	1 or type	2 diabetes and metabolic
Only one CareSens meter per patient. No further prescriptions w For the avoidance of doubt patients who have previously received				·

(er F ns meter. The prescription must be endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylureas.

Meter with 50 lancets, a lancing device and 10 diagnostic test

strips – Note differing brand requirements below – No

1 OP

V	CareSens II
~	CareSens N
~	CareSens N POP

a) CareSens N brand: Brand switch fee payable (Pharmacode 2423138) - see page 182 for details b) CareSens N POP brand: Brand switch fee payable (Pharmacode 2423154) - see page 182 for details

c) CareSens II brand: Brand switch fee payable (Pharmacode 2423146) - see page 182 for details

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP

The number of test strips available on a prescription is restricted to 50 unless:

1) Prescribed with insulin or a sulphonylurea but are on a different prescription and endorsed accordingly; or

- 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; or

4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or

5) Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips	50 test OP	CareSens
-		CareSens N
21.65		Accu-Chek
		Performa
		FreeStyle Lite
		Freestyle Optium
Blood glucose test strips \times 50 and lancets \times 5	50 test OP	✓ CareSens
19.10		On Call Advanced
Franstyla Lita Bland glucosa tast string to be delicted 1 March 2012)		

(FreeStyle Lite Blood glucose test strips to be delisted 1 March 2013)

(CareSens Blood glucose test strips \times 50 and lancets \times 5 to be delisted 1 April 2013)

(On Call Advanced Blood glucose test strips \times 50 and lancets \times 5 to be delisted 1 March 2013)

Subsid (Manufacturer \$	
 BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED) The number of test strips available on a prescription is restricted to 50 unlet 1) Prescribed with insulin or a sulphonylurea but are on a different prescript 2) Prescribed on the same prescription as insulin or a sulphonylurea in white or 3) Prescribed for a pregnant woman with diabetes and endorsed according 4) Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperg 5) Prescribed for a patient with a genetic or an acquired disorder of glucos and metabolic syndrome and endorsed accordingly. 	tion and endorsed accordingly; or ch case the prescription is deemed to be endorsed; ly; or glycaemia and endorsed accordingly; or se homeostasis excluding type 1 or type 2 diabetes
SensoCard Plus Talking Blood Glucose Monitor. Blood glucose test strips	50 test OP V SensoCard
Insulin Syringes and Needles	
Subsidy is available for disposable insulin syringes, needles, and pen needles i the supply of insulin or when prescribed for an insulin patient and the prescription INSULIN PEN NEEDLES – Maximum of 100 dev per prescription * 29 g × 12.7 mm	
10.50	100 Sector B-D Micro-Fine
★ 31 g × 5 mm 11.75 ★ 31 g × 6 mm 10.50 (26.00) (26.00)	100 V B-D Micro-Fine 100 V ABM NovoFine
* 31 g × 8 mm	30 B-D Micro-Fine 100 B-D Micro-Fine ABM
* $32 \text{ g} \times 4 \text{ mm}$	100 B-D Micro-Fine

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	d Generic
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE	- Maximum of 100 c	lev pe	r prescript	tion
* Syringe 0.3 ml with 29 g × 12.7 mm needle		100	· 🗸	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine
	13.00	100	~	B-D Ultra Fine
* Syringe 0.3 ml with 31 g × 8 mm needle		100	~	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine II
	13.00	100	~	B-D Ultra Fine II
* Syringe 0.5 ml with 29 g × 12.7 mm needle		100	~	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine
	13.00	100	~	B-D Ultra Fine
* Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	~	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine II
	13.00	100	~	B-D Ultra Fine II
* Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	~	ABM
	1.30	10		
	(1.99)			B-D Ultra Fine
	13.00	100	~	B-D Ultra Fine
* Syringe 1 ml with 31 g × 8 mm needle	13.00	100	~	ABM
-	1.30	10		
	(1.99)			B-D Ultra Fine II
	13.00	100	~	B-D Ultra Fine II
Insulin Pumps				

INSULIN PUMP – Special Authority see SA1237 on the	next page - Retail pharma	су	
 a) Maximum of 1 dev per prescription 			
 b) Only on a prescription 			
c) Maximum of 1 insulin pump per patient each four y	/ear period.		
Min basal rate 0.025 U/h; black colour	4,500.00	1	Animas Vibe
Min basal rate 0.025 U/h; blue colour	4,500.00	1	Animas Vibe
Min basal rate 0.025 U/h; green colour		1	Animas Vibe
Min basal rate 0.025 U/h; pink colour		1	Animas Vibe
Min basal rate 0.025 U/h; silver colour		1	Animas Vibe
Min basal rate 0.05 U/h; blue colour	4,400.00	1	Paradigm 522
			Paradigm 722
Min basal rate 0.05 U/h; clear colour	4,400.00	1	Paradigm 522
			Paradigm 722
Min basal rate 0.05 U/h; pink colour	4,400.00	1	Paradigm 522
			Paradigm 722
Min basal rate 0.05 U/h; purple colour		1	Paradigm 522
			Paradigm 722
Min basal rate 0.05 U/h; smoke colour		1	✓ Paradigm 522
,	,		✓ Paradigm 722
			· · · · · · · · · · · · · · · · · · ·

		Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
	ay be obtained from PHARMAC's web	osite http://www.pharr	nac.govt.nz or:	
PHARMAC	Phone: (04) 460 4990 Facsimile: (04) 974 7806 Email: ipp@pharmac.govt.nz			
Insulin Pump Consu	Imables			
►SA1240 Special Author Notes: Application details m	rity for Subsidy ay be obtained from PHARMAC's web	osite http://www.pharr	nac.govt.nz or:	
PHARMAC	Phone: (04) 460 4990 Facsimile: (04) 974 7806 Email: ipp@pharmac.govt.nz			
 a) Maximum of 1 cap per b) Only on a prescriptio c) Maximum of 1 prescription 	n iption per 180 days.			
Battery cap			1 🖌 A	nimas Battery Cap

34

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. d) Note: One additional pack of infusion sets will be funded p	·		e preceding page – Retail pharmac
6 mm steel cannula; straight insertion; 60 cm grey line \times 10			
with 10 needles	130.00	1 OP	 Contact-D
8 mm steel cannula; straight insertion; 110 cm grey line \times 10 with 10 needles	130.00	1 OP	Contact-D
8 mm steel cannula; straight insertion; 60 cm grey line \times 10 with 10 needles		1 OP	✓ Contact-D
10 mm steel needle: 29 G: manual insertion: 60 cm tubing \times		1 01	V Oomact-D
10 with 10 needles		1 OP	 Paradigm Sure-T MMT-884
10 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$			
10 with 10 needles; luer lock		1 OP	Sure-T MMT-883
10 mm steel needle; 29 G; manual insertion; 80 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Sure-T MMT-886
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$			
10 with 10 needles; luer lock		1 OP	 Sure-T MMT-885
6 mm steel needle; 29 G; manual insertion; 60 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Sure-T MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$			
10 with 10 needles; luer lock		1 OP	 Sure-T MMT-863
6 mm steel needle; 29 G; manual insertion; 80 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Sure-T
6 mm steel needles 00 C; manual insertions 00 cm tubing v			MMT-866
6 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	✓ Sure-T MMT-865
8 mm steel needle; 29 G; manual insertion; 60 cm tubing \times			
10 with 10 needles	130.00	1 OP	Paradigm Sure-T MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$			
10 with 10 needles; luer lock	130.00	1 OP	Sure-T MMT-873
8 mm steel needle; 29 G; manual insertion; 80 cm tubing \times 10 with 10 needles	130.00	1 OP	✓ Paradigm Sure-T MMT-876
8 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$			
10 with 10 needles; luer lock		1 OP	Sure-T MMT-875

	Subsidy (Manufacturer's Price) \$) Per	Fully Subsidised	Brand or Generic Manufacturer
NSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE I	NSERTION WITH IN	SERTI	ON DEVICE	E) – Special Authority see
A1240 on page 34 – Retail pharmacy 13 mm teflon cannula; angle insertion; insertion device; 110	`			
cm grey line \times 10 with 10 needles		1 OP	🖌 In	set 30
13 mm teflon cannula; angle insertion; insertion device; 60				
cm blue line \times 10 with 10 needles		1 OP	🖌 In	set 30
13 mm teflon cannula; angle insertion; insertion device; 60				
cm grey line \times 10 with 10 needles		1 OP	🖌 In	set 30
13 mm teflon cannula; angle insertion; insertion device; 60		4.00		
cm pink line \times 10 with 10 needles		1 OP		set 30
NSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN	NSERTION) – Spec	ial Autl	hority see S/	A1240 on page 34 – Retail
harmacy a) Maximum of 3 dev per prescription				
b) Only on a prescription				
c) Maximum of 1 prescription per 90 days.				
d) Note: One additional pack of infusion sets will be funded p		i 13 pa	ck per annu	m).
13 mm teflon cannula; angel insertion; 60 cm grey line \times 5		4.00		(t-Olt-
with 10 needles 17 mm teflon cannula; angle insertion; 110 cm grey line × 5		1 OP		omfort Short
with 10 needles		1 OP	10	omfort
13 mm teflon cannula; angle insertion; 120 cm line \times 10 with		1 01		
10 needles		1 OP	🖌 Pa	aradigm Silhouette
				MMT-382
13 mm teflon cannula; angle insertion; 45 cm line \times 10 with				
10 needles	130.00	1 OP		aradigm Silhouette
10 mm toffen commules engle incentions CO and lines at 10 with				MMT-368
13 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles		1 OP		aradigm Silhouette
		101		MMT-381
13 mm teflon cannula; angle insertion; 80 cm line $ imes$ 10 with	ı			
10 needles	130.00	1 OP	🖌 Pa	aradigm Silhouette
				MMT-383
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with			4.5	
10 needles		1 OP		aradigm Silhouette MMT-377
17 mm teflon cannula; angle insertion; 110 cm line $ imes$ 10 with				WIWI 1-577
10 needles; luer lock		1 OP	🖌 Si	ilhouette MMT-371
17 mm teflon cannula; angle insertion; 60 cm grey line × 5				
with 10 needles		1 OP	🖌 C	omfort
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with	ı			
10 needles	130.00	1 OP		aradigm Silhouette
17 mm tollon computer completions (0 are line of the state				MMT-378
17 mm teflon cannula; angle insertion; 60 cm line × 10 with 10 needles; luer lock		1 OP		ilhouette MMT-373
17 mm teflon cannula; angle insertion; 80 cm line \times 10 with		1 UP	₩ 3I	
10 needles		1 OP	🖌 Pa	aradigm Silhouette
				MMT-384

	Subsidy (Manufacturer's P \$	Price) Su Per	lbsidised	Brand or Generic Manufacturer
NSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIG	GHT INSERTION W	/ITH INSERT	ION DEVIC	CE) – Special Authori
ee SA1240 on page 34 – Retail pharmacy				
a) Maximum of 3 dev per prescription				
 b) Only on a prescription 				
c) Note: One additional pack of infusion sets will be funded	l per year (Maximur	m of 13 pack	per annum	ı).
d) Maximum of 1 prescription per 90 days.				
6 mm teflon cannula; straight insertion; insertion device; 1				
cm grey line \times 10 with 10 needles		1 OP	🖌 Ins	et II
6 mm teflon cannula; straight insertionl insertion device;		1.05		
cm blue line \times 10 with 10 needles		1 OP	🖌 Ins	et II
6 mm teflon cannula; straight insertionl insertion device;				
cm grey line \times 10 with 10 needles $\hfill \ldots$		1 OP	V Ins	et II
6 mm teflon cannula; straight insertionl insertion device;	60			
cm pink line \times 10 with 10 needles		1 OP	V Ins	et II
9 mm teflon cannula; straight insertion; insertion device;				
cm blue line \times 10 with 10 needles		1 OP	🖌 Ins	et II
9 mm teflon cannula; straight insertion; insertion device;	60			
cm grey line \times 10 with 10 needles $\hfill \ldots$		1 OP	V Ins	et II
9 mm teflon cannula; straight insertion; insertion device;		1.00		
cm pink line \times 10 with 10 needles		1 OP	🖌 Ins	et II
9 mm teflon cannula; straight insertionl insertion device; 1				
cm grey line \times 10 with 10 needles		1 OP	🖌 Ins	et II
6 mm teflon cannula; straight insertion; insertion device;		1.00	4.5	
cm blue tubing \times 10 with 10 needles		1 OP		adigm Mio IMT-941
C mm tellen connular attraight incertion, incertion devices	AE		IV	1111-941
6 mm teflon cannula; straight insertion; insertion device; - cm pink tubing × 10 with 10 needles		1 OP	A Dar	adigm Mio
chi pink tubing × 10 with 10 needles		TOF		MT-921
6 mm teflon cannula; straight insertion; insertion device;	60		N N	1111-521
cm blue tubing \times 10 with 10 needles		1 OP	🖌 Par	adigm Mio
		101		1MT-943
6 mm teflon cannula; straight insertion; insertion device;	60			
cm pink tubing \times 10 with 10 needles		1 OP	🖌 Par	adigm Mio
				IMT-923
6 mm teflon cannula; straight insertion; insertion device;	80			
cm blue tubing \times 10 with 10 needles		1 OP	🖌 Par	adigm Mio
5				1MT-945
6 mm teflon cannula; straight insertion; insertion device;	80			
cm clear tubing \times 10 with 10 needles		1 OP	🖌 Par	adigm Mio
			N	IMT-965
6 mm teflon cannula; straight insertion; insertion device;	80			
cm pink tubing \times 10 with 10 needles		1 OP	🖌 Par	adigm Mio
			N	IMT-925
9 mm teflon cannula; straight insertion; insertion device;				
cm clear tubing \times 10 with 10 needles		1 OP	🖌 Par	adigm Mio
			N	IMT-975

	Subsidy (Manufacturer's Pr \$	ice) Sul Per	Fully Brand or osidised Generic Manufacturer	
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH Retail pharmacy a) Maximum of 3 pack per prescription b) Only on a prescription	IT INSERTION)	- Special A	uthority see SA1240 on pa	ıge 34 -
 c) Maximum of 1 prescription per 90 days. d) Note: One additional pack of infusion sets will be funded per 	er vear (Maximum	n of 13 pack r	per annum).	
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10			,	
with 10 needles		1 OP	 Paradigm Quick-Se MMT-398 	et
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10 with 10 needles; luer lock	130.00	1 OP	✔ Quick-Set MMT-391	1
6 mm teflon cannula; straight insertion; 60 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Quick-Se MMT-399	et
6 mm teflon cannula; straight insertion; 60 cm tubing \times 10 with 10 needles; luer lock	130.00	1 OP	✔ Quick-Set MMT-393	3
6 mm teflon cannula; straight insertion; 80 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Quick-Se MMT-387	et
9 mm teflon cannula; straight insertion; 106 cm tubing × 10 with 10 needles	130.00	1 OP	✓ Paradigm Quick-Se MMT-396	et
9 mm teflon cannula; straight insertion; 110 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	✔ Quick-Set MMT-390	D
9 mm teflon cannula; straight insertion; 60 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Quick-Se MMT-397	et
9 mm teflon cannula; straight insertion; 60 cm tubing \times 10 with 10 needles; luer lock	130.00	1 OP	✔ Quick-Set MMT-392	2
9 mm teflon cannula; straight insertion; 80 cm tubing \times 10 with 10 needles		1 OP	✓ Paradigm Quick-Se MMT-386	et
INSULIN PUMP RESERVOIR – Special Authority see SA1240 c a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days.	on page 34 – Reta	ail pharmacy		
 d) Note: One additional packs of reservoirs will be funded per 10 × luer lock conversion cartridges 1.8 ml for Paradigm 		of 13 packs p	er annum).	
pumps		1 OP	✓ ADR Cartridge 1.8	
pumps		1 OP	✓ ADR Cartridge 3.0	
Cartridge 200 U, luer lock \times 10 Cartridge for 5 and 7 series pump; 1.8 ml \times 10		1 OP 1 OP	 Animas Cartridge Paradigm 1.8 Reservoir 	
Cartridge for 7 series pump; 3.0 ml \times 10	50.00	1 OP	✓ Paradigm 3.0 Reservoir	
Syringe and cartridge for 50X pump, 3.0 ml \times 10		1 OP	✓ 50X 3.0 Reservoir	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME				
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease		100	✔ C	reon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease		100	✔ C	reon Forte
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease	94.40	100	🖌 Pa	anzytrat
URSODEOXYCHOLIC ACID – Special Authority see SA1188 belo Brand switch fee payable (Pharmacode 2405857) - see page 1 Cap 250 mg – For ursodeoxycholic acid oral liguid formula-		/		
tion refer, page 184	71.50	100	✓ <u>U</u>	rsosan

SA1188 Special Authority for Subsidy

Initial application — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient diagnosed with cholestasis of pregnancy; or

2 Both:

- 2.1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2.2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis).

Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

MUCILAGINOUS LAXATIVES – Only on a prescription * Dry	6.02	500 g OP	✓ Konsyl-D
MUCILAGINOUS LAXATIVES WITH STIMULANTS			
* Dry	2.41	200 g OP	
	(8.72)	•	Normacol Plus
	6.02	500 g OP	
	(17.32)	-	Normacol Plus

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully Brand or osidised Generic ✓ Manufacturer
Faecal Softeners			
DOCUSATE SODIUM – Only on a prescription * Cap 50 mg * Cap 120 mg * Enema conc 18%	3.48	100 100 100 ml OP	✓ <u>Laxofast 50</u> ✓ <u>Laxofast 120</u> ✓ Coloxyl
DOCUSATE SODIUM WITH SENNOSIDES K Tab 50 mg with total sennosides 8 mg POLOXAMER – Only on a prescription	6.38	200	✓ Laxsol
Not funded for use in the ear. ✤ Oral drops 10%		30 ml OP	✓ <u>Coloxyl</u>
Osmotic Laxatives			
GLYCEROL ★ Suppos 3.6 g – Only on a prescription ACTULOSE – Only on a prescription	6.50	20	✔ PSM
Oral liq 10 g per 15 ml	7.68	1,000 ml	✓ Laevolac
 IACROGOL 3350 – Special Authority see SA0891 below – F Powder 13.125 g, sachets – Maximum of 60 sach per p scription Movicol Powder 13.125 g, sachets to be delisted 1 March 201 	ore- 	30	✓ Lax-Sachets Movicol
 SA0891 Special Authority for Subsidy itial application from any relevant practitioner. Approvals equiring intervention with a per rectal preparation despite ar there lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals valid for there energy from the terms of terms of the terms of the terms of terms o	a adequate trial of c	other oral phar	macotherapies including lactulo
ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETAT Enema 90 mg with sodium lauryl sulphoacetate 9 mg per 5 ml	ml,	scription 50	✓ Micolette
Stimulant Laxatives	20.00	50	• Micolette
BISACODYL – Only on a prescription ★ Tab 5 mg ★ Suppos 5 mg ★ Suppos 10 mg DANTHRON WITH POLOXAMER – Only on a prescription Note. Only for the POLOXAMER – Only on a prescription	3.00 3.00	200 6 6	 ✓ <u>Lax-Tab</u> ✓ Dulcolax ✓ Dulcolax
Note: Only for the prevention or treatment of constipation	,	200 ml	A Dinoray

40

Oral liq 25 mg with poloxamer 200 mg per 5 ml9.50

300 ml

300 ml

Pinorax

✓ Pinorax Forte

	Subsidy (Manufacturer's Pr	ice) Sub	Fully Brand or osidised Generic
	\$	Per	✓ Manufacturer
ENNA – Only on a prescription			
K Tab, standardised	0.43	20	
	(1.72)		Senokot
	2.17	100	
	(6.16)		Senokot
Metabolic Disorder Agents			
Gaucher's Disease			
MIGLUCERASE – Special Authority see SA0473 below – R	Retail pharmacy		
Inj 40 iu per ml, 200 iu vial		1	 Cerezyme
Inj 40 iu per ml, 400 iu vial	2,144.00	1	 Cerezyme
SA0473 Special Authority for Subsidy			
pecial Authority approved by the Gaucher's Treatment Pane	el		
lotes: Subject to a budgetary cap. Applications will be consi	idered and approved s	ubject to fund	ing availability.
pplication details may be obtained from PHARMAC's websi	te http://www.pharmad	c.govt.nz or:	·
The Co-ordinator, Gaucher's Treatment Panel Phone: (04) 460 4990		
	e: (04) 916 7571		
	jaucherpanel@pharma	ac.govt.nz	
<u>-</u>		<u> </u>	
Mouth and Throat			
Agents Used in Mouth Ulceration			
BENZYDAMINE HYDROCHLORIDE			
Soln 0.15%	3.60	200 ml	
	(8.50)		Difflam
	9.00	500 ml	
	(17.01)		Difflam
HLORHEXIDINE GLUCONATE			
Mouthwash 0.2%	2.68	200 ml OP	✓ healthE
	(3.87)		Rivacol
Rivacol Mouthwash 0.2% to be delisted 1 March 2013)	()		
HOLINE SALICYLATE WITH CETALKONIUM CHLORIDE			
Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06	15 g OP	
- Addesive ger 6.776 with ostalikonium emoniae 0.0170	(5.62)	10 9 01	Bonjela
	(0.02)		Donjola
ODIUM CARBOXYMETHYLCELLULOSE	17.00		(Otomoha - ha
With pectin and gelatin paste		56 g OP	 Stomahesive
	1.52	5 g OP	Outras
	(3.60)	45	Orabase
	4.55	15 g OP	Outras
MPH and the second sector the second	(7.90)	00 00	Orabase
With nectin and gelatin nowder		28 g OP	Olympik i
With pectin and gelatin powder			Stomahesive
	(10.95)		Stomanesive
RIAMCINOLONE ACETONIDE	(10.95)		Stornariesive

	Subsidy (Manufacturer's Pr \$	ice) Subs Per	Fully idised	Brand or Generic Manufacturer
Oropharyngeal Anti-infectives				
AMPHOTERICIN B Lozenges 10 mg	5.86	20	🖌 Fu	ngilin
MICONAZOLE Oral gel 20 mg per g	4.95 8.70	40 g OP	✔ De ✔ Da	cozol ktarin
NYSTATIN Oral liq 100,000 u per ml	3.19	24 ml OP	✓ <u>Nil</u>	stat
Other Oral Agents				
For folinic mouthwash, pilocarpine oral liquid or saliva substitute for HYDROGEN PEROXIDE	mula refer, page	9 187		
* Soln 10 vol – Maximum of 200 ml per prescription	1.28	100 ml	🖌 PS	SM
THYMOL GLYCERIN * Compound, BPC	9.15	500 ml	🗸 PS	M
Vitamins				

Alpha tocopheryl acetate is available fully subsidised for specific patients at the Medical Director of PHARMAC's discretion. Refer to PHARMAC website www.pharmac.govt.nz for the "Alpha tocopheryl acetate information sheet and application form".

Vitamin A		
VITAMIN A WITH VITAMINS D AND C * Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops	10 ml OP	✓ Vitadol C
Vitamin B		
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO5.10	3	✓ <u>ABM</u> Hydroxocobalamin
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription * Tab 25 mg – No patient co-payment payable2.20	90	✓ <u>PyridoxADE</u>
 * Tab 50 mg	500 100	 <u>Apo-Pyridoxine</u> Apo-Thiamine
VITAMIN B COMPLEX * Tab, strong, BPC	500	✓ <u>B-PlexADE</u>
Vitamin C		
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription * Tab 100 mg13.80	500	✓ <u>Vitala-C</u>

	Subsidy (Manufacturer's I \$	Price) Sul Per	Fully Brand or osidised Generic Manufacturer
Vitamin D			
ALFACALCIDOL			
* Cap 0.25 μg		100	🖌 One-Alpha
* Cap 1 μg		100	One-Alpha
* Oral drops 2 µg per ml	60.68	20 ml OP	One-Alpha
CALCITRIOL			
* Cap 0.25 μg	3.03	30	✓ Airflow
	10.10	100	Calcitriol-AFT
* Cap 0.5 μg	5.62	30	✓ Airflow
	18.73	100	 Calcitriol-AFT
* Oral liq 1 μg per ml		10 ml OP	 Rocaltrol solution
CHOLECALCIFEROL			
* Tab 1.25 mg (50,000 iu) - Maximum of 12 tab per prescrip	otion7.76	12	 Cal-d-Forte
Multivitamin Preparations			
MULTIVITAMINS - Special Authority see SA1036 below - Ret	ail pharmacy		
* Powder	72.00	200 g OP	Paediatric Seravit
Renewal from any relevant practitioner. Approvals valid without approval for multivitamins. VITAMINS	ut turtner renewal I	uniess notified	where patient has had a previous
* Tab (BPC cap strength)	8.00	1,000	✓ <u>MultiADE</u>
* Cap (fat soluble vitamins A, D, E, K) – Special Authority s SA1002 below – Retail pharmacy		60	✓ Vitabdeck
 SA1002 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals v the following criteria: Either: Patient has cystic fibrosis with pancreatic insufficiency; o Patient is an infant or child with liver disease or short gu 	or	renewal unles	s notified for applications meeting
Minerals			
Calcium			
CALCIUM CARBONATE			
* Tab eff 1.75 g (1 g elemental)	6.21	30	Calsource
* Tab 1.25 g (500 mg elemental)		250	✓ Arrow-Calcium
CALCIUM GLUCONATE			
* Inj 10%, 10 ml	21.40	10	Mayne
Fluoride			-
SODIUM FLUORIDE			
* Tab 1.1 mg (0.5 mg elemental)	5.00	100	✔ PSM

	0 1 11		
	Subsidy (Manufacturer's Prio \$	ce) Sul Per	Fully Brand or osidised Generic Manufacturer
lodine	\$	rei	Manulacturer
POTASSIUM IODATE * Tab 256 μg (150 μg elemental iodine)	7.55	90	NeuroKare
Iron			
FERROUS FUMARATE			
* Tab 200 mg (65 mg elemental)	4.35	100	 Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID			
* Tab 310 mg (100 mg elemental) with folic acid 350 μ g	4.75	60	Ferro-F-Tabs
FERROUS SULPHATE			
 Tab long-acting 325 mg (105 mg elemental) 		30	
······································	(4.26)		Ferrograd
	5.06	150	0
	(15.58)		Ferrograd
*‡ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)	10.30	500 ml	Ferodan
FERROUS SULPHATE WITH FOLIC ACID			
* Tab long-acting 325 mg (105 mg elemental) with folic acid			
350 μg		30	
	(4.29)		Ferrograd F
RON POLYMALTOSE			
Inj 50 mg per ml, 2 ml		5	Ferrum H
Magnesium			
For magnesium hydroxide mixture refer, page 187			
MAGNESIUM SULPHATE			
* Inj 2 mmol per ml, 5 ml	18.35	10	Martindale
	26.60	10	Mayne
Zinc			
ZINC SULPHATE			
* Cap 137.4 mg (50 mg elemental)	11.00	100	✓ Zincaps
Agents Used in the Treatment of Poisonings			
CHARCOAL			
* Oral liq 50 g per 250 ml	43.50	250 ml OP	Carbosorb-X
a) Up to 250 ml available on a PSO			
b) Only on a PSO			
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml	53.31	6	
	(156.71)		Calcium Disodium
			Versenate

44

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA0922 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Both:
 - 1.1 patient in chronic renal failure; and
 - 1.2 Haemoglobin \leq 100g/L; and
- 2 Any of the following:
 - 2.1 Both:
 - 2.1.1 patient is not diabetic; and
 - 2.1.2 glomerular filtration rate \leq 30ml/min; or
 - 2.2 Both:
 - 2.2.1 patient is diabetic; and
 - 2.2.2 glomerular filtration rate \leq 45ml/min; or
 - 2.3 patient is on haemodialysis or peritoneal dialysis.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:

GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l)

GFR (ml/min) (female) = Estimated GFR (male) \times 0.85

ERYTHROPOIETIN ALPHA – Special Authority see SA0922 above – Retail pharmacy

Inj human recombinant 1,000 iu prefilled syringe	6	Eprex
Inj human recombinant 2,000 iu, prefilled syringe	6	Eprex
Inj human recombinant 3,000 iu, prefilled syringe	6	 Eprex
Inj human recombinant 4,000 iu, prefilled syringe	6	Eprex
Inj human recombinant 5,000 iu, prefilled syringe	6	Eprex
Inj human recombinant 6,000 iu, prefilled syringe	6	✓ Eprex
Inj human recombinant 10,000 iu, prefilled syringe	6	Eprex
ERYTHROPOIETIN BETA - Special Authority see SA0922 above - Retail pharma	су	
Inj 2,000 iu, prefilled syringe120.18	6	NeoRecormon
Inj 3,000 iu, prefilled syringe166.87	6	NeoRecormon
Inj 4,000 iu, prefilled syringe193.13	6	NeoRecormon
Inj 5,000 iu, prefilled syringe	6	NeoRecormon
Inj 6,000 iu, prefilled syringe	6	NeoRecormon
Inj 10,000 iu, prefilled syringe	6	NeoRecormon
Megaloblastic		
FOLIC ACID		
* Tab 0.8 mg	1.000	Apo-Folic Acid
* Tab 5 mg	500	✓ Apo-Folic Acid
Oral liq 50 μ g per ml	25 ml OP	✓ Biomed

	Subsidy (Manufacturer's Price) \$	Si Per	Fully ubsidised	Brand or Generic Manufacturer
Antifibrinolytics, Haemostatics and Local Sclere	osants			
SODIUM TETRADECYL SULPHATE				
* Inj 0.5% 2 ml		5	-	
* Inj 1% 2 ml	(51.00)	5	F	ibro-vein
	(55.00)	5	Fi	ibro-vein
* Inj 3% 2 ml	(/	5		
	(73.00)		Fi	ibro-vein
TRANEXAMIC ACID				
Tab 500 mg		100	<u>✓ c</u>	<u>yklokapron</u>
Vitamin K				
PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO		5	🖌 К	onakion MM
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	9.21	5	🖌 К	onakion MM
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN				
* Tab 100 mg	14.00	990	🖌 E	thics Aspirin EC
CLOPIDOGREL				
* Tab 75 mg – For clopidogrel oral liquid formulation refer, page	•			
184		90	✓ <u>A</u>	po-Clopidogrel
DIPYRIDAMOLE				
* Tab 25 mg - For dipyridamole oral liquid formulation refer,				
page 184		84		ersantin
* Tab long-acting 150 mg	11.52	60	✓ P	<u>ytazen SR</u>
PRASUGREL - Special Authority see SA1201 below - Retail ph				
Tab 5 mg		28	• -	ffient
Tab 10 mg		28	V E	ffient

➡SA1201 Special Authority for Subsidy

Initial application — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergio*.

Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrelallergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Heparin and Antagonist Preparations					
DALTEPARIN SODIUM - Special Authority see SA1270 below	 Retail pharmacy 				
Inj 2,500 iu per 0.2 ml prefilled syringe		10	🖌 Fi	ragmin	
Inj 5,000 iu per 0.2 ml prefilled syringe		10	🖌 Fi	ragmin	
Ini 7 500 iu per 0 75 ml graduated svringe	60.03	10	V Fr	ragmin	

/ 🖤 Flayillill	10	synnige	ing 7,500 iu per 0.75 mi graduateu synnige
) 🖌 Fragmin	10	ringe77.55	Inj 10,000 iu per 1 ml graduated syringe
) 🖌 Fragmin	10	inge	Inj 12,500 iu per 0.5 ml prefilled syringe
) 🖌 Fragmin	10	inge120.05	Inj 15,000 iu per 0.6 ml prefilled syringe
) 🖌 Fragmin	10	/ringe158.47	Inj 18,000 iu per 0.72 ml prefilled syringe

SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM - Special Authority see SA1174 below - Retail pharmacy

lni 20 ma	 10	Clexane
, ,	10	
Inj 60 mg	 10	Clexane
Inj 80 mg	 10	Clexane
Inj 100 mg	 10	Clexane
Inj 120 mg	 10	Clexane
Inj 150 mg	 10	Clexane

SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	

continued...

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Low molecular weight heparin treatment is required during a patient's pregnancy; or

2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml	13.36	10	Mayne
	66.80	50	Mayne
	11.44	10	Pfizer
	46.30	50	Pfizer
Inj 1,000 iu per ml, 35 ml		1	Mayne
Inj 5,000 iu per ml, 1 ml	14.20	5	Mayne
Inj 5,000 iu per ml, 5 ml		50	Pfizer
Inj 25,000 iu per ml, 0.2 ml	9.50	5	Mayne
HEPARINISED SALINE			
* Inj 10 iu per ml, 5 ml		50	 Pfizer
PROTAMINE SULPHATE			
* Inj 10 mg per ml, 5 ml		10	
, , , ,	(95.87)		Artex

Oral Anticoagulants

DABIGATRAN	
Cap 75 mg – No more than 2 cap per day 148.00 60	Pradaxa
Cap 110 mg	Pradaxa
Cap 150 mg148.00 60	Pradaxa
RIVAROXABAN - Special Authority see SA1066 on the next page - Retail pharmacy	
Tab 10 mg153.00 15	Xarelto

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic	
(Manulaciuler S Fride) Subsidised Generic	
\$ Per 🖌 Manufacturer	

➡SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

1 For the prophylaxis of venous thromboembolism following a total hip replacement; or

2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg	3.46	50	Coumadin
	J J J J J J J J J J J J J J J J J J J	5.69	100	Marevan
*	Tab 2 mg	4.31	50	Coumadin
*	Tab 3 mg	8.00	100	Marevan
*	Tab 5 mg	5.93	50	Coumadin
	·	9.64	100	Marevan

Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see SA1259 below – Retail pharmacy				
Inj 300 μ g per 0.5 ml prefilled syringe	540.00	5	Zarzio	
Inj 480 μ g per 0.5 ml prefilled syringe	864.00	5	Zarzio	

➡SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^{9} /L).

Note: *Febrile neutropenia risk $\geq 20\%$ after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

DEXTROSE

	Inj 50%, 10 ml – Up to 5 inj available on a PSO19.50	5	✓ Biomed
	Inj 50%, 90 ml – Up to 5 inj available on a PSO11.25	1	 Biomed
	TASSIUM CHLORIDE Inj 75 mg per ml, 10 ml55.00	50	✓ AstraZeneca
~		50	AStrazeneca

95 1 50 1 n in conjunctio 06 500 06 1,00	n with an an 0 ml 0 ml e in the home 5 0 0	d Generic Manufacturer Biomed Biomed tibiotic intended for nebulise Baxter Baxter Baxter Batter Batter Biomed Multichem Pfizer Multichem Pfizer Pharmacia
50 1 n in conjunctio 06 500 06 1,00 00st-natal care 25 5 , page 187 85 50 50 50 50 50 50 50 50 72 6	n with an an 0 ml 0 ml e in the home 5 0 0	Biomed tibiotic intended for nebulise Baxter Baxter e of the patient, or on a PSC Biomed Multichem Pfizer Multichem Pfizer
50 1 n in conjunctio 06 500 06 1,00 00st-natal care 25 5 , page 187 85 50 50 50 50 50 50 50 50 72 6	n with an an 0 ml 0 ml e in the home 5 0 0	Biomed tibiotic intended for nebulise Baxter Baxter e of the patient, or on a PSC Biomed Multichem Pfizer Multichem Pfizer
n in conjunctio 06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 50 72 6	on with an an) ml 0 ml 0 ml 5 0 0 0 0 0 0 0 0 0 0	tibiotic intended for nebulise Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
n in conjunctio 06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 50 72 6	on with an an) ml 0 ml 0 ml 5 0 0 0 0 0 0 0 0 0 0	tibiotic intended for nebulise Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
n in conjunctio 06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 50 72 6	on with an an) ml 0 ml 0 ml 5 0 0 0 0 0 0 0 0 0 0	tibiotic intended for nebulise Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 72 6	0 ml 0 ml e in the home 5 0 0 0	Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 72 6	0 ml 0 ml e in the home 5 0 0 0	Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 72 6	0 ml 0 ml e in the home 5 0 0 0	Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
06 500 06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 72 6	0 ml 0 ml e in the home 5 0 0 0	Baxter Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 72 6	0 ml a in the home 5 0 0 0 0 0 0 0 0 0 0	Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
06 1,00 post-natal care 25 5 , page 187 85 50 50 50 50 50 72 6	0 ml a in the home 5 0 0 0 0 0 0 0 0 0 0	Baxter e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
25 5 , page 187 85 50 50 50 50 50 50 72 6	e in the home	e of the patient, or on a PSC <u>Biomed</u> Multichem Pfizer Multichem Pfizer
25 5 , page 187 85 5 50 5 50 5 50 72 6		Biomed Multichem Pfizer Multichem Pfizer
, page 187 85 50 50 50 50 50 72 6		Multichem Pfizer Multichem Pfizer
, page 187 85 50 50 50 50 50 72 6		Multichem Pfizer Multichem Pfizer
85 50 50 50 50 50 50 72 6		Pfizer Multichem Pfizer
50 50 5 50 72 6		Pfizer Multichem Pfizer
50 50 50 72 6	0	Multichem Pfizer
.50 .72 6	<i>v</i>	Pfizer
.72 6	6 v	Pharmacia
	0	Pharmacia
.41 2	0	Multichem
IS 10	DP 🗸	TPN
aama farm aa	on inightion	listed in the Dharmanautice
same ionn as	an injection	
.25 5	0	Multichem
	0	Multichem
	0 🖌	Multichem
85 300 0	n OP	Calcium Resonium
	g 0. •	
10 5	-	Electrol
.12 5		Electral
	105	
.60 1,000	mi OP 🗸	Pedialyte -
		Bubblegum Dedictute
75		Pedialyte - Fruit Pedialyte - Plain
.15	v	reulalyle - Fiaili
.50 10	JU 🗸	Phosphate-Sandoz
	same form as .25 5 .25 5 .50 2 .85 300 9 .12 5 .60 1,000	same form as an injection .25 50 .25 50 .50 20 .85 300 g OP .12 5 .60 1,000 ml OP

	Subsidy (Manufacturer's P	rice) Sub	Fully Brand or osidised Generic
	\$	Per	✓ Manufacturer
POTASSIUM CHLORIDE			
 Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq) 	5 26	60	
	(11.85)	00	Chlorvescent
* Tab long-acting 600 mg		200	✓ Span-K
SODIUM BICARBONATE			
Cap 840 mg		100	✓ Sodibic
SODIUM POLYSTYRENE SULPHONATE			
Powder	89.10	450 g OP	Resonium-A
Lipid Modifying Agents			
Fibrates			
Tiblates			
BEZAFIBRATE			
* Tab 200 mg		90	✓ Bezalip
	9.75		Fibalip
* Tab long-acting 400 mg	5.70	30	Bezalip Retard
GEMFIBROZIL			4 • • • •
* Tab 600 mg	14.00	60	Lipazil
Other Lipid Modifying Agents			
ACIPIMOX			
* Cap 250 mg	18 75	30	Olbetam
		00	• • • • • • • • • • • • • • • • • • •
* Tab 50 mg	4 17	100	Apo-Nicotinic Acid
* Tab 500 mg		100	✓ Apo-Nicotinic Acid
Resins			
CHOLESTYRAMINE WITH ASPARTAME			
Sachets 4 g with aspartame	19.25	50	
	(52.68)	00	Questran-Lite
COLESTIPOL HYDROCHLORIDE	()		
Sachets 5 g		30	Colestid
HMG CoA Reductase Inhibitors (Statins)			
Prescribing Guidelines			
Freatment with HMG CoA Reductase Inhibitors (statins) is reco	mmended for pati	ents with dysl	ipidaemia and an absolute 5 ye
cardiovascular risk of 15% or greater.			
ATORVASTATIN – See prescribing guideline above	0.50	00	A Zavatav
 * Tab 10 mg * Tab 20 mg 		90 90	✓ <u>Zarator</u> ✓ Zarator
★ Tab 20 mg		90 90	✓ Zarator
★ Tab 80 mg		90	Zarator
PRAVASTATIN – See prescribing guideline above			
* Tab 20 mg	5.44	30	Cholvastin
★ Tab 40 mg		30	Cholvastin

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
SIMVASTATIN – See prescribing guideline on the preceding page * Tab 10 mg	1.40 1.95 3.18	90 90 90 90	 <td>Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg</td>	Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg
Selective Cholesterol Absorption Inhibitors				
EZETIMIBE – Special Authority see SA1045 below – Retail pharm Tab 10 mg	,	30	~	Ezetrol

Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and

- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin: or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg		30	🖌 Vytorin
Tab 10 mg with simvastatin 20 mg	51.60	30	Vytorin
Tab 10 mg with simvastatin 40 mg		30	Vytorin
Tab 10 mg with simvastatin 80 mg	60.60	30	 Vytorin

SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
Iron Overload				
DEFERIPRONE – Special Authority see SA1042 below – Retail Tab 500 mg Oral liq 100 mg per 1 ml		100 250 ml OP		erriprox erriprox
► SA1042 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals va been diagnosed with chronic transfusional iron overload due to co Note: For the purposes of this Special Authority, a relevant special	ongenital inherited	d anaemia.		ied where the patient has

DESFERRIOXAMINE	MESYLATE
-----------------	----------

*	Inj 500 mg99.	9.00 10	🖌 Mayne
---	---------------	---------	---------

	Subsidy		Fully	Brand or
	(Manufacturer's Pri	ce) Su		Generic
	\$	Per	~	Manufacturer
Alpha Adrenoceptor Blockers				
DOXAZOSIN MESYLATE				
* Tab 2 mg	8.23	500	🖌 Ар	o-Doxazosin
* Tab 4 mg	12.40	500	V Ap	o-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg	7.82	30	🖌 Dib	enyline S29
	26.05	100	🖌 Dib	enyline S29
PRAZOSIN HYDROCHLORIDE				-
* Tab 1 mg		100	V Ap	o-Prazo
* Tab 2 mg		100		o-Prazo
* Tab 5 mg		100	•	o-Prazo
TERAZOSIN HYDROCHLORIDE				
* Tab 1 mg		28	🖌 Arr	ow
* Tab 2 mg		28	✓ Arr	
* Tab 5 mg		28	🖌 Arr	
Agents Affecting the Renin-Angiotensin System				
Agents Anecting the Renn-Angiotensin System				
ACE Inhibitors				
CAPTOPRIL				
* Tab 12.5 mg		100		Captopril
* Tab 25 mg		100		Captopril
* Tab 50 mg		100		Captopril
*‡ Oral liq 5 mg per ml		95 ml OP	✓ <u>Ca</u>	ooten
Oral liquid restricted to children under 12 years of age.				
CILAZAPRIL	0.05	00		
* Tab 0.5 mg		90	Zaj	
* Tab 2.5 mg		90	✓ <u>Zap</u>	
* Tab 5 mg	9.84	90	✓ <u>Za</u> j	
ENALAPRIL	4.07			
* Tab 5 mg	1.07	90		ow-Enalapril
* Tab 10 mg	1 20	90		Enalapril ow Epolopril
* Tab 10 mg	1.02	90		ow-Enalapril Enalapril
* Tab 20 mg - For enalapril oral liquid formulation refer, page			•	
184		90	🖌 Arr	ow-Enalapril
104	1. <i>1 C</i>	50		Enalapril
(Arrow-Enalapril Tab 5 mg to be delisted 1 March 2013)				
(Arrow-Enalapril Tab 10 mg to be delisted 1 March 2013)				
(Arrow-Enalapril Tab 20 mg to be delisted 1 March 2013)				
LISINOPRIL				
* Tab 5 mg	3 58	90	🖌 🖌	ow-Lisinopril
* Tab 10 mg		90		ow-Lisinopril
* Tab 20 mg		90		ow-Lisinopril

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	

PERINDOPRIL

Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%."

 dorsement 		30	
	(18.50)		Coversyl
* Tab 4 mg - Higher subsidy of \$25.00 per 30 tab with En-			
dorsement	4.05	30	
	(25.00)		Coversyl
QUINAPRIL			
* Tab 5 mg	1.60	30	Accupril
* Tab 10 mg	1.75	30	Accupril
* Tab 20 mg	2.35	30	 Accupril

TRANDOLAPRIL

Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%."

* Cap 1 mg - Higher subsidy of \$18.67 per 28 cap with En-

dorsement	28	Gopten
dorsement	28	Gopten
ACE Inhibitors with Diuretics		
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE * Tab 5 mg with hydrochlorothiazide 12.5 mg	28	✓ Inhibace Plus
ENALAPRIL WITH HYDROCHLOROTHIAZIDE		·
 Tab 20 mg with hydrochlorothiazide 12.5 mg	30	Co-Renitec
QUINAPRIL WITH HYDROCHLOROTHIAZIDE		
* Tab 10 mg with hydrochlorothiazide 12.5 mg	30	Accuretic 10
* Tab 20 mg with hydrochlorothiazide 12.5 mg4.57	30	Accuretic 20

	Subsidy		Fully Brand or
	Subsidy (Manufacturer's Price)) Su	Fully Brand or Ibsidised Generic
	\$	Per	 Manufacturer
Angiotension II Antagonists			
CANDESARTAN – Special Authority see SA1223 below – Retail p	oharmacy		
Brand switch fee payable (Pharmacode 2426781) - see page			
* Tab 4 mg	4.13	90	Candestar
* Tab 8 mg	6.10	90	Candestar
* Tab 16 mg		90	✓ Candestar
₭ Tab 32 mg	17.66	90	✓ Candestar
Salary Special Authority for Subsidy Special Authority for Subsidy Itial application — (ACE inhibitor intolerance) from any rele otified for applications meeting the following criteria: Either: Patient has persistent ACE inhibitor induced cough that is n			
Or			
2 Patient has a history of angioedema.			
Initial application — (Unsatisfactory response to ACE inhibito	r) from any relevan	t practitio	ner. Approvals valid without furth
renewal unless notified where patient is not adequately controlled			
LOSARTAN			
* Tab 12.5 mg	2.88	90	✓ Lostaar
k Tab 25 mg		90	✓ Lostaar
k Tab 20 mg		90	✓ Lostaar
Tab 50 mg with hydrochlorothiazide 12.5 mg		30	✓ Arrow-Losartan &
	4.09	30	Hydrochlorothiazide
₭ Tab 100 mg	8.68	90	✓ Lostaar
Antiarrhythmics			
or lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaest	hetics, Local, page	123	
MIODARONE HYDROCHLORIDE			
Tab 100 mg - Retail pharmacy-Specialist		30	Aratac
			Cordarone-X
Tab 200 mg – Retail pharmacy-Specialist		30	Aratac
			✓ Cordarone-X
Inj 50 mg per ml, 3 ml – Up to 6 inj available on a PSO		6	✓ Cordarone-X
NGOXIN			
	6.67	040	
★ Tab 62.5 μ g – Up to 30 tab available on a PSO		240	Lanoxin PG
k Tab 250 μg – Up to 30 tab available on a PSO		240	Lanoxin
k ‡ Oral liq 50 μ g per ml		60 ml	Lanoxin
DISOPYRAMIDE PHOSPHATE		100	
DISOPYRAMIDE PHOSPHATE ▲ Cap 100 mg	(23.87)	100	Rythmodan
DISOPYRAMIDE PHOSPHATE ▲ Cap 100 mg	(23.87)	100 100	Rythmodan
DISOPYRAMIDE PHOSPHATE Cap 100 mg	(23.87)		2
DISOPYRAMIDE PHOSPHATE ▲ Cap 100 mg ▲ Cap 150 mg ELECAINIDE ACETATE – Retail pharmacy-Specialist	(23.87) 26.21	100	 Rythmodan
DISOPYRAMIDE PHOSPHATE ▲ Cap 100 mg ▲ Cap 150 mg ELECAINIDE ACETATE – Retail pharmacy-Specialist ▲ Tab 50 mg	(23.87) 26.21		2
DISOPYRAMIDE PHOSPHATE Cap 100 mg Cap 150 mg Cap 150 mg Cap 150 mg Cap 150 mg Tab 50 mg Tab 100 mg – For flecainide acetate oral liquid formulation	(23.87) 26.21 45.82	100 60	RythmodanTambocor
 DISOPYRAMIDE PHOSPHATE Cap 100 mg Cap 150 mg Cap 150 mg FLECAINIDE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg – For flecainide acetate oral liquid formulation refer, page 184 	(23.87) 26.21 45.82	100 60 60	 Rýthmodan Tambocor Tambocor
DISOPYRAMIDE PHOSPHATE ▲ Cap 100 mg ▲ Cap 150 mg ELECAINIDE ACETATE – Retail pharmacy-Specialist ▲ Tab 50 mg ▲ Tab 100 mg – For flecainide acetate oral liquid formulation refer, page 184 ▲ Cap long-acting 100 mg	(23.87) 26.21 45.82 80.92 45.82	100 60 60 30	 Rythmodan Tambocor Tambocor Tambocor CR
DISOPYRAMIDE PHOSPHATE ▲ Cap 100 mg ▲ Cap 150 mg FLECAINIDE ACETATE – Retail pharmacy-Specialist ▲ Tab 50 mg ▲ Tab 100 mg – For flecainide acetate oral liquid formulation	(23.87) 26.21 45.82 80.92 45.82 	100 60 60	 Rýthmodan Tambocor Tambocor

56

	Subsidy		Fully Brand or
	(Manufacturer's Pr		ubsidised Generic
	\$	Per	 Manufacturer
IEXILETINE HYDROCHLORIDE			
Cap 150 mg	65.00	100	 Mexiletine Hydrochloride USP (\$29)
Cap 250 mg		100	✓ Mexiletine Hydrochloride USP (\$29)
ROPAFENONE HYDROCHLORIDE – Retail pha Tab 150 mg		FO	1 Dutmonorm
J. J		50	 Rytmonorm
Antihypotensives			
IDODRINE - Special Authority see SA0934 belo	ow – Retail pharmacy		
Tab 2.5 mg		100	 Gutron
Tab 5 mg		100	 Gutron
SA0934 Special Authority for Subsidy			
	ses and titrated upwards as neces	ssary.	
head and trunk at night. lotes: Treatment should be started with small dos lypertension should be avoided, and the usual tar tenewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers	ses and titrated upwards as nece rget is a standing systolic blood p	ssary. pressure of 9	90 mm Hg.
head and trunk at night. lotes: Treatment should be started with small dos lypertension should be avoided, and the usual tar tenewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL	es and titrated upwards as nece rget is a standing systolic blood p Is valid for 2 years where the tre	ssary. pressure of 9	90 mm Hg.
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL = Tab 50 mg	es and titrated upwards as nece rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem	90 mm Hg. nains appropriate and the patien
head and trunk at night. totes: Treatment should be started with small dos ypertension should be avoided, and the usual tau enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL Tab 50 mg	es and titrated upwards as nece rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500	90 mm Hg. nains appropriate and the patien <u> V Mylan Atenolol</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL • Tab 50 mg • Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg	eses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL • Tab 50 mg • Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg	eses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of 9 eatment rem 500 500 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tau enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL • Tab 50 mg • Tab 100 mg SOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg Tab 5 mg Tab 10 mg	eses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500 500 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL © Tab 50 mg Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg Tab 10 mg ARVEDILOL	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500 500 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL \leq Tab 50 mg Tab 50 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg Tab 10 mg ARVEDILOL \leq Tab 6.25 mg	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL \vdots Tab 50 mg \vdots Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg Tab 10 mg ARVEDILOL \vdots Tab 6.25 mg \vdots Tab 12.5 mg \vdots Tab 12.5 mg \vdots Tab 12.5 mg \vdots Tab 12.5 mg	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500 500 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL : Tab 50 mg : Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg 	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL • Tab 50 mg • Tab 100 mg • SOPROLOL FUMARATE Tab 2.5 mg • Tab 10 mg • ARVEDILOL • Tab 6.25 mg • Tab 12.5 mg • Tab 12.5 mg • Tab 2.5 mg • Tab 2.5 mg • Tab 12.5 mg • Tab 2.5 mg • T	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tre 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u>
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL • Tab 50 mg · Tab 100 mg · SOPROLOL FUMARATE Tab 2.5 mg · Tab 10 mg · ARVEDILOL • Tab 6.25 mg · Tab 12.5 mg · Tab 12.5 mg · Tab 2.5 mg · Tab	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tree 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend
head and trunk at night. otes: Treatment should be started with small dos ypertension should be avoided, and the usual tar enewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL = Tab 50 mg 	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tree 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend
head and trunk at night. lotes: Treatment should be started with small dos lypertension should be avoided, and the usual tar tenewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL © Tab 50 mg Tab 50 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg Tab 10 mg ARVEDILOL © Tab 6.25 mg Tab 2.5 mg Tab 2.5 mg Tab 2.5 mg Eliperolou © Tab 200 mg ABETALOL	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tree 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend ✓ Dilatrend ✓ Celol
head and trunk at night. lotes: Treatment should be started with small dos lypertension should be avoided, and the usual tar lenewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL € Tab 50 mg € Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 5 mg Tab 10 mg ARVEDILOL € Tab 6.25 mg 5 Tab 25 mg Tab 5.5 mg Tab 5.5 mg Tab 5.5 mg Tab 2.5 mg Fab 6.25 mg € Tab 2.5 mg Fab 2.5 mg <	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tree 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend
head and trunk at night. lotes: Treatment should be started with small dos lypertension should be avoided, and the usual tar lenewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL © Tab 50 mg © Tab 50 mg Tab 100 mg ISOPROLOL FUMARATE Tab 2.5 mg Tab 10 mg	ses and titrated upwards as neces rget is a standing systolic blood p ls valid for 2 years where the tree 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30 30 30 30 3	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend ✓ Dilatrend ✓ Celol ✓ Hybloc
head and trunk at night. lotes: Treatment should be started with small dos lypertension should be avoided, and the usual tar tenewal from any relevant practitioner. Approval enefiting from treatment. Beta Adrenoceptor Blockers TENOLOL © Tab 50 mg © Tab 100 mg BOPROLOL FUMARATE Tab 2.5 mg Tab 10 mg CARVEDILOL Fab 6.25 mg Tab 2.5 mg Tab 10 mg CARVEDILOL Fab 6.25 mg Fab 2.5 mg F	ses and titrated upwards as neces rget is a standing systolic blood p ls valid for 2 years where the tree 	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30 30 180 100	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend ✓ Dilatrend ✓ Celol ✓ Hybloc ✓ Hybloc
head and trunk at night. Jotes: Treatment should be started with small dos Hypertension should be avoided, and the usual tar Renewal from any relevant practitioner. Approval benefiting from treatment. Beta Adrenoceptor Blockers XTENOLOL	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tree	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30 30 180 100 100 100	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend ✓ Dilatrend ✓ Celol ✓ Hybloc
head and trunk at night. Jotes: Treatment should be started with small dos Hypertension should be avoided, and the usual tar Renewal from any relevant practitioner. Approval benefiting from treatment. Beta Adrenoceptor Blockers XTENOLOL	ses and titrated upwards as neces rget is a standing systolic blood p Is valid for 2 years where the tree	ssary. pressure of S eatment rem 500 500 30 30 30 30 30 30 30 30 30 30 180 100	00 mm Hg. nains appropriate and the patien ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ <u>Dilatrend</u> ✓ Dilatrend ✓ Dilatrend ✓ Celol ✓ Hybloc ✓ Hybloc

	Subsidy		Fully Brand or
	(Manufacturer's Price) \$	Per	Subsidised Generic Manufacturer
METOPROLOL SUCCINATE			
* Tab long-acting 23.75 mg		30	Metoprolol - AFT CR
* Tab long-acting 47.5 mg		30	Metoprolol - AFT CR
* Tab long-acting 95 mg		30	Metoprolol - AFT CR
* Tab long-acting 190 mg		30	Metoprolol - AFT CR
METOPROLOL TARTRATE			
* Tab 50 mg - For metoprolol tartrate oral liquid formulation			
refer, page 184		100	Lopresor
* Tab 100 mg		60	✓ Lopresor
* Tab long-acting 200 mg		28	Slow-Lopresor
* Inj 1 mg per ml, 5 ml	24.00	5	✓ Lopresor
NADOLOL			
* Tab 40 mg		100	Apo-Nadolol
* Tab 80 mg		100	Apo-Nadolol
PINDOLOL			-
* Tab 5 mg		100	Apo-Pindolol
* Tab 10 mg		100	✓ Apo-Pindolol
* Tab 15 mg		100	✓ Apo-Pindolol
PROPRANOLOL			
* Tab 10 mg	3 55	100	Cardinol
	3.65	100	✓ Apo-
	0.00		Propranolol S29
* Tab 40 mg		100	✓ Apo-
			Propranolol S29
* Cap long-acting 160 mg		100	Cardinol LA
(Cardinol Tab 10 mg to be delisted 1 July 2013)			
SOTALOL			
 Tab 80 mg – For sotalol oral liquid formulation refer, page 184 	27 50	500	🖌 Mylan
* Tab 160 mg		100	✓ Mylan
* Inj 10 mg per ml, 4 ml		5	✓ Sotacor
TIMOLOL MALEATE			
* Tab 10 mg	10 55	100	✔ Apo-Timol
		100	
Calcium Channel Blockers			
Dihydropyridine Calcium Channel Blockers (DHF	P CCBs)		
AMLODIPINE			
* Tab 2.5 mg	2.45	100	Apo-Amlodipine
 * Tab 5 mg – For amlodipine oral liquid formulation refer, page 		100	· <u>Apo Annoulpino</u>
184		100	Apo-Amlodipine
* Tab 10 mg		100	✓ Apo-Amlodipine
FELODIPINE			<u></u>
* Tab long-acting 2.5 mg	2 00	30	Plendil ER
 * Tab long-acting 5 mg – Brand switch fee payable (Pharma- 	2.00	00	
code 2430231) - see page 182 for details	3 10	30	Plendil ER
* Tab long-acting 10 mg – Brand switch fee payable (Pharma-		00	
code 2430231) - see page 182 for details	4 60	30	✓ Plendil ER
		00	

58

	Subsidy		Fully Brand or
	(Manufacturer's Price \$) Per	Subsidised Generic Manufacturer
	Ψ	1.01	
ISRADIPINE	7 50	00	
* Cap long-acting 2.5 mg		30	✓ Dynacirc-SRO
* Cap long-acting 5 mg		30	Dynacirc-SRO
NIFEDIPINE			4 • • • • • •
* Tab long-acting 10 mg		60	✓ Adalat 10
* Tab long-acting 20 mg		100	 Nyefax Retard Adefin XL
* Tab long-acting 30 mg	0.30	30	 Adenni XL Arrow-Nifedipine XR
	5.50		
	(19.90)		Adalat Oros
* Tab long-acting 60 mg		30	Adefin XL
5 5 5			Arrow-Nifedipine XR
	8.00		
	(29.50)		Adalat Oros
Other Calcium Channel Blockers			
DILTIAZEM HYDROCHLORIDE			
* Tab 30 mg	4.60	100	Dilzem
* Tab 60 mg - For diltiazem hydrochloride oral liquid form			
tion refer, page 184		100	✓ <u>Dilzem</u>
* Cap long-acting 120 mg	4.34	30	Cardizem CD
	31.83	500	Apo-Diltiazem CD
* Cap long-acting 180 mg		30	Cardizem CD
	47.67	500	✓ Apo-Diltiazem CD
* Cap long-acting 240 mg	8.67 63.58	30 500	Cardizem CD
		500	Apo-Diltiazem CD
PERHEXILINE MALEATE – Special Authority see SA1260 be		400	
* Tab 100 mg		100	Pexsig
► SA1260 Special Authority for Subsidy			
Initial application only from a cardiologist or general physici	an. Approvals valid for 2	2 years	for applications meeting the following
criteria: Both:			
1 Patient has refractory angina; and			
2 Patient is on the maximal tolerated dose of a beta-bloc	ker a calcium channel h	locker a	and a long acting nitrate
Renewal only from a cardiologist or any relevant practitioner			
where the treatment remains appropriate and the patient is be			
VERAPAMIL HYDROCHLORIDE	-		
* Tab 40 mg	7.01	100	✓ Isoptin
* Tab 80 mg - For verapamil hydrochloride oral liquid form			
tion refer, page 184		100	✓ Isoptin
* Tab long-acting 120 mg	15.20	250	 Verpamil SR
* Tab long-acting 240 mg		250	Verpamil SR
* Inj 2.5 mg per ml, 2 ml – Up to 5 inj available on a PSO.	7.54	5	✓ Isoptin
Centrally Acting Agents			
CLONIDINE			
* TDDS 2.5 mg, 100 μ g per day – Only on a prescription .		4	Catapres-TTS-1
* TDDS 5 mg, 200 μ g per day – Only on a prescription		4	✓ Catapres-TTS-2
* TDDS 7.5 mg, 300 μ g per day – Only on a prescription .		4	✓ Catapres-TTS-3

	Subsidy		Fully Brand or
	(Manufacturer's F	,	ubsidised Generic
	\$	Per	 Manufacturer
LONIDINE HYDROCHLORIDE			
Fab 25 μ g	19.25	100	Dixarit
ϵ Tab 150 μ g		100	Catapres
for lnj 150 μ g per ml, 1 ml	16.07	5	Catapres
IETHYLDOPA			
F Tab 125 mg	14.25	100	Prodopa
F Tab 250 mg	15.10	100	Prodopa
• Tab 500 mg	23.15	100	Prodopa
Diuretics			
Loop Diuretics			
UMETANIDE			
Tab 1 mg		100	Burinex
inj 500 μg per ml, 4 ml		5	✓ Burinex
		č	
UROSEMIDE Tab 40 mg – Up to 30 tab available on a PSO	10.25	1,000	Diurin 40
Tab 500 mg		50	✓ Urex Forte
tab 500 mg ∉1 Oral lig 10 mg per ml		30 ml OP	✓ Lasix
f forming forming per ml, 25 ml		5	
 Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO 		5	 Frusemide-Claris
Potassium Sparing Diuretics		-	
	00.00		
Oral liq 1 mg per ml		25 ml OP	Biomed
PIRONOLACTONE			
• Tab 25 mg		100	Spirotone
• Tab 100 mg		100	Spirotone
Oral liq 5 mg per ml		25 ml OP	 Biomed
Potassium Sparing Combination Diuretics			
MILORIDE WITH FRUSEMIDE			
Tab 5 mg with frusemide 40 mg	8.63	28	Frumil
MILORIDE WITH HYDROCHLOROTHIAZIDE			
Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	Moduretic
Thiazide and Related Diuretics			
ENDROFLUAZIDE			
Tab 2.5 mg – Up to 150 tab available on a PSO	6.48	500	Arrow-
5			Bendrofluazide
May be supplied on a PSO for reasons other than emerge			
€ Tab 5 mg	9.95	500	✓ <u>Arrow-</u>
			Bendrofluazide
HLOROTHIAZIDE			
		25 ml OP	Biomed
Oral liq 50 mg per ml		25 ml OP	 Biomed
		25 ml OP 30	 Biomed Igroton s29

	Subsidy		Fully Brand or sidised Generic
	(Manufacturer's \$	Price) Sub Per	Manufacturer
IDAPAMIDE			
€ Tab 2.5 mg	2.95	90	Dapa-Tabs
Nitrates			
LYCERYL TRINITRATE			
Tab 600 μ g – Up to 100 tab available on a PSO	8.00	100 OP	Lycinate
Aerosol spray, 400 μ g per dose – Up to 250 dose available			· · · ·
on a PSO		250 dose OP	Glytrin
TDDS 5 mg		30 30	 <u>Nitroderm TTS</u> <u>Nitroderm TTS</u>
TDDS 10 mg		30	V Milloderni 115
OSORBIDE MONONITRATE	17.10	100	41 00
Tab 20 mg		100	✓ <u>Ismo 20</u>
Tab long-acting 40 mg Tab long-acting 60 mg		30 90	✓ <u>Corangin</u> ✓ Duride
		90	Ullue
Sympathomimetics			
DRENALINE			
Inj 1 in 1,000, 1 ml – Up to 5 inj available on a PSO	4.98	5	Aspen Adrenaline
	5.25	Ū	✓ Mayne
Inj 1 in 10,000, 10 ml – Up to 5 inj available on a PSO		5	Mayne
	49.00	10	Aspen Adrenaline
OPRENALINE HYDROCHLORIDE			
Inj 200 μ g per ml, 1 ml		25	
	(135.00)		Isuprel
/asodilators			
MYLNITRITE			
Ampoule, 0.3 ml crushable		12	Destas
	(73.40)		Baxter
YDRALAZINE		_	4 A
Inj 20 mg per ml, 1 ml	25.90	5	Apresoline
INOXIDIL - Special Authority see SA1271 below - Retail pharm	nacy		
Tab 10 mg	70.00	100	Loniten
SA1271 Special Authority for Subsidy			
itial application only from a relevant specialist. Approvals valid			notified where patient has seve
fractory hypertension which has failed to respond to extensive m	nultiple therapi	es.	
ICORANDIL - Special Authority see SA1263 below - Retail pha	armacy		
Tab 10 mg		60	✓ Ikorel
Tab 20 mg		60	Ikorel
SA1263 Special Authority for Subsidy			
itial application only from a cardiologist or general physician.	Approvals valio	d for 2 years for a	applications meeting the follow
teria:			

Both:

1 Patient has refractory angina; and

2 Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate.

Renewal only from a cardiologist or any relevant practitioner on the recommendation of a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy	01	Fully Brand or
	(Manufacturer's Price) \$	Per	osidised Generic Manufacturer
	Ŷ	1.01	
OXYPENTIFYLLINE			
Tab 400 mg		50	
	(42.26)		Trental 400
PAPAVERINE HYDROCHLORIDE			
* Inj 12 mg per ml, 10 ml	73.12	5	🖌 Mayne
Endothelin Receptor Antagonists			
SA0967 Special Authority for Subsidy			
Special Authority approved by the Pulmonary Arterial Hypertensi			
Notes: Application details may be obtained from PHARMAC's we	bsite http://www.phar	mac.govt.	nz or:
The Coordinator, PAH Panel			
PHARMAC, PO Box 10-254, WELLINGTON			
[el: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.	jovi.nz		
AMBRISENTAN - Special Authority see SA0967 above - Retail	. ,		
Tab 5 mg	,	30	Volibris
Tab 10 mg		30	Volibris
BOSENTAN - Special Authority see SA0967 above - Retail pha	rmacy		
Tab 62.5 mg	,	60	Tracleer
Tab 125 mg	4,585.00	60	Tracleer
Phosphodiesterase Type 5 Inhibitors			
Special Authority for Subsidy			
Special Authority approved by the Pulmonary Arterial Hypertensi		maaad	27 AV
Notes: Application details may be obtained from PHARMAC's we		mac.yovi.	11Z UI.
The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON			
FIANMAC, PO Box 10-234, WELLINGTON Fel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.	novt nz		
SILDENAFIL – Special Authority see SA1086 above – Retail pha	,		4.14
Tab 25 mg		4	Viagra
Tab 50 mg		4	Viagra
Tab 100 mg – For sildenafil oral liquid formulation refer, page		4	Cilorro
184	7.45 47.00	4	✔ Silagra✔ Viagra
	47.00		• viagra
Prostacyclin Analogues			
SA0969 Special Authority for Subsidy			
Special Authority approved by the Pulmonary Arterial Hypertensi	on Panel		
lotes: Application details may be obtained from PHARMAC's we		mac.govt.	nz or:
The Coordinator, PAH Panel	<u> </u>	0	_
PHARMAC, PO Box 10-254, WELLINGTON			
Fel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.	govt.nz		
LOPROST – Special Authority see SA0969 above – Retail phar	macy		
Nebuliser soln 10 μ g per ml, 2 ml	,	30	Ventavis

	Subsidy Manufacturer's Pri \$	ice) Su Per	Fully ubsidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials, pa	ge 87			
ADAPALENE	-			
a) Maximum of 30 g per prescription				
b) Only on a prescription				
Crm 0.1%	22.89	30 g OP	🖌 D	ifferin
Gel 0.1%	22.89	30 g OP	🖌 D	ifferin
ISOTRETINOIN - Special Authority see SA0955 below - Retail pha	armacy			
Cap 10 mg	18.71	120	V 0	ratane
Cap 20 mg	28.91	120	V 0	ratane

➡SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and

4 Either:

- 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g - Maximum of 50 g per prescription13.9	0 50 g OP 🖌 ReTrieve
---	-----------------------------

	Subsidy			Brand or
	(Manufacturer's \$	Price) Sui Per		Generic Manufacturer
Antibacterials Topical				
For systemic antibacterials, refer to INFECTIONS, Antibacteria	als, page 87			
FUSIDIC ACID	iis, page or			
Crm 2%	3 25	15 g OP	🖌 Fol	han
a) Maximum of 15 g per prescription	0.20	10 9 01	• 101	
b) Only on a prescription				
c) Not in combination				
Oint 2%	3.25	15 g OP	✔ <u>Fot</u>	<u>oan</u>
 a) Maximum of 15 g per prescription 				
b) Only on a prescription				
c) Not in combination				
HYDROGEN PEROXIDE				
* Crm 1%	8.56	10 g OP		vstacide
(On sets side One 40) to be delivered 4 April 0040)		15 g OP	V Cry	vstaderm
(Crystacide Crm 1% to be delisted 1 April 2013)				
MUPIROCIN				
Oint 2%		15 g OP	-	
a) Oaks as a susceptible	(9.26)		Bac	ctroban
 a) Only on a prescription b) Not in combination 				
,				
SILVER SULPHADIAZINE	10.00			marina
Crm 1%a) Up to 250 g available on a PSO	12.30	50 g OP	V Fla	mazine
b) Not in combination				
Antifungals Topical				
For systemic antifungals, refer to INFECTIONS, Antifungals, p.	age 92			
AMOROLFINE				
a) Only on a prescription				
b) Not in combination	07.06			
Nail soln 5%		5 ml OP	Loc	eryl
	(01.07)		LUU	егуг
 a) Only on a prescription b) Not in combination 				
Nail soln 8%	4 11	3 g OP		
	(19.85)	0 9 01	Bat	rafen
Nail-soln 8%		7 ml OP	= •••	o-Ciclopirox
Soln 1%	4.36	20 ml OP		
	(11.54)		Bat	rafen
(Batrafen Nail soln 8% to be delisted 1 March 2013)				
CLOTRIMAZOLE				
* Crm 1%	0.54	20 g OP	✓ Clo	mazol
a) Only on a prescription				
b) Not in combination				
* Soln 1%		20 ml OP	~	
	(7.55)		Car	nesten
 a) Only on a prescription b) Not in combination 				
b) Not in combination				

	Subsidy (Manufacturer's Price)		Fully Brand or
	(Manufacturer's \$	Price) Sul Per	bsidised Generic Manufacturer
ECONAZOLE NITRATE			
Crm 1%	1.00	20 g OP	
	(7.48)	-	Pevaryl
a) Only on a prescription			
b) Not in combination			
Foaming soln 1%, 10 ml sachets		3	- .
	(17.23)		Pevaryl
a) Only on a prescription			
b) Not in combination			
MICONAZOLE NITRATE	0.40	45 00	
* Crm 2%	0.46	15 g OP	✓ <u>Multichem</u>
a) Only on a prescription			
b) Not in combination * Lotn 2%	1 26	30 ml OP	
* LOUI 2 /0	(10.03)	30 III OF	Daktarin
a) Only on a prescription	(10.00)		Daktarin
b) Not in combination			
* Tinct 2%	4.36	30 ml OP	
	(12.10)		Daktarin
a) Only on a prescription	. ,		
b) Not in combination			
NYSTATIN			
Crm 100,000 u per g	1.00	15 g OP	
	(7.90)	-	Mycostatin
a) Only on a prescription			
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination			
Crm, aqueous, BP	1.77	100 g	Home Essential
		0	Pharmacy Health
	(2.78)		healthE
Lotn, BP	13.45	2,000 ml	✓ <u>PSM</u>
(Home Essential Crm, aqueous, BP to be delisted 1 July 2013) (healthE Crm, aqueous, BP to be delisted 1 February 2013)			
CROTAMITON a) Only on a prescription			
b) Not in combination			
Crm 10%	3 48	20 g OP	✓ Itch-Soothe
		20 9 01	
MENTHOL – Only in combination	wool fat with mine	val oil lation 1	0/ hudrocorticone with wool fot and
Only in combination with aqueous cream, 10% urea cream, mineral oil lotion, and glycerol, paraffin and cetyl alcohol loti		rai uli iuliun, T	
Crystals		25 g	V PSM
	6.92	20 y	✓ MidWest
	29.60	100 g	✓ MidWest
	_0.00		

	Outraid		Fully Prond or
	Subsidy (Manufacturer's F	Price) Sub	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Ocution stansists Tension!			
Corticosteroids Topical			
For systemic corticosteroids, refer to CORTICOSTEROIDS AND	RELATED AGEN	ITS, page 80	
Corticosteroids - Plain			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%	2.96	15 g OP	
	(6.91)		Diprosone
	8.97	50 g OP	
	(18.36)		Diprosone
Crm 0.05% in propylene glycol base	4.33	30 g OP	
	(13.83)		Diprosone OV
Oint 0.05%	2.96	15 g OP	
	(6.51)		Diprosone
	8.97	50 g OP	
	(17.11)		Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	
	(13.83)	-	Diprosone OV
BETAMETHASONE VALERATE			
* Crm 0.1%	3 20	50 g OP	✓ Beta Cream
★ Oint 0.1%		50 g OP	 Beta Oreann Beta Ointment
* Lotn 0.1%		50 g OI 50 ml OP	 Betnovate
		50 111 01	• Delliovale
CLOBETASOL PROPIONATE			
* Crm 0.05%		30 g OP	✓ Dermol
* Oint 0.05%	3.48	30 g OP	 Dermol
CLOBETASONE BUTYRATE			
Crm 0.05%	5.38	30 g OP	
	(7.09)	Ū	Eumovate
	16.13	100 g OP	
	(22.00)	0	Eumovate
DIFLUCORTOLONE VALERATE	(<i>'</i>		
Crm 0.1%	0.07		
GIII 0.1%		50 g OP	Nerisone
Fatty aint 0 10/	(15.86)		Nerisone
Fatty oint 0.1%		50 g OP	Nerisone
	(15.86)		Nelisone
HYDROCORTISONE			
* Crm 1% – Only on a prescription		100 g	Pharmacy Health
	14.00	500 g	Pharmacy Health
Powder – Only in combination		25 g	✓ <u>ABM</u>
Up to 5% in a dermatological base (not proprietary To galenicals. Refer, page 183	pical Corticosterio	od – Plain) witl	h or without other dermatologica
HYDROCORTISONE BUTYRATE			
Lipocream 0.1%		30 g OP	Locoid Lipocream
	6.85	100 g OP	 Locoid Lipocream
Oint 0.1%		100 g OP	
Milky emul 0.1%		100 g OI 100 ml OP	✓ Locoid Crelo
winity GITIULU.170	0.00		

66

	Subsidy (Manufacturer's	Price) Sul	Fully Brand or osidised Generic
	\$	Per	 ✓ Manufacturer
YDROCORTISONE WITH WOOL FAT AND MINERAL OIL			
Lotn 1% with wool fat hydrous 3% and mineral oil – Only or	า		
a prescription		250 ml	DP Lotn HC
ETHYLPREDNISOLONE ACEPONATE			
Crm 0.1%	4.95	15 g OP	Advantan
Oint 0.1%		15 g OP	Advantan
OMETASONE FUROATE		·	
Crm 0.1%		15 g OP	m-Mometasone
	3.42	45 g OP	✓ m-Mometasone
Oint 0.1%	1.78	15 g OP	✓ m-Mometasone
	3.42	45 g OP	m-Mometasone
Lotn 0.1%	7.35	30 ml OP	Elocon
RIAMCINOLONE ACETONIDE			
Crm 0.02%	6.63	100 g OP	✓ Aristocort
Oint 0.02%	6.69	100 g OP	✓ Aristocort
Corticosteroids - Combination			
ETAMETHASONE VALERATE WITH CLIOQUINOL - Only on	aprescription		
Crm 0.1% with clioquinol 3%		15 g OP	
	(4.90)		Betnovate-C
Oint 0.1% with clioquinol 3%		15 g OP	
·	(4.90)	Ū	Betnovate-C
ETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%		15 g OP	
	(10.45)	0	Fucicort
 a) Maximum of 15 g per prescription b) Only on a prescription 			
YDROCORTISONE WITH MICONAZOLE – Only on a prescrip Crm 1% with miconazole nitrate 2%		15 g OP	✓ Micreme H
		Ū	
YDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – O			
Crm 1% with natamycin 1% and neomycin sulphate 0.5% Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP 15 g OP	 Pimafucort Pimafucort
		0	
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI		IN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg			
and gramicidin 250 μ g per g $-$ Only on a prescription		15 g OP	Viaderm KC
	(6.60)		
Disinfecting and Cleansing Agents			
HLORHEXIDINE GLUCONATE – Subsidy by endorsement			
a) No more than 500 ml per month			
b) Only if prescribed for a dialysis patient and the prescription		cordingly.	
Handrub 1% with ethanol 70%		500 ml	✓ <u>healthE</u>
Soln 4%	5.90	500 ml	✓ Orion

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription			
 a) Maximum of 500 mi per prescription b) 			
a) Only if prescribed for a patient identified with M	ethicillin-resistant	Staphylococcus	aureus (MRSA) prior to elective
surgery in hospital and the prescription is endors	ed accordingly; or		
b) Only if prescribed for a patient with recurrent Sta cordinaly	aphylococcus aure	eus infection and	d the prescription is endorsed ac
Soln 1%	4 50	500 ml OP	Pharmacy Health
	5.90		✓ healthE
Barrier Creams and Emollients			
Barrier Creams			
ZINC AND CASTOR OIL			
* Oint BP	3.83	500 g	✓ <u>Multichem</u>
Emollients			
AQUEOUS CREAM			
* Crm	1.96	500 g	✓ <u>AFT</u>
CETOMACROGOL	0.45	500	. (DOM
* Crm BP	3.15	500 g	✓ <u>PSM</u>
EMULSIFYING OINTMENT * Oint BP	2.04	500 g	🖌 AFT
DIL IN WATER EMULSION		500 g	V <u>ALL</u>
* Crm		500 g	✓ healthE Fatty Cream
JREA			· · · · · · · · · · · · · · · · · · ·
* Crm 10%	3.07	100 g OP	✓ Nutraplus
NOOL FAT WITH MINERAL OIL - Only on a prescription			
₭ Lotn hydrous 3% with mineral oil	1.40	250 ml OP	
	(3.50)	4 000	Hydroderm Lotion
	5.60 (9.54)	1,000 ml	Hydroderm Lotion
	(9.34)	250 ml OP	Hydroderni Lolion
	(4.53)		DP Lotion
	5.60	1,000 ml	
	(11.95)		DP Lotion
	(20.53) 1.40	250 ml OP	Alpha-Keri Lotion
	(7.73)		BK Lotion
	5.60	1,000 ml	
	(23.91)		BK Lotion

RAFFIN White soft - Only in combination		Subsidy		Fully Brand o	
RAFFIN White soft – Only in combination 3.58 500 g IPW 20.20 2.500 g ✓ IPW 3.85 500 g S500 g Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain. Alinor Skin Infections DVIDONE IODINE 3.27 25 g OP ✓ Betadine a) Maximum of 100 g per prescription 0.19 15 ml b) Only on a prescription 0.19 15 ml Antiseptic soln 10% (4.45) Betadine (2.20) S00 ml ✓ Betadine (2.80) 00 ml (4.45) Betadine Skin preparation, povidone lodine 10% with 30% alcohol 1.83 100 ml Fieldine Skin preparation, povidone lodine 10% with 70% alcohol 1.83 100 ml Etadine Skin Prep Skin preparation, povidone lodine 10% with 70% alcohol 1.83 100 ml Etadine Skin Prep Skin preparation, povidone lodine 10% with 70% alcohol 1.83 100 ml Etadine Skin Prep Tab 3 mg - Up to 100 tab available on a PSO 3.50 50 g OP Etadine Skin Prep Tab 3 mg - Up to 100 tab available on a PSO 17					
White soft - Only in combination 3.58 500 g IPW (7.78) IPW 3.58 500 g ✓ IPW 3.59 500 g ✓ IPW 3.50 500 g ✓ IPW 3.61 100 ml IPM 4.45) Betadine IPM 6.20 500 ml ✓ Betadine 6.20 500 ml ✓ Betadine 6.20 500 ml Betadine IPM Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (8.25) Betadine Skin Prep ID.000 S00 ml Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (8.26) Orion ✓ Betadine Skin Prep The Mark BENZENE	Other Dermatological Bases				
(7.78) IPW 20.20 2,500 g ✓ IPW 3.58 500 g PSM Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain. Alion Skin Infections DVIDONE IODINE 00int 0%	ARAFFIN				
20.20 2,500 g ✓ IPW 3.58 500 g Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain. Alfnor Skin Infections DVIDONE IODINE Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10% Antiseptic soln 10% (4.45) Betadine 1.28 100 ml (8.20) Betadine 6.20 500 ml 7.81 Betadine 6.20 500 ml 8.31 100 ml (6.44) Betadine Skin preparation, povidone iodine 10% with 30% alcohol 1.63 10.00 500 ml Fetadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 (6.04) Orion 8.13 500 ml Crim Crim .01 19 SKin preparations AMMA BENZENE HEXACHLORIDE Trim Cm1% .3.50 50 g OP 2 bit noi thit tonian use only. Must be endorsed with the name of the institution for which	White soft – Only in combination	3.58	500 g		
3.58 500 g PSM (8.69) PSM Only in combination with a dermatological galenical or as a diuent for a proprietary Topical Corticosteroid – Plain. Alinor Skin Infections VIDONE IODINE Oint 10% Only on a prescription b) Only on a prescription c) Antiseptic soln 10% Antiseptic soln 10% (4.25) Betadine 6.20 500 ml (8.25) Betadine 6.20 500 ml (8.25) Betadine 6.20 500 ml (8.25) Betadine 6.20 6.20 500 ml (8.25) Betadine 6.20 500 ml (8.40) Crion 8.13 500 ml (18.63) Orion 8.13 500 ml (18.63) Orion 8.13 500 g OP Pa		(7.78)		IPW	
(8.69) PSM Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain. Alinor Skin Infections DVIDONE IODINE Oint 10% Only on a prescription b) Only on a prescription c) Only on a prescription b) Only on a prescription Antiseptic soln 10% (8.25) Betadine 1.28 100 ml (4.40) Riodine 6.20 500 ml Skin preparation, povidone iodine 10% with 30% alcohol (16.04) Orion 8.13 500 ml Yestaticidal Preparations AMMA BENZENE HEXACHLORIDE Crm 1%				V IPW	
Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain. Alinor Skin Infections DVIDONE IODINE Oint 10% 3.27 25 g OP ✓ Betadine a) Maximum of 100 g per prescription 0.19 15 ml b) Only on a prescription 1.28 100 ml Betadine 6.20 500 ml ✓ Betadine 1.28 100 ml (8.25) Betadine 6.20 500 ml ✓ Betadine 6.20 500 ml ✓ Betadine Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml 6.20 500 ml ✓ Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml 6.20 500 ml ✓ Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (6.04) Orion 8.13 500 ml (18.63) Orion 7 Petadine Skin Prep Th 3 mg - Up to 100 tab available on a PSO 7.20 4 ✓ Stromectol 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and valid Special Authority for patient of that inst			500 g	5011	
Alinor Skin Infections DVDONE IODINE Oint 10% 3.27 25 g OP ✓ Betadine a) Maximum of 100 g per prescription 0.19 15 ml b) Orly on a prescription 1.28 100 ml Antiseptic soln 10% 1.28 100 ml (4.45) Betadine 1.28 100 ml Betadine (4.20) Filodine 6.20 500 ml ✓ Betadine 1.28 100 ml Betadine (4.20) Filodine 6.20 Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (6.04) Orion Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (18.63) Orion Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (18.63) Orion Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (18.63) Orion Crion 813 500 ml Charasticicidal Preparations 1.63 100 ml	Only in combination with a dermatological galenical or as		orietary Topic		– Plain
DVIDONE IODINE Oint 10% .3.27 25 g OP ✓ Betadine a) Maximum of 100 g per prescription .0.19 15 ml Antiseptic soln 10% .0.19 15 ml (4.45) Betadine 1.28 100 ml (8.25) Betadine 1.28 100 ml (4.40) Riodine 6.20 500 ml 1.28 100 ml (4.20) Riodine 6.20 500 ml Skin preparation, povidone iodine 10% with 30% alcohol .1.63 (3.65) Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol .1.63 (6.04) Orion 8.13 500 ml (18.63) Orion 8.13 500 ml (18.63) Orion 8.13 50 g OP ✓ Benhex ERMECTIN – Special Authority see SA1225 below – Retail pharmacy Tab 3 mg – Up to 100 tab available on a PSO. .17.20 4 ✓ Stromectol 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and valid Special Authority fo		a andone for a pro	priotary ropic		
Oint 10%					
a) Maximum of 100 g per prescription b) Only on a prescription Antiseptic soln 10%		0.07	ac 00		
b) Only on a prescription Antiseptic soln 10%			25 g OP	Betadine	
Antiseptic soln 10%	, , , , , , , , , , , , , , , , , , , ,				
(4.45) Betadine 1.28 100 ml (8.25) Betadine 6.20 500 ml ✓ Betadine 1.28 100 ml (4.20) Riodine 6.20 500 ml ✓ Riodine 5.40 6.20 500 ml ✓ Riodine 6.20 500 ml ✓ Riodine (5.20 Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (6.40) (6.04) 0 ml (6.04) Orion (8.13) 500 ml Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (8.64) Orion (8.63) 0 ml (8.64) Orion (8.13) 500 ml Crimetal Crm 1%		0.10	15 ml		
1.28 100 ml (8.25) Betadine 6.20 500 ml ✓ Betadine 1.28 100 ml Riodine 6.20 500 ml ✓ Riodine 6.20 500 ml Ø (6.04) 0 Doin (8.63) Orion Ø 8.13 500 ml Orion 8.13 500 ml Orion 2 rasiticidal Preparations 3.50 50 g OP AMMA BENZENE HEXACHLORIDE Tras 3 mg - Up to 100 tab available on a PSO		(· · · - ·	15 111	Botadino	
(8.25) Betadine 6.20 500 ml 1.28 100 ml (4.20) Riodine 6.20 500 ml Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (3.65) Betadine Skin Prep 10.00 500 ml ✓ Betadine Skin Prep 10.00 500 ml (6.04) Orion 8.13 500 ml (18.63) Orion Parasiticidal Preparations 3.50 50 g OP ✓ Benhex ERMECTIN - Special Authority see SA1225 below – Retail pharmacy Tab 3 mg – Up to 100 tab available on a PSO		· · ·	100 ml	Detaume	
6.20 500 ml ✓ Betadine 1.28 100 ml Riodine 6.20 500 ml ✓ Riodine 8kin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (3.65) Betadine Skin Prep 10.00 500 ml Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (6.04) Orion 8.13 500 ml (18.63) Orion 8.13 500 ml (18.63) Orion Parasiticidal Preparations 3.50 50 g OP ✓ Benhex ERMECTIN - Special Authority see SA1225 below – Retail pharmacy Tab 3 mg – Up to 100 tab available on a PSO. 17.20 4 ✓ Stromectol 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and vailable on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. Special Authority for Subsidy titial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting			100 111	Betadine	
(4.20) Riodine 6.20 500 ml ✓ Riodine Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (3.65) 10.00 500 ml ✓ Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (6.04) (8.13 500 ml Orion 2 2 Parasiticidal Preparations (18.63) Orion 2 AMMA BENZENE HEXACHLORIDE		. ,	500 ml	 Betadine 	
6:20 500 ml ✓ Riodine Skin preparation, povidone iodine 10% with 30% alcohol 1.63 100 ml (3.65) Betadine Skin Prep 10.00 500 ml ✓ Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (6.04) Orion 8.13 500 ml Verasiticidal Preparations Orion 8.13 500 g OP AMMA BENZENE HEXACHLORIDE Trab 3 mg – Up to 100 tab available on a PSO 17.20 4 ✓ Stromectol 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and valid Special Authority for patient of that institution. 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability carefacilities or penal institutions. >SA1225] Special Authority for Subsidy Special Special Authority for Subsidy tital application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followiteria: 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and 2 Either: 2.1 Both: <td></td> <td>1.28</td> <td>100 ml</td> <td></td> <td></td>		1.28	100 ml		
Skin preparation, povidone iodine 10% with 30% alcohol		(4.20)		Riodine	
(3.65) Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (6.04) Orion 8.13 500 ml Orion (18.63) Orion 8.13 500 ml (18.63) Orion Orion 0 Parasiticidal Preparations 0 0 0 AMMA BENZENE HEXACHLORIDE 0 0 0 Crm 1% 3.50 50 g OP ✓ Benhex ERMECTIN – Special Authority see SA1225 below – Retail pharmacy 17.20 4 ✓ Stromectol 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and valiable on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 2) lvermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions. *SA1225 Special Authority for Subsidy Ital application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followiteria: orbiologist; and 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease p		6.20	500 ml	Riodine	
10.00 500 ml ✓ Betadine Skin Prep Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml Orion (6.04) 0 0 0 0 8.13 500 ml 0 0 0 0 Parasiticidal Preparations 0 <td>Skin preparation, povidone iodine 10% with 30% alcohol</td> <td></td> <td>100 ml</td> <td></td> <td></td>	Skin preparation, povidone iodine 10% with 30% alcohol		100 ml		
Skin preparation, povidone iodine 10% with 70% alcohol 1.63 100 ml (6.04) Orion 8.13 500 ml (18.63) Orion Parasiticidal Preparations AMMA BENZENE HEXACHLORIDE (18.63) Crm 1%		· · ·	500 1		
 (6.04) Orion 8.13 500 ml Orion Parasiticidal Preparations AMMA BENZENE HEXACHLORIDE Crm 1%	Okin proportion, polyidana jadina 100/ with 700/ alashal			 Betadine 	Skin Prep
8.13 500 ml (18.63) Orion Parasiticidal Preparations AMMA BENZENE HEXACHLORIDE Crm 1%	Skin preparation, povidone todine 10% with 70% alcohol		100 mi	Orion	
(18.63) Orion Parasiticidal Preparations AMMA BENZENE HEXACHLORIDE Crm 1%		()	500 ml	Onon	
 AMMA BENZENE HEXACHLORIDE Crm 1%			000 111	Orion	
 AMMA BENZENE HEXACHLORIDE Crm 1%	Parasiticidal Preparations				
 Crm 1%					
 ERMECTIN - Special Authority see SA1225 below - Retail pharmacy Tab 3 mg - Up to 100 tab available on a PSO			50 a OP	Benhex	
 Tab 3 mg - Up to 100 tab available on a PSO					
 PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and valid Special Authority for patient of that institution. Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability car facilities or penal institutions. Special Authority for Subsidy tital application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followiteria: Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and Either: 2.1 Both: 			4	Stromecto	h
 valid Special Authority for patient of that institution. 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions. *SA1225 Special Authority for Subsidy tital application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followiteria: attention: 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical recrobiologist; and 2 Either: 2.1 Both: 	5 I		-		
 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution. 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions. SA1225 Special Authority for Subsidy itial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followiteria: 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical recobiologist; and 2 Either: 2.1 Both: 					lo required and
 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or penal institutions. *SA1225 Special Authority for Subsidy tital application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following terra: th: Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical recrobiologist; and Either: 2.1 Both: 			ial Authority f	or a patient of the	e institution.
 SA1225 Special Authority for Subsidy itial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followi teria: th: 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and 2 Either: 2.1 Both: 					
 itial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the followi teria: applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and 2 Either: 2.1 Both: 	facilities or penal institutions.				
 tteria: ath: Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and 2 Either: 2.1 Both: 	SA1225 Special Authority for Subsidy				
 a Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and 2 Either: 2.1 Both: 	itial application — (Scabies) from any relevant practitioner.	Approvals valid for	r 1 month for	applications mee	eting the followir
 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical r crobiologist; and Either: 2.1 Both: 	iteria:				
crobiologist; and 2 Either: 2.1 Both:	oth:				
2 Either: 2.1 Both:		s with a dermatolo	gist, infectiou	is disease physic	an or clinical n
2.1 Both:	6				
continued.	2.1 DUII.				continued
					continueu.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1.1 The patient is in the community; and
- 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
- 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy;
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.
- Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 Filaricides; or
 - 2 Cutaneous larva migrans (creeping eruption); or
 - 3 Strongyloidiasis.

	Subsidy (Manufacturer's \$		sidised	Brand or Generic Manufacturer
MALATHION				
Liq 0.5%		200 ml OP	🖌 🖌	ices
Shampoo 1%	2.83	30 ml OP	🖌 🖌	ices
PERMETHRIN				
Crm 5%	4.20	30 g OP	🖌 Lyc	derm
Lotn 5%	3.24	30 ml OP		Scabies
Psoriasis and Eczema Preparations				
ACITRETIN - Special Authority see SA0954 below - Retail pharm	acy	100		

	100	 Neotigason Novatretin
30.00	60	
	60	Novatretin
85.40	100	 Neotigason
	35.95 38.66 83.11 85.40	38.66 60 83.11 60

➡SA0954 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if actiretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if actiretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Oint 500 μ g with calcipotriol 50 μ g	30 g OP 30 g OP	DaivobetDaivobet
CALCIPOTRIOL	5	
Crm 50 μ g per g	30 g OP	Daivonex
45.00	100 g OP	Daivonex
Oint 50 μg per g45.00	100 g OP	Daivonex
Soln 50 μg per ml	30 ml OP	Daivonex
COAL TAR		
Soln BP – Only in combination12.95	200 ml	✓ <u>Midwest</u>

Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain, refer, page 183 With or without other dermatological galenicals.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic ✓ Manufacturer
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULF	PHUR		
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and			
allantoin crm 2.5%	3.43	30 g OP	
	(4.35)		Egopsoryl TA
	6.59	75 g OP	
	(8.00)		Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR			4 a . a .
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	Coco-Scalp
SALICYLIC ACID			
Powder – Only in combination		250 g	✓ PSM
1) Only in combination with a dermatological base or p	proprietary Topica	al Corticosteroio	d – Plain or collodion flexible, refe
page 183			
 With or without other dermatological galenicals. Maximum 20 g or 20 ml per prescription when pres 	cribed with white	soft naraffin o	r collodion flexible
SULPHUR		, son paramit 0	
Precipitated – Only in combination	6.35	100 g	✓ Midwest
1) Only in combination with a dermatological base or			
2) With or without other dermatological galenicals.			
AR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLU	ORESCEIN - O) nlv on a prescr	iption
Soln 2.3% with triethanolamine lauryl sulphate and fluores		,	
cein sodium		500 ml	✓ Pinetarsol
	5.82	1,000 ml	✓ Pinetarsol
Scalp Preparations			
BETAMETHASONE VALERATE			
₭ Scalp app 0.1%	7.22	100 ml OP	🖌 Beta Scalp
CLOBETASOL PROPIONATE			
₭ Scalp app 0.05%	6.36	30 ml OP	Dermol
YDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	3.65	100 ml OP	✓ Locoid
ETOCONAZOLE			
Shampoo 2%	3.08	100 ml OP	✓ Sebizole
a) Maximum of 100 ml per prescription			• <u>Sebizore</u>
b) Only on a prescription			
Sunscreens			
Sunscieens			
SUNSCREENS, PROPRIETARY – Subsidy by endorsement			
Only if prescribed for a patient with severe photosensitivity	secondary to a	defined clinica	I condition and the prescription i
endorsed accordingly.			
Crm	(= = = =)	100 g OP	Liser lines C
l eta	(5.89)		Hamilton Sunscreen
Lotn	2.55	100 ml OP	 Marine Blue Lotion SPF 30+
	5.10	200 ml OP	Marine Blue Lotion
	5.10	200 111 012	SPF 30+
	3.19	125 ml OP	
	(6.94)		Aguasun 30+
	()		

72

DERMATOLOGICALS

	<u></u>			
	Subsidy (Manufacturer's Pr	rice) Sub	Fully Bran sidised Gene	
	\$	Per		ufacturer
Wart Preparations				
For salicylic acid preparations refer to PSORIASIS AND ECZEM/	A PREPARATIONS	S, page 71		
IMIQUIMOD – Special Authority see SA0923 below – Retail pha Crm 5%		12	✓ <u>Aldara</u>	
 SA0923 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Any of the following: The patient has external anogenital warts and podophyllot The patient has external anogenital warts and podophyllot The patient has external anogenital warts and podophyllot The patient has confirmed superficial basal cell carcinoma contraindicated or inappropriate. Notes: Superficial basal cell carcinoma Surgical excision remains first-line treatment for superficial and allows histological assessment of tumour clearance. Imiquimod has not been evaluated for the treatment of s nose, mouth or ears. Imiquimod is not indicated for recurrent, invasive, infiltratin External anogenital warts Imiquimod is only indicated for external genital and periam Renewal from any relevant practitioner. Approvals valid for 4 mor Any of the following: 	oxin has been trie oxin is unable to b where other stan I basal cell carcino uperficial basal co g, or nodular basa al warts (condylon nths for applicatior	d and failed (applied acc dard treatmer oma as it has ell carcinoma al cell carcinon na acuminata	or is contraind surately to the tts, including s a higher cure within 1 cm o ma.	icated); or site; or surgical excision, are rate than imiquimod of the hairline, eyes,
 Inadequate response to initial treatment for anogenital war New confirmed superficial basal cell carcinoma where othe cated or inappropriate; or Inadequate response to initial treatment for superficial bass Note: Every effort should be made to biopsy the lesion to confirm PODOPHYLLOTOXIN Soln 0.5% a) Maximum of 3.50 ml per prescription 	er standard treatm al cell carcinoma. that it is a superf			
b) Only on a prescription Other Skin Preparations				
Antineoplastics				
FLUOROURACIL SODIUM Crm 5%	25.16	20 g OP	🖌 Efudix	
Topical Analgesia				
For aspirin & chloroform application refer, page 187 CAPSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia or accordingly. Crm 0.075%		al neuropathy 45 g OP	and the pres	
Wound Management Products				
-				
MAGNESIUM SULPHATE * Paste	2.98 (4.90)	80 g	PSM	

	-	Subsidy		Fully	Brand or
		(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
•	ontraceptives - Non-hormonal	-			
'	ontraceptives - Non-nonnonal				
)	ondoms				
С	NDOMS				
ł	49 mm – Up to 144 dev available on a PSO	13.36	144		arquisTantiliza hield 49
-	52 mm – Up to 144 dev available on a PSO	13.36	144	🖌 M	arquis Selecta arquis Sensolite arquis Supalite
ŧ	52 mm extra strength - Up to 144 dev available on a PSO		144		arquis Protecta
	53 mm - Up to 144 dev available on a PSO	1.11	12	🖌 SI	hield Blue
		13.36	144	🖌 SI	hield Blue
		1.11	12	🖌 G	old Knight
		13.36	144	🖌 M	old Knight arquis Black arquis Titillata
ŧ	53 mm (chocolate) – Up to 144 dev available on a PSO	1 11	12		old Knight
•		13.36	144		old Knight
÷	53 mm (strawberry) - Up to 144 dev available on a PSO		12		old Knight
•		13.36	144		old Knight
-	53 mm extra strength – Up to 144 dev available on a PSO		12		old Knight
		13.36	144		old Knight
-	54 mm, shaped – Up to 144 dev available on a PSO		144	₽ G	
	54 mm, shapeu – Op to 144 dev available off a FSO		12	1.5	footuloo Elorod
		(1.24) 13.36	144	LI	festyles Flared
			144	13	factulas Flored
,	EE mm	(14.84)	144		festyles Flared
	55 mm – Up to 144 dev available on a PSO				arquis Conforma
~	56 mm – Up to 144 dev available on a PSO		12		old Knight
		13.36	144	V Di	old Knight urex Extra Safe urex Select Flavours
ŧ	56 mm, shaped - Up to 144 dev available on a PSO	1.11	12	🖌 D	urex Confidence
		13.36	144	🖌 D	urex Confidence
ł	60 mm - Up to 144 dev available on a PSO	13.36	144	🖌 SI	hield XL
С	ontraceptive Devices				
IA	PHRAGM – Up to 1 dev available on a PSO One of each size is permitted on a PSO.				
÷	65 mm		1	V 0	rtho All-flex
	70 mm		1		rtho All-flex
	75 mm		1		rtho All-flex
-	80 mm		1	V 0	rtho All-flex
11	RA-UTERINE DEVICE a) Up to 40 dev available on a PSO				
÷	b) Only on a PSO IUD		1		ultiload Cu 375
				🖌 M	ultiload Cu 375 SL

74

Subsidy		Fully	Bi
(Manufacturer's Price)	Su	bsidised	G
\$	Por	~	Μ

Brand or Generic Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 μg with desogestrel 150 μg6.62 (16.50)	63	Mercilon 21
	a) Higher subsidy of \$13.80 per 63 tab with Special Authority see SA050	0 above	
	b) Up to 63 tab available on a PSO		
*	Tab 20 μ g with desogestrel 150 μ g and 7 inert tab	84	
	(16.50)		Mercilon 28
	 a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA050 b) Up to 84 tab available on a PSO 	0 above	
*	Tab 30 μ g with desogestrel 150 μ g6.62	63	
	(16.50)		Marvelon 21
	 a) Higher subsidy of \$13.80 per 63 tab with Special Authority see SA050 b) Up to 63 tab available on a PSO 	0 above	
*	Tab 30 μ g with desogestrel 150 μ g and 7 inert tab6.62 (16.50)	84	Marvelon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA050	0 above	

b) Up to 84 tab available on a PSO

9.45 6.62 (16.50) we SA0500 on the 2.45 182 for details 6.62	84 63 e preceding 84 63	ן pag ע <u>ו</u>	Ava 30 ED
6.62 (16.50) the SA0500 on the 2.45 182 for details 6.62	63 e precedinç 84	ן pag ע <u>ו</u>	Microgynon 30 e Ava 30 ED
6.62 (16.50) the SA0500 on the 2.45 182 for details 6.62	63 e precedinç 84	ן pag ע <u>ו</u>	Microgynon 30 e Ava 30 ED
(16.50) ee SA0500 on the 2.45 182 for details 6.62	e preceding 84	9 pag ✓ <u>1</u>	e Ava 30 ED
e SA0500 on the 2.45 182 for details 6.62	84	9 pag ✓ <u>1</u>	e Ava 30 ED
2.45 182 for details 6.62	84	<u>v</u> <u>1</u>	Ava 30 ED
182 for details		-	
182 for details		-	
6.62	63	•	
	63	~	
	63	•	
	63	1	
6 60			Brevinor 1/21
6.60			
6.62	84	V	Brevinor 1/28
6.62	63	V	Brevinor 21
0.00			la das la
6.62	84	V	Norimin
	84	,	Jaria 1/00
()	o procedine		Norinyl-1/28
e SAUSUU on ine	e preceding	j pag	е
	84	V <u> </u>	Ava 20 ED
182 for details			
e	6.62 (13.80) ee SA0500 on th 2.95 e 182 for details	(13.80) ee SA0500 on the preceding 2.95 84	(13.80) I ee SA0500 on the preceding pag 2.95 84 V

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

continued...

	Subsidy (Manufacturer's Pri \$	ice) Sul Per	Fully Brand or bsidised Generic Manufacturer
continued Special Authorities approved before 1 November 1999 remain va are still either: • on a Social Welfare benefit; or	lid until the expiry o	date and can	be renewed providing that wom
have an income no greater than the benefit. The approval numbers of Special Authorities approved before 1 bined oral contraceptives and progestogen-only contraceptives g			· · · ·
LEVONORGESTREL * Tab 30 μg	6.62 (16.50)	84	Microlut
 a) Higher subsidy of \$13.80 per 84 tab with Special Authors b) Up to 84 tab available on a PSO 	prity see SA0500 or	n the preced	
* Subdermal implant (2 × 75 mg rods) MEDROXYPROGESTERONE ACETATE	133.65	1	✓ <u>Jadelle</u>
* Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a P NORETHISTERONE	SO7.15	1	 Depo-Provera
 Tab 350 μg – Up to 84 tab available on a PSO Emergency Contraceptives 	6.00	84	✓ <u>Noriday 28</u>
LEVONORGESTREL			
 * Tab 1.5 mga) Maximum of 2 tab per prescription b) Up to 5 tab available on a PSO 	12.50	1	Postinor-1
* Tab 750 μ g	12.50	2	✓ Next Choice
Antiandrogen Oral Contraceptives			
Prescribers may code prescriptions "contraceptive" (code "O") w prescription charge will be as per other contraceptives, as follow. • \$5.00 prescription charge (patient co-payment) will apply. • prescription may be written for up to six months supply.	S:		
Prescriptions coded in any other way are subject to the non cor of supply. ie. Prescriptions may be written for up to three months CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL		tion charges	, and the non-contraceptive peri-
* Tab 2 mg with ethinyloestradiol 35 μ g and 7 inert tabs	3.89	84	✓ Ginet 84
Gynaecological Anti-infectives			
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC Jelly with glacial acetic acid 0.94%, hydroxyquinoline su phate 0.025%, glycerol 5% and ricinoleic acid 0.75% wit	-		
applicator		100 g OP	Aci-Jel
CLOTRIMAZOLE * Vaginal crm 1% with applicators * Vaginal crm 2% with applicators		35 g OP 20 g OP	✓ <u>Clomazol</u> ✓ <u>Clomazol</u>
MICONAZOLE NITRATE * Vaginal crm 2% with applicator	2.75 (4.10)	40 g OP	Micreme

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	osidised Generic ✔ Manufacturer
NYSTATIN			4
Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓ Nilstat
Myometrial and Vaginal Hormone Preparations			
RGOMETRINE MALEATE Inj 500 μg per ml, 1 ml – Up to 5 inj available on a PSO	31.00	5	✓ DBL Ergometrine
DESTRIOL Crm 1 mg per g with applicator		15 g OP	✓ Ovestin
✤ Pessaries 500 µg	6.53	15	 Ovestin
XYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml		5	Syntocinon
Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml		5 5	 Syntocinon Syntometrine
Pregnancy Tests - hCG Urine	_	a.	
REGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO			
b) Only on a PSO Cassette	22.80	40 test OP	 Innovacon hCG One Step Pregnancy Test
Urinary Agents	j		
or urinary tract Infections refer to INFECTIONS, Antibacterials, p	age 102		
5-Alpha Reductase Inhibitors			
INASTERIDE – Special Authority see SA0928 below – Retail ph ≰ Tab 5 mg	•	30	✓ <u>Rex Medical</u>
SA0928 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid ne following criteria: Both:	l without further	r renewal unles	s notified for applications meetin
1 Patient has symptomatic benign prostatic hyperplasia; and 2 Either:			d
 2.1 The patient is intolerant of non-selective alpha block 2.2 Symptoms are not adequately controlled with non-selective alpha block Patients with enlarged prostates are the appropriate candidated 	elective alpha b	lockers.	
Alpha-1A Adrenoreceptor Blockers			
AMSULOSIN HYDROCHLORIDE – Special Authority see SA10 ∉ Cap 400 μg		ail pharmacy 30	✓ Tamsulosin-Rex
SA1032 Special Authority for Subsidy itial application from any relevant practitioner. Approvals valid e following criteria:		r renewal unles	
oth:			

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

	Subsidy (Manufacturer's P	rice) Sub	Fully	Brand or Generic
	(Manulacturer 31	Per	<i>v</i>	Manufacturer
Other Urinary Agents				
DXYBUTYNIN				
₭ Tab 5 mg		500		oo-Oxybutynin
₭ Oral liq 5 mg per 5 ml	50.40	473 ml	V Ap	oo-Oxybutynin
POTASSIUM CITRATE				
Oral liq 3 mmol per ml – Special Authority see SA1083 below				
- Retail pharmacy		200 ml OP	V BI	omed
Salution of the second	for 10 months for	opplications r	nooting	the following criteria:
nitial application from any relevant practitioner. Approvals valid Both:	IOF 12 MONUNS IOF	applications r	neeling	the following chiena:
1 The patient has recurrent calcium oxalate urolithiasis; and				
2 The patient has had more than two renal calculi in the two	years prior to the	application.		
Renewal from any relevant practitioner. Approvals valid for 2 ye	ars where the tr	eatment remai	ins appr	opriate and the patient
enefitting from the treatment.				
SODIUM CITRO-TARTRATE				
 Grans eff 4 g sachets 	2.71	28	🖌 <u>Ur</u>	al
SOLIFENACIN SUCCINATE - Special Authority see SA0998 belo	ow – Retail pharr	nacy		
Tab 5 mg		30		sicare
Tab 10 mg	56.50	30	Ve Ve	esicare
SA0998 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals vali	id without further	r renewal unle	ss notifi	ed where the patient ha
overactive bladder and a documented intolerance of oxybutynin.				
OLTERODINE – Special Authority see SA1272 below – Retail p		56		row-Tolterodine
Tab 1 mg Tab 2 mg		56		row-Tolterodine
►SA1272 Special Authority for Subsidy		50	• 1	Tow-Tonerodine
itial application from any relevant practitioner. Approvals valid	without further re	newal unless	notified	where natient has overa
ive bladder and a documented intolerance of oxybutynin.			notinou	intere patient nae evera
Detection of Substances in Urine				
Detection of Substances in Orme				
DRTHO-TOLIDINE				
Compound diagnostic sticks		50 test OP		
	(8.25)		He	emastix
ETRABROMOPHENOL				
 Blue diagnostic strips 	7.02	100 test OP		

Albustix

(13.92)

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Sub Per	sidised Generic Manufacturer
Corticosteroids and Related Agents for Systemic	c Use		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHAS		-	
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml		5	Celestone Chronodose
DEXAMETHASONE ₭ Tab 1 mg – Retail pharmacy-Specialist Up to 30 tab available on a PSO	5.87	100	✓ Douglas
 Tab 4 mg - Retail pharmacy-Specialist Up to 30 tab available on a PSO 	8.16	100	✓ Douglas
Oral liq 1 mg per ml – Retail pharmacy-Specialist Oral lig prescriptions:	45.00	25 ml OP	 Biomed
 Must be written by a Paediatrician or Paediatric Carc On the recommendation of a Paediatrician or Paedia 	0		
EXAMETHASONE SODIUM PHOSPHATE Dexamethasone sodium phosphate injection will not be funde	d for oral use		
 Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO 		5	✓ Hospira
Inj 4 mg per ml, 2 ml − Up to 5 inj available on a PSO		5	✓ Hospira
LUDROCORTISONE ACETATE			
CODROCONTISONE ACETATE Cab 100 μg	14.32	100	✓ Florinef
	14.0L	100	
YDROCORTISONE Tab 5 mg	9 10	100	
	0.10	100	Douglas
 Tab 20 mg – For hydrocortisone oral liquid formulation refer, page 184 	20 32	100	V Douglas
⊊ Inj 50 mg per ml, 2 ml		1	Solu-Cortef
a) Up to 5 inj available on a PSO b) Only on a PSO		·	
IETHYLPREDNISOLONE – Retail pharmacy-Specialist			
← Tab 4 mg		100	✓ Medrol
F Tab 100 mg		20	✓ Medrol
ETHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml	6 70	1	Depo-Medrol
1 01 /	0.70	·	
IETHYLPREDNISOLONE ACETATE WITH LIGNOCAINE Inj 40 mg per ml with lignocaine 1 ml	7.50	1	Depo-Medrol with
		1	Lidocaine
	nov Crossialist		Eldocame
ETHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharm Inj 40 mg per ml, 1 ml		1	✓ Solu-Medrol
Inj 62.5 mg per ml, 2 ml		1	Solu-Medrol
Inj 500 mg		1	Solu-Medrol
Inj 1 g		1	Solu-Medrol
REDNISOLONE SODIUM PHOSPHATE			
 Cral liq 5 mg per ml – Up to 30 ml available on a PSO	10.45	30 ml OP	Redipred

(Subsidy Manufacturer's Price) \$	Su Per	Fully ubsidised	Brand or Generic Manufacturer
PREDNISONE				
* Tab 1 mg	10.68	500	🖌 A	po-Prednisone
* Tab 2.5 mg		500		po-Prednisone
* Tab 5 mg – Up to 30 tab available on a PSO		500		po-Prednisone
* Tab 20 mg	29.03	500	✓ A	po-Prednisone
TETRACOSACTRIN				
st Inj 250 μ g		10		ynacthen
k Inj 1 mg per ml, 1 ml	29.56	1	✓ <u>s</u>	ynacthen Depot
RIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml	21.90	5	<u>к</u>	enacort-A
Inj 40 mg per ml, 1 ml	53.79	5	✓ <u>K</u>	enacort-A40
Sex Hormones Non Contraceptive				
Androgen Agonists and Antagonists				
CYPROTERONE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg	18.80	50	✓ <u>s</u>	iterone
Tab 100 mg	34.25	50	✓ <u>s</u>	iterone
ESTOSTERONE				
Transdermal patch, 2.5 mg per day	80.00	60	🗸 A	ndroderm
ESTOSTERONE CYPIONATE – Retail pharmacy-Specialist				
Inj long-acting 100 mg per ml, 10 ml	76.50	1		epo-Testosterone
			• •	
ESTOSTERONE ESTERS – Retail pharmacy-Specialist Inj 250 mg per ml, 1 ml	12.09	1		ustanon Ampoules
	12.90	I	¥ 3	ustanon Ampoules
TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist				
Cap 40 mg		60		Indriol Testocaps
Inj 250 mg per ml, 4 ml	86.00	1	V H	eandron 1000

Hormone Replacement Therapy - Systemic

➡SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least $2 \times$ normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

	Subsidy (Manufacturer's Pr \$	rice) Sul Per	Fully Brand or bsidised Generic ✓ Manufacturer
Oestrogens			
ESTRADIOL – See prescribing guideline on the preceding patholic section of	age		
 Tab 1 mg 		28 OP	
	(10.55)		Estrofem
€ Tab 2 mg	4.12	28 OP	
	(10.55)		Estrofem
ϵ TDDS 25 μ g per day		8	
	(10.86)		Estradot
a) Higher subsidy of \$10.86 per 8 patch with Special Au	thority see SA1018	on the preced	ding page
b) No more than 2 patch per week			
c) Only on a prescription			
 TDDS 3.9 mg (releases 50 μg of oestradiol per day) 		4	0.11
	(13.18)		Climara 50
	(32.50)		Femtran 50
 a) Higher subsidy of \$13.18 per 4 patch with Special Au b) No more than 1 patch per week c) Only on a prescription 	thority see SA1018	on the preced	ding page
ϵ TDDS 50 μ g per day	4.12	8	
	(13.18)	U U	Estradot 50 μ g
 a) Higher subsidy of \$13.18 per 8 patch with Special Au b) No more than 2 patch per week c) Only on a prescription TDDS 7.8 mg (releases 100 µg of oestradiol per day) 		on the preced	ding page
· · · · · · · · · · · · · · · · ·	(16.14)		Climara 100
	(35.00)		Femtran 100
 a) Higher subsidy of \$16.14 per 4 patch with Special Au b) No more than 1 patch per week c) Only on a prescription 		·	ding page
TDDS 100 μg per day		8	-
	(16.14)		Estradot
 a) Higher subsidy of \$16.14 per 8 patch with Special Au b) No more than 2 patch per week c) Only on a prescription 		on the preced	aing page
ESTRADIOL VALERATE – See prescribing guideline on the	010		
Tab 1 mg		56	Progynova
Fab 2 mg	8.24	56	Progynova
ESTROGENS – See prescribing guideline on the preceding	bage		
 Conjugated, equine tab 300 μg 		28	
	(11.48)		Premarin
Conjugated, equine tab 625 µg	4.12	28	
	(11.48)		Premarin
Progestogens			
EDROXYPROGESTERONE ACETATE - See prescribing gui	ideline on the prece	dina page	
 Tab 2.5 mg 		30	Provera
 Tab 5 mg 		100	✓ Provera
← Tab 10 mg		30	Provera

82

Subsidy (Manufacturer's Price \$	e) Sub Per	Fully Brand or osidised Generic Manufacturer
tions		
deline on page 81		
	28 OP	Kliovance
	28 OP	Kliogest
5.40 (14.52)	28 OP	Trisequens
	n page 81	
5.40 (22.96)	28 OP	Premia 2.5 Continuous
5.40 (22.96)	28 OP	Premia 5 Continuous
17.60	100	✓ <u>NZ Medical and</u> Scientific
7.00	30	✓ Ovestin
	1	🗸 Mirena
eding; and		r. Approvals valid for 6 months f eutical therapies as per the Hea
	(14.52) 5.40 (14.52) cribing guideline or 5.40 (22.96) 	(14.52) 5.40 28 OP (14.52) cribing guideline on page 81 5.40 28 OP (22.96) 28 OP (22.96) 29 OP (22.96) 20 OP (22.96)

- 3 Either:
 - 3.1 serum ferritin level $< 16 \,\mu$ g/l (within the last 12 months); or
 - 3.2 haemoglobin level < 120 g/l.
- Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

continued...

	Subsidy (Manufacturer's Price \$) Su Per	Fully ubsidised	Brand or Generic Manufacturer
continued				
Renewal only from a relevant specialist or general practitioner. Ap	provals valid for 6 r	months fo	r applicat	ions meeting the following
criteria:				
Both:				
1 Either:	manatrial blanding	~		
 1.1 Patient demonstrated clinical improvement of heavy 1.2 Previous insertion was removed or expelled within 3 	0.			
2 Applicant to state date of the previous insertion.		, anu		
MEDROXYPROGESTERONE ACETATE				
* Tab 100 mg - Retail pharmacy-Specialist	96 50	100		rovera
 * Tab 200 mg – Retail pharmacy-Specialist 		30		rovera
		00	• •	
NORETHISTERONE * Tab 5 mg – Up to 30 tab available on a PSO	26 50	100		rimolut N
5 1		100	<u>v</u> <u>P</u>	rimolut N
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg		100	🖌 N	eo-Mercazole
LEVOTHYROXINE				
* Tab 25 μ g	3.89	90	V S	vnthroid
	43.24	1,000		ynthroid
‡ Safety cap for extemporaneously compounded oral liquid	preparations.	,		
* Tab 50 μg		28	🖌 G	oldshield
	4.05	90		ynthroid
	45.00	1,000		ynthroid
	64.28		🖌 E	Itroxin
\$ Safety cap for extemporaneously compounded oral liquid		00		aldahiald
* Tab 100 μg		28 90		oldshield
	66.78	90 1,000		ynthroid Itroxin
‡ Safety cap for extemporaneously compounded oral liquid		1,000	₩ L	
PROPYLTHIOURACIL – Special Authority see SA1199 below – R				
Tab 50 mg		100	• P	TU S29
ing			÷ 1	

SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 The patient has hyperthyroidism; and

2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

➡SA1279 Special Authority for Subsidy

Special Authority approved by the Growth Hormone Committee

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

NZGHC Coordinator

PHARMAC, PO Box 10-254, WELLINGTON

Tel: 0800 808 476, Fax: (09) 929 3221, Email: growthhormone@pharmac.govt.nz

	Subsidy	-) 01	Fully Brand or
	(Manufacturer's Price \$	e) Suc Per	sidised Generic ✓ Manufacturer
COMATROPIN - Special Authority and SA1970 on the precede			
SOMATROPIN – Special Authority see SA1279 on the precedi * Inj cartridge 16 iu (5.3 mg)		1	✓ Genotropin
 * Inj cartridge 10 la (3.5 mg) * Inj cartridge 36 iu (12 mg) 		1	Genotropin
GnRH Analogues		I	
-			
	100.00		
Inj 3.6 mg Inj 10.8 mg		1 1	 ✓ Zoladex ✓ Zoladex
, ,		I	
LEUPRORELIN			<i></i>
Inj 3.75 mg		1	✓ Lucrin Depot
Inj 3.75 mg prefilled syringe		1	Lucrin Depot PDS
Inj 7.5 mg		1	Eligard
Inj 11.25 mg Inj 11.25 mg prefilled syringe		1 1	 Lucrin Depot Lucrin Depot PDS
Inj 22.5 mg		1	Eligard
Inj 30 mg		1	✓ Eligard
Inj 30 mg prefilled syringe		1	 Lucrin Depot PDS
Inj 45 mg		1	Eligard
Vasopressin Agonists			J
DESMOPRESSIN			
Nasal drops 100 μg per ml – Retail pharmacy-Specialist		2.5 ml OP	 Minirin
 Nasal spray 10 µg per dose – Retail pharmacy-Specialist. 	27.48	6 ml OP	Desmopressin-
lai A successi A set - Occasi d'A disarity and OA0000 had			<u>PH&T</u>
Inj 4 μ g per ml, 1 ml – Special Authority see SA0090 bel	OW		
Botail pharmany	67 10	10	Minirin
– Retail pharmacy	67.18	10	🖌 Minirin
SA0090 Special Authority for Subsidy			
►SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals			
SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops.	valid for 2 years where	e the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals of spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2	valid for 2 years where	e the patien	t cannot use desmopressin nasa
►SA0090 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals y spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment.	valid for 2 years where	e the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals of spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2	valid for 2 years where	e the patien	t cannot use desmopressin nasa
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals of spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents 	valid for 2 years where	e the patien	t cannot use desmopressin nasa
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals y spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE 	valid for 2 years where ? years where the trea	e the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals of spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can	valid for 2 years where ? years where the trea be	e the patien	t cannot use desmopressin nasa
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals y spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE 	valid for 2 years where 2 years where the trea be 6.25	e the patien tment rema	t cannot use desmopressin nasa ins appropriate and the patient i
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below	valid for 2 years where ? years where the trea be	e the patien	t cannot use desmopressin nasa
 →SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below →SA1031 Special Authority for Waiver of Rule	valid for 2 years where 2 years where the trea be 	e the patien tment rema 2 8	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u>
 →SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg - Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below →SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist	valid for 2 years where e years where the treat be 6.25 25.00 or gynaecologist. Ap	e the patien tment rema 2 8	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u>
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg - Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ▶SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist	valid for 2 years where e years where the treat be 6.25 25.00 or gynaecologist. Ap	e the patien tment rema 2 8 oprovals val	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ▶SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia.	valid for 2 years where 2 years where the trea be 	e the patien tment rema 2 8 oprovals val without furf	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 ⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ⇒SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which 	valid for 2 years where 2 years where the trea be 	e the patien tment rema 2 8 oprovals val without furf	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals vispray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg - Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ▶SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. 	valid for 2 years where 2 years where the trea be 	e the patien tment rema 2 8 oprovals val without furf	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 ⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals vispray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg - Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below >SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. 	valid for 2 years where e years where the treat be 6.25 25.00 or gynaecologist. Ap logist. Approvals valid has expired and the tr	2 2 8 oprovals val without furf reatment re	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher mains appropriate and the patier
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below >>SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist of the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg	valid for 2 years where e years where the treat be 6.25 25.00 or gynaecologist. Ap logist. Approvals valid has expired and the tr	e the patien tment rema 2 8 oprovals val without furf	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 ⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below >>SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist other patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist	valid for 2 years where e years where the treat be 	2 8 oprovals val without furfreatment re	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher mains appropriate and the patier <u>Serophene</u>
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals v spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg - Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist otified from an obstetrician, endocrinologist rotified from treatment. CLOMIPHENE CITRATE 	valid for 2 years where 2 years where the treat be 	2 2 8 oprovals val without furf reatment re	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher mains appropriate and the patier

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
METYRAPONE Cap 250 mg – Retail pharmacy-Specialist		50	M	etopirone

	Subsidy (Manufacturer's P	rice) Su	Fully Brand or bsidised Generic
	\$	Per	Manufacturer
Anthelmintics			
MEBENDAZOLE – Only on a prescription			
Tab 100 mg	24.19	24	✓ <u>De-Worm</u>
Oral liq 100 mg per 5 ml	2.18	15 ml	
	(7.17)		Vermox
Antibacterials			
 a) For topical antibacterials, refer to DERMATOLOGICALS, page b) For anti-infective eye preparations, refer to SENSORY ORGAN 			
Cephalosporins and Cephamycins			
CEFACLOR MONOHYDRATE			
Cap 250 mg	24.57	100	Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml	3.53	100 ml	Ranbaxy-Cefaclor
CEFAZOLIN SODIUM – Subsidy by endorsement			
Only if prescribed for dialysis or cystic fibrosis patient and the		ndorsed acco	rdingly.
Inj 500 mg		5	✓ <u>AFT</u>
Inj 1 g		5	✓ <u>AFT</u>
CEFOXITIN SODIUM - Retail pharmacy-Specialist - Subsidy by			
Only if prescribed for dialysis or cystic fibrosis patient and the			
lnj 1 g		5	Mayne
CEFTRIAXONE SODIUM – Subsidy by endorsement			
a) Up to 5 inj available on a PSOb) Subsidised only if prescribed for a dialysis or cystic fibro	osis nationt or th	a traatmant c	of confirmed ciproflovacin-resistant
gonorrhoea, or the treatment of suspected meningitis in patie			
PSO is endorsed accordingly.			
Inj 500 mg	2.70	1	Veracol
Inj 1 g	10.49	5	Aspen Ceftriaxone
CEFUROXIME AXETIL – Subsidy by endorsement			
Only if prescribed for prophylaxis of endocarditis and the pre			
Tab 250 mg	29.40	50	 Zinnat
CEFUROXIME SODIUM			
Inj 250 mg – Maximum of 3 inj per prescription; can be waived			4
by endorsement		10	✓ Mayne
Waiver by endorsement must state that the prescription is Inj 750 mg – Maximum of 1 inj per prescription; can be waived		stic tibrosis pa	ment.
by endorsement		5	m-Cefuroxime
Waiver by endorsement must state that the prescription is			
Inj 1.5 g - Retail pharmacy-Specialist - Subsidy by endorse			
ment		1	✓ Mylan
Only if proparihad for dialysis or ovatic fibracia patient and	4.04 the proceription i	c andoraad a	✓ Zinacef
Only if prescribed for dialysis or cystic fibrosis patient and	i the prescription I	s enuorsed a	corungiy.
CEPHALEXIN MONOHYDRATE Cap 500 mg	8 00	20	Cephalexin ABM
Grans for oral lig 125 mg per 5 ml		20 100 ml	Cefalexin Abi
Grans for oral liq 250 mg per 5 ml		100 ml	 Cefalexin Sandoz

	Subsidy (Manufacturer's F \$	Price) Su Per	Fully Brand or Ibsidised Generic ✔ Manufacturer
Macrolides			
AZITHROMYCIN Maximum of 5 days treatment per prescription; can be waived For Endorsement, patient has either: i) Received a lung transplant and requires treatment or proph ii) Cystic fibrosis and has chronic infection with Pseudomonas	ylaxis for bronch	niolitis oblitera	ans syndrome *; or
Indications marked with * are Unapproved Indications Tab 250 mg Tab 500 mg – Up to 8 tab available on a PSO		30 2 2 OP	 ✓ Apo-Azithromycin ✓ Apo-Azithromycin ✓ Arrow-Azithromycin
Grans for oral liq 200 mg per 5 ml	6.60	15 ml	Zithromax
CLARITHROMYCIN – Maximum of 500 mg per prescription; can Tab 250 mg Grans for oral liq 125 mg per 5 ml ⇒SA1131 Special Authority for Waiver of Rule Initial application – (Mycobacterial infections) only from a res	4.19 23.12	14 70 ml	 ✓ <u>Apo-Clarithromycin</u> ✓ Klacid
Either: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug-rr Renewal — (Mycobacterial infections) only from a respiratory si valid for 2 years where the treatment remains appropriate and the ERYTHROMYCIN ETHYL SUCCINATE To h do may Lib a 20 the precisible are a BSO	pecialist, infection patient is benefi	ous disease sp	pecialist or paediatrician. Approva
Tab 400 mg – Up to 30 tab available on a PSO Grans for oral liq 200 mg per 5 ml – Up to 200 ml available			
on a PSO Grans for oral liq 400 mg per 5 ml – Up to 200 ml available		100 ml	 E-Mycin
on a PSO	5.85	100 ml	E-Mycin
ERYTHROMYCIN LACTOBIONATE Inj 1 g	10.93	1	 Erythrocin IV
ERYTHROMYCIN STEARATE Tab 250 mg – Up to 30 tab available on a PSO		100	ERA
Tab 500 mg	(22.29) 29.90 (44.58)	100	ERA
ROXITHROMYCIN	(/		
Tab 150 mg	7.48	50	✓ <u>Arrow-</u> Roxithromycin
Tab 300 mg	14.40	50	✓ <u>Arrow-</u> Roxithromycin

	Subsidy (Manufacturer's		Fully Brand or osidised Generic
Penicillins	\$	Per	 Manufacturer
AMOXYCILLIN Cap 250 mg – Up to 30 cap available on a PSO Cap 500 mg		500 500	✓ <u>Alphamox</u> ✓ <u>Alphamox</u>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO Grans for oral lig 250 mg per 5 ml – Up to 200 ml available	1.55	100 ml	 Ospamox
on a PSO	1 10	100 ml	Ospamox
Drops 125 mg per 1.25 ml		30 ml OP	 Ospamox Paediatric Drops
Inj 250 mg		10	✓ Ibiamox
Inj 500 mg	15.08	10	V Ibiamox
Inj 1 g – Up to 5 inj available on a PSO	21.94	10	✓ Ibiamox
AMOXYCILLIN CLAVULANATE			
Tab amoxycillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO		100	Curam Duo
Grans for oral liq amoxycillin 125 mg with potassium clavu- lanate 31.25 mg per 5 ml - Up to 200 ml available on a			- <u> </u>
PSO	1.61	100 ml	Augmentin
	(2.20)		Curam
Grans for oral liq amoxycillin 250 mg with potassium clavu- lanate 62.5 mg per 5 ml – Up to 200 ml available on a			
PSO		100 ml	 Augmentin
	(3.85)		Curam
(Curam Grans for oral liq amoxycillin 125 mg with potassium clavu (Curam Grans for oral liq amoxycillin 250 mg with potassium clavu		01	. ,
BENZATHINE BENZYLPENICILLIN			
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO	315.00	10	Bicillin LA
BENZYLPENICILLIN SODIUM (PENICILLIN G)			
Inj 600 mg – Up to 5 inj available on a PSO	11.50	10	✓ Sandoz
FLUCLOXACILLIN SODIUM			
Cap 250 mg – Up to 30 cap available on a PSO	22.00	250	✓ <u>Staphlex</u>
Cap 500 mg	74.00	500	✓ <u>Staphlex</u>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available			
on a PSO	2.49	100 ml	✓ <u>AFT</u>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available	0.05	100 1	()
on a PSO		100 ml 10	✓ <u>AFT</u>
Inj 250 mg Inj 500 mg		10	 ✓ <u>Flucloxin</u> ✓ Flucloxin
Inj 500 mg Inj 1 g – Up to 5 inj available on a PSO		10	✓ Flucloxin
		10	
PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO		10	 Bicillin LA

	Subsidy		Fully	Brand or
	(Manufacturer's P		bsidised	Generic
	\$	Per	~	Manufacturer
PHENOXYMETHYLPENICILLIN (PENICILLIN V)		_		
Cap potassium salt 250 mg - Up to 30 cap available on a PSC		50		Cilicaine VK
Cap potassium salt 500 mg	11.70	50	<u> </u>	Cilicaine VK
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO	1 60	100 ml		ACT
Grans for oral lig 250 mg per 5 ml – Up to 200 ml available	1.00	100 111	• 1	<u>AFT</u>
on a PSO	1.78	100 ml	~	4FT
PROCAINE PENICILLIN			• -	
Inj 1.5 mega u – Up to 5 inj available on a PSO	123.50	5	~	Cilicaine
		0	• -	<u>enrounio</u>
Tetracyclines				
DOXYCYCLINE HYDROCHLORIDE				
₭ Tab 50 mg – Up to 30 tab available on a PSO	2.90	30		
	(6.00)			Doxy-50
* Tab 100 mg – Up to 30 tab available on a PSO	7.95	250		Doxine
/INOCYCLINE HYDROCHLORIDE				
₭ Tab 50 mg		60		Alexandra I.
₭ Cap 100 mg	(12.05)	100	I	Vino-tabs
Cap 100 mg	19.32 (52.04)	100	ı	Vinomycin
Other Antibiotics	(02:0.)			
For topical antibiotics, refer to DERMATOLOGICALS, page 64				
CIPROFLOXACIN Tab 250 mg – Up to 5 tab available on a PSO	2.20	28		Cipflox
Tab 500 mg – Up to 5 tab available on a PSO		28		Cipflox
Tab 750 mg – Retail pharmacy-Specialist		28	-	Cipflox
CLINDAMYCIN			-	<u> </u>
Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip-				
tion; can be waived by endorsement - Retail pharmacy -				
Specialist	9.90	16	~	Clindamycin ABM
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-			-	
Specialist	160.00	10	1	Dalacin C
O-TRIMOXAZOLE				
₭ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg -				
Up to 30 tab available on a PSO	20.97	500	v .	Frisul
✤ Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg				
per 5 ml – Up to 200 ml available on a PSO	2.15	100 ml	v 1	Deprim
COLISTIN SULPHOMETHATE - Retail pharmacy-Specialist - Sub				
Only if prescribed for dialysis or cystic fibrosis patient and the p				
Inj 150 mg	65.00	1		Colistin-Link
USIDIC ACID	a 4 = -			
Tab 250 mg – Retail pharmacy-Specialist	34.50	12	v 1	Fucidin
Inj 500 mg sodium fusidate per 10 ml - Retail pharmacy-	10.07	4		
Specialist – Subsidy by endorsement		1	1	Fucidin
Only if prescribed for a dialysis or cystic fibrosis patient and		is endorsed		

Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

	Subsidy (Manufacturer's Price)	Si	Fully bsidised	Brand or Generic
	(Manulastalor or 1100) \$	Per	V	Manufacturer
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml – Subsidy by endorsement		5	🖌 M	
Only if prescribed for a dialysis or cystic fibrosis patient	or for prophylaxis of en	docardit	is and th	e prescription is endorsed
accordingly. Inj 40 mg per ml, 2 ml – Subsidy by endorsement	6 50	10	V P	lizor
Only if prescribed for a dialysis or cystic fibrosis patient accordingly.				
INCOMYCIN – Retail pharmacy-Specialist				
Inj 300 mg per ml, 2 ml		5	🖌 Li	ncocin
MOXIFLOXACIN – Special Authority see SA1065 below – Retai No patient co-payment payable				
Tab 400 mg		5	🖌 A	velox
SA1065 Special Authority for Subsidy				
nitial application only from a respiratory specialist or infectio neeting the following criteria:	us disease specialist.	Approv	als valid	for 1 year for applications
Either:				
1 Both:				
 Active tuberculosis*; and Any of the following: 				
1.2.1 Documented resistance to one or more first	lina madications: or			
1.2.2 Suspected resistance to one or more first-lin	,	ulocic a	sournod t	a be contracted in an area
with known resistance), as part of regimen				
1.2.3 Impaired visual acuity (considered to preclu			101113, 01	
1.2.4 Significant pre-existing liver disease or hepa	<i>,,</i>		dications	: or
1.2.5 Significant documented intolerance and/or				
2 Mycobacterium avium-intracellulare complex not respond	ing to other therapy or			
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref				
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6).	fer to Section A: Gener	ral Rules	s, Part I (Interpretations and Defini-
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (reli ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease	fer to Section A: Gener	ral Rules	s, Part I (Interpretations and Defini-
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6).	fer to Section A: Gener	ral Rules	s, Part I (Interpretations and Defini-
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. TOBRAMYCIN	fer to Section A: Gener specialist. Approvals v	ral Rules	s, Part I (I year wh	nterpretations and Defini- ere the treatment remains
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and	fer to Section A: Gener specialist. Approvals v 	ral Rules ralid for ⁻ 5	s, Part I (I year wh ⁄ <u>D</u>	Interpretations and Defini- ere the treatment remains BL Tobramycin
 2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. FOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and TRIMETHOPRIM 	fer to Section A: Gener specialist. Approvals v 	ral Rules ralid for ⁻ 5 dorsed a	s, Part I (I year wh ✓ <u>D</u> ccordingl	Interpretations and Defini- ere the treatment remains BL Tobramycin y.
2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement	fer to Section A: Gener specialist. Approvals v 	ral Rules ralid for ⁻ 5	s, Part I (I year wh ⁄ <u>D</u>	Interpretations and Defini- ere the treatment remains BL Tobramycin y.
 2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (reli ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and TRIMETHOPRIM 	fer to Section A: Gener specialist. Approvals v 	ral Rules ralid for ⁻ 5 dorsed a 50	s, Part I (I year wh <u> </u>	Interpretations and Defini- ere the treatment remains <u>BL Tobramycin</u> y. MP
 2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and TRIMETHOPRIM * Tab 300 mg – Up to 30 tab available on a PSO VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or in 	fer to Section A: Gener specialist. Approvals v 	ral Rules ralid for ⁻ 5 dorsed a 50	s, Part I (I year wh <u> </u>	Interpretations and Defini- ere the treatment remains <u>BL Tobramycin</u> y. MP
 2 Mycobacterium avium-intracellulare complex not respond Note: Indications marked with * are Unapproved Indications (ref ions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment. TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and TRIMETHOPRIM * Tab 300 mg – Up to 30 tab available on a PSO VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement 	fer to Section A: Gener specialist. Approvals v 	ral Rules ralid for ⁻ 5 dorsed a 50	s, Part I (I year wh <u> </u>	Interpretations and Defini- ere the treatment remains BL Tobramycin y. MP colitis or for prophylaxis of

	Subsidy (Manufacturer's I \$	Price) S Per	Fully Subsidised	Brand or Generic Manufacturer
Antifungals				
 a) For topical antifungals refer to DERMATOLOGICALS, page 64 b) For topical antifungals refer to GENITO URINARY, page 77 	ļ			
FLUCONAZOLE				
Cap 50 mg – Retail pharmacy-Specialist		28		
Cap 150 mg – Subsidy by endorsement		1 toil nhormor		<u>)zole</u>
 a) Maximum of 1 cap per prescription; can be waived by e b) Patient has vaginal candida albicans and the practitior 				
recommended and the prescription is endorsed according				
Cap 200 mg – Retail pharmacy-Specialist		28 28	lilenii - 11e ✔ 0	
Powder for oral suspension 10 mg per ml – Special Authority		20	• •	2010
see SA1148 below – Retail pharmacy		35 ml	V D	liflucan
			• -	
 SA1148 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both: Patient requires prophlaxis for, or treatment of systemic ca Patient is unable to swallow capsules. Renewal from any relevant practitioner. Approvals valid for 6 wee Both: 	andidiasis; and		Ū	,
 Patient requires prophlaxis for, or treatment of systemic ca Patient is unable to swallow capsules. 	andidiasis; and			
ITRACONAZOLE – Retail pharmacy-Specialist				
Cap 100 mg	4.25	15	🖌 lt	razole
KETOCONAZOLE				
Tab 200 mg – Retail pharmacy-Specialist	38 12	30	V N	lizoral
		00	•	
NYSTATIN Tab 500.000 u	14.10	50	. / N	lilatet
Cap 500,000 u		50 50		l <u>ilstat</u> lilstat
		50	• <u>N</u>	liistat
POSACONAZOLE - Special Authority see SA1285 below - Reta				
Oral liq 40 mg per ml	761.13	105 ml OF	V N	loxafil
►>SA1285 Special Authority for Subsidy	se specialist. App	provals valid	for 6 weel	ks for applications meeting
Initial application only from a haematologist or infectious diseas the following criteria: Either:				

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

	Subsidy (Manufacturer's P	rice) Su	Fully Brand or Ibsidised Generic
	\$	Per	 Manufacturer
ERBINAFINE			
Tab 250 mg – For terbinafine oral liquid formulation reference	ſ,		
page 184	1.78	14	Dr Reddy's
			Terbinafine
ORICONAZOLE – Special Authority see SA1273 below – Reta			
Tab 50 mg		56	✓ Vfend
Tab 200 mg	,	56	Vfend
Powder for oral suspension 40 mg per ml		70 ml	Vfend
 SA1273 Special Authority for Subsidy nitial application — (invasive fungal infection) only from a happrovals valid for 3 months for applications meeting the following: Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: Patient has proven or probable invasive aspergillus	g criteria: fectious disease s infection; or or d Scedosporium s logist, infectious c	specialist; and	d
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 	r probable invasive invasive aspergillu	e aspergillus is infection; o	infection; or
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar 	r probable invasive invasive aspergillu	e aspergillus is infection; o	infection; or
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven or 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. an 	r probable invasive invasive aspergillu	e aspergillus is infection; o	infection; or
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. an Antimalarials YDROXYCHLOROQUINE SULPHATE 	r probable invasive invasive aspergillu d Scedosporium s	e aspergillus s infection; o spp.	infection; or r
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg 	r probable invasive invasive aspergillu d Scedosporium s	e aspergillus is infection; o	infection; or
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg 	r probable invasive invasive aspergillu d Scedosporium s	e aspergillus s infection; o spp.	infection; or r
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. an Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg 	r probable invasive invasive aspergillu d Scedosporium s	e aspergillus s infection; o spp.	infection; or r
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. an Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg Antitrichomonal Agents 	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus s infection; o spp.	infection; or r
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. an Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg 	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100	infection; or r ✔ <u>Plaquenil</u>
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg Antitrichomonal Agents IETRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO. 	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg Antitrichomonal Agents IETRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg ETRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 100 ml	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole ✓ FlagyI-S
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg ETRONIDAZOLE Tab 200 mg – Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 100 ml	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole ✓ FlagyI-S
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg ETRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 100 ml 10	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole ✓ FlagyI-S ✓ FlagyI
1 Patient is immunocompromised; and 2 Applicant is part of a multidisciplinary team including an ir 3 Any of the following: 3.1 Patient continues to require treatment for proven or 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg — Antitrichomonal Agents ETRONIDAZOLE Tab 200 mg – Up to 30 tab available on a PSO Tab 400 mg Oral liq benzoate 200 mg per 5 ml Suppos 500 mg RNIDAZOLE Tab 500 mg Antituberculotics and Antileprotics ote: There is no co-payment charge for all pharmaceuticals lis	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 ml 10 10	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole ✓ FlagyI-S ✓ FlagyI ✓ Arrow-Ornidazole
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg Antitrichomonal Agents HETRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 ml 10 10	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole ✓ FlagyI-S ✓ FlagyI ✓ Arrow-Ornidazole
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an ir Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. ar Antimalarials MYDROXYCHLOROQUINE SULPHATE Tab 200 mg Antitrichomonal Agents METRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 ml 10 10 10 erculotics an	infection; or r
 2 Applicant is part of a multidisciplinary team including an ir 3 Any of the following: 3.1 Patient continues to require treatment for proven of 3.2 Patient continues to require treatment for possible 3.3 Patient continues to require treatment for possible 3.3 Patient has fluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. an Antimalarials YDROXYCHLOROQUINE SULPHATE Tab 200 mg METRONIDAZOLE Tab 200 mg Up to 30 tab available on a PSO	r probable invasive invasive aspergillu d Scedosporium s 	e aspergillus is infection; o spp. 100 100 100 ml 10 10	infection; or r ✓ <u>Plaquenil</u> ✓ Trichozole ✓ Trichozole ✓ FlagyI-S ✓ FlagyI ✓ Arrow-Ornidazole

	Subsidy (Manufacturer's Price))	Full Subsidise	
	\$	Per	v	Manufacturer
ETHAMBUTOL HYDROCHLORIDE - No patient co-payment pay				
Tab 100 mg		56		Myambutol
Tab 400 mg		56	V	Myambutol
ISONIAZID – Retail pharmacy-Specialist				
No patient co-payment payable				
* Tab 100 mg		100	-	PSM
* Tab 100 mg with rifampicin 150 mg		100		Rifinah
* Tab 150 mg with rifampicin 300 mg		100	V	Rifinah
PYRAZINAMIDE – Retail pharmacy-Specialist				
No patient co-payment payable				
 * Tab 500 mg – For pyrazinamide oral liquid formulation refer, 		100		
page 184		100	v	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist				
No patient co-payment payable				
* Cap 150 mg – For rifabutin oral liquid formulation refer, page 184		30	~	Mycobutin
		30		wycobulin
RIFAMPICIN – Retail pharmacy-Specialist				
No patient co-payment payable	114.40	30		Rifadin
 ✤ Tab 600 mg ✤ Cap 150 mg 		30 100		Rifadin
* Cap 300 mg		100		Rifadin
* Oral lig 100 mg per 5 ml		60 ml		Rifadin
	2.00		·	
Antivirals				
For eye preparations refer to Eye Preparations, Anti-Infective Prep	parations, page 178			
Hepatitis B Treatment				
ADEFOVIR DIPIVOXIL - Special Authority see SA0829 below -	Retail pharmacy			
Tab 10 mg	670.00	30	~	Hepsera
SA0829 Special Authority for Subsidy				
Initial application only from a gastroenterologist or infectious dise	ease specialist. Appr	ovals v	alid for 1	vear for applications meeting
he following criteria:				,
All of the following:				
1 Patient has confirmed Hepatitis B infection (HBsAg+); and				
Documented resistance to lamivudine, defined as:				
2 Patient has raised serum ALT (> 1 \times ULN); and				
3 Patient has HBV DNA greater than 100,000 copies per mL	, or viral load \geq 10 f	old ove	er nadir; a	nd
4 Detection of M204I or M204V mutation; and				
5 Either:				
5.1 Both:				
5.1.1 Patient is cirrhotic; and	uith Iomivudino: or			
5.1.2 adefovir dipivoxil to be used in combination w5.2 Both:	vitri lattivuulite; or			
5.2 Dotti. 5.2.1 Patient is not cirrhotic; and				
5.2.2 adefovir dipivoxil to be used as monotherapy.				
Renewal only from a gastroenterologist or infectious disease sp		alid fo	r 2 years	where in the opinion of th
tracting physician tractment remains appropriate and patient is h			_ ,	· · · · · · · · · · · · · · · · · · ·

treating physician, treatment remains appropriate and patient is benefiting from treatment.

continued...

30

Baraclude

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

i) raised serum ALT (> 1 \times ULN); and

ii) HBV DNA greater than 100,000 copies per mL, or viral load \geq 10 fold over nadir; and

iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children.

ENTECAVIR - Special Authority see SA0977 below - Retail pharmacy

SA0977 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and
- 3 Entecavir dose 0.5 mg/day; and

4 Either:

- 4.1 ALT greater than upper limit of normal; or
- 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and

5 Either:

5.1 HBeAg positive; or

5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and

6 No continuing alcohol abuse or intravenous drug use; and

- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

 Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).

• Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA0832 below - Retail pharmacy

Tab 100 mg		28	 Zetlam
-	(143.00)		Zeffix
Oral liq 5 mg per ml		240 ml	Zeffix
(Zoffix Tab 100 mg to be deligted 1 March 2012)			

(Zeffix Tab 100 mg to be delisted 1 March 2013)

SA0832 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria: Both:

1 Any of the following:

1.1 All of the following:

continued...

Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 1.1.1 HBsAg positive for more than 6 months; and
- 1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and
- 1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology clinical/radiological evidence of cirrhosis; or
- 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or
- 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 2 All of the following:
 - 2.1 No continuing alcohol abuse or intravenous drug use; and
 - 2.2 Not coinfected with HCV or HDV; and
 - 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and
 - 2.4 No history of hypersensitivity to lamivudine; and
 - 2.5 No previous lamivudine therapy with genotypically proven lamivudine resistance.

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
 - 1.1 Have maintained continuous treatment with lamivudine; and
 - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
 - 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or
 - Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine
- 2 All of the following:
 - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
 - 2.2 Patient is cirrhotic; and
 - Documented resistance to lamivudine, defined as:
 - 2.3 Patient has raised serum ALT (> 1 \times ULN); and
 - 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 2.5 Detection of M204I or M204V mutation; or

Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

- 3 All of the following:
 - 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and
 - Documented resistance to adefovir, defined as:
 - 3.2 Patient has raised serum ALT (> 1 $\times\,$ ULN); and
 - 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR

* Tab dispersible 200 mg 1.98 * Tab dispersible 400 mg 6.64 * Tab dispersible 800 mg 7.38	25 56 35	✓ <u>Lovir</u> ✓ <u>Lovir</u> ✓ <u>Lovir</u>
VALACICLOVIR – Special Authority see SA0957 on the next page – Retail pharmacy Tab 500 mg102.72	30	✓ Valtrex

	INFECTIONS -	AGENT	SFOR	SYSTEMIC USE
	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
⇒SA0957 Special Authority for Subsidy Initial application — (recurrent genital herpes) from an has genital herpes with 2 or more breakthrough episodes in Renewal — (recurrent genital herpes) from any medical appropriate and the patient is benefiting from treatment. Initial application — (ophthalmic zoster) from any med where the patient has previous history of ophthalmic zoster Initial application — (CMV prophylaxis) from any medical	n any 6 month period while practitioner. Approvals va ical practitioner. Approval r and the patient is at risk	e treated lid for 12 s valid w of vision	with acicle months with without furth	ovir 400 mg twice daily. here the treatment remain her renewal unless notifie it.
undergone organ transplantation. VALGANCICLOVIR – Special Authority see SA1274 below Tab 450 mg		60		/alcyte
Initial application — (Lung transplant cytomegalovirus months for applications meeting the following criteria: Both: 1 Patient has undergone a lung transplant; and 2 Either: 2.1 The donor was cytomegalovirus positive and				
 2.2 The recipient is cytomegalovirus positive. Initial application — (Cytomegalovirus in immunocomp months for applications meeting the following criteria: Both: Patient is immunocompromised; and 	romised patients) only f	rom a rel	evant spec	cialist. Approvals valid for
 Patient is infinition of the following: Any of the following: 2.1 Patient has cytomegalovirus syndrome or tiss 2.2 Patient has rapidly rising plasma CMV DNA i 2.3 Patient has cytomegalovirus retinitis. 				
Renewal — (Cytomegalovirus in immunocompromised for applications meeting the following criteria: Both:	patients) only from a rel	levant sp	ecialist. A	pprovals valid for 3 month
1 Patient is immunocompromised; and				

- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE - Subsidy by endorsement; can be waived by Special Authority see SA1047 on the next page

Endorsement for treatment of HIV/AIDS: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1025 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1025, page 99

Viread

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

►SA1047 Special Authority for Waiver of Rule

Initial application — (Confirmed Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased $\geq~$ 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Initial application — (Pregnant) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Either:
 - 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
 - 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent Pregnancy) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative
 prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	ubsidised	Generic
\$	Per	V	Manufacture

Antiretrovirals

➡SA1025 Special Authority for Subsidy

Initial application — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:

2.3.1 Patient aged 1 to 5 years; and

- 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
- 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 350 cells/mm³.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Prevention of maternal foetal transmission; or

2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
 - 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Either:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

continued...

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsidi	sed	Generic
\$	Per	~	Manufacturer

continued...

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

1 Treatment course to be initiated within 72 hours post exposure; and

2 Either:

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ - Special Authority see SA1025 on the pre	ceding page – Retail phar	macy	
Tab 50 mg		30	Stocrin S29
Tab 200 mg		90	 Stocrin
Tab 600 mg		30	 Stocrin
ETRAVIRINE - Special Authority see SA1025 on the pr	eceding page – Retail pha	rmacy	
Tab 100 mg	770.00	120	Intelence
Tab 200 mg	770.00	60	Intelence
NEVIRAPINE - Special Authority see SA1025 on the pr	eceding page – Retail pha	armacy	
Tab 200 mg		60	 Nevirapine Alphapharm
	(319.80)		Viramune
Oral suspension 10 mg per ml		240 ml	 Viramune Suspension

(Viramune Tab 200 mg to be delisted 1 April 2013)

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE - Special Authority see SA1025 on the pre	ceding page -	– Retail pharma	су
Tab 300 mg	229.00	60	✓ <u>Ziagen</u>
Oral liq 20 mg per ml	50.00	240 ml OP	✓ <u>Ziagen</u>
ABACAVIR SULPHATE WITH LAMIVUDINE - Special Authority se	e SA1025 on	the preceding p	oage – Retail pharmacy
Note: abacavir with lamivudine (combination tablets) counts a	as two anti-re	troviral medicat	ions for the purposes of the anti-
retroviral Special Authority.			
Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa

	Subsidy (Manufacturer's Pri	ice) Sub	Fully Brand or sidised Generic
	\$	Per	Manufacturer
DIDANOSINE [DDI] - Special Authority see SA1025 on page 99	- Retail pharmacy	1	
Cap 125 mg		30	Videx EC
Cap 200 mg		30	Videx EC
Cap 250 mg		30	Videx EC
Cap 400 mg		30	✓ Videx EC
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROR	OXIL FUMARATE		
Note: Efavirenz with emtricitabine and tenofovir disoproxil fum of the anti-retroviral Special Authority	arate counts as th	ree anti-retro	viral medications for the purposes
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg	1,313.19	30	✓ Atripla
EMTRICITABINE – Special Authority see SA1025 on page 99 – F Cap 200 mg		30	🖌 Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE		hy soo SA102	5 on page 99 - Retail pharmacy
Note: Emtricitabine with tenofovir disoproxil fumarate counts retroviral Special Authority	s as two anti-retro	oviral medicat	ions for the purposes of the anti-
Tab 200 mg with tenofovir disoproxil fumarate 300 mg		30	 Truvada
LAMIVUDINE – Special Authority see SA1025 on page 99 – Reta Tab 150 mg		60	A 2TC
Oral liq 10 mg per ml		240 ml OP	✓ <u>3TC</u> ✓ 3TC
		240 IIII OF	• <u>510</u>
STAVUDINE [D4T] - Special Authority see SA1025 on page 99 -			
Cap 30 mg		60	✓ Zerit
Cap 40 mg (Zerit Cap 30 mg to be delisted 1 June 2013)		60	 Zerit
ZIDOVUDINE [AZT] – Special Authority see SA1025 on page 99			
Cap 100 mg		100	Retrovir
Oral liq 10 mg per ml		200 ml OP	Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see Note: zidovudine [AZT] with lamivudine (combination tablets) anti-retroviral Special Authority.	counts as two an		
Tab 300 mg with lamivudine 150 mg	63.50	60	 Alphapharm
(Combivir Tab 300 mg with lamivudine 150 mg to be delisted 1 Ma	(667.20) arch 2013)		Combivir
Protease Inhibitors			
ATAZANAVIR SULPHATE - Special Authority see SA1025 on page	ge 99 – Retail pha	armacy	
Cap 150 mg		60	✓ Reyataz
Cap 200 mg	757.79	60	 Reyataz
DARUNAVIR – Special Authority see SA1025 on page 99 – Retai Tab 400 mg	, ,	60	✓ Prezista
Tab 600 mg		60	✓ Prezista
INDINAVIR – Special Authority see SA1025 on page 99 – Retail p			
Cap 200 mg		360	Crixivan
Cap 200 mg		180	✓ Crixivan
LOPINAVIR WITH RITONAVIR – Special Authority see SA1025 c	1 0		✓ Kaletra
Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg		60 120	 ✓ Kaletra ✓ Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml		300 ml OP	✓ Kaletra
oral ne oo nig war nonawi zo nig por nir aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa			• 1141414

	Subsidy (Manufacturer's P \$	rice) Su Per	Fully Brand or bsidised Generic Manufacturer	
RITONAVIR – Special Authority see SA1025 on page 99 – Reta Tab 100 mg Oral liq 80 mg per ml		30 90 ml OP	✓ <u>Norvir</u> ✓ Norvir	
Strand Transfer Inhibitors				
RALTEGRAVIR POTASSIUM – Special Authority see SA1025 c Tab 400 mg	1 0	pharmacy 60	✓ Isentress	
Antiretrovirals - Additional Therapies				
HIV Fusion Inhibitors				
 ENFUVIRTIDE – Special Authority see SA0845 below – Retail Powder for inj 90 mg per ml × 60	d for 3 months for a ckground therapy (atment failure; and ngoing therapy; or untiretroviral agents s has failed; and transcriptase inhib scriptase inhibitor h	including at le ; and itor has failed	east 1 other antiretrovira I; and	
Renewal only from a named specialist. Approvals valid for 1 yea Both: 1 Evidence of at least a 10 fold reduction in viral load at 12	ar for applications r ; and	Ū	ollowing criteria:	
2 The treatment remains appropriate and the patient is ben Immune Modulators	nefiting from treatm	ent.		
Guidelines for the use of interferon in the treatment of hepa Physicians considering treatment of patients with hepatitis C sho physician. All subjects undergoing treatment require careful mor Patients should be otherwise fit.	uld discuss cases white the second seco	ects.	J. J	us disease

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.
- 2) Establishing Active Chronic Liver Disease
 - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging
 - > 1.5 \times upper limit of normal. (ALT is the preferable enzyme); or

continued...

	Subsidy		Fully	Brand or
(Manufacturer's Price)	Subs Per	idised	Generic Manufacturer
continued	Ŷ	101	-	Manalabialor
 Liver biopsy showing significant inflammatory activity sary requirement for those patients with coagulopathy transaminase enzymes). 				
Exclusion Criteria				
 Autoimmune liver disease. (Interferon may exacerbate auto such as thyroid disease). Pregnancy. Neutropenia (<2.0 × 10⁹) and/or thrombocytopenia. Continuing alcohol abuse and/or continuing intravenous drug 		ise as wel	l as oti	her autoimmune diseases
Dosage				
The current recommended dosage is 3 million units of interferon a times a week for 52 weeks (twelve months) Exit Criteria	lpha-2a or interfero	n alpha-2b	admir	nistered subcutaneously 3
The patient's response to interferon treatment should be reviewed discontinued in patients who do not show a substantial reduction (5) $$				
INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist				
See prescribing guideline on the preceding page				
Inj 3 m iu prefilled syringe	31.32	1	🖌 R	oferon-A
Inj 6 m iu prefilled syringe	62.64	1	🖌 R	oferon-A
Inj 9 m iu prefilled syringe	93.96	1	🖌 R	oferon-A
INTERFERON ALPHA-2B – PCT – Retail pharmacy-Specialist				
See prescribing guideline on the preceding page				
Inj 18 m iu, 1.2 ml multidose pen	187.92	1	🖌 In	tron-A
Inj 30 m iu, 1.2 ml multidose pen		1	V In	tron-A
Inj 60 m iu, 1.2 ml multidose pen		1		tron-A
PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA		ago Potr		
See prescribing guideline on the preceding page	ATT54 OFT THE NEXT P	aye – nela	iii priai	macy
Inj 135 μ g prefilled syringe	362.00	1		egasys
Inj 155 μ g premied synnige	1.448.00	4		egasys
Inj 180 μ g prefilled syringe		4		egasys
Inj 100 μ g premied synnige	1.800.00	4		egasys
Init 105 was prefilled environment of with viberisin teb 000 many	1,000.00	4	• F	egasys
Inj 135 μ g prefilled syringe \times 4 with ribavirin tab 200 mg \times	1 700 60			
112	1,799.00	OP		egasys RBV
				Combination Pack
Inj 135 μ g prefilled syringe \times 4 with ribavirin tab 200 mg \times 168	1,975.00 1	OP		egasys RBV Combination Pack
Inj 180 μ g prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$				
112	2,059.84 1	OP	🖌 P(egasys RBV
				Combination Pack
Inj 180 μ g prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$				
168	2,190.00 1	OP	V Pe	egasys RBV
				Combination Pack

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	~	Manufacturer	

SA1134 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

- Both: 1 Either:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; and
 - 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml
- Initial application (chronic hepatitis C genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA \geq 2,000 units/ml and significant fibrosis (\geq Metavir Stage F2); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 µg once weekly.
- The recommended dose of Pegylated Interferon-alpha 2a is 180 µg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 μg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alpha 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE			
* Tab 1 g	18.40	100	
	(38.10)		Hiprex
NITROFURANTOIN			
* Tab 50 mg - For nitrofurantoin oral liquid formulation refer,			
page 184	22.20	100	Nifuran
* Tab 100 mg	37.50	100	Nifuran

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
NORFLOXACIN				
Tab 400 mg - Maximum of 6 tab per prescription; can be	ł			
waived by endorsement - Retail pharmacy - Specialist		100	✓ <u>A</u>	rrow-Norfloxacin

MUSCULOSKELETAL SYSTEM

		Subsidy		Full	y Brand or
		(Manufacturer's Price		Subsidise	
		\$	Per		 Manufacturer
Anticholine	sterases				
NEOSTIGMINE		110.00			
lnj 2.5 mg p	er ml, 1 ml	140.00	50	~	<u>AstraZeneca</u>
PYRIDOSTIGM	INE BROMIDE				
		38.90	100	~	Mestinon
			100	•	
Non-steroid	dal Anti-inflammatory Drugs (NSAIDs	5)			
	ecial Authority for Manufacturers Price				
	or patients with existing approvals prior to 1 Septer	nber 2010. Approval	s valid v	vithout fu	rther renewal unless notified.
No new approva	Is will be granted from 1 September 2010.				
DICLOFENAC S	SODIUM				
	ng	1.63	50	~	Diclofenac Sandoz
10 20 201		4.00	100		Apo-Diclo
* Toh EO ma	disparsible Additional subsidy by Special Av		100	•	יוטוע-טער
•	dispersible – Additional subsidy by Special Au-		00		
thority s	see SA1038 above – Retail pharmacy		20		
		(8.00)			Voltaren D
* Tab EC 50 i	ng	2.13	50	~	Diclofenac Sandoz
		16.00	500	~	Apo-Diclo
* Tab long-ac	ting 75 mg	24.52	500	~	Diclax SR
0	ting 100 mg		500		Diclax SR
	er ml, 3 ml		5		Voltaren
, ,,	nj available on a PSO		Ŭ	•	- Contarion
		1 05	10		Voltoron
	5 mg		10		Voltaren
	mg		10		Voltaren
	mg	3.84	10	V	Voltaren
	supp available on a PSO				
* Suppos 100) mg	6.36	10	~	Voltaren
	Additional subsidy by Special Authority see SA10		harmac		
			1,000		Arrowcare
			30		Allowcale
* Tab 400 mg		(30		De la
		(4.56)			Brufen
* Tab 600 mg		1.15	30		
		(6.84)			Brufen
	ting 800 mg		30	~	Brufen SR
*‡ Oral liq 100	mg per 5 ml	2.69	200 ml	~	Fenpaed
KETOPROFEN					
	sting 100 mg	01 56	100		
	cting 100 mg		100	· · · ·	Oruvail SR
* Cap long-ad	cting 200 mg		100	V	Oruvail SR
MEFENAMIC A	CID - Additional subsidy by Special Authority see	e SA1038 above – F	letail pha	armacy	
-	· · · · · · · · · · · · · · · · · · ·		20		
. oop 200 mg	······	(5.60)			Ponstan
		1.25	50		
			00		Ponstan
		(9.16)			runslall
NAPROXEN					
* Tab 250 mg		21.25	500	~	Noflam 250
•			250		Noflam 500
	ting 750 mg		90		Naprosyn SR 750
-	ting 1,000 mg		90		Naprosyn SR 1000
a in ingat	ang 1,000 mg		00	•	

MUSCULOSKELETAL SYSTEM

(Manufacturer's Price) Subsidised Gen SULINDAC - Additional subsidy by Special Authority see SA1038 on the preceding page - Retail pharmacy * Tab 100 mg .2.66 50 * Tab 200 mg (8.55) Aclin * Tab 200 mg .3.36 50 (15.10) Aclin ** Tab 200 mg .3.36 50 (15.10) Aclin ** Tab 20 mg .23.75 100 ✓ Tilcotili ** Tab 300 mg .9.95 1 ✓ AFT TIAPPOFENIC ACID ** ** Tab 300 mg .9.95 1 ✓ AFT TIAPROFENIC ACID ** Tab 300 mg .19.26 60 ✓ Surgan NSAIDS Other ** ** Tab 7.5 mg .11.50 30 ✓ Arrow-I **>SA1034] Special Authority for Subsidy ** ** Tab 7.5 mg .11.50 30 ✓ Arrow-I **>SA1034] Special Authority for Subsidy ** ** ** ** ** * * * * * * * * * * * * * *	nd or
SULINDAC - Additional subsidy by Special Authority see SA1038 on the preceding page - Retail pharmacy * Tab 100 mg 2.66 50 * Tab 200 mg (8.55) Aclin ** Tab 200 mg 3.36 50 (15.10) Aclin (15.10) TENOXICAM * Tab 20 mg 23.75 100 ✓ Tilcottil ** Tab 300 mg	
* Tab 100 mg 2.66 50 * Tab 200 mg 3.36 50 (8.55) Aclin * Tab 200 mg 3.36 50 (15.10) Aclin * Tab 20 mg 23.75 100 ✓ Tilcotil * Inj 20 mg 9.95 1 ✓ AFT TLAPROFENIC ACID * * Tab 300 mg 19.26 60 ✓ Surgan NSAIDS Other * Tab 7.5 mg 11.50 30 ✓ Arrow-I ●SA1034] Special Authority see SA1034 below – Retail pharmacy * Tab 7.5 mg 11.50 30 ✓ Arrow-I ●SA1034] Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for a the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating function and 2 The patient has moderate to severe haemophilic arthropathy is inadequately controlled by alternatic options, or alternative funded treatment options are contraindicated. AURANOFIN Tab 3 mg .68.99 60 ✓ Ridaura IEFLUNOMIDE .68.99 60 ✓ Arava ✓ Arava Tab 10 mg .55.00 30	
(8.55) Aclin * Tab 200 mg 3.36 50 (15.10) Aclin TENOXICAM * * Tab 20 mg 23.75 100 ✓ Tilcotil * Inj 20 mg 9.95 1 ✓ AFT TIAPROFENIC ACID * Tab 300 mg 19.26 60 ✓ Surgan NSAIDS Other * MELOXICAM – Special Authority see SA1034 below – Retail pharmacy * Tab 7.5 mg 11.50 30 ✓ Arrow-I >>SA1034 Special Authority for Subsidy 11.150 30 ✓ Arrow-I Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for a the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating function and 2 The patient has moderate to severe haemophilic arthropathy is inadequately controlled by alternatic options, or alternative funded treatment options are contraindicated. AURANOFIN 68.99 60 ✓ Ridaura Tab 20 mg 76.00 30 ✓ AFT-Le Y Arava 74.00 Y Arava Y Arava Tab 20 mg 76.00 30 ✓ AFT-Le Y Arava	
(15.10) Aclin TENOXICAM * Tab 20 mg 23.75 100 ✓ Tilcotill * Inj 20 mg .9.95 1 ✓ AFT TIAPROFENIC ACID * Tab 300 mg .9.95 1 ✓ AFT TIAPROFENIC ACID * Tab 300 mg .9.26 60 ✓ Surgan NSAIDS Other * MELOXICAM – Special Authority see SA1034 below – Retail pharmacy * Tab 7.5 mg .11.50 30 ✓ Arrow-I >>SA1034 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for a the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating funct and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. Antirheumatoid Agents AIRANOFIN .68.99 60 ✓ Arava Tab 20 mg .55.00 30 ✓ AFT-Le ✓ Arava Tab 10 mg .54.44 3 ✓ Arava Tab 100 mg .54.44 3 ✓ Arava </td <td></td>	
TENOXICAM * Tab 20 mg	
 * Tab 20 mg	
 * Inj 20 mg	
TIAPROFENIC ACID * Tab 300 mg 19.26 60 ✓ Surgam NSAIDS Other ** Tab 7.5 mg 11.50 30 ✓ Arrow-I ■>SA1034 Special Authority see SA1034 below – Retail pharmacy ** Tab 7.5 mg 11.50 30 ✓ Arrow-I ■>SA1034 Special Authority for Subsidy 11.50 30 ✓ Arrow-I ■>SA1034 Special Authority for Subsidy 11.50 30 ✓ Arrow-I ■>SA1034 Special Authority for Subsidy 11.50 30 ✓ Arrow-I ■>SA1034 Special Authority for Subsidy 11.50 30 ✓ Arrow-I Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for a the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating function and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. ALTRHeumatoid Agents AURANOFIN 68.99 60 ✓ Ridaura Tab 20 mg 76.00 30 ✓ AFT-Le ✓ Arava Tab 20 mg 5	
 ★ Tab 300 mg	
MELOXICAM - Special Authority see SA1034 below - Retail pharmacy ★ Tab 7.5 mg	n
MELOXICAM - Special Authority see SA1034 below - Retail pharmacy ★ Tab 7.5 mg	
 ★ Tab 7.5 mg	
▶SA1034 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for a the following criteria: All of the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating function and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. AURANOFIN ▲ Tab 3 mg 68.99 60 ✓ Ridaura LEFLUNOMIDE ★ 76.00 30 ✓ AFT-Le Tab 20 mg ₹54.44 3 ✓ Arava Tab 100 mg 54.44 3 ✓ Arava Tab 100 mg 100 mg to be delisted 1 March 2013) (AFT-Leflunomide Tab 10 mg to be delisted 1 March 2013) ✓ Arava PENICILLAMINE 61.93 100 ✓ D-Pena Tab 250 mg 98.98 100 ✓ D-Pena SODIUM AUROTHIOMALATE SODIUM AUROTHIOMALATE	Melovicam
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for a the following criteria: All of the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating function and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. AURANOFIN Tab 3 mg Tab 10 mg	Weloxicam
the following criteria: All of the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating func- and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternati- options, or alternative funded treatment options are contraindicated. ANTIRHEUMATOID Agents AURANOFIN Tab 3 mg	applications meeting
1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating function and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. Antirheumatoid Agents AURANOFIN Tab 3 mg	
and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. AURANOFIN Tab 3 mg	tional eletting factory
2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative options, or alternative funded treatment options are contraindicated. Antirheumatoid Agents AURANOFIN Tab 3 mg	
options, or alternative funded treatment options are contraindicated. Antirheumatoid Agents AURANOFIN Tab 3 mg	
Antirheumatoid Agents AURANOFIN Tab 3 mg	ve funded treatment
AURANOFIN Tab 3 mg	
Tab 3 mg	
✓ Ridaura LEFLUNOMIDE Tab 10 mg .55.00 30 ✓ AFT-Let ✓ Arava Tab 20 mg .76.00 30 ✓ AFT-Let ✓ Tab 100 mg	
LEFLUNOMIDE Tab 10 mg	
Tab 10 mg	a s29 S29
✓ Arava Tab 20 mg	diam a sector
Tab 20 mg	flunomide
Tab 100 mg	flunomide
(AFT-Leflunomide Tab 10 mg to be delisted 1 March 2013) (AFT-Leflunomide Tab 20 mg to be delisted 1 March 2013) PENICILLAMINE Tab 125 mg	
(AFT-Leflunomide Tab 20 mg to be delisted 1 March 2013) PENICILLAMINE Tab 125 mg	
PENICILLAMINE Tab 125 mg	
Tab 125 mg 100 ✓ D-Pena Tab 250 mg 100 ✓ D-Pena SODIUM AUROTHIOMALATE 100 ✓ D-Pena	
SODIUM AUROTHIOMALATE	mine
	imine
lni 10 mg ner 0.5 ml 76.97 10 4/ Muserie	
Inj 10 mg per 0.5 ml	
Inj 20 mg per 0.5 ml	
	5111
Tumour Necrosis Factor (TNF) Inhibitors	
ADALIMUMAB – Special Authority see SA1156 on the next page – Retail pharmacy	_
Inj 40 mg per 0.8 ml prefilled pen 1,799.92 2 V Humira	
Inj 40 mg per 0.8 ml prefilled syringe1,799.92 2 V Humira	1

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
--	--	---	-----	---------------------	-------------------------------------

➡SA1156 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.
- Initial application (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:
- All of the following:
 - 1 Patient has severe active Crohn's disease; and
 - 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
 - 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
 - 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

Subsidy (Manufacturer's	Fully Price) Subsidised	
\$	Per 🗸	Manufacturer

continued...

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting

the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

\$ Per 🖌 Manufacturer	Subsidy (Manufacturer's Price)	Subsid	Fully lised	Brand or Generic
	\$	Per	~	Manufacturer

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm: Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

	Subsidy cturer's Price) S		Brand or Generic
· · · · · · · · · · · · · · · · · · ·	\$ Per	~	Manufacturer

continued...

- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.
- **Renewal** (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:
- All of the following:
 - 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
 - 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
- Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:

(Subsidy Manufacturer's Price)	Subsid	-ully lised	Brand or Generic
	\$	Per	~	Manufacturer

continued...

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

ETANERCEPT – Special Authority see SA1157 below – Retail pharmacy

Inj 25 mg	 4	 Enbrel
Inj 50 mg autoinjector	 4	 Enbrel
Inj 50 mg prefilled syringe	 4	 Enbrel

➡SA1157 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 5 Both:
 - 5.1 Either:
 - 5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	
•		

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per 🖌 Manufacturer
--

continued...

- 1.1 Applicant is a dermatologist: or
- 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Fither:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment: and
 - 2.2.2 Fither:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values: or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
 - 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist: or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Fither:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Fully

1

Subsidv (Manufacturer's Price) Subsidised Per \$

Brand or Generic Manufacturer

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note): or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically: or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria) or raloxifene.

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

continued...

- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALE	ENDRONATE SODIUM - Special Authority see SA1039 on the	preceding page	ge – Retail phai	rmacy	
*	Tab 70 mg		4	Fosamax	
	ENDRONATE SODIUM WITH CHOLECALCIFEROL – Special / Tab 70 mg with cholecalciferol 5,600 iu			preceding page – Retail pharma	асу
_	•				

Alendronate for Paget's Disease

➡SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM	- Special Author	rity see SA0949	above – Retail	pharmac
--------------------	------------------	-----------------	----------------	---------

*	Tab 40 mg	.133.00	30	Fosamax
01	ther Treatments			
	_CITONIN Inj 100 iu per ml, 1 ml	.110.00	5	✓ <u>Miacalcic</u>
*	DRONATE DISODIUM – See prescribing guideline below Tab 200 mg	15.80	100	✓ <u>Arrow-Etidronate</u>

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic Manufacturer
PAMIDRONATE DISODIUM			
Inj 3 mg per ml, 5 ml		1	Pamisol
Inj 3 mg per ml, 10 ml		1	Pamidronate BNM
	37.50		Pamisol
Inj 6 mg per ml, 10 ml		1	Pamidronate BNM
	75.00		Pamisol
Inj 9 mg per ml, 10 ml		1	Pamidronate BNM
	112.50		Pamisol
RALOXIFENE HYDROCHLORIDE - Special Authority see SA	A1138 below – Retail pha	irmac	2V
* Tab 60 mg		28	🖌 Evista

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause Osteoporosis).

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by the UK National Institute for Health and Clinical Excellence (NICE) in developing its guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per 🖌 Manufacturer	Subsidy (Manufacturer's Price) \$		Generic	
--	---	--	---------	--

continued...

- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).
- Notes:
 - a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
 - b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
 - c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

100 ml

Aclasta

d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID - Special Authority see SA1187 below - Retail pharmacy

Soln for infusion 5 mg in	100 ml	 600.00

➡SA1187 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

Subsidy (Manufacturer's Price		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 2 Any of the following:
 - The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces

	Subsidy (Manufacturer's Pric \$	e) Su Per	Fully bsidised	Brand or Generic Manufacturer
continued				
that would not ordinarily cause fracture (minimal trauma).	The WHO has qua	ntified this a	as forces	equivalent to a fall from a
standing height or less. d) A vertebral fracture is defined as a 20% or greater reduc	tion in height of th	e anterior	or mid p	ortion of a vertebral body
relative to the posterior height of that body, or a 20% or group body above or below the affected vertebral body.				
Hyperuricaemia and Antigout				
ALLOPURINOL				
* Tab 100 mg		1,000	✓ <u>A</u>	po-Allopurinol
* Tab 300 mg – For allopurinol oral liquid formulation refer, page 184		500	🗸 A	po-Allopurinol
COLCHICINE				·
st Tab 500 μ g	9.60	100	✓ <u>C</u>	<u>olgout</u>
PROBENECID				
* Tab 500 mg		100	V P	robenecid-AFT
Muscle Relaxants				
BACLOFEN				
* Tab 10 mg - For baclofen oral liquid formulation refer, page				
184	4.75	100	V P	acifen
DANTROLENE SODIUM * Cap 25 mg	22.06	100		
* Cap 25 mg	(65.00)	100	D	antrium
* Cap 50 mg		100		
	(77.00)		D	antrium
ORPHENADRINE CITRATE Tab 100 mg	18 5/	100	M N	orflex
QUININE SULPHATE		100	₩ N	UTIEA
* Tab 300 mg		500	V Q	300
‡ Safety cap for extemporaneously compounded oral liquid				

	Subsidy (Manufacturer's Price \$	e) S Per	Fully Brand or iubsidised Generic Vanufacturer
Agents for Parkinsonism and Related Disord	ers		
Dopamine Agonists and Related Agents			
MANTADINE HYDROCHLORIDE			
Cap 100 mg		60	✓ Symmetrel
POMORPHINE HYDROCHLORIDE ▲ Inj 10 mg per ml, 2 ml	110.00	5	✓ Apomine
ROMOCRIPTINE MESYLATE		5	• Aponine
← Tab 2.5 mg	32.08	100	Apo-Bromocriptine
 Cap 5 mg 		100	✓ Apo-Bromocriptine
NTACAPONE			
Tab 200 mg		100	Entapone
,	(116.00)		Comtan
Comtan Tab 200 mg to be delisted 1 March 2013)			
EVODOPA WITH BENSERAZIDE			
 Tab dispersible 50 mg with benserazide 12.5 mg 	10.00	100	Madopar
Con E0 mg with honograpide 10 E mg	0.00	100	Dispersible
Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg		100 100	 ✓ Madopar 62.5 ✓ Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100	Madopar HBS
Cap 200 mg with benserazide 50 mg		100	Madopar 250
EVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg - For levodopa with	car-		
bidopa oral liquid formulation refer, page 184		50	Sindopa
	20.00	100	Sinemet
 Tab long-acting 200 mg with carbidopa 50 mg 		100	Sinemet CR
Tab 250 mg with carbidopa 25 mg		100	 Sinemet
SURIDE HYDROGEN MALEATE			
Tab 200 μg		30	Dopergin
ERGOLIDE			
Tab 0.25 mg		100	Permax
Tab 1 mg	170.00	100	Permax
RAMIPEXOLE HYDROCHLORIDE			4
Tab 0.125 mg	1.95	30	✓ <u>Dr Reddy's</u>
Tab 0.25 mg	2.40	30	<u>Pramipexole</u> ✔ Dr Reddy's
a 1ab 0.25 mg		00	Pramipexole
Tab 0.5 mg	4.20	30	✓ Dr Reddy's
-			Pramipexole
OPINIROLE HYDROCHLORIDE			
Tab 0.25 mg	6.20	84	✓ <u>Ropin</u>
Tab 1 mg		84	✓ Ropin
Tab 2 mg		84	Ropin
Tab 5 mg		84	Ropin
		105	() ()
₭ Tab 5 mg		100	Apo-Selegiline

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
TOLCAPONE Tab 100 mg	126.20	100	<u>.</u>	Tasmar
Anticholinergics	120.20	100	•	Tasiliai
BENZTROPINE MESYLATE				
Tab 2 mg	7.99	60	~	Benztrop
Inj 1 mg per ml, 2 ml a) Up to 5 inj available on a PSO b) Only on a PSO	95.00	5		Cogentin
ORPHENADRINE HYDROCHLORIDE Tab 50 mg		250	~	Disipal
PROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	~	Kemadrin
Agents for Essential Tremor, Chorea and Rela	ated Disorders			
TETRABENAZINE Tab 25 mg		112	<u>~ </u>	<u>Motetis</u>
Anaesthetics				
Local				
LIGNOCAINE Gel 2%, 10 ml urethral syringe – Subsidy by endorsemen a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical		10 rescrir		Pfizer
LIGNOCAINE HYDROCHLORIDE	administration and the p	100011		action accortaingly.
Viscous soln 2%		200 ml	~	Xylocaine Viscous
Inj 1%, 5 ml – Up to 5 inj available on a PSO		50		Xylocaine
Inj 2%, 5 ml – Up to 5 inj available on a PSO		50		Xylocaine
Inj 1%, 20 ml – Up to 5 inj available on a PSO		5		Xylocaine
Inj 2%, 20 ml – Up to 5 inj available on a PSO	15.00	5		Xylocaine
LIGNOCAINE WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe				
Subsidy by endorsement		10	~	Pfizer
a) Up to 5 each available on a PSO				
b) Subsidised only if prescribed for urethral or cervical				dorsed accordingly.
LIGNOCAINE WITH PRILOCAINE - Special Authority see S				
Crm 2.5% with prilocaine 2.5%		0 g OF		EMLA
Crm 2.5% with prilocaine 2.5% (5 g tubes)		5	<u>~</u>	EMLA
➡SA0906 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals	valid for 2 years where	the pa	tient is a c	child with a chronic medic

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Cubaidu		Fully	Drond or
	Subsidy (Manufacturer's Pric \$	e) Sul Per	Fully osidised	Brand or Generic Manufacturer
Analgesics				
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pa	age 106			
Non-opioid Analgesics				
ASPIRIN				
* Tab EC 300 mg	2.00	100		
	(8.10)			spec 300
* Tab dispersible 300 mg – Up to 30 tab available on a PSO	2.00	100	✓ <u>E</u>	thics Aspirin
NEFOPAM HYDROCHLORIDE				
Tab 30 mg	23.40	90	🗸 A	cupan
PARACETAMOL				
₭ Tab 500 mg – Up to 30 tab available on a PSO	9.38	1,000		arafast
★‡ Oral liq 120 mg per 5 mla) Up to 200 ml available on a PSO b) Not in combination	2.21	500 ml	✓ <u>E</u>	thics Paracetamol
k≰ Oral liq 250 mg per 5 ml	6.70	1,000 ml		aracare Double Strength
a) Up to 100 ml available on a PSO				<u></u>
b) Not in combination				
₭ Suppos 125 mg		20		anadol
₭ Suppos 250 mg		20		anadol
₭ Suppos 500 mg		50	V Pa	aracare
RAMADOL HYDROCHLORIDE			4-	
Tab sustained-release 100 mg		20		amal SR
Tab sustained-release 150 mg Tab sustained-release 200 mg		20 20	• •	amal SR amal SR
Cap 50 mg		100		rrow-Tramadol
Opioid Analgesics		100	• <u>A</u>	now numador
CODEINE PHOSPHATE – Safety medicine; prescriber may dete				014
Tab 15 mg		100	P P	
Tab 30 mg Tab 60 mg		100 100	P	
5		100		
	07.07	60		HC Continue
Tab long-acting 60 mg		60	✓ <u>U</u>	HC Continus

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
FE	NTANYL a) Only on a controlled drug form b) No patient co-payment payable				
	c) Safety medicine; prescriber may determine dispensing free Transdermal patch 12.5 μ g per hour	luency 8.90	5	✓ <u>N</u>	Iylan Fentanyl
	Transdermal patch 25 μ g per hour	9.15	5	✓ <u>N</u>	<u>Patch</u> Iylan Fentanyl Patch
	Transdermal patch 50 μ g per hour	11.50	5	✓ <u>N</u>	lylan Fentanyl Patch
	Transdermal patch 75 μ g per hour	13.60	5	✓ <u>N</u>	Iylan Fentanyl Patch
	Transdermal patch 100 μ g per hour	14.50	5	✓ <u>N</u>	lylan Fentanyl Patch
FE	 NTANYL CITRATE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frec Inj 50 μg per ml, 2 ml Inj 50 μg per ml, 10 ml 	4.50	10 10		Coucher and Muir Boucher and Muir
ME	THADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fred d) For methadone hydrochloride oral liquid refer, page 187 e) Extemporaneously compounded methadone will only be re powder, not methadone tablets).	juency	e of the	e cheapest	form available (methadone
	Tab 5 mg		10	V N	lethatabs
‡	Oral liq 2 mg per ml		200 ml	V B	liodone
‡	Oral liq 5 mg per ml		200 ml		liodone Forte
‡	Oral liq 10 mg per ml		200 ml		iodone Extra Forte
	Inj 10 mg per ml, 1 ml		10	🗸 A	IF I
M	DRPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frec	juency			
‡	Óral liq 1 mg per ml	8.84	200 ml	✓ <u>R</u>	A-Morph
‡	Oral liq 2 mg per ml		200 ml		A-Morph
‡	Oral liq 5 mg per ml		200 ml		A-Morph
‡	Oral liq 10 mg per ml		200 ml	✓ <u>R</u>	A-Morph

	Subsidy		Fully	Brand or
(M	anufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
DRPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequer	ncv			
Tab immediate-release 10 mg		10	🖌 Se	evredol
Tab long-acting 10 mg		10	🖌 Ai	row-Morphine LA
Tab immediate-release 20 mg		10		evredol
Tab long-acting 30 mg	3.15	10	🖌 🖌	row-Morphine LA
Tab long-acting 60 mg		10	V AI	row-Morphine LA
Tab long-acting 100 mg	7.85	10	🖌 🖌	rrow-Morphine LA
Cap long-acting 10 mg	2.22	10	🖌 <u>m</u>	-Eslon
Cap long-acting 30 mg	3.20	10	🖌 <u>m</u>	-Eslon
Cap long-acting 60 mg		10	🗸 <u>m</u>	-Eslon
Cap long-acting 100 mg		10		-Eslon
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.51	5	🖌 <u>D</u>	BL Morphine
				Sulphate
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	4.79	5	D	BL Morphine
				Sulphate
Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.01	5		BL Morphine
		_		Sulphate
Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.30	5		BL Morphine
				Sulphate
ORPHINE TARTRATE				
 a) Only on a controlled drug form 				
 b) No patient co-payment payable 				
c) Safety medicine; prescriber may determine dispensing frequer				
Inj 80 mg per ml, 1.5 ml		5		ospira
Inj 80 mg per ml, 5 ml	75.00	5	✓ <u>He</u>	ospira
YCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) See prescribing guideline below				
c) No patient co-payment payable				
d) Safety medicine; prescriber may determine dispensing frequer	псу			
Tab controlled-release 5 mg	7.51	20	🖌 O:	xyContin
Tab controlled-release 10 mg	11.14	20	🖌 O:	xyContin
Tab controlled-release 20 mg	18.93	20		xyContin
Tab controlled-release 40 mg		20		xyContin
Tab controlled-release 80 mg		20		xyContin
Cap 5 mg		20		xyNorm
Cap 10 mg		20		xyNorm
Cap 20 mg		20		xyNorm
Oral liq 5 mg per 5 ml		50 ml		xyNorm
Inj 10 mg per ml, 1 ml		5		xyNorm
	10.08	_		xycodone Orion
	10.07	5		xyNorm
Inj 10 mg per ml, 2 ml	19.87	5		xycodone Orion

(OxyNorm Inj 10 mg per ml, 1 ml to be delisted 1 March 2013) (OxyNorm Inj 10 mg per ml, 2 ml to be delisted 1 March 2013)

Prescribing Guideline

Prescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.

	Subsidy		Fully Brand or
	(Manufacturer's Pr \$	ice) S Per	ubsidised Generic Manufacturer
ARACETAMOL WITH CODEINE - Safety medicine; prescribe	r may determine dis	spensing fre	equency
Tab paracetamol 500 mg with codeine phosphate 8 mg		100	✓ <u>Paracetamol +</u> Codeine (Relieve)
THIDINE HYDROCHLORIDE			, ,
a) Only on a controlled drug form			
b) No patient co-payment payable			
 c) Safety medicine; prescriber may determine dispensing free Table 50 mg 		10	V PSM
Tab 50 mg Tab 100 mg		10 10	✓ PSM ✓ PSM
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	✓ DBL Pethidine
		0	Hydrochloride
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	5	✓ DBL Pethidine
			Hydrochloride
Intidepressants			
Cyclic and Related Agents			
MITRIPTYLINE – Safety medicine; prescriber may determine			
Tab 10 mg		100	Arrow Amitriptyline
	1.66	50	Amirol
Tab 25 mg	(2.77)	100	Amirol Amitrip
Tab 50 mg		100	✓ Amitrip
mirol Tab 10 mg to be delisted 1 April 2013)		100	• <u>Annalp</u>
_OMIPRAMINE HYDROCHLORIDE - Safety medicine; presc	riber may determin	e disnensin	a frequency
Tab 10 mg	,	100	Apo-Clomipramine
Tab 25 mg		100	✓ Apo-Clomipramine
THIEPIN HYDROCHLORIDE - Safety medicine; prescriber	may determine disr	nensina frea	 111encv
Tab 75 mg		100	V Dopress
Cap 25 mg		100	✓ Dopress
XEPIN HYDROCHLORIDE – Safety medicine; prescriber m	av determine disner	nsina freau	-ncv
Cap 10 mg		100	Anten
Cap 25 mg		100	✓ Anten
Cap 50 mg		100	✓ Anten
PRAMINE HYDROCHLORIDE – Safety medicine; prescribe	r may determine di	snensina fre	allency
Tab 10 mg		50	✓ Tofranil
Tab 25 mg		50	✓ Tofranil
APROTILINE HYDROCHLORIDE – Safety medicine; prescrib		dispensing	frequency
Tab 25 mg		100	
Tab 75 mg		30	✓ Ludiomil
ANSERIN HYDROCHLORIDE – Special Authority see SA10	48 on the next nade	– Rotail ni	harmacy

				(Man	Subsidy ufacturer's Price \$) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
		nority for Subsic ny relevant practit		als valid for 2 y	ears for applic	ations me	eeting the	e following criteria:
1 Both:								
	Depression;	and						
1.2		kistent bladder ne ovascular diseas		; or				
2 Both:			.,					
	2 Either:	has a severe maj						
								o tolerate the treatments or east four weeks); or
	2.2.2.1	The patient is c The patient must respond to an a	st have had a	trial of one othe	er antidepress	ant and ei		e episode; and d not tolerate it or failed to
	om any relevai om treatment.						ains app	ropriate and the patient is
NORTRIPTY	YLINE HYDRO	CHLORIDE - S	afety medicine	; prescriber m	ay determine	dispensing	g frequer	ю
	0					100 180		orpress orpress
Monoam	nine-Oxida	se Inhibitors	(MAOIs) - I	Non Selecti	ve			
	NE SULPHATE				95.00	100	V N	ardil
TRANYLCY	PROMINE SU					50		arnate
	0				22.94	50	₩ Fe	amate
Monoam	nine-Oxida	se Type A Inf	libitors					
expensi ing pres	here is a signi ive). For depre scribing moclol	ssive syndromes pemide.	it is therefore	more cost-effe	ctive to start t			ng about three times more etine first before consider-
						500		po-Moclobemide
	5				31.33	100	V A	po-Moclobemide
Selectiv	e Serotonii	n Reuptake li	nhibitors					
	M HYDROBR	OMIDE			2 34	84		rrow-Citalopram
ESCITALOP	•					0-1	* <u>A</u>	
					2.65	28	✓ <u>L</u>	oxalate
	-					28	✓ L	oxalate

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Sul Per	bsidised V	Generic Manufacturer
FLUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement Subsidised by endorsement	2.50	30	✓ <u>F</u>	luox
 When prescribed for a patient who cannot swallow ingly; or 	whole tablets or capsu	les and th	ne presc	ription is endorsed accord-
When prescribed in a daily dose that is not a m endorsed. Note: Tablets should be combined with	capsules to facilitate ir			
* Cap 20 mg	2.70	84	✓ <u>F</u>	luox
PAROXETINE HYDROCHLORIDE				
* Tab 20 mg	2.38	30	✓ L	oxamine
SERTRALINE				
* Tab 50 mg		90		rrow-Sertraline
* Tab 100 mg	9.60	90	✓ <u>A</u>	rrow-Sertraline
Other Antidepressants				
MIRTAZAPINE - Special Authority see SA0994 below - Retail p	harmacy			
Tab 30 mg		30	✓ <u>A</u>	vanza
Tab 45 mg	13.95	30	✓ <u>A</u>	vanza
SA0994 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	for 2 years for application	ations me	eting the	e following criteria:
Both:				
1 The patient has a severe major depressive episode; and 2 Either:				
2.1 The patient must have had a trial of two different a	ntidepressants and wa	as unable	to tolera	ate the treatments or failed
to respond to an adequate dose over an adequate 2.2 Both:				
2.2.1 The patient is currently a hospital in-patient 2.2.2 The patient must have had a trial of one other				
to an adequate dose over an adequate peri				
Renewal from any relevant practitioner. Approvals valid for 2 ye mined).		has a hig	h risk of	relapse (prescriber deter-
VENLAFAXINE - Special Authority see SA1061 below - Retail	pharmacy			
Tab 37.5 mg		28	🗸 A	rrow-Venlafaxine XR
Tab 75 mg	19.00	28	🗸 A	rrow-Venlafaxine XR

	XR
28	 Arrow-Venlafaxine XR
28	Efexor XR
28	Efexor XR
28	 Efexor XR
	28 28 28

■SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:

continued...

- 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
- 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM – Safety medicine; prescriber may determine dispens Inj 1 mg per ml, 1 ml	0 1 7	5	✓ Rivotril
DIAZEPAM – Safety medicine; prescriber may determine dispensing Inj 5 mg per ml, 2 ml – Subsidy by endorsement a) Up to 5 inj available on a PSO		5	✔ Mayne
 b) Only on a PSO c) PSO must be endorsed "not for anaesthetic procedures". 			
Rectal tubes 5 mg – Up to 5 tube available on a PSO	25.05	5	✓ Stesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO	30.50	5	Stesolid
PARALDEHYDE	500.00	_	4
* lnj 5 ml	,500.00	5	🖌 AFT
PHENYTOIN SODIUM * Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	69 24	5	🗸 Mayne
 * Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO 		5	✓ Mayne
Control of Epilepsy			
CARBAMAZEPINE			
* Tab 200 mg		100	✓ Tegretol
* Tab long-acting 200 mg * Tab 400 mg		100 100	 Tegretol CR Tegretol
* Tab long-acting 400 mg		100	✓ Tegretol CR
*‡ Oral liq 100 mg per 5 ml		250 ml	✓ Tegretol
CLOBAZAM - Safety medicine; prescriber may determine dispensing	frequency		
Tab 10 mg ‡ Safety cap for extemporaneously compounded oral liquid pre		50	✓ Frisium
1 Salety cap for extemporaneously compounded oral liquid pre CLONAZEPAM – Safety medicine; prescriber may determine dispens			
Oral drops 2.5 mg per ml	0 1 7	0 ml OP	✓ Rivotril
ETHOSUXIMIDE			
* Cap 250 mg		200	Zarontin
₩‡ Oral liq 250 mg per 5 ml		200 ml	 Zarontin
GABAPENTIN – Special Authority see SA1071 on the next page – Re ▲ Cap 100 mg		100	Nupentin
 Cap 100 mg — For gabapentin oral liquid formulation refer, 		100	
page 184	11.50	100	Nupentin
▲ Cap 400 mg	14.75	100	Nupentin

Subsidy		Fully	Brand or
(Manufacturer's Price)	:	Subsidised	Generic
\$	Per	~	Manufacturer

SA1071 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Fither:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application - (Neuropathic pain) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed guality of life from the patient's perspective.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

GABAPENTIN (NEURONTIN) - Special Authority see SA0973 below - Retail pharmacy

▲ Tab 600 mg	 100	Neurontin
▲ Cap 100 mg	100	Neurontin
▲ Cap 300 mg – For gabapentin (neurontin) oral liquid formu-		
lation refer, page 184	 100	Neurontin
▲ Cap 400 mg	100	Neurontin

SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

LACOSAMIDE - Special Authority see SA1125 below - Retail pharmacy

Tab 50 mg	25.04	14	Vimpat
Tab 100 mg		14	Vimpat
·	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
-	300.40	56	Vimpat
Tab 200 mg	400.55	56	 Vimpat

SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

	Subsidy (Manufacturer's Price \$) (Per	Fully Subsidised	Brand or Generic Manufacturer
ntinued				
enewal from any relevant practitioner. Approvals valid for 24 istained improvement in seizure rate or severity and/or quality of ee Note).				0
bte: As a guideline, clinical trials have referred to a notional 50%	% reduction in seizu	re frequ	ency as a	n indicator of success
ticonvulsant therapy and have assessed quality of life from the p			,	
MOTRIGINE				
Tab dispersible 2 mg		30		amictal
Tab dispersible 5 mg	9.64	30		amictal
	15.00	56		rrow-Lamotrigine
Tab dispersible 25 mg	19.38	56		ogem
	20.40			rrow-Lamotrigine
				logine
	29.09			amictal
Tab dispersible 50 mg		56		ogem
	34.70			rrow-Lamotrigine
	47.00			logine
Tab diamanaible 100 mm	47.89	50	· · ·	amictal
Tab dispersible 100 mg		56		ogem
	59.90			rrow-Lamotrigine
	79.16			amictal
	79.10		V L	amiciai
VETIRACETAM				
Tab 250 mg		60	V L	evetiracetam-Rex
Tab 500 mg - For levetiracetam oral liquid formulation refer,				
page 184		60		evetiracetam-Rex
Tab 750 mg		60	V L	evetiracetam-Rex
ENOBARBITONE				
For phenobarbitone oral liquid refer, page 187				
Tab 15 mg		500	🖌 P	•
Tab 30 mg		500	🖌 P	SM
ENYTOIN SODIUM				
Tab 50 mg		200	🖌 D	ilantin Infatab
Cap 30 mg		200	🖌 D	ilantin
Cap 100 mg		200	🖌 D	ilantin
: Oral liq 30 mg per 5 ml		500 ml	🖌 D	ilantin
IMIDONE				
Tab 250 mg		100	🖌 A	po-Primidone
U				
DDIUM VALPROATE	10 65	100		nilim Cruchable
Tab 100 mg Tab 200 mg EC		100 100		pilim Crushable
Tab 500 mg EC		100		pilim pilim
tab 500 mg EC t Oral lig 200 mg per 5 ml		300 ml		pilim S/F Liquid
	20.40	000 111		pilim Syrup
			V C	pinin Syrup

(Subsidy Manufacturer's Price) \$	Per	Fully Subsidised	d Generic
OPIRAMATE				
Tab 25 mg	11.07	60	~	Arrow-Topiramate
-	26.04		~	Topamax
▲ Tab 50 mg		60	~	Arrow-Topiramate
-	44.26		~	Topamax
Tab 100 mg		60	~	Arrow-Topiramate
-	75.25		~	Topamax
Tab 200 mg	55.19	60	~	Arrow-Topiramate
-	129.85		~	Topamax
Sprinkle cap 15 mg		60	~	Topamax
Sprinkle cap 25 mg		60	~	Topamax
/IGABATRIN - Special Authority see SA1072 below - Retail pharr				
Tab 500 mg		100	~	Sabril

➡SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient has infantile spasms; or
- 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 106

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE

Cafergot

100

	Subsidy		Fully Brand or
	(Manufacturer's Pri \$	ce) Su Per	bsidised Generic Manufacturer
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL			
Tab 5 mg with paracetamol 500 mg	6.77	60	Paramax
RIZATRIPTAN – Brand switch fee payable (Pharmacode 2405849) Tab orodispersible 10 mg) - see page 182 18.00	for details 30	✓ <u>Rizamelt</u>
SUMATRIPTAN			
Tab 50 mg		4	Arrow-Sumatriptan
Tab 100 mg	38.83	100	✓ <u>Arrow-Sumatriptan</u>
Tab Too Tig		2 100	 <u>Arrow-Sumatriptan</u> Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml - Maximum of 10 inj per prescription		2 OP	✓ <u>Arrow-Sumatriptan</u>
Prophylaxis of Migraine			
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYS	TEM, page 57		
PIZOTIFEN	, 15		
* Tab 500 μg	23.21	100	 Sandomigran
Antinausea and Vertigo Agents			
For Antispasmodics refer to ALIMENTARY TRACT, page 27			
APREPITANT - Special Authority see SA0987 below - Retail pha	rmacy		
Cap 2 \times 80 mg and 1 \times 125 mg		3 OP	Emend Tri-Pack
Renewal from any relevant practitioner. Approvals valid for 12 mont apy and/or anthracycline-based chemotherapy for the treatment of		ent is underg	joing highly emetogenic chemother
BETAHISTINE DIHYDROCHLORIDE * Tab 16 mg		84	✔ Vergo 16
CYCLIZINE HYDROCHLORIDE			-
Tab 50 mg	0.59	10	✓ Nausicalm
CYCLIZINE LACTATE			
Inj 50 mg per ml, 1 ml	14.95	5	Nausicalm
DOMPERIDONE			
* Tab 10 mg – For domperidone oral liquid formulation refer,	0.05	100	
page 184		100	 Prokinex Motilium
LIVOCOINE (COOROLAMINE) Creation Authority and CA0020 ha			• Mothum
HYOSCINE (SCOPOLAMINE) – Special Authority see SA0939 be Patch 1.5 mg		macy 2	Scopoderm TTS
SA0939 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals valid for	or 1 year for appli	cations mee	ting the following criteria:
All of the following: 1 Control of intractable nausea, vomiting, or inability to swallo	w saliva in the tre	atment of m	alignancy or chronic disease: and
2 Patient cannot tolerate or does not adequately respond to o			angliancy of childric disease, and
3 The applicant must specify the underlying malignancy or ch		J • • • , • • •	
Renewal from any relevant practitioner. Approvals valid for 1 ye	ar where the trea	atment rema	ains appropriate and the patient is
benefiting from treatment.			
HYOSCINE HYDROBROMIDE * Inj 400 μg per ml, 1 ml			
* Ini 400 μ g per ml. 1 ml.	0.00	5	Mayne

	Subsidy (Manufacturer's Price) \$) S Per	Fully ubsidised	Brand or Generic Manufacturer
METOCLOPRAMIDE HYDROCHLORIDE				
* Tab 10 mg		100		etamide_
* Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO	4.50	10	✓ <u>Pi</u>	lizer
ONDANSETRON				
* Tab 4 mg	5.10	30	D	r Reddy's
				Ondansetron
* Tab disp 4 mg	0.68	4		r Reddy's
				Ondansetron
	1.70	10		r Reddy's
				Ondansetron
	17.18	10		ofran Zydis
* Tab 8 mg	1.70	10		<u>r Reddy's</u>
* Tab disp 8 mg	2.00	10		<u>Ondansetron</u> r Reddy's
* Tab disp of the	2.00	10		Ondansetron
PROCHLORPERAZINE				ondanseaton
* Tab 3 mg buccal	5 07	50		
* Tab 5 Tily buccai	(15.00)	50	B	uccastem
* Tab 5 mg – Up to 30 tab available on a PSO	()	500		ntinaus
 Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO 		10		temetil
* Suppos 25 mg		5	V Si	temetil
PROMETHAZINE THEOCLATE				
* Tab 25 mg	1 20	10		
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	(6.24)	10	A	vomine
FROPISETRON	X- /			
a) Maximum of 6 cap per prescription				
b) Maximum of 3 cap per dispensing				
c) Not more than one prescription per month.				
Cap 5 mg	77.41	5	🖌 Na	avoban
Antipsychotics				

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE - Safety medicine; prescriber may determine dis	spensing frequenc	у	
Tab 100 mg		30	Solian
Tab 200 mg		60	Solian
Tab 400 mg		60	Solian
Oral liq 100 mg per ml	55.44	60 ml	 Solian

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
ARIPIPRAZOLE – Special Authority see SA0920 below – Retail p	,			
Safety medicine; prescriber may determine dispensing frequent Tab 10 mg	,	30	v	Abilify
Tab 15 mg	175.28	30	v	Abilify
Tab 20 mg	213.42	30	v	Abilify
Tab 30 mg	260.07	30	\checkmark	Abilify

SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Patient is suffering from schizophrenia or related psychoses; and

- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	CHLORPROMAZINE HYDROCHLORIDE	- Safety	medicine:	prescriber may	determine	dispensing frequency
--	------------------------------	----------	-----------	----------------	-----------	----------------------

Checken and the state of the salety medicine, pres	scriber may dele	innine uispen:	sing nequency
Tab 10 mg – Up to 30 tab available on a PSO	12.36	100	Largactil
Tab 25 mg – Up to 30 tab available on a PSO	13.02	100	Largactil
Tab 100 mg – Up to 30 tab available on a PSO		100	 Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	25.66	10	Largactil
CLOZAPINE – Hospital pharmacy [HP4]			
Safety medicine; prescriber may determine dispensing freque	ncy		
Tab 25 mg		50	Clozaril
	26.74	100	Clozaril
	6.69	50	Clopine
	13.37	100	 Clopine
Tab 50 mg	8.67	50	Clopine
	17.33	100	 Clopine
Tab 100 mg	34.65	50	Clozaril
	69.30	100	Clozaril
	17.33	50	Clopine
	34.65	100	 Clopine
Tab 200 mg	34.65	50	 Clopine
	69.30	100	 Clopine
Suspension 50 mg per ml	17.33	100 ml	 Clopine
HALOPERIDOL - Safety medicine; prescriber may determine dis	pensing frequen	су	
Tab 500 μ g – Up to 30 tab available on a PSO	5.42	100	✓ Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO	8.20	100	Serenace
Tab 5 mg – Up to 30 tab available on a PSO	25.84	100	Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO	19.87	100 ml	Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	18.74	10	✓ Serenace
LEVOMEPROMAZINE - Safety medicine; prescriber may determ	ine dispensing f	requency	
Tab 25 mg		100	 Nozinan
Tab 100 mg	43.96	100	 Nozinan
Inj 25 mg per ml, 1 ml	73.68	10	 Nozinan

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
LITHIUM CARBONATE - Safety medicine; prescriber may dete	ermine dispensing frequ	uency	
Tab 250 mg		500	Lithicarb FC
Tab 400 mg	12.83	100	Lithicarb FC
Tab long-acting 400 mg		100	Priadel
Cap 250 mg	9.42	100	✓ Douglas
OLANZAPINE - Safety medicine; prescriber may determine dis	spensing frequency		
Tab 2.5 mg	2.00	28	Dr Reddy's
			Olanzapine
			Olanzine
	(51.07)		Zyprexa
Tab 5 mg		28	V Dr Reddy's
-			Olanzapine
			Olanzine
	(101.21)		Zyprexa
Tab 10 mg		28	V Dr Reddy's
ů –			Olanzapine
			Olanzine
	(204.49)		Zyprexa
DEDICVAZINE Sofety modicine: properiher may determine di	, , , , , , , , , , , , , , , , , , ,		Дургола
PERICYAZINE – Safety medicine; prescriber may determine di	spensing frequency	100	
Tab 2.5 mg	spensing frequency	100	✓ Neulactil
Tab 2.5 mg Tab 10 mg	spensing frequency 12.49 44.45	100 100	
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis	spensing frequency 	100	✓ Neulactil✓ Neulactil
Tab 2.5 mg	spensing frequency 		 ✓ Neulactil ✓ Neulactil ✓ Dr Reddy's
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis	spensing frequency 	100	 Neulactil Neulactil Dr Reddy's Quetiapine
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis	spensing frequency 	100 60	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg	spensing frequency 	100 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis	spensing frequency 	100 60	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg	spensing frequency 	100 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg	spensing frequency 	100 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Seroquel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg	spensing frequency 	100 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Seroquel Quetapel Quetapel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg	spensing frequency 	100 60 90 60	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Seroquel Quetapel Dr Reddy's Dr Reddy's
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg	spensing frequency 	100 60 90 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Seroquel Quetapel Quetapel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg	spensing frequency 	100 60 90 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Seroquel Quetapel Dr Reddy's Dr Reddy's
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg	spensing frequency 	100 60 90 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Guetapel Dr Reddy's Quetapine Seroquel Dr Reddy's Quetapel Dr Reddy's Quetapel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg	spensing frequency 	100 60 90 60 90 60	 Neulactii Neulactii Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetapel Seroquel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg Tab 200 mg	spensing frequency 	100 60 90 60 90 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Quetapel Quetapel Quetapel Quetapel
Tab 2.5 mg Tab 10 mg QUETIAPINE – Safety medicine; prescriber may determine dis Tab 25 mg Tab 100 mg Tab 200 mg	spensing frequency 	100 60 90 60 90 60 90	 Neulactil Neulactil Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Quetapel Dr Reddy's Quetiapine Seroquel Dr Reddy's Dr Reddy's Quetapel Dr Reddy's Quetapel Dr Reddy's

	Subsidy (Manufacturer's Price \$) S Per	Fully Brand or ubsidised Generic Manufacturer
RISPERIDONE - Safety medicine; prescriber may determine d			
Tab 0.5 mg	3.51	60	 ✓ Apo-Risperidone ✓ Dr Reddy's Risperidone
			✓ Ridal
	1.17	20	
	(2.86)		Risperdal
Tab 1 mg	6.00	60	Apo-Risperidone
			 Dr Reddy's Risperidone
			Ridal
	(16.92)		Risperdal
Tab 2 mg	11.00	60	 Apo-Risperidone Dr Reddy's Risperidone
			✓ Ridal
	(33.84)		Risperdal
Tab 3 mg		60	 ✓ Apo-Risperidone ✓ Dr Reddy's
			Risperidone
	(50.30)		✓ Ridal
Tab. A second	(50.78)	00	Risperdal
Tab 4 mg	20.00	60	 Apo-Risperidone Dr Reddy's Risperidone
			✔ Ridal
	(67.68)		Risperdal
Oral liq 1 mg per ml		30 ml	Apo-Risperidone
	(25.26)		 Risperon Risperdal
TRIFLUOPERAZINE HYDROCHLORIDE - Safety medicine; p	rescriber mav determi	ne disper	nsing frequency
Tab 1 mg	,	100	✓ Stelazine
Tab 2 mg	14.64	100	 Stelazine
Tab 5 mg		100	✓ Stelazine
ZIPRASIDONE – Subsidy by endorsement			
a) Safety medicine; prescriber may determine dispensing fr b) Ziprasidone is subsidised for patients suffering from sch risperidone or quetiapine that has been discontinued, or is i effects or inadequate response, and the prescription is end	izophrenia or related p in the process of being orsed accordingly.	discontir	nued, because of unacceptable side
Cap 20 mg		60	Zeldox
Cap 40 mg		60	✓ Zeldox
Cap 60 mg		60	✓ Zeldox
Cap 80 mg		60	 Zeldox
ZUCLOPENTHIXOL HYDROCHLORIDE - Safety medicine; pr			
Tab 10 mg	04.45	100	Clopixol

	Subsidy (Manufacturer's Price) \$	Sub Per	sidised G	Brand or Generic Manufacturer
Depot Injections				
FLUPENTHIXOL DECANOATE – Safety medicine; prescriber ma	y determine dispensi	ng freque	ncy	
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	🖌 Flua	
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO		5	🖌 Flua	
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	🖌 Flua	nxol
FLUPHENAZINE DECANOATE – Safety medicine; prescriber ma				
Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSC		5 5	✓ Mod ✓ Mod	
Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		э 5	✓ Mod	
		-		ecale
HALOPERIDOL DECANOATE – Safety medicine; prescriber may		0 1	icy V Hald	
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		5 5		lol Concentrate
OLANZAPINE PAMOATE MONOHYDRATE – Special Authority s		Retail pha	rmacy	
Safety medicine; prescriber may determine dispensing freque Inj 210 mg		1		rexa Relprevv
Inj 200 mg		1		rexa Relprevv
Inj 405 mg		1		rexa Relprevv
SA1146 Special Authority for Subsidy			//-	
 Initial application from any relevant practitioner. Approvals valid All of the following: 1 The patient has schizophrenia; and 2 The patient has tried but failed to comply with treatment us 3 The patient has been admitted to hospital or treated in residays or more in the last 12 months. 	ing oral atypical antip	sychotic a	agents; and	ł
Renewal from any relevant practitioner. Approvals valid for 12 mo	nths for applications	meeting th	ne following	g criteria:
Either:		•		-
1 Both:				
1.1 The patient has had less than 12 months' treatment		ot injectior	n; and	
 1.2 There is no clinical reason to discontinue treatment; 2 The initiation of olanzapine depot injection has been assoc during a corresponding period of time prior to the initiation Note: The patient should be monitored for post-injection syndrome 	iated with fewer days of olanzapine depot i	njection.		
PIPOTHIAZINE PALMITATE - Safety medicine; prescriber may d				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		10	🖌 Pipo	ortil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO		10	🖌 Pipo	
RISPERIDONE – Special Authority see SA0926 below – Retail p Safety medicine; prescriber may determine dispensing freque	harmacy			
Inj 25 mg per 2 ml		1	🖌 Risp	erdal Consta
Inj 37.5 mg per 2 ml	230.00	1	🖌 Risp	erdal Consta
Inj 50 mg per 2 ml	280.00	1	🖌 Risp	erdal Consta
► SA0926 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid	for 6 months for appli	cations m	eeting the	following criteria:

All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 The patient has had less than 12 months treatment with risperidone depot injection; and
 - 1.2 There is no clinical reason to discontinue treatment; or
- 2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determi	1 0	quency
Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO19.80	5	Clopixol
Orodispersible Antipsychotics		
OLANZAPINE - Safety medicine; prescriber may determine dispensing freque	ency	
Orodispersible tab 5 mg6.36	28	 Dr Reddy's Olanzapine
		 Olanzine-D
Orodispersible tab 10 mg8.76	28	 Dr Reddy's Olanzapine
		 Olanzine-D
Wafer 5 mg6.36	28	
(102.19)		Zyprexa Zydis
Wafer 10 mg8.76	28	
(204.37))	Zyprexa Zydis
RISPERIDONE - Special Authority see SA0927 below - Retail pharmacy		
Safety medicine; prescriber may determine dispensing frequency		
Orally-disintegrating tablets 0.5 mg	28	 Risperdal Quicklet
Orally-disintegrating tablets 1 mg	28	Risperdal Quicklet
Orally-disintegrating tablets 2 mg	28	Risperdal Quicklet

►SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

	ubsidy cturer's Price) \$P	Full Subsidise er •	
Anxiolytics			
PRAZOLAM – Safety medicine; prescriber may determine dispensing fr Tab 250 μg	.15 50	~	Arrow-Alprazolam
Tab 500 μ g4. ‡ Safety cap for extemporaneously compounded oral liquid preparat	.10 50	~	Arrow-Alprazolam
Tab 1 mg 7. ‡ Safety cap for extemporaneously compounded oral liquid preparat	tions.		Arrow-Alprazolam
JSPIRONE HYDROCHLORIDE – Special Authority see SA0863 below –			
Tab 5 mg28.			Pacific Buspirone
Tab 10 mg17.	.00 100		Pacific Buspirone
tial application from any relevant practitioner. Approvals valid for 2 year: th: 1 For use only as an anxiolytic; and	rs for application	s meeting t	he following criteria:
2 Other agents are contraindicated or have failed. newal from any relevant practitioner. Approvals valid for 2 years where	e the treatment	remains a	opropriate and the patier
2 Other agents are contraindicated or have failed. enewal from any relevant practitioner. Approvals valid for 2 years where nefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr	requency	·	
2 Other agents are contraindicated or have failed. newal from any relevant practitioner. Approvals valid for 2 years where nefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr Tab 500 µg	requency .68 100		Paxam
2 Other agents are contraindicated or have failed. newal from any relevant practitioner. Approvals valid for 2 years where nefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr	requency .68 100		
2 Other agents are contraindicated or have failed. newal from any relevant practitioner. Approvals valid for 2 years where hefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr Tab 500 μg6. Tab 2 mg12. AZEPAM – Safety medicine; prescriber may determine dispensing freque Tab 2 mg11.	requency .68 100 .75 100 ency .44 500		Paxam
2 Other agents are contraindicated or have failed. enewal from any relevant practitioner. Approvals valid for 2 years where nefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr Tab 500 μg 6. Tab 2 mg 12. AZEPAM – Safety medicine; prescriber may determine dispensing frequence Tab 2 mg 12. AZEPAM – Safety medicine; prescriber may determine dispensing frequence Tab 2 mg 11. ‡ Safety cap for extemporaneously compounded oral liquid preparat Tab 5 mg 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat	requency .68 100 .75 100 ency .44 500 tions. .71 500 tions.		Paxam Paxam
2 Other agents are contraindicated or have failed. newal from any relevant practitioner. Approvals valid for 2 years where nefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr Tab 500 μg Tab 2 mg 6. Tab 2 mg 12. AZEPAM – Safety medicine; prescriber may determine dispensing frequence 11. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 13. ‡ Safety medicine; prescriber may determine dispensing frequence 14. Tab 5 mg 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat 14. PAZEPAM – Safety medicine; prescriber may determine dispensing frequence 16.	requency .68 100 .75 100 ency .44 500 tions. .71 500 tions. quency .42 250		Paxam Paxam Arrow-Diazepam
2 Other agents are contraindicated or have failed. newal from any relevant practitioner. Approvals valid for 2 years where hefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing from treatment. AZEPAM – Safety medicine; prescriber may determine dispensing frequencies. AZEPAM – Safety medicine; prescriber may determine dispensing frequencies. Tab 2 mg 11. ‡ Safety cap for extemporaneously compounded oral liquid preparat Tab 5 mg 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat RAZEPAM – Safety medicine; prescriber may determine dispensing frequencies.	requency .68 100 .75 100 ency .44 500 tions. .71 500 tions. quency .42 250 tions. .17 100		Paxam Paxam Arrow-Diazepam Arrow-Diazepam
2 Other agents are contraindicated or have failed. mewal from any relevant practitioner. Approvals valid for 2 years where nefiting from treatment. ONAZEPAM – Safety medicine; prescriber may determine dispensing fr Tab 500 μg Tab 2 mg 6. Tab 2 mg 12. AZEPAM – Safety medicine; prescriber may determine dispensing frequents Tab 2 mg 11. ‡ Safety cap for extemporaneously compounded oral liquid preparat Tab 5 mg 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat TAZEPAM – Safety medicine; prescriber may determine dispensing frequents Tab 5 mg 13. ‡ Safety cap for extemporaneously compounded oral liquid preparat Tab 5 mg 16. ‡ Safety cap for extemporaneously compounded oral liquid preparat RAZEPAM – Safety medicine; prescriber may determine dispensing frequents Tab 1 mg 16. ‡ Safety cap for extemporaneously compounded oral liquid preparat Tab 1 mg 16. ‡ Safety cap for extemporaneously compounded oral liquid preparat Tab 2.5 mg 11.	requency .68 100 .75 100 ency .44 500 tions. .71 500 tions. quency .42 250 tions. .17 100 tions. .17 100 tions. .89 100		Paxam Paxam Arrow-Diazepam Arrow-Diazepam <u>Ativan</u>

➡SA1062 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

Subsidy (Manufacturer's Pri	ce)	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

The coordinator	Phone: 04 4
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 0
PHARMAC PO Box 10 254	Email: msta

Phone: 04 460 4990 Facsimile: 04 916 7571 Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
 - a) EDSS score 2.5 5.5 with 2+ relapses:
 - experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
 - b) EDSS score 2.0 with 3+ relapses:
 - experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- 4) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- 7) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and

Subsidy		Fully	Brand or
(Manufacturer's Price)	Sub		Generic
\$	Per	~	Manufacturer

continued...

 patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability in defined as any of
 - of disability is defined as any of:
 - a) an increase of 2 EDSS points where starting EDSS was 2.0; or
 - b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or
 - c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - d) an increase in EDSS score to 6.0 or more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) pregnancy and/or lactation; or
- within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or
- 6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1062 on page 142 Inj 20 mg prefilled syringe	28	 Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA1062 on page 142		
Inj 6 million iu prefilled syringe	4	Avonex
Injection 6 million iu per 0.5 ml pen injector1,425.10	4	Avonex Pen
Inj 6 million iu per vial1,425.10	4	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA1062 on page 142		
Inj 8 million iu per 1 ml1,322.89	15	 Betaferon

Sedatives and Hypnotics

Tab 1 mg ± Safety cap for extemporaneously compounded oral liquid p	(23.50)	30	Noctamid
MIDAZOLAM – Safety medicine; prescriber may determine dispensi	0 1 2		
Inj 1 mg per ml, 5 ml	10.00	10	Pfizer
	10.75		Hypnovel
Inj 5 mg per ml, 3 ml	11.90	5	Hypnovel
			✓ Pfizer
NITRAZEPAM – Safety medicine; prescriber may determine dispension	sing frequency		
Tab 5 mg		100	
	(4.98)		Nitrados
± Safety cap for extemporaneously compounded oral liquid p	reparations.		

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
TEMAZEPAM – Safety medicine; prescriber may determine dispe Tab 10 mg ‡ Safety cap for extemporaneously compounded oral liquid		25	✓ <u>N</u>	lormison_
TRIAZOLAM – Safety medicine; prescriber may determine disper Tab 125 μ g	0 1 2	100	F	lypam
 ‡ Safety cap for extemporaneously compounded oral liquid Tab 250 μg ‡ Safety cap for extemporaneously compounded oral liquid 	4.10 (8.70)	100	F	lypam
2OPICLONE Tab 7.5 mg		30 500		po-Zopiclone

Stimulants/ADHD Treatments

Stimulants/ADHD treatments

ATOMOXETINE - Special Authority see SA0951 below	 Retail pharmacy 		
Cap 10 mg		28	Strattera
Cap 18 mg		28	 Strattera
Cap 25 mg		28	 Strattera
Cap 40 mg		28	 Strattera
Cap 60 mg		28	 Strattera
Cap 80 mg		28	 Strattera
Cap 100 mg		28	 Strattera

■SA0951 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

DEXAMPHETAMINE SULPHATE - Special Authority see SA1149 on the next page - Retail pharmacy

a) Only on a controlled drug form		
b) Safety medicine; prescriber may determine dispensing frequency		
Tab 5 mg	100	🖌 PSM

Subsidy (Manufacturer's Price)	ç	Fully Subsidised	Brand or Generic	
\$	Per	V	Manufacturer	

SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and

- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE - Special Authority see SA1150 below - Retail pharmacy

a) Only on a controlled drug form

 b) Safety medicine; prescriber may determine dispension 	sing frequency		
Tab immediate-release 5 mg		30	Rubifen
Tab immediate-release 10 mg		30	Ritalin
-			Rubifen
Tab immediate-release 20 mg	7.85	30	Rubifen
Tab sustained-release 20 mg		30	Rubifen SR
-	50.00	100	Ritalin SR

SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

NERVOUS SYSTEM

	Subsidy	Fully	Brand or
(Ma	anufacturer's Price)	Subsidised	Generic
	\$ P	Per 🖌	Manufacturer

continued...

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
 - 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

- 2.1 Applicant is a paediatrician or psychiatrist; or
- 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA1151 below - Retail pharmacy

 a) Only on a controlled drug 	form
--	------

b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 18 mg		30 🖌	Concerta
Tab extended-release 27 mg		30 🖌	Concerta
Tab extended-release 36 mg	71.93	30 🖌	Concerta
Tab extended-release 54 mg		30 🖌	Concerta
Cap modified-release 10 mg		30 🖌	Ritalin LA
Cap modified-release 20 mg		30 🖌	Ritalin LA
Cap modified-release 30 mg		30 🖌	Ritalin LA
Cap modified-release 40 mg		30 🖌	Ritalin LA

➡SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustainedrelease) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
continued 1 The treatment remains appropriate and the patient is be 2 Either:	nefiting from treatment;	and		
 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Applicant is a medical practitioner and confirms tand has recommended treatment for the patient. 	hat a relevant specialis	t has bee	en consul	ted within the last 2 year
IODAFINIL – Special Authority see SA1126 below – Retail ph Tab 100 mg		30	🗸 M	odavigil
SA1126 Special Authority for Subsidy nitial application only from a neurologist or respiratory special billowing criteria: Ill of the following:	cialist. Approvals valid	for 24 m	onths for	r applications meeting th
 The patient has a diagnosis of narcolepsy and has ex almost daily for three months or more; and Either: 	cessive daytime sleepi	ness ass	sociated	with narcolepsy occurrir
 2.1 The patient has a multiple sleep latency test with more sleep onset rapid eye movement periods; o 2.2 The patient has at least one of: cataplexy, sleep p 3 Either: 	r			
 3.1 An effective dose of a subsidised formulation of tinued because of intolerable side effects; or 3.2 Methylphenidate and dexamphetamine are contra enewal only from a neurologist or respiratory specialist. Applied the patient is benefiting from treatment. 	aindicated.			
Treatments for Dementia				
			4.5	
← Tab 5 mg		90 90		onepezil-Rex onepezil-Rex
Treatments for Opioid Overdose				
ALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO				
 Inj 400 μg per ml, 1 ml 		5	🖌 M	ayne
Treatments for Substance Dependence				
BUPRENORPHRINE WITH NALOXONE - Special Authority s	ee SA1203 on the next	page – F	letail pha	rmacy
 a) No patient co-payment payable b) Safety medicine; prescriber may determine dispensing f 	requency			
Tab sublingual 2 mg with naloxone 0.5 mg		28	🖌 Si	uboxone
Tab cublingual 8 mg with palayona 2 mg	166.00	20	10	uhovono

Tab sublingual 8 mg with naloxone 2 mg	 28	 Suboxone

NERVOUS SYSTEM

(Mani	Subsidy Jfacturer's Price)	Fu Subsidise	,	Brand or Generic
(Manu	liaciurers Frice)	Subsidise	eu	Generic
	\$	Per	~	Manufacturer

SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health..

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

	•
DISULFIRAM Tab 200 mg24.30 100	Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 on the next page – Retail pha Tab 50 mg	

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
	ą	rei	~	Manulaclurer
SA0909 Special Authority for Subsidy				
Initial application from any medical practitioner. Approvals valid for	or 3 months for appli	cation	s meeting th	ne following criteria:
Both:				
1 Patient is currently enrolled in a recognised comprehensive				
2 Applicant works in or with a community Alcohol and Drug Ser				
against the New Zealand Alcohol and Other Drug Sector Sta				
Renewal from any medical practitioner. Approvals valid for 3 month	hs for applications m	eeting	g the followir	ng criteria:
Both:				
1 Compliance with the medication (prescriber determined); an	nd			
2 Any of the following:				
2.1 Patient is still unstable and requires further treatment				
2.2 Patient achieved significant improvement but requires2.3 Patient is well controlled but requires maintenance the		or		
The patient must not have had more than 1 prior approval in the la				
	51 12 11011115.			
NICOTINE	de la constructo de ser			to t
Nicotine will not be funded under the Dispensing Frequency R				
Patch 7 mg – Up to 28 patch available on a PSO		28		abitrol
Patch 14 mg – Up to 28 patch available on a PSO		28		abitrol
Patch 21 mg – Up to 28 patch available on a PSO		28		abitrol
Lozenge 1 mg – Up to 216 loz available on a PSO		216		abitrol
Lozenge 2 mg – Up to 216 loz available on a PSO		216 384		abitrol
Gum 2 mg (Classic) – Up to 384 piece available on a PSO		384 384		abitrol
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO Gum 2 mg (Mint) – Up to 384 piece available on a PSO		384 384		<u>abitrol</u> abitrol
Gum 2 mg (Mint) – Op to 384 piece available on a PSO Gum 4 mg (Classic) – Up to 384 piece available on a PSO		384		abitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO		384		abitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO		384		abitrol
		004	• <u>11</u>	

VARENICLINE TARTRATE - Special Authority see SA1161 below - Retail pharmacy

a) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment.
 b) A maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

Champix	28		Tab 1 mg
Champix	56	135.48	-
Champix	25 OP	460.48	Tab 0.5 mg $ imes$ 11 and 1 mg $ imes$ 14 .

SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and

Subsidy (Manufacturer's Price		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg	59.50	100	V M	yleran
CARBOPLATIN – PCT only – Specialist	~~~~		4.0	
Inj 10 mg per ml, 5 ml		1		arboplatin Ebewe
Inj 10 mg per ml, 15 ml		1		arbaccord
	22.50			arboplatin Ebewe
Inj 10 mg per ml, 45 ml		1		arbaccord
	50.00			arboplatin Ebewe
	105.00			BL Carboplatin
Inj 10 mg per ml, 100 ml		1	V B	arboplatin Ebewe
Inj 1 mg for ECP	0.13	1 mg	V D	axter
CARMUSTINE – PCT only – Specialist				
Inj 100 mg		1	V B	
Inj 100 mg for ECP	204.13	100 mg OP	🗸 В	axter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg		25	🖌 Lo	eukeran FC
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml	15.00	1	V C	isplatin Ebewe
		·		BL Cisplatin
Inj 1 mg per ml, 100 ml		1		isplatin Ebewe
		·		BL Cisplatin
Inj 1 mg for ECP	0.27	1 mg	V B	
CYCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist	25 71	50	10	vcloblastin
Inj 1 g – PCT – Retail pharmacy-Specialist		50 1		ndoxan
		6		ytoxan
Inj 2 g – PCT only – Specialist		1		ndoxan
Inj 1 mg for ECP – PCT only – Specialist		1 mg	✓ B	
		i ng	• 0	
FOSFAMIDE – PCT only – Specialist	~~~~			
lnj 1 g		1		oloxan
Inj 2 g		1		oloxan
Inj 1 mg for ECP	0.10	1 mg	🗸 В	axter
OMUSTINE – PCT only – Specialist				
Cap 10 mg		20	V C	
Cap 40 mg		20	V C	eeNU
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist	31.31	25	🖌 A	lkeran
Inj 50 mg – PCT only – Specialist		1	🖌 A	lkeran

	Subsidy (Manufacturer's Pric	e) (Fully Brand or Subsidised Generic
	(Manulactuler's Frid \$	Per	Manufacturer
OXALIPLATIN – PCT only – Specialist			
Inj 50 mg	15.32	1	 Oxaliplatin Actavis
	55.00		50
	55.00 200.00		 Oxaliplatin Ebewe Eloxatin
Inj 100 mg		1	 Oxaliplatin Actavis
	20.01		100
	110.00		Oxaliplatin Ebewe
	400.00		Eloxatin
Inj 1 mg for ECP	0.28	1 mg	Baxter
THIOTEPA – PCT only – Specialist			
Inj 15 mg	CBS	1	Bedford S29
			THIO-TEPA S29
Antimetabolites			
CALCIUM FOLINATE			
Tab 15 mg – PCT – Retail pharmacy-Specialist		10	✓ DBL Leucovorin
			Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist		5	Mayne
Inj 50 mg – PCT – Retail pharmacy-Specialist		5	 Calcium Folinate
hei 400 mm - DOT anha - Os asialist	0.75		Ebewe
Inj 100 mg – PCT only – Specialist	9.75	1	 Calcium Folinate Ebewe
Inj 300 mg – PCT only – Specialist	30.00	1	Calcium Folinate
		I	Ebewe
Inj 1 g – PCT only – Specialist		1	✓ Calcium Folinate
			Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.10	1 mg	Baxter
CAPECITABINE – Retail pharmacy-Specialist			
Tab 150 mg		60	Xeloda
Tab 500 mg	705.00	120	Xeloda
CLADRIBINE – PCT only – Specialist			
Inj 1 mg per ml, 10 ml	5,249.72	7	 Leustatin
Inj 10 mg for ECP		10 mg OP	Baxter
CYTARABINE			
Inj 100 mg – PCT – Retail pharmacy-Specialist	76.00	5	Pfizer
	80.00		Mayne
Inj 500 mg – PCT – Retail pharmacy-Specialist		1	✓ Pfizer
Inj 1 g – PCT – Retail pharmacy-Specialist	95.36	5 1	 ✓ Mayne ✓ Pfizer
	42.65	I	Mayne
Inj 2 g – PCT – Retail pharmacy-Specialist		1	✓ Pfizer
	34.47		✓ Mayne
Inj 1 mg for ECP – PCT only – Specialist		10 mg	✓ Baxter
Inj 100 mg intrathecal syringe for ECP - PCT only - Specialis	st15.20 1	00 mg OF	Baxter

	Subsidy		Fully Brand or
()	Vanufacturer's I \$	Price) Sub Per	osidised Generic Manufacturer
	Ŧ		
UDARABINE PHOSPHATE – PCT only – Specialist	100 50	20	Fludara Oral
Tab 10 mg		20 5	✓ Fludarabine Ebewe
Inj 50 mg		5	✓ Fludara
Inj 50 mg for ECP	1,430.00	50 mg OB	Baxter
	105.00	50 mg OP	
UOROURACIL SODIUM			
Inj 50 mg per ml, 10 ml – PCT only – Specialist		5	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml – PCT only – Specialist		1	Fluorouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist		1	Mayne
Inj 50 mg per ml, 50 ml – PCT only – Specialist		1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml – PCT only – Specialist		1	Fluorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.77	100 mg	Baxter
MCITABINE HYDROCHLORIDE - PCT only - Specialist			
	62 50	1	DBL Gemcitabine
iii) i g	02.00		✓ Gemcitabine
			Actavis 1000
			Gemcitabine Ebewe
	240.00		Gemzar
lai 000 ma	349.20		
Inj 200 mg	12.50	1	Gemcitabine
			Actavis 200
			Gemcitabine Ebewe
	78.00		Gemzar
Inj 1 mg for ECP	0.07	1 mg	Baxter
NOTECAN – PCT only – Specialist			
Inj 20 mg per ml, 2 ml	9.34	1	Irinotecan Actavis
J - 3			40
	41.00		✓ Camptosar
	41.00		✓ Irinotecan-Rex
Inj 20 mg per ml, 5 ml	23 34	1	 Irinotecan Actavis
	20.04	1	100
	100.00		
	100.00		Camptosar
	0.04	4	✓ Irinotecan-Rex
Inj 1 mg for ECP	0.24	1 mg	Baxter
RCAPTOPURINE – PCT – Retail pharmacy-Specialist			
Tab 50 mg	47.06	25	Purinethol
THOTREXATE			
Tab 2.5 mg - PCT - Retail pharmacy-Specialist	5 22	30	Methoblastin
Tab 10 mg – PCT – Retail pharmacy-Specialist		50	✓ Methoblastin
Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist		5	
			Mayne
Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist		5	✓ <u>Hospira</u>
Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist		1	✓ <u>Hospira</u>
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist.		1	Methotrexate Ebewe
Inj 25 mg per ml, 40 ml – PCT – Retail pharmacy-Specialist	25.00	1	✓ DBL
			Methotrexate S29
Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist		1	 Methotrexate Ebewe
Inj 1 mg for ECP – PCT only – Specialist		1 mg	Baxter
Inj 5 mg intrathecal syringe for ECP - PCT only - Specialist	4.73	5 mg OP	Baxter
IOGUANINE – PCT – Retail pharmacy-Specialist		-	
Tab 40 mg	97 16	25	Lanvis

	Subsidy (Manufacturer's Price) \$) Per	Full Subsidise	
Other Cytotoxic Agents				
AMSACRINE – PCT only – Specialist Inj 75 mg	CBS	6	~	Amsidine S29
ANAGRELIDE HYDROCHLORIDE – PCT only – Specialist Cap 0.5 mg	CBS	100		Agrylin S29 Teva S29
ARSENIC TRIOXIDE – PCT only – Specialist Inj 10 mg	4,817.00	10	~	AFT \$29
BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu	120.00	1	V	DBL Bleomycin Sulfate
Inj 1,000 iu for ECP		,000 iu	. 🗸	Baxter
BORTEZOMIB - PCT only - Specialist - Special Authority see	SA1127 below			
Inj 1 mg		1	~	Velcade
Inj 3.5 mg		1	• .	Velcade
Inj 1 mg for ECP	594.77	1 mg	V	Baxter

SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.
- Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

a) a known therapeutic chemotherapy regimen and supportive treatments; or

b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

	1 OT Only	opeoialist		
Inj 10,000 iu			1	Leunase
Inj 10,000 iu for ECP			10,000 iu OP	 Baxter

COLASPASE [L-ASPARAGINASE] - PCT only - Specialist

	Subsidy (Manufacturer's Price)		Fully Brand or osidised Generic
	(Manulacturer 3	Per	Manufacturer
DACARBAZINE – PCT only – Specialist			
Inj 200 mg		1	Hospira
Inj 200 mg for ECP		200 mg OP	✓ Baxter
DACTINOMYCIN [ACTINOMYCIN D] - PCT only - Specialist			
Inj 0.5 mg		1	Cosmegen
Inj 0.5 mg for ECP		0.5 mg OP	✓ Baxter
DAUNORUBICIN – PCT only – Specialist		olo llig ol	
5 1	110 70	4	✓ Pfizer
Inj 2 mg per ml, 10 ml		1 20 ma OB	Baxter
Inj 20 mg for ECP		20 mg OP	
DOCETAXEL – PCT only – Specialist			
lnj 20 mg		1	Docetaxel Ebewe
lnj 20 mg per ml, 1 ml		1	✓ Taxotere
Inj 20 mg per ml, 4 ml		1	✓ Taxotere
lnj 80 mg		1	Docetaxel Ebewe
Inj 1 mg for ECP	3.71	1 mg	Baxter
DOXORUBICIN – PCT only – Specialist			
lnj 10 mg		1	Doxorubicin Ebewe
lni 50 mg		1	Arrow-Doxorubicin
, ,	40.00		DBL Doxorubicin
			DBL Doxorubicin
			S29 S29
			Doxorubicin Ebewe
Inj 100 mg	80.00	1	Doxorubicin Ebewe
Inj 200 mg		1	✓ Arrow-Doxorubicin
	150.00		✓ Adriamycin
			✓ Doxorubicin Ebewe
Inj 1 mg for ECP	0.88	1 mg	Baxter
, .		5	
EPIRUBICIN – PCT only – Specialist	05.00	1	Christophiain Ebaura
Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 25 ml		1	Epirubicin Ebewe
ing 2 mg per mi, 25 mi		I	DBL Epirubicin
	07 50		Hydrochloride
	87.50		Epirubicin Ebewe
Inj 2 mg per ml, 50 ml		1	DBL Epirubicin Hydrophlarida
	105 00		Hydrochloride
	125.00		Epirubicin Ebewe
Inj 2 mg per ml, 100 ml		1	DBL Epirubicin
	040.00		Hydrochloride
	210.00		Epirubicin Ebewe
Inj 1 mg for ECP	0.82	1 mg	Baxter
ETOPOSIDE			
Cap 50 mg – PCT – Retail pharmacy-Specialist		20	Vepesid
Cap 100 mg - PCT - Retail pharmacy-Specialist		10	✓ Vepesid
Inj 20 mg per ml, 5 ml - PCT - Retail pharmacy-Specialist.		1	✓ Mayne
	612.20	10	Vepesid
Inj 1 mg for ECP – PCT only – Specialist	0.30	1 mg	✓ Baxter
ETOPOSIDE PHOSPHATE – PCT only – Specialist		-	
Inj 100 mg (of etoposide base)	40.00	1	Etopophos
Inj 1 mg (of etoposide base) for ECP			Baxter
ing i my (vi elupuside base) ivi EUF	0.47	1 mg	

	Subsidy (Manufacturer's I	Prico) Su	Fully Brand or bsidised Generic
	(ivialiulaciulei si \$	Per	Manufacturer
YDROXYUREA – PCT – Retail pharmacy-Specialist			
Cap 500 mg		100	Hydrea
ARUBICIN HYDROCHLORIDE – PCT only – Specialist			•
Cap 5 mg	115.00	1	Zavedos
Cap 10 mg		1	✓ Zavedos
Inj 5 mg		1	✓ Zavedos
Inj 10 mg		1	✓ Zavedos
Inj 1 mg for ECP		1 mg	✓ Baxter
, ,		Ting	U Daxlei
ESNA – PCT only – Specialist			
Tab 400 mg	210.65	50	Uromitexan
Tab 600 mg		50	 Uromitexan
Inj 100 mg per ml, 4 ml	137.04	15	Uromitexan
Inj 100 mg per ml, 10 ml		15	Uromitexan
Inj 1 mg for ECP	2.29	100 mg	Baxter
ITOMYCIN C – PCT only – Specialist		-	
, ,	70 75	1	✓ Arrow
Inj 5 mg			✓ Anow ✓ Baxter
Inj 1 mg for ECP		1 mg	V Daxler
ITOZANTRONE – PCT only – Specialist			
Inj 2 mg per ml, 5 ml		1	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml		1	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml		1	Onkotrone
Inj 1 mg for ECP		1 mg	Baxter
ACLITAXEL – PCT only – Specialist		Ũ	
	127 50	5	Paclitaxel Ebewe
Inj 30 mg		5 1	
Inj 100 mg	91.67	I	Paclitaxel Actavis
	407 50		Paclitaxel Ebewe
Inj 150 mg		1	Anzatax
			Paclitaxel Actavis
			Paclitaxel Ebewe
Inj 300 mg	275.00	1	Anzatax
			Paclitaxel Actavis
			Paclitaxel Ebewe
Inj 600 mg		1	Paclitaxel Ebewe
Inj 1 mg for ECP	1.02	1 mg	Baxter
ENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Speciali	st		
Inj 10 mg		1	V Nipent S29
· •			t inpontozo
ROCARBAZINE HYDROCHLORIDE – PCT only – Specialist			A 11 - 1 -
Cap 50 mg		50	Natulan S29
EMOZOLOMIDE - Special Authority see SA1063 on the next	page – Retail pha	rmacy	
Cap 5 mg		5	Temaccord
Cap 20 mg		5	✓ Temaccord
		•	
Cap 20 mg	350.00	5	Temaccord

	Subsidy (Manufacturer's Prio \$	ce) (Per	Fully Subsidised	Brand or Generic Manufacturer
=> CA10C2 Crossial Authority for Cubaidy	Ψ	1.61	•	Manulacturer
SA1063 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals valid for a special spec	or 10 months for	annlicatio	ns meeting	the following criteria:
All of the following:		applicatio	no meeting	r the following officina.
1 Either:				
1.1 Patient has newly diagnosed glioblastoma multiforme	; or			
1.2 Patient has newly diagnosed anaplastic astrocytoma*	; and			
2 Temozolomide is to be (or has been) given concomitantly wi				
3 Following concomitant treatment temozolomide is to be used dose of 200 mg/m ² .				
Notes: Indication marked with a * is an Unapproved Indication.	Temozolomide is	not subs	sidised for	the treatment of relapse
lioblastoma multiforme. Reapplications will not be approved.				
Studies of temozolomide show that its benefit is predominantly in the				e status (WHO grade 0
or Karnofsky score >80), and in patients who have had at least a	•	or the tur	iour.	
THALIDOMIDE – PCT only – Specialist – Special Authority see S		00		h a la un i d
Cap 50 mg		28 28		halomid halomid
Cap 100 mg	1,008.00	28	V 11	naiomia
SA1124 Special Authority for Subsidy				
				evant specialist. Approva
nitial application only from a relevant specialist or medical practiti	ioner on the reco	nmendati	on of a rele	
nitial application only from a relevant specialist or medical practiti alid for 12 months for applications meeting the following criteria:	ioner on the reco	nmendati	on of a rele	
nitial application only from a relevant specialist or medical practiti alid for 12 months for applications meeting the following criteria: ither:	ioner on the reco	nmendati	on of a rele	
nitial application only from a relevant specialist or medical practiti ralid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or	ioner on the reco	nmendati	on of a rele	
nitial application only from a relevant specialist or medical practiti alid for 12 months for applications meeting the following criteria: ither:				
nitial application only from a relevant specialist or medical practiti ralid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*.	n the recommend	ation of a	a relevant s	specialist. Approvals va
nitial application only from a relevant specialist or medical practiti ralid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or	n the recommend	ation of a	a relevant s ent during	specialist. Approvals va the initial approval perio
 nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in supplier. 	n the recommend ned a response fro the thalidomide n	lation of a om treatm isk mana	a relevant s ent during	specialist. Approvals va the initial approval perio
nitial application only from a relevant specialist or medical practiti ralid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in supplier. Maximum dose of 400 mg daily as monotherapy or in a combination	n the recommend ned a response fro the thalidomide n	lation of a om treatm isk mana	a relevant s ent during	specialist. Approvals va the initial approval perio
 nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in supplier. 	n the recommend ned a response fro the thalidomide n	lation of a om treatm isk mana	a relevant s ent during	specialist. Approvals va the initial approval peric
nitial application only from a relevant specialist or medical practiti ralid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in supplier. Maximum dose of 400 mg daily as monotherapy or in a combination	n the recommend ned a response fro the thalidomide n	lation of a om treatm isk mana	a relevant s ient during gement pro	specialist. Approvals va the initial approval peric ogramme operated by tl
nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in upplier. <i>M</i> aximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication.	n the recommend ned a response frr the thalidomide r n therapy regimen	lation of a om treatm isk mana	a relevant s ient during gement pro	specialist. Approvals va the initial approval perio
nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in upplier. <i>Aaximum</i> dose of 400 mg daily as monotherapy or in a combination indication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg Cap 10 mg PCT – Retail pharmacy-Specialist VINBLASTINE SULPHATE Vinbut Attente	n the recommend ned a response frr the thalidomide r n therapy regimer 435.90	lation of a om treatm isk mana n.	a relevant s ient during gement pro	specialist. Approvals va the initial approval peric ogramme operated by t
nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in upplier. <i>Aaximum</i> dose of 400 mg daily as monotherapy or in a combination indication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg Cap 10 mg PCT – Retail pharmacy-Specialist VINBLASTINE SULPHATE Vinbut Attente	n the recommend ned a response frr the thalidomide r n therapy regimer 435.90	lation of a om treatm isk mana n.	a relevant s ient during gement pro	specialist. Approvals va the initial approval peric ogramme operated by th esanoid
nitial application only from a relevant specialist or medical practiti alid for 12 months for applications meeting the following criteria: cither: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in upplier. Aaximum dose of 400 mg daily as monotherapy or in a combination indication marked with * is an Unapproved Indication. RETINOIN Cap 10 mg PCT – Retail pharmacy-Specialist VINBLASTINE SULPHATE Inj 10 mg Inj 10 mg PCT – Retail pharmacy-Specialist	n the recommend ned a response frr the thalidomide r n therapy regimen 435.90 	lation of a com treatm isk mana n. 100	a relevant s eent during gement pro	specialist. Approvals va the initial approval peric ogramme operated by th esanoid ayne
nitial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in upplier. Naximum dose of 400 mg daily as monotherapy or in a combination indication marked with * is an Unapproved Indication. RETINOIN Cap 10 mg Cap 10 mg PCT – Retail pharmacy-Specialist VINBLASTINE SULPHATE Vindex Patient PatientPatient Patient PatientPatient Patient Patient Patient Patient Pa	n the recommend ned a response frr the thalidomide r n therapy regimen 435.90 	lation of a com treatm isk mana n. 100 1	a relevant s eent during gement pro Va V Va V M	specialist. Approvals va the initial approval peric ogramme operated by th esanoid ayne ayne
nitial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain Notes: Prescription must be written by a registered prescriber in upplier. Aximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. "RETINOIN Cap 10 mg - PCT - Retail pharmacy-Specialist VINBLASTINE SULPHATE Inj 10 mg - PCT - Retail pharmacy-Specialist	n the recommend ned a response frr the thalidomide r n therapy regimen 435.90 	lation of a om treatm isk mana n. 100 1 5	a relevant s eent during gement pro Va V M V M	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne
nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in supplier. Maximum dose of 400 mg daily as monotherapy or in a combination indication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg - PCT – Retail pharmacy-Specialist Inj 1 mg for ECP - PCT only – Specialist	n the recommend red a response for the thalidomide of n therapy regiment 435.90 	lation of a om treatm isk mana n. 100 1 5	a relevant s eent during gement pro V Ve V M V M V B	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne
nitial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain Notes: Prescription must be written by a registered prescriber in upplier. Aaximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg PCT – Retail pharmacy-Specialist Inj 10 mg PCT – Retail pharmacy-Specialist Inj 1 mg for ECP PCT only – Specialist /INCRISTINE SULPHATE Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist /INCRISTINE SULPHATE Inj 1 mg per ml, 2 ml Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist /INCRISTINE SULPHATE Inj 1 mg per ml, 2 ml Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist	n the recommend red a response fro the thalidomide of n therapy regimen 435.90 	ation of a om treatm isk mana n. 100 1 5 1 mg	a relevant s eent during gement pro Va M M M M B B H	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne axter
nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lotes: Prescription must be written by a registered prescriber in upplier. Aaximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg PCT – Retail pharmacy-Specialist Inj 10 mg PCT – Retail pharmacy-Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg per ml, 1 ml PCT – Retail pharmacy-Specialist	n the recommend red a response fro the thalidomide of n therapy regimen 435.90 	ation of a om treatm isk mana n. 100 1 5 1 mg 5	a relevant s eent during gement pro Va M M M M B B H	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne axter ospira ospira
nitial application only from a relevant specialist or medical practitivalid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain lootes: Prescription must be written by a registered prescriber in supplier. Maximum dose of 400 mg daily as monotherapy or in a combination indication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg - PCT – Retail pharmacy-Specialist. Inj 1 mg for ECP - PCT only – Specialist. Inj 1 mg per ml, 1 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist. Inj 1 mg per ml, 2 ml - PCT – Retail pharmacy-Specialist.	n the recommend red a response fro the thalidomide of n therapy regimen 435.90 	ation of a om treatm isk mana n. 100 1 5 1 mg 5 5	a relevant s eent during gement pro Va V M V M V B H V H V H	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne axter ospira ospira
nitial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain Notes: Prescription must be written by a registered prescriber in auximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg PCT – Retail pharmacy-Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg per ml, 1 ml PCT – Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist	n the recommend red a response for the thalidomide of n therapy regimes 435.90 435.90 	ation of a om treatm isk mana n. 100 1 5 1 mg 5 5	a relevant s ent during gement pro V Va V M V M V B V H V H V H V H V B	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne axter ospira ospira
initial application only from a relevant specialist or medical practiti initial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain Notes: Prescription must be written by a registered prescriber in upplier. Aaximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg - PCT - Retail pharmacy-Specialist Inj 10 mg - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP - PCT only - Specialist Inj 1 mg per ml, 1 ml - PCT - Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP	n the recommend hed a response fr the thalidomide n n therapy regimen 435.90 	lation of a om treatm isk mana n. 100 1 5 1 mg 5 5 1 mg	a relevant s eent during gement pro V Va V M V M V B V H V H V H V H V H V H V H V H V H V H	specialist. Approvals va the initial approval perio ogramme operated by t esanoid ayne ayne axter ospira ospira axter
nitial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain Notes: Prescription must be written by a registered prescriber in auximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg PCT – Retail pharmacy-Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg per ml, 1 ml PCT – Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml PCT – Retail pharmacy-Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist Inj 1 mg for ECP PCT only – Specialist	n the recommend hed a response fr the thalidomide n n therapy regimen 435.90 	lation of a om treatm isk mana n. 100 1 5 1 mg 5 5 1 mg	a relevant s eent during gement pro V Ve V M V M V B V H V H V H V B S V N V Vi	specialist. Approvals va the initial approval perio ogramme operated by th esanoid ayne ayne ayne axter ospira ospira axter avelbine
initial application only from a relevant specialist or medical practiti initial application only from a relevant specialist or medical practiti raid for 12 months for applications meeting the following criteria: Either: 1 The patient has multiple myeloma; or 2 The patient has systemic AL amyloidosis*. Renewal only from a relevant specialist or medical practitioner or vithout further renewal unless notified where the patient has obtain Notes: Prescription must be written by a registered prescriber in upplier. Aaximum dose of 400 mg daily as monotherapy or in a combination ndication marked with * is an Unapproved Indication. TRETINOIN Cap 10 mg - PCT - Retail pharmacy-Specialist Inj 10 mg - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP - PCT only - Specialist Inj 1 mg per ml, 1 ml - PCT - Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist Inj 1 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP - PCT - Retail pharmacy-Specialist Inj 1 mg for ECP	n the recommend ned a response fr the thalidomide n n therapy regimen 435.90 27.50 137.50 3.05 108.00 116.00 15.77 12.85 42.00 64.25 210.00	ation of a om treatm isk mana n. 100 1 5 1 mg 5 5 1 mg 1	e relevant s ient during gement pro Ve Ve M M M B B H H V H V B V N X V N X	specialist. Approvals va the initial approval perio ogramme operated by th esanoid ayne ayne ayne axter ospira ospira axter avelbine inorelbine Ebewe

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic	
Protein-tyrosine Kinase Inhibitors					
DASATINIB – Special Authority see SA0976 below					
Tab 20 mg	3,774.06	60	v 9	Sprycel	
Tab 50 mg	6,214.20	60	v 9	Sprycel	
Tab 70 mg	7,692.58	60	V 9	Sprycel	
Tab 100 mg	6,214.20	30	v 9	Sprycel	

➡SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz

Wellington

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^9 /L, platelets > 100×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 10⁹/L, platelets > 20 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB HYDROCHLORIDE	- Retail pharmacy-Specialist - Special Authority	see SA104	4 on the next page
Tab 100 mg		30	 Tarceva
Tab 150 mg		30	Tarceva

		Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
►SA1044 Special Authority fr Initial application only from a rel valid for 4 months for applications All of the following:	evant specialist or medical pra	ctitioner on the recomm	endation o	f a rele	vant specialist. Approvals
 Patient has advanced, unr. Patient has documented d Erlotinib is to be given for a Renewal only from a relevant spe 	ecialist or medical practitioner of	eatment with first line plant	of a releva	ant spe	cialist. Approvals valid for
6 months where radiological asse		T scan) indicates NSCL	.C has not	progre	ssed.
GEFITINIB – Retail pharmacy-Sp Tab 250 mg Special Auto	pecialist rity see SA1226 below	1 700 00	30	🖌 Ire	1000
►SA1226 Special Authority f		1,700.00	30	• ne	:55a
Initial application only from a rel valid for 4 months for applications Either:	evant specialist or medical pra	ctitioner on the recomm	endation o	f a rele	vant specialist. Approvals
cer (NSCLC); and 1.2 There is documenta	nt naive locally advanced, or n tion confirming that disease ex	presses activating muta			-
0	en for a maximum of 3 months nib treatment prior to 1 August progressed.	·	assessmer	nt (prefe	erably including CT scan)
Renewal only from a relevant spe 6 months where radiological asse					
IMATINIB MESYLATE – Special Tab 100 mg	Authority see SA0643 below	2,400.00	60	🖌 GI	ivec
SA0643 Special Authority fr Special Authority approved by the Notes: Application details may be sent to: The CML/GIST Co-ordinator PHARMAC PO Box 10 254 Wellington	CML/GIST Co-ordinator		rmac.govt.	<u>nz</u> , an	d prescriptions should be
Special Authority criteria for CI	/L – access by application				
a) Funded for patients with o accelerated phase, or in ch	liagnosis (confirmed by a hae pronic phase. day for accelerated or blast ph	č ,			

- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Guideline on discontinuation of treatment for patients with CML

a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

- 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^9 /L, platelets > 100×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
- 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
- return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

Special Authority criteria for GIST - access by application

- a) Funded for patients:
 - with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

Tvkerb

70

➡SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.
- Renewal (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:
- All of the following:
 - 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
 - 3 Lapatinib not to be given in combination with trastuzumab; and
 - 4 Lapatinib to be discontinued at disease progression.

PAZOPANIB - Special Authority see SA1190 on the next pa	age – Retail pharmacy		
Tab 200 mg	1,334.70	30	 Votrient
Tab 400 mg	2,669.40	30	 Votrient

	Subsidy (Manufacturer's Price)	l Subsid	Fully dised	Brand or Generic		
	\$	Per	~	Manufacturer		
SA1190 Special Authority for Subsidy						
Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals						
valid for 3 months for applications meeting the following criteria:						

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of $\leq~$ 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – Special Authority see SA1266 below – Retail pharmacy

Cap 12.5 mg2,315.38	28	Sutent
Cap 25 mg4,630.77	28	Sutent
Cap 50 mg9,261.54	28	 Sutent

SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- The patient has metastatic renal cell carcinoma: and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and

|--|

continued...

The patient has intermediate or poor prognosis defined as:

- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST): and

2 Either:

- 2.1 The patient's disease has progressed following treatment with imatinib; or
- 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of $\geq 10\%$ or decrease in tumour density in Hounsfield Units (HU) of $\geq 15\%$ on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PRE	PARATIONS, Trophic Hormones, pa	age	84
BICALUTAMIDE - Special Authority see SA0941 be	elow – Retail pharmacy		
Tab 50 mg		28	Bicalaccord
► SA0941 Special Authority for Subsidy Initial application from any medical practitioner. A advanced prostate cancer.	Approvals valid without further rene	wal	unless notified where the patient has
FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg		100	✓ <u>Flutamin</u>
± safety cap	▲Three months supply ma	av be	dispensed at one time

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	d Generic
MEGESTROL ACETATE – Retail pharmacy-Specialist				
Tab 160 mg	51.55 (57.92)	30		Apo-Megestrol Megace
(Megace Tab 160 mg to be delisted 1 April 2013)				-
OCTREOTIDE (SOMATOSTATIN ANALOGUE)				
Inj 50 μ g per ml, 1 ml	19.24	5	~	Octreotide MaxRx
Inj 100 μ g per ml, 1 ml		5	~	Octreotide MaxRx
Inj 500 μ g per ml, 1 ml		5	~	Octreotide MaxRx
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) - Special Au	uthority see SA1016 b	below	– Retail p	harmacy
Inj LAR 10 mg prefilled syringe	1,772.50	1	V	Sandostatin LAR
Inj LAR 20 mg prefilled syringe	2,358.75	1	~	Sandostatin LAR
Inj LAR 30 mg prefilled syringe	2,951.25	1	~	Sandostatin LAR

➡SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 μ g daily for up to 4 weeks.
- Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:

	Subsidy (Manufacturer's Pr \$	rice) Sub Per	Fully osidised	Brand or Generic Manufacturer
continued				
2.2.1 Patient has failed surgery; or 2.2.2 Patient in metastatic disease after H2 anta	aonists (or proton p	ump inhibitor	s) have f	ailed: or
3 Both:	gonisis (or proton p		b) Have I	alleu, ol
3.1 Insulinomas; and				
3.2 Surgery is contraindicated or has failed; or				
4 For pre-operative control of hypoglycaemia and for main	tenance therapy; or			
5 Both: 5.1 Carcinoid syndrome (diagnosed by tissue patholo	av and/or urinary 5	HIAA analysis). and	
5.2 Disabling symptoms not controlled by maximal m		i iinn anaiyoio	<i>y</i> , and	
Note: The use of octreotide in patients with fistulae, oesopha		llaneous diarr	hoea ar	nd hypotension will not be
funded as a Special Authority item				
Renewal — (Other Indications) only from a relevant special				
specialist. Approvals valid for 2 years where the treatment rema	ains appropriate and	the patient is	s benefit	ing from treatment.
TAMOXIFEN CITRATE * Tab 10 mg	10.80	100	🖌 G	enov
* Tab 20 mg		100	✓ G	
Aromatase Inhibitors				
Alomatase ministors				
ANASTROZOLE				
* Tab 1 mg		30		remed rimidex
			• • •	rimidex P-Anastrozole
EXEMESTANE			• •	
* Tab 25 mg		30	🗸 A	romasin
LETROZOLE			_	
* Tab 2.5 mg	4.85	30	✓ <u>L</u> e	etraccord
Immunosuppressants				
Cytotoxic Immunosuppressants				
AZATHIOPRINE – Retail pharmacy-Specialist				
* Tab 50 mg - For azathioprine oral liquid formulation ref				
page 184		100	_	nuprine
* Inj 50 mg		1		nuran
MYCOPHENOLATE MOFETIL – Special Authority see SA104 ⁻ Dispensing pharmacy should check which brand to dispense				colly
Tab 500 mg		50	0	eptolate
		00		yaccord
	70.00			elicept
Cap 250 mg		50		eptolate
	60.00	100		yaccord
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	70.00 285.00	165 ml OP		ellcept ellcept
Mycophenolate powder for oral liquid is subsidised only				•
, the start of the				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	
SA1041 Special Authority for Subsidy Initial application only from a relevant specialist or medical pract	titioner on the recomm	endation of a re	levant specialist. Approvals
valid without further renewal unless notified for applications meeti Either:			, pp
1 Transplant recipient; or 2 Both:			
Patients with diseases where 2.1 Steroids and azathioprine have been trialled and c clinical response; and 2.2 Either:	liscontinued because of	of unacceptable	side effects or inadequate
Patients with diseases where 2.2.1 Cyclophosphamide has been trialled and di clinical response; or 2.2.2 Cyclophosphamide treatment is contraindica		of unacceptable	side effects or inadequate
Immune Modulators			
ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Special Inj 50 mg per ml, 5 ml		5 🗸	ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU		1 🗸	DncoTICE
RITUXIMAB – PCT only – Specialist – Special Authority see SA Inj 100 mg per 10 ml vial Inj 500 mg per 50 ml vial Inj 1 mg for ECP	1,075.50 2,688.30	1 VN	labthera labthera Baxter

➡SA1152 Special Authority for Subsidy

Initial application — (**Post-transplant**) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.
- Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Fither:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and

	Subsidy (Manufacturer's Price) \$	F Subsidi Per	iully Brand or sed Generic Manufactur	er
--	---	---------------------	---	----

continued...

- 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	Brand or Generic Manufacturer
TRASTUZUMAB - PCT only - Specialist - Special Authority see	e SA1192 below			
Inj 150 mg vial	1,350.00	1	🖌 Н	erceptin
Inj 440 mg vial	3,875.00	1	🖌 Н	erceptin
Inj 1 mg for ECP	9.36	1 mg	🖌 В	axter

➡SA1192 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and

(Manufacturer's Price) Subsidised Generic \$ Per ✔ Manufacturer	Subsidy (Manufacturer's Price) \$		Generic	
--	---	--	---------	--

continued...

- 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
- 3.1.3 Trastuzumab to be discontinued at disease progression; or
- 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
- 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CYCLOSPORIN

Cap 25 mg		50	Neoral
Cap 50 mg		50	Neoral
Cap 100 mg		50	Neoral
Oral liq 100 mg per ml		50 ml OP	✓ Neoral
SIROLIMUS - Special Authority see SA0866 below -	Retail pharmacy		
Tab 1 mg	813.00	100	Rapamune
Tab 2 mg	1,626.00	100	 Rapamune
Oral liq 1 mg per ml		60 ml OP	 Rapamune

➡SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

TACROLIMUS - Special Authority see SA0669 below - Retail pha	armacy		
Cap 0.5 mg	214.00	100	Prograf
Cap 1 mg	428.00	100	Prograf
Cap 5 mg - For tacrolimus oral liquid formulation refer, page			
184	1,070.00	50	Prograf
			•

►SA0669 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

	Cubaidu		Fully Propd or
	Subsidy (Manufacturer's P	rice) Sul	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
Antiallergy Preparations			
BEE VENOM ALLERGY TREATMENT - Special Authority see S	A0053 below – R	letail pharmad	Υ.
Maintenance kit - 6 vials 120 μ g freeze dried venom, 6 diluen			,
1.8 ml		1 OP	Albay
Treatment kit - 1 vial 550 μ g freeze dried venom, 1 diluen 9 ml, 3 diluent 1.8 ml		1 OP	✓ Albay
SA0053 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals valid	l for 2 years for a	oplications me	eeting the following criteria:
Both:			
 RAST or skin test positive; and Patient has had severe generalised reaction to the sensitis 	ing agent		
Renewal only from a relevant specialist. Approvals valid for 2 y		eatment rema	ains appropriate and the patient is
benefiting from treatment.			
WASP VENOM ALLERGY TREATMENT - Special Authority see	SA0053 below -	Retail pharm	acy
Treatment kit (Paper wasp venom) - 1 vial 550 μ g freeze dried			
polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	Albay
Treatment kit (Yellow jacket venom) - 1 vial 550 μ g freeze			4.4.11
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	Albay
► SA0053 Special Authority for Subsidy	1 (and an all a fall and a scalar stands
Initial application only from a relevant specialist. Approvals valid Both:	t for 2 years for a	oplications me	eeting the following criteria:
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitis	sing agent.		
Renewal only from a relevant specialist. Approvals valid for 2 y	ears where the tr	eatment rema	ains appropriate and the patient is
benefiting from treatment.			
Antihistamines			
CETIRIZINE HYDROCHLORIDE			
* Tab 10 mg		100	✓ Zetop
*‡ Oral liq 1 mg per ml		200 ml	Cetirizine - AFT
CHLORPHENIRAMINE MALEATE			
*‡ Oral liq 2 mg per 5 ml	8.06	500 ml	✓ Histafen
DEXTROCHLORPHENIRAMINE MALEATE			
* Tab 2 mg	1.01	20	
	(4.93)		Polaramine
	2.02	40	
No. Carl lin Carrow and Fard	(7.99)	100	Polaramine
*‡ Oral liq 2 mg per 5 ml	1.// (10.29)	100 ml	Polaramine
	(10.29)		Foldramme
FEXOFENADINE HYDROCHLORIDE * Tab 60 mg	1 31	20	
* Tab 60 mg	4.34 (11.53)	20	Telfast
* Tab 120 mg		10	TUILLOL
	(11.53)	-	Telfast
	14.22	30	
	(29.81)		Telfast

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
LOBATADINE			
* Tab 10 mg	2.09	100	Loraclear Hayfever
* Oral lig 1 mg per ml	3 10	100 ml	<u>Relief</u> ✔ Lorapaed
		100 111	
	1 00	50	
* Tab 10 mg		50 50	 <u>Allersoothe</u> Allersoothe
* Tab 25 mg		50 100 ml	✓ <u>Allersoothe</u>
*‡ Oral liq 5 mg per 5 ml	2.79 3.10	100 111	 Allersoothe Promethazine
	5.10		Winthrop Elixir
* Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO		5	✓ Mayne
TRIMEPRAZINE TARTRATE			
	0.70	100 ml OP	
‡ Oral liq 30 mg per 5 ml	2.79 (8.06)	100 IIII OP	Vallergan Forte
	(8.00)		vallergan Forte
Inhaled Corticosteroids			
BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 100 μ g per dose CFC-free		200 dose OP	Beclazone 100
Aerosol inhaler, 250 µg per dose CFC-free	22.67	200 dose OP	 Beclazone 250
Aerosol inhaler, 50 μ g per dose CFC-free	8.54	200 dose OP	 Beclazone 50
BUDESONIDE			
Powder for inhalation, 100 μ g per dose		200 dose OP	Pulmicort
· • • • • • • • • • • • • • • • • • • •			Turbuhaler
Powder for inhalation, 200 μ g per dose		200 dose OP	✓ Budenocort
, <i>F</i> -3 F	19.00		✓ Pulmicort
			Turbuhaler
Powder for inhalation, 400 μ g per dose		200 dose OP	✓ Budenocort
· · · · · · · · · · · · · · · · · · ·	32.00		✓ Pulmicort
			Turbuhaler
FLUTICASONE			
Aerosol inhaler, 50 μ g per dose CFC-free	7.50	120 dose OP	Flixotide
Powder for inhalation, 50 μ g per dose		60 dose OP	 Flixotide Accuhaler
Powder for inhalation, 100 µg per dose	7.50	60 dose OP	 Flixotide Accuhaler
Aerosol inhaler, 125 µg per dose CFC-free	13.60	120 dose OP	Flixotide
Aerosol inhaler, 250 μ g per dose CFC-free		120 dose OP	Flixotide
Powder for inhalation, 250 μ g per dose	13.60	60 dose OP	Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 μg beclomethasone or budesonide (or 100 μg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 µg beclomethasone or budesonide (or 200 µg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

	Subsidy (Manufacturer's \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
EFORMOTEROL FUMARATE – See prescribing guideline on the	preceding pag	е		
Powder for inhalation, 6 µg per dose, breath activated		60 dose OP		
	(16.90)		0	xis Turbuhaler
Powder for inhalation, 12 μ g per dose, and monodose device	20.64	60 dose		
	(35.80)		Fo	oradil
SALMETEROL - See prescribing guideline on the preceding page	e			
Aerosol inhaler CFC-free, 25 µg per dose		120 dose OP	V S	erevent
Powder for inhalation, 50 μ g per dose, breath activated		60 dose OP	🗸 S	erevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

SA1179 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Has been treated with inhaled corticosteroids of at least 400 μ g per day beclomethasone or budesonide, or 200 μ g per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Has been treated with inhaled corticosteroids of at least 800 μ g per day beclomethasone or budesonide, or 500 μ g per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

BUDESONIDE WITH EFORMOTEROL – Special Authority see SA1179 above Aerosol inhaler 100 µg with eformoterol fumarate 6 µg	 Retail pharmacy 120 dose OP 	∕ ✔ Vannair
Powder for inhalation 100 μ g with eformoterol furnarate 6 μ g	120 dose OP	 Symbicort Turbuhaler 100/6
Aerosol inhaler 200 μ g with eformoterol fumarate 6 μ g	120 dose OP	🗸 Vannair
Powder for inhalation 200 μ g with eformoterol furnarate 6 μ g60.00	120 dose OP	 Symbicort Turbuhaler 200/6
Powder for inhalation 400 μ g with eformoterol fumarate 12 μ g		
- No more than 2 dose per day60.00	60 dose OP	 Symbicort Turbuhaler 400/12
FLUTICASONE WITH SALMETEROL - Special Authority see SA1179 above -	Retail pharmacy	
Aerosol inhaler 50 μ g with salmeterol 25 μ g	120 dose OP	 Seretide
Aerosol inhaler 125 μ g with salmeterol 25 μ g	120 dose OP	 Seretide
Powder for inhalation 100 μ g with salmeterol 50 μ g – No		
more than 2 dose per day	60 dose OP	 Seretide Accuhaler
Powder for inhalation 250 μ g with salmeterol 50 μ g – No		
more than 2 dose per day49.69	60 dose OP	Seretide Accuhaler

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic Manufacturer
Beta-Adrenoceptor Agonists			
SALBUTAMOL ‡ Oral liq 2 mg per 5 ml	1.20 1.99	90 ml 150 ml	✓ Broncolin s₂s ✓ Salapin ✓ Ventolin
Infusion 1 mg per ml, 5 ml	118.38 (130.21)	10	Ventolin
Inj 500 μ g per ml, 1 ml – Up to 5 inj available on a PSO		5	✓ Ventolin
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL Aerosol inhaler, 100 μg per dose CFC free – Up to 1000 dose available on a PSO		200 dose OP	 ✓ Respigen ✓ Salamol
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO		20	Ventolin Asthalin
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO		20	✓ <u>Asthalin</u>
TERBUTALINE SULPHATE Powder for inhalation, 250 μ g per dose, breath activated	22.00	200 dose OP	 Bricanyl Turbuhaler
Inhaled Anticholinergic Agents			
IPRATROPIUM BROMIDE Aerosol inhaler, 20 μ g per dose CFC-free Nebuliser soln, 250 μ g per ml, 1 ml – Up to 40 neb available)	200 dose OP 20	✓ Atrovent
on a PSO Nebuliser soln, 250 μ g per ml, 2 ml $-$ Up to 40 neb available on a PSO)	20	 ✓ <u>Univent</u> ✓ <u>Univent</u>
TIOTROPIUM BROMIDE – Special Authority see SA1193 below Powder for inhalation, 18 μ g per dose		acy 30 dose	✓ Spiriva

➡SA1193 Special Authority for Subsidy

Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

- All of the following:
 - 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
 - 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator of at least 40 µg ipratropium q.i.d for one month; and
 - 3 Either:
 - The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
 - 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
 - 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
 - Applicant must state recent measurement of:
 - 4 All of the following:
 - 4.1 Actual FEV_1 (litres); and
 - 4.2 Predicted FEV₁ (litres); and

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic
\$	Per 🖌	Manufacturer

continued...

- 4.3 Actual FEV₁ as a % of predicted (must be below 60%); and
- 5 Either:
 - 5.1 Patient is not a smoker (for reporting purposes only); or
 - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunisation.

Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined); and Applicant must state recent measurement of:
- 3 All of the following:
 - 3.1 Actual FEV₁ (litres); and
 - 3.2 Predicted FEV₁ (litres); and
 - 3.3 Actual FEV1 as a % of predicted.

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler, 100 μg with ipratropium bromide, 20 μg per dose CFC-free	200 dose OP	🖌 Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml – Up to 20 neb available on a PSO	20	✔ Duolin

Leukotriene Receptor Antagonists

MONTELUKAST - Special Authority see SA1227 below - Retail pharmacy

Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses.

1ab 4 mg	40 2	0	Siliyulali
Tab 5 mg	48 2	8 🖌	Singulair
Tab 10 mg	48 2	8 🖌	Singulair

SA1227 Special Authority for Subsidy

Initial application — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has trialled inhaled corticosteroids at a dose of up to 400 μ g per day beclomethasone or budesonide, or 200 μ g per day fluticasone for at least one month; and
- 3 The patient continues to have at least three severe exacerbations at least one of which required hospitalisation (defined as in-patient stay or prolonged Emergency Department treatment) in the past 12 months.

Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient is being treated with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Initial application — (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

NSAID where challenge would be considered of		a on notor	
Mast Cell Stabilisers			
NEDOCROMIL			
Aerosol inhaler, 2 mg per dose CFC-free		112 dose OP	🗸 Tilade
SODIUM CROMOGLYCATE			
Powder for inhalation, 20 mg per dose	17.94	50 dose	Intal Spincaps
Aerosol inhaler, 5 mg per dose CFC-free		112 dose OP	Intal Forte CFC Free
(Vicrom Aerosol inhaler, 5 mg per dose CFC-free to b	e delisted 1 March 2013)		Vicrom
Methylxanthines			
AMINOPHYLLINE			
 * Inj 25 mg per ml, 10 ml – Up to 5 inj available on 	a PSO 53.75	5	DBL Aminophylline
THEOPHYLLINE		C C	<u></u>
* Tab long-acting 250 mg		100	✓ Nuelin-SR
*‡ Oral liq 80 mg per 15 ml		500 ml	✓ Nuelin
Mucolytics			
DORNASE ALFA – Special Authority see SA0611 be	low – Retail pharmacy		
Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	 Pulmozyme
➡SA0611 Special Authority for Subsidy			
Special Authority approved by the Cystic Fibrosis Adv			
Notes: Application details may be obtained from PHA		w.pharmac.govt.r	nz or:
The Co-ordinator, Cystic Fibrosis Advisory Panel	()		
PHARMAC, PO Box 10 254 Wellington	Facsimile: (04) 916 7571 Email: CFPanel@pharm	ac govt nz	
Prescriptions for patients approved for treatment mus		ů.	ediatricians who have experience
and expertise in treating cystic fibrosis.		physiciano el pa	
SODIUM CHLORIDE			
Not funded for use as a nasal drop.			
Soln 7%	23.50	90 ml OP	 Biomed

	Subsidy (Manufacturer's		Fully Brand or sidised Generic
	(Manulacturers	Per Per	Manufacturer
lasal Preparations			
Allergy Prophylactics			
ECLOMETHASONE DIPROPIONATE			
Metered aqueous nasal spray, 50 μ g per dose	2.35 (4.85)	200 dose OP	Alanase
Metered aqueous nasal spray, 100 μ g per dose	2.46	200 dose OP	Alanase
125001125	(5.75)		Aldridse
JDESONIDE	0.05		
Metered aqueous nasal spray, 50 μ g per dose	2.35 (4.85)	200 dose OP	Butacort Aqueous
Metered aqueous nasal spray, 100 μ g per dose	()	200 dose OP	Dulacon Aqueous
Necered aqueous hasal spray, roo μ g per dose	(5.75)	200 005e OF	Butacort Aqueous
LUTICASONE PROPIONATE			
Metered aqueous nasal spray, 50 μ g per dose	13.34	120 dose OP	Flixonase Hayfever <u>& Allergy</u>
RATROPIUM BROMIDE			
Aqueous nasal spray, 0.03%	4.03	15 ml OP	Univent
DDIUM CROMOGLYCATE			
Nasal spray, 4%		22 ml OP	Rex
Respiratory Devices			
ASK FOR SPACER DEVICE			
a) Up to 20 dev available on a PSO			
b) Only on a PSO			
c) Only for children aged six years and under			
Size 2		1	 EZ-fit Paediatric
			Mask
EAK FLOW METER			
a) Up to 10 dev available on a PSO			
b) Only on a PSO			
Low range	11.44	1	Breath-Alert
Normal range		1	✓ Breath-Alert
PACER DEVICE			
a) Up to 20 dev available on a PSO			
b) Only on a PSO			
230 ml (single patient)	4.72	1	Space Chamber
			Plus
800 ml	8.50	1	Volumatic
PACER DEVICE AUTOCLAVABLE			_
a) Up to 5 dev available on a PSO			
a) Up to 5 dev available on a PSO b) Only on a PSO		1	Space Chamber
a) Up to 5 dev available on a PSO			✓ Space Chamber in an autoclave and the PSC

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Respiratory Stimulants				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		5 ml OP	🖌 🖌 Bi	iomed

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
Ear Preparations			
CETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN For Vosol ear drops with hydrocortisone powder refer, page 14 Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02%	87	35 ml OP	✔ Vosol
HLORAMPHENICOL Ear drops 0.5%		5 ml OP	✓ Chloromycetin
LUMETASONE PIVALATE Ear drops 0.02% with clioquinol 1%		7.5 ml OP	 ✓ Locacorten-Viaform ED's ✓ Locorten-Vioform
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN	N AND NYSTATI	N	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 μ g per g	5.16	7.5 ml OP	✓ Kenacomb
Ear/Eye Preparations			
EXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN Ear/Eye drops 500 μg with framycetin sulphate 5 mg and gramicidin 50 μg per ml		8 ml OP	Sofradex
RAMYCETIN SULPHATE Ear/Eye drops 0.5%	() ,	8 ml OP	Soframycin
Eye Preparations ye preparations are only funded for use in the eye. The exceptio r oral use pursuant to the Standard Formulae. Anti-Infective Preparations	n is pilocarpine	eye drops 1%,	2% and 4% which are subsidis
•			
CICLOVIR E Eye oint 3%	37.53	4.5 g OP	 Zovirax
HLORAMPHENICOL Eye oint 1% Eye drops 0.5%		4 g OP 10 ml OP	 ✓ Chlorsig ✓ Chlorafast
IPROFLOXACIN Eye Drops 0.3% For treatment of bacterial keratitis or severe bacterial conju		5 ml OP It to chloramph	Ciloxan
USIDIC ACID Eye drops 1%		5 g OP	Fucithalmic
ENTAMICIN SULPHATE Eye drops 0.3%		5 ml OP	✓ Genoptic
ROPAMIDINE ISETHIONATE			•

Brolene

(7.99)

SENSORY ORGANS

	Subsidy (Manufacturer's	/	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
FOBRAMYCIN Eye oint 0.3%	10.45	2 5 a OB	
Eye drops 0.3%		3.5 g OP 5 ml OP	✓ <u>Tobrex</u> ✓ Tobrex
Corticosteroids and Other Anti-Inflammatory F		0 111 01	
DEXAMETHASONE	•		
★ Eye oint 0.1%		3.5 g OP	Maxidex
* Eye drops 0.1%		5 ml OP	Maxidex
DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B S	ULPHATE		
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyx			
B sulphate 6,000 u per g		3.5 g OP	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polym	iy-		
xin B sulphate 6,000 u per ml	4.50	5 ml OP	Maxitrol
DICLOFENAC SODIUM			
* Eye drops 1 mg per ml	13.80	5 ml OP	Voltaren Ophtha
FLUOROMETHOLONE			
* Eye drops 0.1%	3.80	5 ml OP	Flucon
	(4.05)		FML
(FML Eye drops 0.1% to be delisted 1 March 2013)			
EVOCABASTINE			
Eye drops 0.5 mg per ml		4 ml OP	Livestia
	(10.34)		Livostin
	0.74		A 1 1 1
Eye drops 0.1%	8./1	10 ml OP	Lomide
PREDNISOLONE ACETATE	4.50	- 105	
* Eye drops 0.12%		5 ml OP 5 ml OP	 Pred Mild Pred Forte
* Eye drops 1%	4.50	5 III OF	
SODIUM CROMOGLYCATE	1 10		
Eye drops 2%	1.18	5 ml OP	✓ <u>Rexacrom</u>
Glaucoma Preparations - Beta Blockers			
BETAXOLOL HYDROCHLORIDE			
* Eye drops 0.25%		5 ml OP	Betoptic S
* Eye drops 0.5%		5 ml OP	Betoptic
EVOBUNOLOL	7.00	E	
 ₭ Eye drops 0.25% ₭ Eye drops 0.5% 		5 ml OP	 Betagan Betagan
		5 ml OP	 Betagan
FIMOLOL MALEATE	0.00		Arrow Timolol
 ₭ Eye drops 0.25% ₭ Eye drops 0.25%, gel forming 		5 ml OP 2.5 ml OP	 ✓ <u>Arrow-Timolol</u> ✓ Timoptol XE
* Eye drops 0.25%, ger forming		2.5 ml OP	✓ Arrow-Timolol
✤ Eye drops 0.5%, gel forming		2.5 ml OP	✓ Timoptol XE
Glaucoma Preparations - Carbonic Anhydrase			
ACETAZOLAMIDE			
 Tab 250 mg – For acetazolamide oral liquid formulation refe 	or		
page 184		100	Diamox
		100	* BINITIVA

*Three months or six months, as applicable, dispensed all-at-once

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or osidised Generic ✓ Manufacturer
BRINZOLAMIDE * Eye Drops 1%	0.77	5 ml OP	✔ Azopt
		51111 01	
DORZOLAMIDE HYDROCHLORIDE * Eye drops 2%	9.77 (13.95)	5 ml OP	Trusopt
DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE	· · · ·	5 ml OD	
* Eye drops 2% with timolol maleate 0.5%		5 ml OP	✓ Cosopt
Glaucoma Preparations - Prostaglandin Analogu	les		
BIMATOPROST – Retail pharmacy-Specialist * Eye drops 0.03%		3 ml OP	🗸 Lumigan
LATANOPROST – Retail pharmacy-Specialist * Eye drops 50 μ g per ml, 2.5 ml	1.99	2.5 ml OP	✓ <u>Hysite</u>
TRAVOPROST – Retail pharmacy-Specialist * Eye drops 0.004%		2.5 ml OP	✓ Travatan
Glaucoma Preparations - Other			
BRIMONIDINE TARTRATE			
* Eye Drops 0.2%	6.45	5 ml OP	Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE			
* Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	Combigan
PILOCARPINE			-
* Eye drops 1%	4.26	15 ml OP	Isopto Carpine
* Eye drops 2%	5.35	15 ml OP	Isopto Carpine
* Eye drops 4%		15 ml OP	Isopto Carpine
* Eye drops 2% single dose – Special Authority see SA0895			
below – Retail pharmacy	31.95 (32.72)	20 dose	Minims

➡SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient has to use an unpreserved solution due to an allergy to the preservative; or

2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics		
ATROPINE SULPHATE * Eye drops 1%	15 ml OP	✓ Atropt
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%8.76	15 ml OP	Cyclogyl
HOMATROPINE HYDROBROMIDE * Eye drops 2%	15 ml OP	Isopto Homatropine
TROPICAMIDE 7.15 * Eye drops 0.5% 7.15 * Eye drops 1% 8.66	15 ml OP 15 ml OP	 ✓ <u>Mydriacyl</u> ✓ <u>Mydriacyl</u>

SENSORY ORGANS

	Subsidy (Manufacturer's Pr \$	rice) Sub Per	Fully Brand or osidised Generic ✔ Manufacturer
Preparations for Tear Deficiency			
For acetylcysteine eye drops refer, page 187 HYPROMELLOSE			
* Eye drops 0.3%		15 ml OP	Poly-Tears
* Eye drops 0.5%	2.00 (3.92)	15 ml OP	Methopt
POLYVINYL ALCOHOL * Eye drops 1.4%	2.68	15 ml OP	✔ Vistil
* Eye drops 3%		15 ml OP	Vistil Forte
TYLOXAPOL * Eye drops 0.25% (Enuclene Eye drops 0.25% to be delisted 1 May 2013)	8.63	15 ml OP	✓ Enuclene
Other Eye Preparations			
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4.15	15 ml OP	✓ Naphcon Forte
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin	3.63	3.5 g OP	✓ Lacri-Lube
PARAFFIN LIQUID WITH WOOL FAT LIQUID * Eye oint 3% with wool fat liq 3%	3.63	3.5 g OP	✔ Poly-Visc
PHENYLEPHRINE HYDROCHLORIDE * Eye drops 0.12% (Prefrin Eye drops 0.12% to be delisted 1 March 2013)	4.47	15 ml OP	✔ Prefrin

VARIOUS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Various				
May only be claimed once per patient.				
PHARMACY SERVICES				
* Brand switch fee	4.33	1 fee	✓ B ✓ B ✓ B ✓ B ✓ B	SF Ava 20 ED SF Ava 30 ED SF Candestar SF CareSens II SF CareSens N SF CareSens N POP SF Plendil ER
 a) The Pharmacode for BSF CareSens N is 2423138 - see b) The Pharmacode for BSF CareSens II is 2423146 - see c) The Pharmacode for BSF CareSens N POP is 2423154 d) The Pharmacode for BSF Ava 30 ED is 2405865 - see a 	also page 31 - see also page 31			
 e) The Pharmacode for BSF Candestar is 2426781 - see al f) The Pharmacode for BSF Ava 20 ED is 2427958 - see al g) The Pharmacode for BSF Plendil ER is 2430231 - see a (BSF Ava 20 ED Brand switch fee to be delisted 1 June 2013) (BSF Ava 30 ED Brand switch fee to be delisted 1 March 2013) (BSF Candestar Brand switch fee to be delisted 1 February 2013) (BSF CareSens II Brand switch fee to be delisted 1 March 2013) (BSF CareSens N Brand switch fee to be delisted 1 March 2013) (BSF Plendil ER Brand switch fee to be delisted 1 March 2013) 	so page 76 Iso page 58			

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).

 c) Menthol crystals only in the following bases: Aqueous cream Urea cream 10% Wool fat with mineral oil lotion Hydrocortisone 1% with wool fat and mineral oil lotion Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- · Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website **www.pharminfotech.co.nz** has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Rifabutin 20 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Sildenafil 2 mg/ml
Amlodipine 1 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sotalol 5 mg/ml
Azathioprine 50 mg/ml	Hydrocortisone 1 mg/ml	Sulphasalazine 100 mg/ml
Baclofen 10 mg/ml	Labetolol 10 mg/ml	Tacrolimus 1 mg/ml
Carvedilol 1 mg/ml	Levetiracetam 100 mg/ml	Terbinafine 25 mg/ml
Clopidogrel 5 mg/ml	Levodopa with carbidopa (5 mg lev-	Ursodeoxycholic acid 50 mg/ml
Diltiazem hydrochloride 12 mg/ml	odopa + 1.25 mg carbidopa)/ml	Valganciclovir 60 mg/ml*
Dipyridamole 10 mg/ml	Metoprolol tartrate 10 mg/ml	Verapamil hydrochloride 50 mg/ml
Domperidone 1 mg/ml	Nitrofurantoin 10 mg/ml	
Enalapril 1 mg/ml	Pyrazinamide 100 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

qs to 100%

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF to 100% Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 183) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICATI Aspirin Soluble tabs 300 mg Chloroform	ION 12 tabs to 100 ml
CODEINE LINCTUS PAEDIATRIC (3 mg pa Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	^r 5 ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pre	
MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste Methyl hydroxybenzoate Water	275 g 1.5 g 770 ml
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml
METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml of mixture)	10 g to 100 ml

OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml
PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATR LIQUID (10 mg per ml) Phenobarbitone Sodium Glycerol BP Water	IC ORAL 400 mg 4 ml to 40 ml
PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops Preservative Water (Preservative should be used if quantity su more than 5 days.)	qs qs to 500 ml pplied is for
SALIVA SUBSTITUTE FORMULA Methylcellulose Preservative Water (Preservative should be used if quantity su more than 5 days. Maximum 500 ml per pr	
SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml Water (Only funded if prescribed for treatment of	qs qs hyponatraemia)
VOSOL EAR DROPS WITH HYDROCORTISONE POWDER 1% Hydrocortisone powder Vosol Ear Drops	1% to 35 ml

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or
	(Manufacturer's I		bsidised Generic
	\$	Per	 Manufacturer
Extemporaneously Compounded Preparations	and Galenica	als	
ACETYLCYSTEINE – Retail pharmacy-Specialist			
Inj 200 mg per ml, 10 ml	178.00	10	✓ Martindale
			Acetylcysteine
Inj 200 mg per ml, 30 ml	219.00	4	Acetadote
BENZOIN			
Tincture compound BP		50 ml	DOM
	(5.10) 24.42	500 ml	PSM
	(38.00)	500 mi	PSM
OUR OPOEDBM - Ontoin combination	(00.00)		
CHLOROFORM – Only in combination Only in aspirin and chloroform application.			
Chloroform BP	25 50	500 ml	V PSM
			♥ FSM
CODEINE PHOSPHATE – Safety medicine; prescriber may dete Powder – Only in combination		· · _ ·	
	(25.46)	5 g	Douglas
	63.09	25 g	Douglas
	(90.09)	_0 g	Douglas
a) Only in extemporaneously compounded codeine linctus	diabetic or code	eine linctus pa	ediatric.
b) ‡ Safety cap for extemporaneously compounded oral li	quid preparations	S.	
COLLODION FLEXIBLE			
Collodion flexible	19.30	100 ml	🖌 PSM
COMPOUND HYDROXYBENZOATE - Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln	34.18	100 ml	David Craig
GLYCERIN WITH SODIUM SACCHARIN - Only in combination			
Only in combination with Ora-Plus.			
Suspension		473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination			
Only in combination with Ora-Plus.			
Suspension		473 ml	 Ora-Sweet
GLYCEROL			
* Liquid – Only in combination		2,000 ml	✓ <u>healthE</u>
Only in extemporaneously compounded oral liquid prepar	ations.		
MAGNESIUM HYDROXIDE			
Paste	22.61	500 g	✓ PSM
METHADONE HYDROCHLORIDE			
a) Only on a controlled drug form			
 b) No patient co-payment payable 			
c) Safety medicine; prescriber may determine dispensing fre	quency		
d) Extemporaneously compounded methadone will only be r	empursed at the	e rate of the ch	eapest form available (methadone
powder, not methadone tablets). Powder	7 0/	1 0	🗸 AFT
‡ Safety cap for extemporaneously compounded oral liqui		1 g	
A Salety cap to extemporaneously compounded oral liqui			
Powder	8.00	25 g	V PSM
	8.98	20 g	✓ Midwest
	0.00		

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully	Brand or	
	(Manufacturer's Pri	ce)	Subsidised	Generic	
	\$	Per	~	Manufacturer	
METHYLCELLULOSE					
Powder		100 g	🖌 Al	BM	
	(17.72)	0	M	idWest	
Suspension – Only in combination	()	473 ml	V 0	ra-Plus	
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHA	BIN – Only in co	mbination			
Suspension		473 ml		ra-Blend SF	
•		110111			
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - Only		470	4.0	D I I	
Suspension		473 ml	V 0	ra-Blend	
PHENOBARBITONE SODIUM					
Powder – Only in combination		10 g	🖌 M	idWest	
,	325.00	100 g	🖌 M	idWest	
a) Only in children up to 12 years		0			
b) ‡ Safety cap for extemporaneously compounded oral lig	uid preparations.				
PROPYLENE GLYCOL					
Only in extemporaneously compounded methyl hydroxybenzo	ate 10% colution				
Lig		500 ml	V PS	SW	
Цү		500 111	• • •	idwest	
	11.25		V IVI	lawesi	
SODIUM BICARBONATE					
Powder BP – Only in combination	8.95	500 g	🖌 M	idwest	
	9.80				
	(29.50)		Da	avid Craig	
Only in extemporaneously compounded omeprazole and la	ansoprazole suspe	ension.			
SYRUP (PHARMACEUTICAL GRADE) - Only in combination					
Only in extemporaneously compounded oral liquid preparation	ns.				
Lig		2.000 m	🖌 🖌 Mi	idwest	
WATEB	-	,		-	
Tap – Only in combination	0.00	1 ml	·/ T-	n watar	
	0.00	1 1111	✓ 18	ip water	

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

Initial Applications:	Only from a dietitian, relevant specialist or a vocationally registered general
	practitioner.
Reapplications:	Only from a dietitian, relevant specialist or a vocationally registered general
	practitioner or general practitioner on the recommendation of a dietitian, rele-
	vant specialist or a vocationally registered general practitioner. Other general
	practitioners must include the name of the dietitian, relevant specialist or voca-
	tionally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ASCORBIC ACID Tab 100 mg

CALCIUM CARBONATE
✓ Tab eff 1.75 g (1 g elemental)
✓ Tab 1.25 g (500 mg elemental)

COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g

DEXTROSE WITH ELECTROLYTES Soln with electrolytes

FERROUS FUMARATE ✓ Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID

 \checkmark Tab 310 mg (100 mg elemental) with folic acid 350 $\mu {\rm g}$

FERROUS SULPHATE

Tab long-acting 325 mg (105 mg elemental) ✓ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)

FERROUS SULPHATE WITH FOLIC ACID

Tab long-acting 325 mg (105 mg elemental) with folic acid 350 $\mu \rm g$

FOLIC ACID Tab 0.8 mg

MULTIVITAMINS Powder

PANCREATIC ENZYME

✓ Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease

POTASSIUM BICARBONATE

✓ Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg

POTASSIUM CHLORIDE

Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)

✓ Tab long-acting 600 mg

POTASSIUM IODATE

✓ Tab 256 µg (150 µg elemental iodine)

PYRIDOXINE HYDROCHLORIDE

- ✔ Tab 25 mg
- ✔ Tab 50 mg

SODIUM CHLORIDE

🖌 lnj 23.4%, 20 ml

SODIUM FLUORIDE

Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE

✔ Tab 50 mg

VITAMIN A WITH VITAMINS D AND C

✓ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX

✓ Tab, strong, BPC

VITAMINS

- ✓ Tab (BPC cap strength)
- ✓ Cap (fat soluble vitamins A, D, E, K)

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Nutrient Modules

Carbohydrate

➡SA1090 Special Authority for Subsidy

Initial application — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children: or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 failure to thrive; or
- 4 growth deficiency; or
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1090 above – Hospital pharmacy [HP3]

Powder		5.29 1.30	400 g OP 368 g OP	Polycal
		(12.00)	g	Moducal
	· - ·			

Carbohydrate And Fat

➡SA1091 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 infant aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1 infant aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 failure to thrive; or
 - 2.3 growth deficiency; or
 - 2.4 bronchopulmonary dysplasia; or
 - 2.5 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPL	EMENT - Special Authority	see SA1091 o	on the preceding p	age -	- Hospital pharmacy [HP3]
Powder (neutral)		60.31	400 g OP	V	Duocal Super
			-		Soluble Powder

Fat

SA1092 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive where other high calorie products are inappropriate or inadequate; or
- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per 🖌 Manufacturer	
--	--

continued...

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT	SUPPLEMENT -	Special Authority see SA1092 on	the preceding page – Hos	spital pharmacy	/ [HP3]
	Emulsion (neutral))		200 ml OP	Calogen
	. ,		30.75	500 ml OP	Calogen
	Emulsion (strawbe	ərry)		200 ml OP	Calogen
	Oil			250 ml OP	Liquigen
			30.00	500 ml OP	 MCT oil (Nutricia)

Protein

F

➡SA1093 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 protein losing enteropathy; or
- 2 high protein needs (eg burns).

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEM	ENT – Special Author	rity see SA109	93 above – Hosp	oital pharm	acy [HP3]	
Powder				7.90	225 g OP	Protifar
				8.95	227 g OP	 Resource Beneprotein
Powder (vanilla)			1	2.90	275 g OP	Promod
<u> </u>						

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

➡SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA1094 above – Hospital pharmacy [HP3]

Liquid1.6	66 237 ml OP	Pulmocare
-----------	--------------	-----------

Subsidy	Fu	lly Brand or	
(Manufacturer's F	Price) Subsidise	ed Generic	
\$	Per	 Manufacturer 	

Diabetic Products

➡SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML - Special Authority see SA1095 above	 Hospital pharn 	nacy [HP3]
Liquid7.50		 Diason RTH Glucerna Select RTH
DIABETIC ORAL FEED 1KCAL/ML - Special Authority see SA1095 above - Ho	spital pharmacy	[HP3]
Liquid (strawberry)1.50	200 ml OP	Diasip
Liquid (vanilla)1.50	200 ml OP	Diasip
1.88	250 ml OP	Glucerna Select
1.78	237 ml OP	
(2.10)		Resource Diabetic

Fat Modified Products

➡SA1096 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has chylothorax.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED - Special Authority see SA1096 above - Hospital pharmacy [HP3]

Powdor			60 / 8	////	
Powder	 	 	00.40	400	y Oi

High Protein Products

►SA1097 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Anorexia and weight loss; and
- 2 Either:
 - 2.1 decompensating liver disease without encephalopathy; or
 - 2.2 protein losing gastro-enteropathy.

continued...

Monogen

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

Liquid

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

HIGH PROTEIN ORAL FEED 1KCAL/ML	 Special Authority see SA1097 	on the preceding page - Hospita	al pharmacy [HP3]
---------------------------------	--	---------------------------------	-------------------

	200 ml OP	Fortimel Regular
--	-----------	------------------

Paediatric Products For Children Awaiting Liver Transplant

►SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who is awaiting liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA1098 above - Hospital pharmacy [HP3]

Powder	78.97	400 g OP	Generaid Plus
--------	-------	----------	---------------

Paediatric Products For Children With Chronic Renal Failure

SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with chronic renal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA1099 above - Hospital pharmacy [HP3]

Liquid54.00	400 g OP	 Kindergen
-------------	----------	-------------------------------

Paediatric Products

SA1224 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 failure to thrive; or

	Subsidy (Manufacturer's P \$	rice) Per	Fully Subsidised	Brand or Generic Manufacturer
continued 2.4 increased nutritional requirements. Renewal only from a dietitian, relevant specialist, vocationally register mendation of a dietitian, relevant specialist or vocationally register meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is ber	ered general practi	tioner. Ap		
 2 General Practitioners must include the name of the dietitia and date contacted. PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority s 	an, relevant specia	list or voca	, ,	0 1
Liquid		500 ml C)P 🖌 N	utrini RTH ediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML - pharmacy [HP3]	, ,			010 1
Liquid	6.00	500 ml C		utrini Energy Multi Fibre
PAEDIATRIC ORAL FEED – Special Authority see SA1224 on t Powder (vanilla)		e – Hospita 900 g O	al pharmacy	utrini Energy RTH / [HP3] ediasure
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see Liquid (strawberry) Liquid (vanilla)	1.60	receding p 200 ml C 200 ml C) P 🖌 🖌 F	ital pharmacy [HP3] ortini ortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see S Liquid (chocolate) Liquid (strawberry) Liquid (vanilla)	1.07 1.07	ceding pag 200 ml C 200 ml C 200 ml C 237 ml C		al pharmacy [HP3] ediasure ediasure ediasure ediasure ediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special [HP3]	Authority see SA1	224 on the	e preceding	page – Hospital pharmacy
Liquid (chocolate) Liquid (strawberry) Liquid (vanilla)	1.60	200 ml C 200 ml C 200 ml C	P / F	ortini Multi Fibre ortini Multi Fibre ortini Multi Fibre
Renal Products				

➡SA1101 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic renal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ENTERAL FEED 2 KCAL/ML – Special Authority see SA1101 above – Hospital pharmacy [HP3]

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
RENAL ORAL FEED 2KCAL/ML – Special Authority see SA1101 Liquid		g page – Hosp 200 ml OP	V N	rmacy [HP3] epro (strawberry) epro (vanilla)
	2.88	237 ml OP		
	(3.31)		N	ovaSource Renal
Liquid (apricot)	2.88	125 ml OP	🖌 R	enilon 7.5
Liquid (caramel)	2.88	125 ml OP	🖌 R	enilon 7.5

Specialised And Elemental Products

➡SA1102 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 pancreatitis.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML - Special Authority see SA1102 above - Hospital pharmacy [HP3]

Powder		79 g OP	Vital HN
	7.50	76 g OP	Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML - Special Authority see S	SA1102 above -	- Hospital pharm	nacy [HP3]
Liquid (grapefruit)	9.50	250 ml OP	 Elemental 028 Extra
Liquid (pineapple & orange)	9.50		 Elemental 028 Extra
Liquid (summer fruit)	9.50	250 ml OP	 Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML - Special Authority see SA	1102 above – H	lospital pharma	cy [HP3]
Powder (unflavoured)	4.50	80.4 g OP	 Vivonex TEN
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Autho Liquid			

Undyalised End Stage Renal Failure

➡SA1103 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has undialysed end stage renal failure.

Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietitian.

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ORAL FEED 1KCAL/ML - Special Authority see SA1103 on the preceding page - Hospital pharmacy [HP3]

Paediatric Products For Children With Low Energy Requirements

SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Standard Supplements

➡SA1228 Special Authority for Subsidy

Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Subsidy (Manufacturer's Price)	5	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

All of the following:

- 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
 - 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:
 - Patient is Malnourished
 - 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or

(Mar	Subsidy	Fully	Brand or
	nufacturer's Price)	Subsidised	Generic
	\$ P	Per 🖌	Manufacturer

continued...

5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms

SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

Λ)	Subsidy /anufacturer's \$		Fully Brand or sidised Generic ✔ Manufacturer
ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1228 on p Liquid		Hospital pharmad 1,000 ml	cy [HP3] ✔ Nutrison Energy
ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 on pa Liquid	-	spital pharmacy 250 ml OP	[HP3] ✓ Isosource Standard ✓ Osmolite
	2.65	500 ml OP	 Nutrison Standard RTH
	5.29	1,000 ml OP	 Nutrison Standard RTH
			 Isosource Standard RTH
	2.65 5.29	500 ml OP 1,000 ml OP	 ✓ Osmolite RTH ✓ Osmolite RTH
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see Liquid		page 199 – Hosp 237 ml OP 500 ml OP 1,000 ml OP 500 ml OP 1,000 ml OP	 bital pharmacy [HP3] Jevity Nutrison Multi Fibre Nutrison Multi Fibre Jevity RTH Jevity RTH
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see Liquid		n page 199 – Hos 250 ml OP 1,000 ml OP	spital pharmacy [HP3] Final Ensure Plus HN Sensure Plus RTH Sevity HiCal RTH Nutrison Energy Multi Fibre
DRAL FEED (POWDER) – Special Authority see SA1228 on page 1 Powder (chocolate)		al pharmacy [HF 900 g OP	P3] ✔ Sustagen Hospital
	13.00		Formula
Powder (vanilla)		900 g OP	 Fortisip Sustagen Hospital Formula
	13.00		✓ Ensure

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Subs Per	idised Generic Manufacturer
ORAL FEED 1.5KCAL/ML - Special Authority see SA1228 on pa	ge 199 – Hospi	tal pharmacy [HF	23]
Additional subsidy by endorsement is available for patients be endorsed accordingly.			
Liquid (banana) - Higher subsidy of \$1.26 per 200 ml with			
Endorsement		200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement		200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	Ensure Plus
	(1.33) 0.72	200 ml OP	Ensure Plus
	(1.26)	200 111 0F	Fortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml	()		Torusip
with Endorsement		200 ml OP	
with Endoisement	(1.26)	200 111 01	Ensure Plus
Liquid (strawberry) - Higher subsidy of up to \$1.33 per	()		Ensure Flus
237 ml with Endorsement		200 ml OP	
	(1.26)	200 111 01	Ensure Plus
	0.85	237 ml OP	
	(1.33)	207 01	Ensure Plus
	0.72	200 ml OP	
	(1.26)		Fortisip
Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En-	· · ·		
dorsement	0.72	200 ml OP	
	(1.26)		Fortisip
Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml			
with Endorsement		200 ml OP	
	(1.26)		Fortisip
Liquid (vanilla) - Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement	0.72	200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)		Ensure Plus
	0.72	200 ml OP	
	(1.26)		Fortisip
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see Additional subsidy by endorsement is available for patients be endorsed accordingly.	eing bolus fed f		
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement		200 ml OP	Fortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with	()		
Endorsement		200 ml OP	
	(1.26)	200 111 01	Fortisip Multi Fibre
Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with	()		
Endorsement		200 ml OP	
	(1.26)	200 01	Fortisip Multi Fibre
	(P

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

Adult Products High Calorie

SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 failure to thrive; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 above – Hospital pharmacy [HP3]

Liquid	5.50	500 ml OP	 Nutrison Concentrated
	11.00	1,000 ml OP	Two Cal HN RTH
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 above – Ho Additional subsidy by endorsement is available for patients being endorsed accordingly. Liquid (vanilla) – Higher subsidy of \$2.25 per 237 ml with			g tube. The prescription must be
Endorsement	1.14 (2.25)	237 ml OP	Two Cal HN

	Subsidy (Manufacturer's Price) \$	Subsic Per	Fully lised	Brand or Generic Manufacturer
Food Thickeners				
SA1106 Special Authority for Subsidy				
Initial application only from a dietitian, relevant specialist or	vocationally registered ger	neral practit	ioner.	Approvals valid for 1 year
where the patient has motor neurone disease with swallowing				
Renewal only from a dietitian, relevant specialist, vocationally	0 0 1	•		
mendation of a dietitian, relevant specialist or vocationally reg	istered general practitione	r. Approvals	s valid	for 1 year for application
meeting the following criteria: Both:				
 The treatment remains appropriate and the patient is b 	enefiting from treatment:	and		
 2 General Practitioners must include the name of the die and date contacted. 			y regi	stered general practitione
FOOD THICKENER - Special Authority see SA1106 above -	- Hospital pharmacy [HP3]	1		
Powder			🖌 Ka	aricare Food
				Thickener
Gluten Free Foods				
The funding of gluten free foods is no longer being actively m longer considering the listing of new products, or making subs that the range of funded items will reduce over time. Manage outcomes. A range of gluten free options are available throug	idy, or other changes to th ment of Coeliac disease v	e existing li	stings	. As a result we anticipate
SA1107 Special Authority for Subsidy				
nitial application only from a dietitian, relevant specialist of	r vocationally registered g	eneral pract	titione	er. Approvals valid withou
urther renewal unless notified for applications meeting the fol		P		
Either:	-			
 Gluten enteropathy has been diagnosed by biopsy; or Patient suffers from dermatitis herpetiformis. 				
GLUTEN FREE BAKING MIX – Special Authority see SA110	7 above – Hospital pharm			

Powder		00 g OP
	(5.15)	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX - Special Authority see SA110	7 above – Hospital pharma	acy [HP3]
Powder		00 g OP
	(7.32)	NZB Low Gluten Bread Mix
	4.77	
	(8.71)	Bakels Gluten Free Health Bread Mix
	3.51	
	(10.87)	Horleys Bread Mix
GLUTEN FREE FLOUR – Special Authority see SA1107 abo Powder		HP3] 00 a OP
	(18.10)	Horleys Flour

	Subsidy (Manufacturer's Pri \$		Fully Brand or dised Generic ✔ Manufacturer
LUTEN FREE PASTA - Special Authority see SA1107 on t	he preceding page – H	lospital pharma	cy [HP3]
Buckwheat Spirals	2.00	250 g OP	
	(3.11)		Orgran
Corn and Vegetable Shells	2.00	250 g OP	
	(2.92)		Orgran
Corn and Vegetable Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Lasagne Sheets	1.60	200 g OP	
	(3.82)		Orgran
Rice and Corn Macaroni	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Penne	2.00	250 g OP	
	(2.92)		Orgran
Rice and Maize Pasta Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Millet Spirals	2.00	250 g OP	
	(3.11)		Orgran
Rice and corn spaghetti noodles	2.00	375 g OP	
	(2.92)		Orgran
Vegetable and Rice Spirals	2.00	250 g OP	
	(2.92)		Orgran
Italian long style spaghetti	2.00	220 g OP	
	(3.11)		Orgran

Foods And Supplements For Inborn Errors Of Metabolism

SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA Powder		bital pharmacy [HP3]
Supplements For MSUD		
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE pharmacy [HP3]	- Special Authority	/ see SA1108 above - Hospital
Powder	500 g OP	 MSUD Maxamaid MSUD Maxamum

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
Supplements For PKU			
AMINOACID FORMULA WITHOUT PHENYLALANINE – Speci	al Authority see	SA1108 on the	preceding page – Hospital pha
nacy [HP3]	ai nationty 500		proceeding page Theophai pha
Tabs		75 OP	Phlexy 10
Sachets (tropical)	324.00	30	Phiexy 10
Infant formula		400 g OP	PKU Anamix Infant
Powder (orange)		500 g OP	V XP Maxamaid
	320.00	500 × 00	✓ XP Maxamum
Powder (unflavoured)		500 g OP	✓ XP Maxamaid
liquid (hown)	320.00	105 ml OD	 XP Maxamum PKU Anamix Junior
Liquid (berry)	13.10	125 ml OP	LQ
Liquid (citrus)	15 65	62.5 ml OP	PKU Lophlex LQ 10
	31.20	125 ml OP	✓ PKU Lophlex LQ 20
Liquid (forest berries)		250 ml OP	 Easiphen Liquid
Liquid (juicy berries)		62.5 ml OP	PKU Lophlex LQ 10
	31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (juicy orange)	15.65	62.5 ml OP	PKU Lophlex LQ 10
	31.20	125 ml OP	PKU Lophlex LQ 20
Liquid (orange)	13.10	125 ml OP	✓ PKU Anamix Junior
Liquid (unflavoured)	13.10	125 ml OP	LQ V PKU Anamix Junior
			LQ
Foods			Lu
Foods .OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder	, ,	page – Hospital 500 g OP	
.OW PROTEIN BAKING MIX – Special Authority see SA1108 or	8.22	500 g OP	pharmacy [HP3]
.OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder	8.22 receding page -	500 g OP	pharmacy [HP3]
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne	8.22 receding page - 11.91 5.95	500 g OP - Hospital pharn	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3]
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta		500 g OP - Hospital pharn 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni		500 g OP - Hospital pharn 500 g OP 250 g OP 500 g OP 250 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne	8.22 receding page - 11.91 5.95 11.91 5.95 11.91	500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 250 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
.OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti	8.22 receding page - 11.91 5.95 11.91 5.95 11.91 11.91	500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
.OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder .OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals	8.22 receding page - 11.91 5.95 11.91 5.95 11.91 11.91	500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 250 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals	8.22 receding page - 11.91 5.95 11.91 5.95 11.91 11.91	500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals	8.22 receding page - 11.91 5.95 11.91 5.95 11.91 11.91	500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals Infant Formulae For Premature Infants PREMATURE BIRTH FORMULA – Special Authority see SA122		500 g OP - Hospital pharm 500 g OP 250 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals Infant Formulae For Premature Infants PREMATURE BIRTH FORMULA – Special Authority see SA122 Liquid		500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals		500 g OP - Hospital pharm 500 g OP 250 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals Infant Formulae For Premature Infants PREMATURE BIRTH FORMULA – Special Authority see SA122 Liquid S26LBW Gold RTF Liquid to be delisted 1 April 2013)		500 g OP - Hospital pharm 500 g OP 250 g OP 250 g OP 250 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals Infant Formulae For Premature Infants PREMATURE BIRTH FORMULA – Special Authority see SA122 Liquid S26LBW Gold RTF Liquid to be delisted 1 April 2013) ■SA1221 Special Authority for Subsidy lote: Subsidy for patients approved prior to 1 July 2012. Approv		500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP	pharmacy [HP3] ✓ Loprofin Mix hacy [HP3] ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ Loprofin ✓ S26LBW Gold RTF
OW PROTEIN BAKING MIX – Special Authority see SA1108 or Powder OW PROTEIN PASTA – Special Authority see SA1108 on the p Animal shapes Lasagne Low protein rice pasta Macaroni Penne Spaghetti Spirals Infant Formulae For Premature Infants PREMATURE BIRTH FORMULA – Special Authority see SA122		500 g OP - Hospital pharm 500 g OP 250 g OP 500 g OP 250 g OP 500 g OP 500 g OP 500 g OP 500 g OP 500 g OP 100 ml OP months. No new	pharmacy [HP3]

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	sidised	Generic	
\$	Per	~	Manufacturer	

Locasol

►SA1198 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and
- 2 Either:
 - 2.1 The infant has faltering growth (downward crossing of percentiles); or
 - 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

For Williams Syndrome

SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Roth.

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA - Special Authority see SA1110 above - Hospital pharmacy [HP3]

400 a OP

Gastrointestinal and Other Malabsorptive Problems

AMINO ACID FORMULA - Special Authority see SA1219 below	- Hospital phar	macy [HP3]	
Powder	6.00	48.5 g OP	Vivonex Pediatric
	53.00	400 g OP	Neocate
		Ũ	Neocate LCP
Powder (tropical)		400 g OP	Neocate Advance
Powder (unflavoured)		400 g OP	Elecare
		Ũ	Elecare LCP
			Neocate Advance
			Neocate Gold
Powder (vanilla)		400 g OP	Elecare
· · · · ·		Ũ	Neocate Advance

(Neocate Powder to be delisted 1 July 2013)

(Neocate Advance Powder (tropical) to be delisted 1 May 2013)

SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

EXTENSIVELY HYDROLYSED FORMULA - Special Authority see SA1220 below - Hospital pharmacy [HP3]

SA1220 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Chylous ascite; or
- 8 Chylothorax; or
- 9 Cystic fibrosis; or
- 10 Proven fat malabsorption; or
- 11 Severe intestinal motility disorders causing significant malabsorption; or
- 12 Intestinal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Ketogenic Diet

➡SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATE – Special Authority see SA1197 above – Retail pharmacy

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml
AMINOPHYLLINE ✓ Inj 25 mg per ml, 10 ml
AMIODARONE HYDROCHLORIDE Inj 50 mg per ml, 3 ml
AMOXYCILLIN ✓ Cap 250 mg
AMOXYCILLIN CLAVULANATE ✓ Tab amoxycillin 500 mg with potassium clavulanate 125 mg
✓ Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml
ASPIRIN ✔ Tab dispersible 300 mg30
ATROPINE SULPHATE \checkmark Inj 600 μ g, 1 ml
AZITHROMYCIN ✓ Tab 500 mg – See note on page 88
BENDROFLUAZIDE ✔ Tab 2.5 mg – See note on page 60150
BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE ✔ Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) ✔ Inj 600 mg
 CEFTRIAXONE SODIUM ✓ Inj 500 mg – Subsidy by endorsement – See note on page 87
CHARCOAL ✓ Oral liq 50 g per 250 ml

CHLORPROMAZINE HYDROCHLORIDE ✓ Tab 10 mg
CIPROFLOXACIN ✓ Tab 250 mg
 CO-TRIMOXAZOLE ✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg
COMPOUND ELECTROLYTES V Powder for soln for oral use 4.4 g
CONDOMS 144 ✓ 49 mm 144 ✓ 52 mm extra strength 144 ✓ 52 mm extra strength 144 ✓ 53 mm 144 ✓ 53 mm (chocolate) 144 ✓ 53 mm (strawberry) 144 ✓ 53 mm extra strength 144 ✓ 55 mm 144 ✓ 55 mm 144 ✓ 56 mm, shaped 144 ✓ 56 mm, shaped 144 ✓ 60 mm 144
DEXAMETHASONE ✓ Tab 1 mg – Retail pharmacy-Specialist
DEXAMETHASONE SODIUM PHOSPHATE Inj 4 mg per ml, 1 ml – See note on page 805 Inj 4 mg per ml, 2 ml – See note on page 805
DEXTROSE ✓ Inj 50%, 10 ml
DIAPHRAGM ✓ 65 mm – See note on page 74

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

(continued)

DIAZEPAM V Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 1315 V Rectal tubes 5 mg
DICLOFENAC SODIUM ✓ Inj 25 mg per ml, 3 ml
DIGOXIN ✔ Tab 62.5 µg
DOXYCYCLINE HYDROCHLORIDE Tab 50 mg
ERGOMETRINE MALEATE \checkmark Inj 500 μg per ml, 1 ml
ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg
ERYTHROMYCIN STEARATE Tab 250 mg
ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 μ g with desogestrel 150 μ g63 Tab 20 μ g with desogestrel 150 μ g and 7 inert tab
 ETHINYLOESTRADIOL WITH LEVONORGESTREL Tab 50 μg with levonorgestrel 125 μg and 7 inert tab
ETHINYLOESTRADIOL WITH NORETHISTERONE \checkmark Tab 35 μ g with norethisterone 1 mg63 \checkmark Tab 35 μ g with norethisterone 1 mg and 7 inert tab

FLUCI OXACILLIN SODIUM ✓ Grans for oral lig 125 mg per 5 ml 200 ml ✓ Grans for oral lig 250 mg per 5 ml 200 ml ✓ Inj 1 g......5 FLUPENTHIXOL DECANOATE ✓ Inj 20 mg per ml, 1 ml5 ✓ Inj 100 mg per ml, 1 ml5 FLUPHENAZINE DECANOATE ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml5 FUROSEMIDE ✓ Inj 10 mg per ml, 2 ml5 GLUCAGON HYDROCHLORIDE ✓ Inj 1 mg syringe kit......5 GLYCERYL TRINITRATE ✓ Tab 600 µg......100 HALOPERIDOL ✓ Oral lig 2 mg per ml 200 ml HALOPERIDOL DECANOATE ✓ Inj 100 mg per ml, 1 ml5 **HYDROCORTISONE** ✓ Inj 50 mg per ml, 2 ml5 **HYDROXOCOBALAMIN** HYOSCINE N-BUTYLBROMIDE ✓ Inj 20 mg, 1 ml5 INTRA-UTERINE DEVICE **IPRATROPIUM BROMIDE** ✓ Nebuliser soln, 250 µg per ml, 1 ml......40 ✓ Nebuliser soln, 250 µg per ml, 2 ml.......40 **IVERMECTIN** ✓ Tab 3 mg – See note on page 69......100

PRACTITIONER'S SUPPLY ORDERS

(continued) LEVONORGESTREL Tab 30 µg
LIGNOCAINE ✓ Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 1245
LIGNOCAINE HYDROCHLORIDE ✓ Inj 1%, 5 ml
LIGNOCAINE WITH CHLORHEXIDINE ✓ Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 1245
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg
MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 17620
MEDROXYPROGESTERONE ACETATE ✓ Inj 150 mg per ml, 1 ml syringe5
METOCLOPRAMIDE HYDROCHLORIDE ✓ Inj 5 mg per ml, 2 ml
METRONIDAZOLE ✓ Tab 200 mg
 MORPHINE SULPHATE ✓ Inj 5 mg per ml, 1 ml – Only on a controlled drug form
drug form5 NALOXONE HYDROCHLORIDE ✔ Inj 400 μg per ml, 1 ml5
 NICOTINE Patch 7 mg - See note on page 150

 ✓ Gum 2 mg (Mint) – See note on page 150
NORETHISTERONE ✔ Tab 350 µg
NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 μ g and 7 inert tab84
OXYTOCIN ✓ Inj 5 iu per ml, 1 ml
PARACETAMOL ✓ Tab 500 mg
PEAK FLOW METER ✓ Low range
PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN] ✓ Inj 1.2 mega u per 2 ml
 PETHIDINE HYDROCHLORIDE ✓ Inj 50 mg per ml, 1 ml – Only on a controlled drug form
PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap potassium salt 250 mg
PHENYTOIN SODIUM ✔ Inj 50 mg per ml, 2 ml
PHYTOMENADIONE ✔ Inj 2 mg per 0.2 ml
PIPOTHIAZINE PALMITATE ✓ Inj 50 mg per ml, 1 ml
PREDNISOLONE SODIUM PHOSPHATE ✓ Oral liq 5 mg per ml – See note on page 80
page 80 30 mi continued

(continued)

PREDNISONE V Tab 5 mg
PREGNANCY TESTS - HCG URINE Cassette
PROCAINE PENICILLIN ✓ Inj 1.5 mega u
PROCHLORPERAZINE ✓ Tab 5 mg
PROMETHAZINE HYDROCHLORIDE V Inj 25 mg per ml, 2 ml
SALBUTAMOL ✓ Inj 500 μg per ml, 1 ml
SALBUTAMOL WITH IPRATROPIUM BROMIDE Vebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml
SILVER SULPHADIAZINE ✓ Crm 1%

SODIUM BICARBONATE ✓ Inj 8.4%, 50 ml
SODIUM CHLORIDE ✓ Inf 0.9% – See note on page 50
SPACER DEVICE ✓ 230 ml (single patient)20 ✓ 800 ml
SPACER DEVICE AUTOCLAVABLE ✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 1765
TRIMETHOPRIM V Tab 300 mg30
VERAPAMIL HYDROCHLORIDE V Inj 2.5 mg per ml, 2 ml5
WATER ✓ Purified for inj, 5 ml – See note on page 50
ZUCLOPENTHIXOL DECANOATE

V	1	Inj	200	mg per	ml,	1	ml	 	 	 5

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB

Tuakau Waiuku

Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB Mangakino

Turangi Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa **Whanganui DHB** Bulls Marton Ohakune Raetihi Taihape Waiouru

MidCentral DHB

Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville

Wairarapa DHB

Carteron Featherston Greytown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberley Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburah Tapanui Te Anau Tokonui Tuatapere Wanaka

Winton

SECTION F: PART I

A Community Pharmaceutical identified with a ***** within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
 - i) have limited physical mobility;
 - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - iii) are relocating to another area;
 - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a ***** within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a * please refer to Section F; Part II
- Note the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.

The following Community Pharmaceuticals are identified with a A within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

INSULIN NEUTRAL

CARDIOVASCULAR SYSTEM

AMIODARONE HYDROCHLORIDE Tab 100 mg Cordarone-X Tab 200 mg Cordarone-X

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE

Tab 50 mg	Tambocor
Tab 100 mg	Tambocor
Cap long-acting 100 mg	Tambocor CR
Cap long-acting 200 mg	Tambocor CR

MEXILETINE HYDROCHLORIDE

MINOXIDIL

NICORANDIL

PROPAFENONE HYDROCHLORIDE

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN

Nasal drops 100 μg per Minirin ml Nasal spray 10 μg per Desmopressin-PH&T dose

MUSCULOSKELETAL SYSTEM PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PERGOLIDE

PRAMIPEXOLE HYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG

SAFETY CAP MEDICINES

ALIMENTARY TRACT AND METABOLISM

FERROUS SULPHATE Oral lig 30 mg per 1 ml Ferodan (6 mg elemental per 1 ml)

CARDIOVASCULAR SYSTEM

AMII ORIDE Oral lig 1 mg per ml Biomed

CAPTOPRI

Oral lig 5 mg per ml Capoten

CHLOROTHIAZIDE

Biomed Oral lig 50 mg per ml DIGOXIN I anoxin

Oral lig 50 μ g per ml FUROSEMIDE Oral lig 10 mg per ml Lasix

SPIRONOLACTONE Oral liq 5 mg per ml

Biomed

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

LEVOTHYROXINE Tab 25 μg Synthroid Tab 50 µg Fltroxin Goldshield Svnthroid Tab 100 µg Eltroxin Goldshield Synthroid (Extemporaneously compounded oral liquid preparations)

MUSCULOSKELETAL SYSTEM

IBUPROFEN Oral liq 100 mg per 5 ml Fenpaed

QUININE SULPHATE Q 300 Tab 300 mg (Extemporaneously compounded oral liquid preparations)

NERVOUS SYSTEM

ALPRAZOLAM Tab 250 µg Arrow-Alprazolam Arrow-Alprazolam Tab 500 μ g Tab 1 mg Arrow-Alprazolam (Extemporaneously compounded oral liquid preparations)

CARBAMAZEPINE Oral lig 100 mg per 5 ml Tegretol

CLOBAZAM Tab 10 mg Frisium (Extemporaneously compounded oral liquid preparations) **CLONAZEPAM** Oral drops 2.5 mg per Rivotril ml DIAZEPAM Tab 2 mg Arrow-Diazepam Tab 5 mg Arrow-Diazepam (Extemporaneously compounded oral liquid preparations) **ETHOSUXIMIDE** Oral lig 250 mg per 5 ml Zarontin I ORAZEPAM Tab 1 mg Ativan Tab 2.5 mg Ativan (Extemporaneously compounded oral liquid preparations) LORMETAZEPAM Tab 1 mg Noctamid (Extemporaneously compounded oral liquid preparations) METHADONE HYDROCHLORIDE Oral lig 2 mg per ml Biodone Oral lig 5 mg per ml **Biodone Forte** Oral liq 10 mg per ml Biodone Extra Forte MORPHINE HYDROCHLORIDE RA-Morph

Oral lig 1 mg per ml Oral liq 2 mg per ml Oral lig 5 mg per ml Oral lig 10 mg per ml

RA-Morph RA-Morph RA-Morph

NITRAZEPAM

Tab 5 mg Nitrados (Extemporaneously compounded oral liquid preparations)

OXAZEPAM

Ox-Pam Tab 10 mg Tab 15 mg Ox-Pam (Extemporaneously compounded oral liquid preparations)

OXYCODONE HYDROCHLORIDE Oral lig 5 mg per 5 ml OxvNorm

PARACETAMOL

Oral lig 120 mg per 5 ml Oral lig 250 mg per 5 ml

Ethics Paracetamol Paracare Double Strength

PHENYTOIN SODIUM Oral lig 30 mg per 5 ml Dilantin

SAFETY CAP MEDICINES

SODIUM VALPROATE Oral liq 200 mg per 5 ml

nl Epilim S/F Liquid Epilim Syrup

TEMAZEPAM Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM Tab 125 μg Hypam Tab 250 μg Hypam (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Cetirizine - AFT

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Promethazine Elixir

Promethazine Winthrop Elixir Allersoothe SALBUTAMOL

Oral liq 2 mg per 5 ml Ventolin Salapin Broncolin

THEOPHYLLINE Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price \$) S Per	Fully ubsidised	Brand or Generic Manufacturer
Vaccinations				
BACILLUS CALMETTE-GUERIN VACCINE – Hospital pharmacy For infants at increased risk of tuberculosis. Increased risk is 1) living in a house or family with a person with current or pas 2) have one or more household members or carers who withi 40 per 100,000 for 6 months or longer or 3) during their first 5 years will be living 3 months or longer in Note a list of countries with high rates of TB are available at www Inj multi-dose vial (10 dose) 0.5 ml	defined as: st history of TB or n the last 5 years liv a country with a rate .moh.govt.nz/immun	e of TB >	or equal t www.bcg	to 40 per 100,000
DIPHTHERIA AND TETANUS VACCINE – Hospital pharmacy [X For adults aged 45 and 65 years old, and for susceptible indi- Inj 0.5 ml	viduals.	1	🖌 A	DT Booster
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Hospita For children aged 11 years old and pregnant women between Inj 0.5 ml	l pharmacy [Xpharm n gestional weeks 28		0 1	demics. oostrix
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – For children aged 4 years old. Inj 0.5 ml		[Xpharm] 1		fanrix-IPV
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B An pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months old. Inj 0.5 ml		INFLUEN		PE B VACCINE – Hospital
HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital pha For children aged 15 months old, children aged 0-16 years w Inj 0.5 ml	armacy [Xpharm] ith functional asplen	ia, or for 1		re- and post-splenectomy. ct-HIB
HEPATITIS B VACCINE – Hospital pharmacy [Xpharm] For household or sexual contacts of known hepatitis B carri antigen (HBsAg) postive. Inj 0.5 ml		born to m		ho are hepatitis B surface BvaxPro
HUMAN PAPILOMAVIRUS VACCINE – Hospital pharmacy [Xpha Three doses over a period of six months for young women ag Inj 0.5 ml	arm] ged between 12 and		old.	ardasil
INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj		10	🖌 Fl	luarix
 A) is available 1 March until vaccine supplies are exhausted e Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative th 2) other chronic respiratory disease with 	ierapy, or		• • •	luvax wing criteria, as set by the

continued...

NATIONAL IMMUNISATION SCHEDULE


	Subsidy (Manufacturer's Price) Cul	Fully	Brand or Generic
	(Manulacturers Frice \$	Per		Manufacturer
continued				
iii) diabetes;				
iv) chronic renal disease;				
 v) any cancer, excluding basal and squamous 	s skin cancers if not inv	/asive;		
vi) the following other conditions:				
a) autoimmune disease,b) immune suppression,				
c) HIV.				
d) transplant recipients,				
e) neuromuscular and CNS diseases,				
f) haemoglobinopathies,				
g) children on long term aspirin, or				
h) pregnancy.				
c) people under 18 years of age living within the bou	ndaries of the Canterb	oury Distric	t Health	Board.
The following conditions are excluded from funding:				
 a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence 		20		
B) Doctors are the only Contractors entitled to claim payme			lv of inf	luenza vaccine to patients
eligible under the above criteria for subsidised immunisi				
listed in the Pharmaceutical Schedule.				
C) Individual DHBs may fund patients over and above the	above criteria. The cl	aiming pro	ocess fo	r these additional patients
should be determined between the DHB and Contractor.				
D) Influenza Vaccine does not fall within the definition Common service Products Plasma site are unable to algor for the				
ceutical Budget. Pharmacists are unable to claim for the		a vaccine i	rom the	Funder.
MEASLES, MUMPS AND RUBELLA VACCINE – Hospital phar For children aged 15 months and 4 years old or for any indi				, whallo
Inj 0.5 ml		ieasies, m		rudella. I -M-R II
•			• 11	
MENINGOCOCCAL A, C, Y AND W-135 VACCINE – Hospital For patients pre- and post-splenectomy or children aged 0-		al acolonia	Eor or	application and community
based outbreaks.	To years with function	ai aspieriia	. 10101	ganisation and community
Inj 0.5 ml	0.00	1	V M	lenomune
PNEUMOCOCCAL (PCV13) VACCINE – Hospital pharmacy [X				
For high risk children under the age of 5 and those aged less		post-splen	ectomv	or with functional asplenia.
Inj 0.5 ml		1		revenar 13
PNEUMOCOCCAL POLYSACCHARIDE VACCINE - Hospital				
For patients pre- and post-splenectomy or children aged 0-		al asplenia.		
Inj 0.5 ml		1		neumovax 23
PNEUMOCOCCAL VACCINE – Hospital pharmacy [Xpharm]				
For children aged 6 weeks, 3 months, and 5 months, and 1	5 months old.			
Inj 0.5 ml		1	🗸 S	ynflorix
POLIOMYELITIS VACCINE – Hospital pharmacy [Xpharm]				
A primary course of three doses for previously unvaccinated	d individuals.			
Inj 0.5 ml	0.00	1	🖌 IF	POL

	INDEX
Generic Chemicals and	Brands

- Symbols -	
3TC	101
50X 3.0 Reservoir	38
- A -	
A-Lices	71
A-Scabies	
Abacavir sulphate	100
Abacavir sulphate with	100
lamivudine	100
Abilify	137
ABM Hydroxocobalamin	42
Acarbose	29
Accarb	
Accu-Chek Ketur-Test	
Accu-Chek Performa	
Accupril	55
Accuretic 10	
Accuretic 20	
Acetadote	
Acetazolamide	
Acetic acid with 1, 2- propanediol	
diacetate and	
benzethonium	178
Acetic acid with hydroxyquinoline	
and ricinoleic acid	77
Acetylcysteine	188
Aci-Jel	
Aciclovir	
Infection	96
Sensory	
Acidex	
Acipimox	51
Acitretin	
Aclasta	120
Aclin	107
Act-HIB	.221
Actinomycin D	156
Actrapid	28
Actrapid Penfill	28
Acupan	
Adalat 10	
Adalat Oros	
Adalimumab	107
Adapalene	63
Adefin XL	
Adefovir dipivoxil	94
ADR Cartridge 1.8 ADR Cartridge 3.0	38
ADR Cartridge 3.0	38
Adrenaline	
Adriamycin	
ADT Booster	
Advantan	67

AFT-Leflunomide107	
AFT-Pyrazinamide94	
Agents Affecting the	
Renin-Angiotensin System54 Agents for Parkinsonism and	
Agents for Parkinsonism and	
Related Disorders 123	
Agents Used in the Treatment of	
Poisonings	
Agndin 155	
Poisonings	
Albay	
Albustix79	
Aldara73	
Alendronate sodium118	
Alendronate sodium with cholecalciferol	
cholecalciferol 118	
Alfacalcidol43	
Alginic acid25	
Alitraq198	
Alkeran152	
Allersoothe171	
Allopurinol122	
Alpha Adrenoceptor Blockers54	
Alpha-Keri Lotion	
Alphamox89	
Alphanhox101	
Alprazolam142	
Alu-Tab25	
Aluminium hydroxide25	
Amantadine hydrochloride123	
Ambrisentan62	
Amiloride60	
Amiloride with frusemide60	
Amiloride with	
hydrochlorothiazide	
hydrochlorothiazide	
Amiodarone hydrochloride56	
Amirol	
Amisulpride136	
Amitrip128	
Amitriptyline128	
Amlodipine58	
Amorolfine64	
Amoxycillin89	
Amoxycillin clavulanate	
Amphotericin B42	
Amsacrine155	
Amsidine155	
Amyl nitrite61	
Anaesthetics124	
Anagrelide hydrochloride155	
Analgesics125	

Anastrozole	165
Andriol Testocaps	
Androderm	81
Animas Battery Cap	34
Animas Cartridge	38
Animas Vibe	33
Antabuse	149
Antacids and Antiflatulants	25
Anten	128
Anthelmintics	87
Antiacne Preparations	63
Antiacne Preparations Antiallergy Preparations	170
Antianaemics	45
Antiandrogen Oral	
Contraceptives	77
Antiarrhythmics	
Antibacterials	87
Antibacterials Topical	64
Anticholinesterases	106
Antidepressants	128
Antidiarrhoeals	25
Antiepilepsy Drugs	131
Antifibrinolytics, Haemostatics	
and Local Sclerosants	46
Antifungals	
Antifungals Topical	
Antihaemorrhoidals	
Antihistamines	
Antihypotensives	
Antimalarials	
Antimigraine Preparations	.134
Antinaus	.136
Antinausea and Vertigo	
Agents	135
Antipruritic Preparations	65
Antipsychotics	136
Antiretrovirals	
Antiretrovirals - Additional	
Therapies	102
Antirheumatoid Agents	
Antispasmodics and Other	
Agente Altering Gut	
Motility	27
Antithrombotic Agents	46
Antithymocyte globulin	
(equine)	166
Antitrichomonal Agents	00
Antituberculotics and	
Antileprotics	93
Antiulcerants	
Antivirals	
Anxiolytics	



Anzatax157
Apidra29
Apidra SoloStar29
Apo-Allopurinol122
Apo-Amlodipine
Apo-Azithromycin
Apo-Bromocriptine123
Apo-Ciclopirox64
Apo-Cimetidine27
Apo-Clarithromycin
Alimentary27
Infection88
Apo-Clomipramine128
Apo-Clopidogrel46
Apo-Diclo106
Apo-Diltiazem CD
Apo-Doxazosin
Apo-Folic Acid45
Apo-Gliclazide
Apo-Megestrol164
Apo-Moclobemide
Apo-Nadolol
Apo-Ivadolol
Apo-Nicotinic Acid
Apo-Oxybutynin
Apo-Pindolol
Apo-Prazo54
Apo-Prednisone81
Apo-Primidone
Apo-Propranolol58
Apo-Pyridoxine42
Apo-Risperidone139
Apo-Selegiline123
Apo-Thiamine42
Apo-Timol58
Apo-Zopiclone145
Apomine123
Apomorphine hydrochloride123
Aprepitant135
Apresoline61
Aquasun 30+72
Aqueous cream
Aratac
Arava107
Aremed165
Arimidex165
Aripiprazole137
Aristocort
Aromasin165
Arrow Amitriptyline128
Arrow-Alprazolam142
Arrow-Azithromycin
Arrow-Bendrofluazide
Arrow-Brimonidine

Arrow-Calcium43
Arrow-Citalopram129
Arrow-Diazepam142
Arrow-Doxorubicin156
Arrow-Enalapril54
Arrow-Etidronate118
Arrow-Lamotrigine133
Arrow-Lisinopril
Arrow-Losartan &
Hydrochlorothiazide56
Arrow-Meloxicam107
Arrow-Morphine LA127
Arrow-Nifedipine XR59
Arrow-Norfloxacin105
Arrow-Ornidazole
Arrow-Ranitidine
Arrow-Roxithromycin88
Arrow-Sertraline
Arrow-Simva 10mg52
Arrow-Simva 20mg52
Arrow-Simva 40mg52
Arrow-Simva 80mg52
Arrow-Sumatriptan
Arrow-Timolol
Arrow-Tolterodine
Arrow-Topiramate
Arrow-Tramadol
Arrow-Venlafaxine XR
Arrowcare
Arsenic trioxide
Asacol
Asamax
Ascorbic acid
Aspec 300125
Aspen Adrenaline61 Aspen Ceftriaxone87
Asperi Centraxone
Blood
Nervous
Asthalin
Atazanavir sulphate
ATGAM
Ativan
Atomoxetine
Atorvastatin
Atripla
Atropine sulphate
Alimentary
Sensory
Atropt
Atrovent
Augmentin89

Auranofin	
Ava 20 ED	
Ava 30 ED	76
Avanza	130
Avelox	91
Avomine	136
Avonex	144
Avonex Pen	144
Azathioprine	165
Azithromycin	88
Azol	85
Azopt	180
AZT	101
- B -	
B-D Micro-Fine	32
B-D Ultra Fine	
B-D Ultra Fine II	
B-PlexADE	42
Bacillus Calmette-Guerin (BCG)	
vaccine	166
Bacillus Calmette-Guerin	100
vaccine	221
Baclofen	
Bactroban	
Bakels Gluten Free Health Bread	04
Mix	205
Baraclude	
Barrier Creams and	90
Emollients	69
Batrafen	
BCG Vaccine	
Beclazone 100	
Beclazone 250	171
Beclazone 50	
Beclomethasone	171
dipropionate 171,	176
Bee venom allergy	170
treatment	170
Bendrofluazide	
Benhex Benzathine benzylpenicillin	
benzathine benzylpenicillin Benzoin	89
Benztrop	
Benztropine mesylate	124
Benzydamine hydrochloride	41
Benzylpenicillin sodium (penicillin	00
G) Beta Adrenoceptor Blockers	89
Beta Cream	
Beta Ointment	
Beta Scalp	
Beta-Adrenoceptor Agonists	173


Calcium gluconate43

Betadine69
Betadine Skin Prep69
Betaferon144
Betagan179
Betahistine dihydrochloride
Betamethasone dipropionate
Betamethasone dipropionate
with calcipotriol71
Betamethasone sodium
phosphate with
betamethasone acetate
Betamethasone valerate
Betamethasone valerate with
clioquinol67
Betamethasone valerate with
fusidic acid67
Betaxolol hydrochloride179
Betnovate
Betnovate-C67
Betoptic179
Betoptic S179
Bezafibrate51
Bezalip51
Bezalip Retard51
Bicalaccord163
Bicalutamide163
Bicillin LA89
BiCNU152
Bimatoprost180
Biodone126
Biodone Extra Forte126
Biodone Forte126
Bisacodyl40
Bisoprolol fumarate57
BK Lotion68
Bleomycin sulphate155
Blood Colony-stimulating
Factors
Blood glucose diagnostic test
meter
Blood glucose diagnostic test
strip31
Blood glucose test strips (visually
impaired) 32
Blood ketone diagnostic test
meter
Bonjela41
Boostrix221
Bortezomib155
Bosentan62
Bosvate
Breath-Alert
Brevinor 1/21 76

Brevinor 1/2876
Brevinor 21
Bricanyl Turbuhaler173
Brimonidine tartrate
Brimonidine tartrate with timolol
maleate
Brinzolamide
Brolene
Bromocriptine mesylate
Broncolin173
Brufen106
Brufen SR106
BSF Ava 20 ED182
BSF Ava 30 ED182
BSF Candestar182
BSF CareSens II182
BSF CareSens N182
BSF CareSens N POP182
BSF Plendil ER182
Buccastem136
Budenocort171
Budesonide
Alimentary
Respiratory171, 176
Budesonide with
eformoterol
Bumetanide60
Buprenorphrine with
naloxone148
Bupropion hydrochloride149
Burinex60
Buscopan27
Buspirone hydrochloride142
Busulphan152
Butacort Aqueous176
- C -
Cabergoline85
Cafergot134
Caffeine citrate
Cal-d-Forte43

Calcium carbonate with

Calcium polystyrene
sulphonate
Calcium Resonium
Calogen
Camptosar154
Campiosar
Candesartan
Candestar
Canesten
Capecitabine
Capoten
Capsaicin
Captopril54
Carafate
Carbaccord152
Carbamazepine131
Carbimazole84
Carboplatin152
Carboplatin Ebewe152
Carbosorb-X44
Cardinol58
Cardinol LA58
Cardizem CD59
CareSens31
CareSens II31
CareSens N
CareSens N POP31
Carmustine152
Carvedilol57
Catapres60
Catapres-TTS-159
Catapres-TTS-259
Catapres-TTS-359
CeeNU152
Cefaclor monohydrate87
Cefalexin Sandoz87
Cefazolin sodium87
Cefoxitin sodium87
Ceftriaxone sodium87
Cefuroxime axetil
Cefuroxime sodium87
Celestone Chronodose80
Celiprolol
Cellcept165
Celol
Centrally Acting Agents59
Cephalexin ABM87
Cephalexin monohydrate87
Ceptolate165
Cerezyme41
Cetirizine - AFT170
Cetirizine hydrochloride170



Cetomacrogol
Dermatological67
Chloroform
Chloromycetin178
Chlorothiazide60
Chlorpheniramine maleate170
Chlorpromazine
hydrochloride137
Chlorsig178
Chlorthalidone60
Chlorvescent51
Cholecalciferol43
Cholestyramine with
aspartame51
Choline salicylate with cetalkonium chloride
Cholvastin
Ciclopirox olamine64
Cilazapril
Cilazapril with
hydrochlorothiazide55
Cilicaine
Cilicaine VK90
Ciloxan178
Cimetidine27
Cipflox90
Ciprofloxacin
Infection90
Sensory178
Cisplatin
Cisplatin Ebewe152
Citalopram hydrobromide129
Cladribine153
Clarithromycin
Alimentary27
Infection
Clexane
Climara 100
Climara 50
Clindamycin90 Clindamycin ABM90
Clobazam
Clobetasone butyrate
Clomazol
Olomazoi

Dermatological64
Genito-Urinary77
Clomiphene citrate85
Clomipramine hydrochloride128
Clonazepam
Clonidine
Clonidine hydrochloride60
Clopidogrel46
Clopine
Clopixol139, 141
Clotrimazole
Dermatological64
Genito-Urinary77
Clozapine
Clozaril137
Co-Renitec
Co-trimoxazole90
Coal tar71
Coal tar with allantoin, menthol,
phenol and sulphur72
Coal tar with salicylic acid and
sulphur72
Coco-Scalp72
Codeine phosphate
Extemporaneous
Nervous125
Cogentin
Colaspase [L-asparaginase]155
Colchicine
Colestid51
Colestipol hydrochloride51
Colgout
Colifoam
Colistin sulphomethate90
Colistin-Link90
Collodion flexible
Colofac
Coloxyl40
Combigan
Combivir101
Comfort
Comfort Short
Compound electrolytes50
Compound
hydroxybenzoate
Comtan
Concerta147
Condoms74
Condyline73
Contact-D35
Contraceptives - Hormonal
Contraceptives -
Non-hormonal74

Copaxone	.144
Corangin	
Cordarone-X	56
Corticosteroids and Related	
Agents for Systemic Use	80
Corticosteroids Topical	66
Cosmegen	.156
Cosopt	.180
Coumadin	49
Coversyl	
Creon 10000	
Creon Forte	39
Crixivan	.101
Crotamiton	65
Crystacide	64
Crystaderm	
Curam	
Curam Duo	
Cyclizine hydrochloride	.135
Cyclizine lactate	135
Cycloblastin	152
Cyclogyl	180
Cyclopentolate	. 100
hydrochloride	180
Cyclophosphamide	152
Cyclosporin	160
Cyklokapron	
Cyproterone acetate	
Cyproterone acetate with	01
ethinyloestradiol	77
Cytarabine	150
Cytotec	
Cytoxan	
-	. 152
- D -	
D-Penamine	
d4T	
Dabigatran	
Dacarbazine	.156
Dactinomycin [Actinomycin	
D]	
Daivobet	
Daivonex	71
Daktarin	
Alimentary	42
Dermatological	65
Dalacin C	
Dalteparin sodium	90
Danazol	90 47
	90 47 85
Danthron with poloxamer	90 47 85 40
Danthron with poloxamer Dantrium	90 47 85 40 .122
Danthron with poloxamer Dantrium Dantrolene sodium	90 47 85 40 .122 .122
Danthron with poloxamer Dantrium	90 47 85 40 .122 .122

Dapa-Tabs 61 Dapsone 93 Darunavir 101 Dasatinib 159 Daunorubicin 156 DBL Aminophylline 175 DBL Bleomycin Sulfate 155 DBL Carboplatin 152 DBL Cisplatin 152 DBL Doxorubicin 156 DBL Doxorubicin S29 156 DBL Dirubicin 156
Hydrochloride
DBL Ergometrine
DBL Pethidine
Hydrochloride
De-Worm
Decozol
Deferiprone53
Deoxycoformycin157
Depo-Medrol80
Depo-Medrol with Lidocaine80
Depo-Provera77
Depo-Testosterone81
Deprim90
Dermol66, 72
Desferrioxamine mesylate53
Desmopressin85
Desmopressin-PH&T85
Detection of Substances in
Urine
Dexamethasone
Hormone80
Sensory179
Dexamethasone sodium
phosphate 80
Dexamethasone with framycetin
and gramicidin 178
Dexamethasone with neomycin
and polymyxin b sulphate179
Dexamphetamine sulphate145
Dextrochlorpheniramine
maleate 170
Dextrose
Dextrose with electrolytes50
DHC Continus125
Diabetes

Diabetes Management
Diamide Relief25
Diamox179
Diaphragm74
Diasip
Diason RTH195
Diastop25
Diazepam131, 142
Dibenyline
Diclax SR106
Diclofenac Sandoz106
Diclofenac sodium
Musculoskeletal System106
Sensory179
Didanosine [DDI]101
Differin
Difflam41
Diflucan
Diffucortolone valerate
Digestives Including
Enzymes
Elizymes
Digoxin
Dihydrocodeine tartrate
Dilantin
Dilantin Infatab
Dilatrend
Diltiazem hydrochloride59
Dilzem59
Dipentum26
Diphenoxylate hydrochloride with
atropine sulphate25
Diphtheria and tetanus
vaccine221
Diphtheria, tetanus and pertussis
vaccine
Diphtheria, tetanus, pertussis
and polio vaccine 221
Diphtheria, tetanus, pertussis,
polio, hepatitis B and
haemophilus influenzae type B
vaccine
Diprosone66
Diprosone OV
Dipyridamole
Disinfecting and Cleansing
Agents 67
Disipal
Disopyramide phosphate
Disulfiram149
Discillant
Diurences
Dixarit60
Docetaxel156

Docetaxel Ebewe156
Docusate sodium40
Docusate sodium with
sennosides 40
Domperidone135
Donepezil hydrochloride148
Donepezil-Rex148
Dopergin123
Dopress128
Dornase alfa175
Dorzolamide hydrochloride180
Dorzolamide hydrochloride with
timolol maleate 180
Dostinex85
Dothiepin hydrochloride128
Doxazosin mesylate54
Doxepin hydrochloride128
Doxine90
Doxorubicin156
Doxorubicin Ebewe156
Doxy-5090
Doxycycline hydrochloride90
DP Lotion68
DP Lotn HC67
DP-Anastrozole165
Dr Reddy's Olanzapine
Dr Reddy's Omeprazole
Dr Reddy's Ondansetron
Dr Reddy's Pantoprazole
Dr Reddy's Pramipexole
Dr Reddy's Quetiapine138 Dr Reddy's Risperidone139
Dr Reddy's Terbinafine
Drugs Affecting Bone
Metabolism 117
Dulcolax40
Duocal Super Soluble
Powder 193
Duolin
Duolin HFA
Durex Confidence74
Durex Extra Safe74
Durex Select Flavours74
Duride61
Dynacirc-SRO59
- E -
E-Mycin
Ear Preparations178
Ear/Eye Preparations178
Easiphen Liquid207
Econazole nitrate65
Efavirenz100
Efavirenz with emtricitabine and

to a offer the elis of a second	
tenofovir disoproxil fumarate101	
Efexor XR130	
Effient	
Eformoterol fumarate	
Efudix	
Egopsoryl TA72	
Elecare	
Elecare LCP	
Electral50 Elemental 028 Extra198	
Eligard85	
Elocon	
Eloxatin	
Eltroxin	
Emend Tri-Pack	
EMLA	
Emtricitabine	
Emtricitabine with tenofovir	
disoproxil fumarate	
Emtriva	
Emulsifying ointment	
Enalapril	
Enalapril with	
hydrochlorothiazide	
Enbrel112 Endocrine Therapy163	
Endoxan152 Enfuvirtide102	
Enoxaparin sodium47	
Ensure	
Ensure Plus203	
Ensure Plus HN	
Ensure Plus RTH202	
Entacapone	
Entapone	
Entecavir	
Entocort CIR	
Enuclene	
Epilim	
Epilim Crushable	
Epilim IV133	
Epilim S/F Liquid133	
Epilim Syrup	
Epirubicin	
Epirubicin Ebewe	
Eprex	
ERA	
Ergometrine maleate	
Ergotamine tartrate with	
caffeine	
Erlotinib hydrochloride159	
Erythrocin IV88	
,	

Erythromycin ethyl succinate	88
Erythromycin lactobionate	88
Erythromycin stearate	88
Ervthropoietin alpha	45
Erythropoietin alpha Erythropoietin beta	45
Escitalopram	129
Estradot	
Estrofem	
Etanercept	
Ethambutol hydrochloride	0/
Ethics Aspirin	125
Ethics Aspirin EC	120
Ethics Paracetamol	
Ethinyloestradiol	00
Ethinyloostradial with	03
Ethinyloestradiol with desogestrel	75
desogestrei	. /5
Ethinyloestradiol with	
levonorgestrel	. 76
Ethinyloestradiol with	=0
norethisterone	
Ethosuximide	131
Etidronate disodium	118
Etopophos	156
Etoposide	156
Etoposide phosphate	156
Etravirine	100
Eumovate	
Evista	119
Exemestane	165
Extemporaneously Compounded	
Preparations and	
Galenicals	188
Eye Preparations	178
EZ-fit Paediatric Mask	
Ezetimibe	
Ezetimibe with simvastatin	
Ezetrol	52
- F -	02
Famotidine	07
Famox	27
Felodipine	58
Femtran 100	82
Femtran 50	82
Fenpaed	106
Fentanyl	126
Fentanyl citrate	
Ferodan	
Ferriprox	53
Ferro-F-Tabs	
Ferro-tab	44
Ferrograd	44
Ferrograd F	44
Ferrous fumarate	

Ferrous fumarate with folic
acid
Ferrous sulphate44
Ferrous sulphate with folic
acid
Ferrum H44
Fexofenadine hydrochloride170
Fibalip51
Fibro-vein46
Filgrastim49
Finasteride78
Flagyl93
FlagyI-S93
Flamazine64
Flecainide acetate56
Fleet Phosphate Enema40
Flixonase Hayfever &
Allergy 176
Flixotide171
Flixotide Accuhaler171
Florinef80
Fluanxol140
Fluarix221
Flucloxacillin sodium89
Flucloxin89
Flucon
Fluconazole
Fludara154
Fludara Oral154
Fludarabine Ebewe
Fludarabine phosphate
Fludrocortisone acetate
Fluids and Electrolytes
Flumetasone pivalate
Fluocortolone caproate with fluocortolone pivalate and
cinchocaine
Fluorometholone
Fluorouracil Ebewe
Fluorouracil sodium
Dermatological73
Oncology154
Fluox
Fluoxetine hydrochloride
Flupenthixol decanoate140
Fluphenazine decanoate
Flutamide
Flutamin
Fluticasone171
Fluticasone propionate
Fluticasone with salmeterol
Fluvax
FML179

Foban	64
Folic acid	
Food Thickeners	
Foods And Supplements For	200
Inborn Errors Of	
Metabolism	
Foradil	172
Forteo	119
Fortimel Regular	196
Fortini	
Fortini Multi Fibre	
Fortisip	
Fortisip	202, 203
Fortisip Multi Fibre	
Fosamax	
Fosamax Plus	
Fragmin	
Framycetin sulphate	178
FreeStyle Lite	
Freestyle Optium	30 31
Freestyle Optium Ketone	30
Frisium	121
Frumil	
Frusemide-Claris	
Fucicort	
Fucidin	
Fucithalmic	178
Fungilin	42
Furosemide	60
Fusidic acid	
Dermatological	64
Infection	
Sensory	
Fuzeon	102
- G -	
Gabapentin	131
Gabapentin (Neurontin)	132
Gamma benzene	
hexachloride	69
Gardasil	221
Gastrosoothe	27
Gaviscon Double Strength	
Gaviscon Infant	
Gefitinib	
Gemcitabine Actavis 1000	
Gemcitabine Actavis 200	
Gemcitabine Ebewe	154
Gemcitabine hydrochloride	154
Gemfibrozil	51
Gemzar	
Generaid Plus	
Genoptic	
Genotropin	
Genox	165

Gentamicin sulphate	
Infection91	
Sensory178	
Ginet 84	
Glatiramer acetate	
Glibenclamide	
Glipizide	
Glivec	
Glucagen Hypokit28	
Glucagon hydrochloride	
Glucerna Select195	
Glucerna Select RTH195	
Glucobay29	
Gluten Free Foods205	
Glycerin with sodium	
saccharin 188	
Glycerin with sucrose	
Glycerol	
Alimentary40 Extemporaneous188	
Glyceryl trinitrate61	
Glytrin61	
Gold Knight74	
Gopten55	
Goserelin acetate85	
Gutron57	
Gynaecological	
aynaecological	
Anti-infectives77	
Anti-infectives77 - H -	
Anti-infectives	
Anti-infectives77 - H - Habitrol150 Haemophilus influenzae type B	
Anti-infectives	
Anti-infectives 77 - H - Habitrol 150 Haemophilus influenzae type B 221 Haldol 140 Haldol 140 Haldol Concentrate 140 Haloperidol 137 Haloperidol decanoate 140 Hamilton Sunscreen 72 HbvaxPro 221 healthE Fatty Cream 68 Healtheries Simple Baking Mix Mix 205 Hemastix 79	
Anti-infectives	

Home Essential
Systemic81
Humalog29
Humalog Mix 25
Humalog Mix 5029
Human papilomavirus vaccine
Humira
HumiraPen107 Humulin 30/7029
Humulin NPH29
Humulin R29
Hybloc
Hydralazine61
Hydrea157
Hydrocortisone
Dermatological
Hormone
Hydrocortisone acetate26
Hydrocortisone butyrate
Hydrocortisone with
cinchocaine27
Hydrocortisone with
miconazole67
Hydrocortisone with natamycin
and neomycin67
Hydrocortisone with wool fat and
mineral oil67
Hydroderm Lotion68
Hydrogen peroxide
Alimentary42
Dermatological
Hydroxocobalamin42 Hydroxychloroquine sulphate93
Hydroxyurea
Hygroton60
Hyoscine (scopolamine)135
Hyoscine hydrobromide135
Hyoscine N-butylbromide27
Hypam145
Hyperuricaemia and
Antigout 122
Hypnovel144
Hypromellose181
Hysite
-1-
lbiamox
Ibuprofen106
Idarubicin hydrochloride157
Ifosfamide152



Igroton60
lkorel61
lloprost62
Imatinib mesylate160
Imiglucerase41
Imipramine hydrochloride128
Imiquimod73
Immune Modulators102
Immunosuppressants165
Imuprine
Imuran
Indapamide61
Indinavir101
Infanrix-hexa
Infanrix-IPV
Infant Formulae
Influenza vaccine
Inhaled Anticholinergic
Agents
Inhaled Corticosteroids171
Inhaled Long-acting
Beta-adrenoceptor
Agonists 171
Inhibace Plus55
Innovacon hCG One Step
Pregnancy Test78
Inset 30
Inset II
Insulin aspart29
Insulin aspart with insulin aspart
protamine29
Insulin glargine29
Insulin glulisine
Insulin isophane29
Insulin isophane with insulin
neutral
Insulin lispro
Insulin lispro with insulin lispro
protamine
protarnine
Insulin neutral
Insulin pen needles
Insulin pump
Insulin pump accessories
Insulin pump infusion set (steel
cannula)35
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, angle insertion)
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device)

nsulin pump infusion set (teflon	
cannula, straight insertion)38	3
nsulin pump reservoir	3
nsulin syringes, disposable with	
attached needle 33	3
ntal Forte CFC Free175	
ntal Spincaps175	5
ntelence100)
nterferon alpha-2a103	3
nterferon alpha-2b103	3
nterferon beta-1-alpha144	1
nterferon beta-1-beta144	
ntra-uterine device74	1
ntron-A103	3
POL222	2
pratropium bromide173, 176	3
ressa	
rinotecan154	1
rinotecan Actavis 100154	
rinotecan Actavis 40154	
rinotecan-Rex154	
ron Overload53	
ron polymaltose44	
sentress102	
smo 2061	
soniazid94	
soprenaline hydrochloride61	
soptin59	
sopto Carpine180	
sopto Homatropine180	
sosorbide mononitrate61	1
sosource Standard202	2
sosource Standard RTH202	
sotretinoin63	
sradipine59	
suprel61	
tch-Soothe65	
traconazole92	
trazole92	
vermectin69	9
- J -	
Jadelle77	7
Jevity202 Jevity HiCal RTH202	2
Jevity HiCal RTH202	2
Jevity RTH202	2
- K -	
Kaletra101	
Karicare Food Thickener205	
Kemadrin124	1
Kenacomb178	
Kenacort-A81	1
Kenacort-A4081	1

KetoCal	210
Ketoconazole	
Dermatological	72
Infection	92
Ketogenic Diet	210
Ketone blood beta-ketone	
electrodes	
Ketoprofen	106
Ketostix	30
Kindergen	196
Kivexa	100
Klacid	
Kliogest	83
Kliovance	83
Konakion MM	46
Konsyl-D	39
·	

L-asparaginase155 Lacosamide132 Lacri-Lube181 Lactulose40 Laevolac40 Lamivudine95, 101 Lamotrigine133 Lanoxin56 Lanoxin PG56 Lantus29 Lantus SoloStar29 Lanvis154 Lapatinib Ditosylate161 Largactil137 Lasix60 Latanoprost180 Lax-Sachets40 Lax-Tab40 Laxofast 12040 Laxofast 5040 Laxsol40 Leflunomide107 Letraccord165 Letrozole165 Leukeran FC152 Leukotriene Receptor Antagonists 174 Leunase155 Leuprorelin85 Leustatin153 Levetiracetam133

Levetiracetam-Rex133
Levobunolol179
Levocabastine179
Levodopa with benserazide123
Levodopa with carbidopa123
Levomepromazine
Levonorgestrel
Genito-Urinary77
Hormone83
Levothyroxine84
Lifestyles Flared74
Lignocaine124
Lignocaine hydrochloride124
Lignocaine with
chlorhexidine
Lignocaine with prilocaine
Lincocin
Lincomycin91
Lipazil
Lipid Modifying Agents51
Liquigen
Lisinopril
Listinicarb FC
Lithium carbonate
Livostin
Locacorten-Viaform ED's178
Locasol
Loceryl64
Locoid
Locoid Crelo
Locoid Lipocream
Locorten-Vioform178
Lodoxamide trometamol179
Logem
Lomide
Lomustine152
Loniten61
Loperamide hydrochloride25
Lopinavir with ritonavir101
Lopresor58
Loprofin207
Loprofin Mix207
Loraclear Hayfever Relief171
Lorapaed171
Loratadine171
Lorazepam142
Lormetazepam144
Losartan
Lostaar56
Lovir96
Loxalate129
Loxamine130

	G
Lucrin Depot Lucrin Depot PDS Ludiomil Lumigan Lycinate Lyderm	85 128 180 61
- M -	
m-Captopril	54
m-Cefuroxime	87
m-Enalapril	54
m-Eslon	
M-M-R II	222
m-Mometasone	67
Mabthera	166
Macrogol 3350	40
Madopar 125	123
Madopar 250	123
Madopar 62.5	123
Madopar Dispersible	123
Madopar HBS	123
Magnesium hydrovide	188

Magnesium hydroxide	188
Magnesium sulphate	
Alimentary	
Dermatological	73
Malathion	
Maprotiline hydrochloride	128
Marevan	
Marine Blue Lotion SPF 30+	
Marquis Black	74
Marquis Conforma	74
Marquis Protecta	74
Marquis Selecta	74
Marquis Sensolite	74
Marquis Supalite	
Marquis Titillata	74
MarquisTantiliza	74
Martindale Acetylcysteine	188
Marvelon 21	75
Marvelon 28	
Mask for spacer device	176
Mast Cell Stabilisers	175
Maxidex	179
Maxitrol	179
MCT oil (Nutricia)	194
Measles, mumps and rubella	
vaccine	
Mebendazole	
Mebeverine hydrochloride	27
Medrol	80
Medroxyprogesterone acetate	
Genito-Urinary	77
Hormone	.82, 84
Mefenamic acid	106

INDEX Generic Chemicals and Brands

Megace164
Megestrol acetate164
Meloxicam107
Melphalan152
Meningococcal A, C, Y and
W-135 vaccine 222
Menomune222
Menthol65
Mercaptopurine154
Mercilon 2175
Mercilon 2875
Mesalazine26
Mesna157
Mestinon106
Metabolic Disorder Agents41
Metamide136
Metformin hydrochloride30
Methadone hydrochloride
Extemporaneous188
Nervous126
Methatabs126
Methoblastin154
Methopt181
Methotrexate154
Methotrexate Ebewe154
Methyl hydroxybenzoate188
Methylcellulose189
Methylcellulose with glycerin and
sodium saccharin 189
Methylcellulose with glycerin and
sucrose 189
Methyldopa60
Methylphenidate
hydrochloride146
Methylphenidate hydrochloride
extended-release 147
Methylprednisolone80
Methylprednisolone
aceponate 67
Methylprednisolone acetate80
Methylprednisolone acetate with
lignocaine80
Methylprednisolone sodium
succinate 80
Methylxanthines175
Metoclopramide
hydrochloride 136
Metoclopramide hydrochloride
with paracetamol 135
Metopirone
Metoprolol - AFT CR58
Metoprolol succinate58
Metoprolol tartrate58



Metronidazole93
Metyrapone86
Mexiletine hydrochloride57
Mexiletine Hydrochloride
USP
Miacalcic118
Mianserin hydrochloride128
Micolette40
Miconazole42
Miconazole nitrate
Dermatological
Genito-Urinary77
Micreme
Micreme H
Microgynon 30
Microgynon 50 ED76
Microlut77
Midazolam144
Midodrine57
Minerals43
Minidiab
Minirin85
Mino-tabs90
Minocycline hydrochloride90
Minomycin
Minor Skin Infections69
Minoxidil61
Mirena
Mirtazapine130
Misoprostol27
Mitomycin C157
Mitozantrone
Mitozantrone Ebewe157
Mixtard 3029
Moclobemide
Modafinil
Modavigil148
Modecate140
Moducal192
Moduretic60
Mogine133
Mometasone furoate67
Monogen195
Montelukast174
Morphine hydrochloride126
Morphine sulphate127
Morphine tartrate127
Motetis
Motilium
Mouth and Throat41
Movicol
Moxifloxacin
MSUD Maxamaid
1000D 101aAamaiu200

MSUD Maxamum206
Mucilaginous laxatives
Mucilaginous laxatives with
Muchaginous laxatives with
stimulants
Mucolytics
MultiADE43
Multiload Cu 37574
Multiload Cu 375 SL74
Multiple Sclerosis
Treatments 142
Multivitamins43
Mupirocin64
Muscle Relaxants122
Myaccord165
Myambutol94
Mycobutin
Mycophenolate mofetil
Mycostatin65
Mydriacyl180
Mylan Atenolol
Mylan Fentanyl Patch126
Mylanta P25
Myleran152
Myocrisin107
Myometrial and Vaginal Hormone
Preparations
- N -
Nadolol
Nalcrom
Naloxone hydrochloride148
Naltraccord149
Naltrexone hydrochloride
Naphazoline hydrochloride
Naphcon Forte
Naprosyn SR 1000106 Naprosyn SR 750106
Nonrovan 100
Naproxen106
Nardil129
Nardil
Nardil
Nardil 129 Nasal Preparations 176 Natulan 157 Nausicalm 135
Nardil 129 Nasal Preparations 176 Natulan 157 Nausicalm 135 Navelbine 158
Nardil 129 Nasal Preparations 176 Natulan 157 Nausicalm 135 Navelbine 158 Navoban 136
Nardil129Nasal Preparations176Natulan157Nausicalm135Navelbine158Navoban136Nedocromil175
Nardil 129 Nasal Preparations 176 Natulan 157 Nausicalm 135 Navelbine 158 Navoban 136

 Neocate
 208

 Neocate Advance
 208

 Neocate Gold
 208

 Neocate LCP
 208

 Neoral
 169

 NeoRecormon
 45


Neostigmine106	1
Neotigason	
Nepro (strawberry)198	
Nepro (vanilla)	
Nepro RTH197	
Nerisone	
Neulactil138	
NeuroKare44	
Neurontin132	
Nevirapine100	
Nevirapine Alphapharm100	
Next Choice	
Nicorandil61	
Nicotine150	
Nicotinic acid51	
Nifedipine59	
Nifuran104	
Nilstat	
Alimentary42	
Genito-Urinary78	
Infection92	
Nipent157	
Nitrados144	
Nitrates61	
Nitrazepam144	
Nitroderm TTS61	
Nitrofurantoin104	
Nizoral92	
Noctamid144	
Nodia25	
Noflam 250106	
Noflam 500106	
Non-steroidal Anti-inflammatory	
Drugs (NSAIDs) 106	
Norethisterone	
Genito-Urinary77	
Hormone	
Norethisterone with	
mestranol76	
Norflex122	
Norfloxacin105	
Noriday 2877	
Norimin76	
Norinyl-1/2876	
Normacol Plus	
Normison145	
Norpress129	
Nortriptyline hydrochloride129	
Norvir	
NovaSource Renal198	
Novatretin71	
NovoFine32	
NovoMix 30 FlexPen29	

NovoRapid29 NovoRapid Penfill29 Noxafil92	
Noxafil	
Nozinan137	
Nuelin175	
Nuelin-SR175	
Nupentin131	
Nutraplus68	
Nutrient Modules192	
Nutrini Energy Multi Fibre197	
Nutrini Energy RTH197 Nutrini Low Energy Multi	
Nutrini Low Energy Multi	
Fibre 199	
Nutrini RTH197	
Nutrison Concentrated204	
Nutrison Energy202	
Nutrison Energy Multi Fibre	
Nutrison Multi Fibre202	
Nutrison Standard RTH202	
Nyefax Retard59	
Nystatin	
Alimentary42	
Dermatological65	
Genito-Urinary78	
Infection92	
NZB Low Gluten Bread Mix205	
INZO LOW GIULEIT DIEdu IVIIX	
- 0 -	
- O - Octreotide (somatostatin	
- O - Octreotide (somatostatin analogue)164	
- O - Octreotide (somatostatin analogue)	
- 0 - Octreotide (somatostatin analogue)	
- 0 - Octreotide (somatostatin analogue)	
- 0 - Octreotide (somatostatin analogue)	
- O - Octreotide (somatostatin analogue)	
- O - Octreotide (somatostatin analogue)	
- O - Octreotide (somatostatin analogue)	

	INDEX
Generic Chemicals and	Brands

OncoTICE Ondansetron		l
One-Alpha		i
Onkotrone		i
Ora-Blend		i
		1
Ora-Blend SF		
Ora-Plus		
Ora-Sweet		
Ora-Sweet SF		
Orabase		
Oracort	41	
Oral Supplements/Complete Diet		
(Nasogastric/Gastrostomy		
Tube Feed)	194	
Oratane		
Orgran		Í
Ornidazole		i
Orphenadrine citrate		
Orphenadrine hydrochloride		
Ortho All-flex		
Ortho-tolidine		
Oruvail SR		
Osmolite		
Osmolite RTH		
Ospamox		
Ospamox Paediatric Drops	89	
Other Endocrine Agents	85	
Other Oestrogen		
Preparations	83	
Other Progestogen		
Preparations	83	
Other Skin Preparations	73	
Ovestin		
Genito-Urinary	78	
Hormone		
Ox-Pam		
Oxaliplatin		
Oxaliplatin Actavis 100		
Oxaliplatin Actavis 50	153	
Oxaliplatin Ebewe		
Oxazepam	140	
Ovia Turbubalar	170	
Oxis Turbuhaler		
Oxybutynin		
Oxycodone hydrochloride		
Oxycodone Orion		
OxyContin		
OxyNorm		
Oxypentifylline		
Oxytocin	78	
Ozole	92	
- P -		
Pacifen	.122	
Pacific Buspirone		

Paclitaxel157Paclitaxel Actavis157Paclitaxel Ebewe157Paediatric Seravit43Pamidronate BNM119Pamidronate disodium119Pamisol125Pancreatic enzyme39Pantocid IV28Pantoprazole28Panzytrat39Papaverine hydrochloride62Paracare125Paracetamol125Paracetamol125Paracetamol125Paracetamol125Paracetamol125
Paracetamol + Codelne
(Relieve)
Paradigm 1.8 Reservoir38
Paradigm 3.0 Reservoir38
Paradigm 522
Paradigm 72233
Paradigm Mio MMT-92137
5
Paradigm Mio MMT-92337
Paradigm Mio MMT-92537
Paradigm Mio MMT-94137
Paradigm Mio MMT-94337
Paradigm Mio MMT-94537
Paradigm Mio MMT-96537
Paradigm Mio MMT-97537
Paradigm Quick-Set
Paradigm Quick-Set
MMT-386
Paradigm Quick-Set
Paradigm Quick-Set MMT-387
Paradigm Quick-Set
MMT-396
Paradigm Quick-Set
MMT-397
NINT-097
Paradigm Quick-Set MMT-398
MM I-398
Paradigm Quick-Set
Paradigm Quick-Set MMT-399
Paradigm Silhouette
MMT-368
Paradiam Silbouatto
Paradigm Silhouette MMT-377
WIWI 1-377
Paradigm Silhouette MMT-378
MMT-378
Paradigm Silhouette
MMT-381
Paradiam Silhouette
MMT-382
WIWH 00200



Paradigm Silhouette
MMT-383
Paradigm Silhouette
MMT-384
Paradigm Sure-T MMT-86435
Paradigm Sure-T MMT-86635
Paradigm Sure-T MMT-87435
Paradigm Sure-T MMT-87635
Paradigm Sure-T MMT-88435
Parafast
Paraffin
Paraffin liquid with soft white
paraffin
Paraffin liquid with wool fat
liquid181
Paraldehyde131
Paramax135
Parasiticidal Preparations69
Parnate129
Paroxetine hydrochloride130
Paxam142
Pazopanib161
Peak flow meter176
Pedialyte - Bubblegum50
Pedialyte - Fruit
Pedialyte - Plain
Pediasure197
Pediasure RTH197
Pegasys103
Pegasys RBV Combination
Pegasys RBV Combination Pack 103
B
Pegylated interferon alpha-2a103
Penicillamine107
Penicillin G benzathine
[benzathine
benzylpenicillin]89
PenMix 3029
PenMix 4029
PenMix 5029
Pentasa26
Pentostatin
[Deoxycoformycin]157
Pepti Junior Gold209
Peptisoothe
Peptisorb198
Pergolide123
Perhexiline maleate
Pericyazine138
Perindopril55
Permax123
Permethrin71

Persantin Pethidine hydrochloride Pevaryl Pexsig Pharmacy Services Phenelzine sulphate Phenobarbitone Phenobarbitone sodium Phenobarbitone sodium	.128 65 59 .182 .129 .133 .189
hydrochloride Phenoxymethylpenicillin	
(Penicillin V) Phenylephrine	90
hydrochloride	101
nyarochioride	181
Phenytoin sodium131,	133
Phlexy 10	.207
Phosphate-Sandoz	
Phytomenadione	
Pilocarpine	
Pimafucort	
Pindolol	
Pinetarsol	
Pinorax	
Pinorax Forte	40
Pioglitazone	30
Piportil	.140
Pipothiazine palmitate	
Pizaccord	30
Pizotifen	.135
PKU Anamix Infant	.207
PKU Anamix Junior LQ	
PKU Lophlex LQ 10	.207
PKU Lophlex LQ 20	.207
Plaquenil	
Plendil ER	58
Pneumococcal (PCV13)	
vaccine	222
Pneumococcal polysaccharide	
vaccine	222
Pneumococcal vaccine	.222
Pneumovax 23	.222
Podophyllotoxin	73
Polaramine	.170
Poliomyelitis vaccine	.222
Poloxamer	40
Poly-Tears	
Poly-Visc	.181
Polycal	.192
Polyvinyl alcohol	.181
Ponstan	
Posaconazole	
Postinor-1	
Potassium bicarbonate	

Potassium chloride49, 5	51
Potassium citrate	
Potassium iodate	14
Povidone iodine6	
Pradaxa	18
Pramipexole hydrochloride12	23
Prasugrel	
Pravastatin	51
Prazosin hydrochloride	54
Pred Forte	
Pred Mild17	
Prednisolone acetate17	
Prednisolone sodium	
phosphate	30
Prednisone	31
Prefrin18	31
Pregnancy Tests - hCG Urine7	78
Premarin	32
Premia 2.5 Continuous8	33
Premia 5 Continuous	33
Prevenar 1322	22
Prezista10)1
Priadel13	38
Primidone13	33
Primolut N	34
Probenecid12	
Probenecid-AFT12	22
Procaine penicillin	90
Procarbazine hydrochloride15	57
Prochlorperazine13	36
Proctosedyl	
Procyclidine hydrochloride12	
Prodopa6	
Prograf16	
Progynova	32
Prokinex13	35
Promethazine hydrochloride17	71
Promethazine theoclate13	
Promethazine Winthrop	
Elixir	71
Promod19	
Propafenone hydrochloride	57
Propamidine isethionate17	78
Propranolol	
Propylene glycol18	39
Propylthiouracil	
Protamine sulphate4	18
Protaphane	29
Protaphane Penfill	29
Protifar19	94
Provera82, 8	34
PSO211-21	4
Psoriasis and Eczema	

Preparations	71
PTU	84
Pulmicort Turbuhaler	171
Pulmocare	194
Pulmozyme	175
Purinethol	154
Pyrazinamide	94
Pyridostigmine bromide	106
PyridoxADE	42
Pyridoxine hydrochloride	42
Pytazen SR	46

- Q -	
Q 3001	22
Questran-Lite	51
Quetapel1	38
Quetiapine1	38
Quick-Set MMT-390	38
Quick-Set MMT-391	38
Quick-Set MMT-392	38
Quick-Set MMT-393	38
Quinapril	55
Quinapril with	
hydrochlorothiazide	55
Quinine sulphate1	22

- R -

RA-Morph	126
Raloxifene hydrochloride	119
Raltegravir potassium	102
Ranbaxy-Cefaclor	87
Ranitidine hydrochloride	28
Rapamune	
Reandron 1000	
Redipred	
Renilon 7.5	
Resonium-A	51
Resource Beneprotein	
Resource Diabetic	195
Respigen	
Respiratory Devices	
Respiratory Stimulants	
ReTrieve	
Retrovir	
Rex Medical	
Rexacrom	
Reyataz	
Ridal	139
Ridaura	
Ridaura s29	
Rifabutin	
Rifadin	
Rifampicin	
Rifinah	94


Riodine	
Risperdal	
Risperdal Consta	
Risperdal Quicklet	
Risperidone	139–141
Risperon	139
Ritalin	146
Ritalin LA	147
Ritalin SR	146
Ritonavir	102
Rituximab	166
Rivacol	41
Rivaroxaban	48
Rivotril	131
Rizamelt	135
Rizatriptan	
Rocaltrol solution	43
Roferon-A	103
Ropin	
Ropinirole hydrochloride	
Roxane	
Roxithromycin	
Rubifen	
Rubifen SR	
Rythmodan	
Rytmonorm	

- S -

S-26 Gold Premgro S26LBW Gold RTF Sabril Salamol Salapin Salazopyrin EN	207 134 173 173 26 26
Salbutamol	173
Salbutamol with ipratropium bromide	
Serevent	172

INDEX Generic Chemicals and Brands

Serevent Accuhaler172
Serophene85
Seroquel138
Sertraline
Sevredol127
Sex Hormones Non
Contraceptive81
Shield 49
Shield Blue74
Shield XL74
Silagra62
Sildenafil62
Silhouette MMT-37136
Silhouette MMT-37336
Silver sulphadiazine64
Simethicone
Simvastatin52
Sindopa123
Sinemet
Sinemet CR123
Singulair
Sirolimus169
Siterone81
Slow-Lopresor
Sodibic
Sodium acid phosphate40
Sodium alginate25
Sodium aurothiomalate107
Sodium bicarbonate
Blood50–51
Extemporaneous189
Sodium calcium edetate44
Sodium
carboxymethylcellulose 41
Sodium chloride
Blood50
Respiratory175
Sodium citrate with sodium lauryl
sulphoacetate 40
Sodium citro-tartrate79
Sodium cromoglycate
Alimentary26
Respiratory175–176
Sensory179
Sodium fluoride43
Sodium nitroprusside
Sodium polystyrene
sulphonate
Sodium tetradecyl sulphate46
Sodium valproate133
Sofradex
Soframycin178
Solian



Synacthen	81		
Synacthen Depot			
Synflorix			
Synthroid			
Syntocinon	78		
Syntometrine			
Syrup (pharmaceutical			
grade)	189		
.т.			

Tacrolimus	169
Tambocor	
Tambocor CR	
Tamoxifen citrate	165
Tamsulosin hydrochloride	78
Tamsulosin-Rex	
Tap water	189
Tar with triethanolamine lauryl	
sulphate and fluorescein	
Tarceva	
Tasmar	
Taxotere	156
Tegretol	131
Tegretol CR	131
Telfast	
Temaccord	157
Temazepam	145
Temozolomide	157
Tenofovir disoproxil fumarate	
Tenoxicam	107
Terazosin hydrochloride	54
Terbinafine	93
Terbutaline sulphate	173
Teriparatide	
Testosterone	
Testosterone cypionate	
Testosterone esters	81
Testosterone undecanoate	
Tetrabenazine	
Tetrabromophenol	
Tetracosactrin	
Teva	
Thalidomide	
Thalomid	
Theophylline	1/5
Thiamine hydrochloride	42
THIO-TEPA	
Thioguanine	
Thiotepa	
Thymol glycerin Thyroid and Antithyroid	42
Agents	04
Tiaprofenic acid	107
Tilade	175
	1/3

Tilcotil107	
Timolol maleate	
Cardiovascular58	
Sensory179	
Timoptol XE179	
Tiotropium bromide173	
Titralac25	
TMP91	
Tobramycin	
Infection91	
Sensory179	
Tobrex179	
Tofranil128	
Tolcapone124	
Tolterodine79	
Tolvon128	
Topamax134	
Topiramate134	
Total parenteral nutrition	
(TPN)	
TPN50	
Tracleer62	
Tramadol hydrochloride125	
Tramal SR125	
Trandate57	
Trandolapril55	
Tranexamic acid46	
Tranylcypromine sulphate129	
Trastuzumab168	
Travatan180	
Travoprost180	
Treatments for Dementia148	
Treatments for Opioid	
Overdose	
Treatments for Substance	
Dependence148	
Trental 40062	
Tretinoin	
Dermatological63	
Oncology158	
Triamcinolone acetonide	
Alimentary41	
Dermatological67	
Hormone81	
Triamcinolone acetonide with	
gramicidin, neomycin and nystatin	
Dermatological67	
Sensory	
Triazolam145	
Trichozole93	
Triclosan68	
Trifluoperazine	
hydrochloride139	

Trimeprazine tartrate 171 Trimethoprim 91 Trisequens 83 Trisul 90 Trophic Hormones 84 Tropisetron 136 Trusopt 180 Truvada 101
Two Cal HN
Two Cal HN RTH204 Tykerb161
Tyloxapol181
- U -
Ultraproct27
Univent
Ural
Urea
Urex Forte
Urinary Agents78 Urinary Tract Infections104
Uromitexan
Ursodeoxycholic acid
Ursosan
- V -
Vaccinations
Valaciclovir
Valcyte97
Valganciclovir97
Vallergan Forte171
Valtrex
Vancomycin hydrochloride91
Vannair
Varenicline tartrate150
Various182
Vasodilators61
Vasopressin Agonists85
Velcade155
Velcade
Velcade
Velcade155 Venlafaxine
Velcade 155 Venlafaxine 130 Ventavis 62 Ventolin 173 Vepesid 156
Velcade 155 Venlafaxine 130 Ventavis 62 Ventolin 173 Vepesid 156 Veracol 87
Velcade 155 Venlafaxine 130 Ventavis 62 Ventolin 173 Vepesid 156 Veracol 87 Verapamil hydrochloride 59
Velcade 155 Venlafaxine 130 Ventavis 62 Ventolin 173 Vepesid 156 Veracol 87

Verpamil SR59
Vesanoid158
Vesicare
Vfend
Viaderm KC67
Viagra
Viagra
Videx EC101
Vigabatrin134
Vigabatrin
Vimpat
Vinblastine sulphate158
Vincristine sulphate158
Vinorelbine158
Vinorelbine Ebewe158
Viramune100
Viramune Suspension100
Viread
Vistil
Vistil Forte181
Vitabdeck43
Vitadol C42
Vital HN
Vitala-C
Vitamin A with vitamins D and
C
Vitamin B complex42
Vitamins
Vivonex Pediatric
Vivonex TEN198
Volibris62
Voltaren106
Voltaren
Voltaren106Voltaren D106Voltaren Ophtha179Volumatic176Voriconazole93
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - -
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium Wart Preparations 73
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium Wart Preparations 73
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium Wart Preparations 73 Wasp venom allergy treatment
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium Wart Preparations 73 Wasp venom allergy treatment 170 Water
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium Wart Preparations 73 Wasp venom allergy treatment treatment 170 Water Blood 50
Voltaren 106 Voltaren D 106 Voltaren Ophtha 179 Volumatic 176 Voriconazole 93 Vosol 178 Votrient 161 Vytorin 52 - W - Warfarin sodium Wart Preparations 73 Wasp venom allergy treatment 170 Water

Wool fat with mineral oil	68
- X -	
Xarelto	
Xeloda	
XMET Maxamum	
XP Maxamaid	
XP Maxamum	207
Xylocaine	124
Xylocaine Viscous	124
-Z-	
Zantac	28
Zapril	
Zarator	
Zarontin	
Zarzio	
Zavedos	
Zeffix	
Zeldox	
Zerit Zetlam	
Zetop	
Ziagen	
Zidovudine [AZT]	101
Zidovudine [AZT] with	
lamivudine	
Zinacef	87
Zinc and castor oil	68
Zinc sulphate	44
Zincaps	
Zinnat	
Ziprasidone	
Zithromax	
Zofran Zydis	136
Zoladex	
Zoledronic acid	
Zopiclone	
Zostrix HP	
Zovirax	178
Zuclopenthixol decanoate	141
Zuclopenthixol	
hydrochloride	139
Zyban	149
Zyprexa	138
Zyprexa Relprevv	140
Zyprexa Zydis	141

NOTES



NOTES